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ABSTRACT 
Hepatitis C virus (HCV) is the main cause of viral hepatitis in the UK and leads to 
chronic liver disease in many infected individuals. There is a substantial burden on 
diagnostic laboratories to provide rapid, cost-effective tests for monitoring HCV 
infection. Commercial assays are expensive and so the development of validated 
in-house methods is beneficial. This thesis describes the development and 
implementation of rapid and inexpensive real-time PCR assays for HCV 
quantitation and genotyping to support clinical practice. Additionally, the 
development of methods for defining HCV isolates at the subtype level, important 
in epidemiological and transmission studies, is described. These assays were 
utilised in a study on spontaneous HCV clearance, the results of which suggest 
that HCV type 1 infection and younger age at infection are factors which are 
associated with spontaneous viral clearance. 
Chronic HCV infection is linked to oxidative stress with numerous deleterious 
cellular effects. Mitochondrial DNA (mtDNA) is more susceptible to oxidative 
damage than nuclear DNA making it an ideal marker to assess the overall level of 
cellular DNA damage - including deletions and mutations. This thesis illustrates 
the development of real-time PCR assays to detect and quantify two major mtDNA 
deletions. The D-loop region of mtDNA is particularly prone to damage - with two 
well recognised 'hotspots of mutation'. The creation of an RSCA (heteroduplex- 
based) method using capillary electrophoresis, to detect and quantify damage in 
this region, is described. 
11 
To evaluate the clinical utility of these assays, a study of mtDNA damage in 
patients with liver disease was undertaken. The aim of this study was to identify 
whether chronic HCV infection results in increased levels of mtDNA damage 
compared to other liver pathologies. Low levels of mtDNA deletions were detected 
in the majority of liver biopsy specimens and there was no correlation between liver 
aetiology and quantity of deletions. The RSCA method identified numerous D-loop 
mtDNA species within the liver tissue of several individuals. There was no 
correlation between liver aetiology and the presence of multiple D-loop species. 
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CHAPTER ONE 
Part One 
Hepatitis C Virus 
1.1 Hepatitis C virus 
An infectious human hepatitis agent was first identified in 1989 as the main cause 
of post-transfusion and sporadic non-A, non-B hepatitis and was named the 
hepatitis C virus (Choo et al, 1989; Kuo et al, 1989). At the turn of the century, 
there were an estimated 170 million people worldwide infected chronically with 
HCV (WHO, 1999) and it is now the most common blood-borne virus in Europe and 
the USA. The UK is probably a low prevalence country, although there have been 
very few studies on HCV prevalence to confirm this. Seroprevalence studies on 
samples collected from the mid-1990s estimated prevalence to be around 0.5% 
(Balogun et al, 2002). In a study of pregnant women in the UK, HCV antibody was 
detected in 0.4% in London and 0.2% in Yorkshire, demonstrating that HCV is 
seen, albeit at low rates, even in lower risk populations (Balogun et al, 2000). 
Statistical modelling has suggested that, in 2003, there were an estimated 231,000 
HCV-antibody positive individuals between 15-59 years of age living in England 
and Wales, equating to anti-HCV prevalence in this population of 0.72% (HPA, 
2006). However, estimates of HCV prevalence must take into account the fact that 
injecting drug users (IDUs) are at very high risk of HCV infection and make up the 
bulk of prevalent HCV infections in the UK. This population group is very difficult to 
study because they move around frequently and are often homeless; as a result 
they are under-represented in national data sources. 
A cumulative total of 62,726 laboratory-confirmed diagnoses of HCV in England 
were reported to the Health Protection Agency between 1992 and 2006 (HPA, 
2007). There has been a steady increase in the number of reports during this time 
(Figure 1.1). There is no evidence of an increase in incidence, and the rise in 
1 
reports is consistent with an increase in testing and public awareness through 
campaigns and media coverage. Laboratory reporting is, however, incomplete. 
Data from sentinel surveillance of Hepatitis C testing, which commenced in 2002 
and which extracts test results on all individuals tested for hepatitis in participating 
sentinel centres suggests that routine laboratory reporting underestimates HCV 
infections by as much as 60% (Brant et al, 2007). 
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Figure 1.1: Cumulative laboratory reports of confirmed HCV infection in England to 
the Health Protection Agency: 1992 to 2006 (HPA, 2007). Although this appears to 
demonstrate a rise in HCV incidence/prevalence, it is actually consistent with an 
increase in HCV testing. 
1.2 HCV transmission 
HCV is transmitted through contact with blood and blood products. In the UK, 
sharing of contaminated equipment whilst injecting recreational drugs is the single 
most important reported risk factor, with 82% of HCV positive individuals reporting 
injecting drug use (IDU) as the main risk exposure (Brant et al, 2007). In this 
country, HCV infection is most common in the younger age group and is highest in 
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25-34 year olds, regardless of whether injecting drug use is reported as a risk 
factor (HPA, 2006). 
Other, less common risk factors include vertical (mother to baby) transmission 
(Ohto et a!, 1994). The reported rate of vertical transmission varies between 
studies, but is around 6%, with increased rates seen when mothers have high HCV 
viral loads and/or are co-infected with HIV (Thomas et a!, 1998). Sexual 
transmission does occur (Alter, 1993) but is very rare (Balogun eta!, 2003). Some 
studies have suggested a link between skin piercing or tattooing with non-sterile 
equipment (Ko et a!, 1992). However, evidence for this association is weak and 
piercing/tattooing may often be used as an excuse to hide other risk factors such 
as IDU. Recently, a worrying rise in acute HCV infection in HIV-positive 
homosexual men has been observed (Browne et a!, 2004). 
Prior to 1991, when screening of blood donors was introduced, blood transfusions 
and receiving blood products were major risk factors for HCV (Alter et al, 1992; van 
der Poel, 1999; Soldan et al, 2002). This led to HCV infection in almost all 
haemophiliacs treated with clotting factors. Each unit of factor VIII received by a 
haemophiliac consisted of blood plasma from 30-40 donors, vastly increasing the 
likelihood of HCV transmission to these individuals. Following the introduction of 
donor screening, and more recently, nucleic acid testing (NAT) of blood donations, 
infection through these routes is now extremely rare (Soldan et al, 2005). For 
HCV, the frequency of infectious donations was 1 in 520,000 during 1993-1998 
and fell to I in 30 million during 1999-2001 when all donations were tested for 
HCV RNA (Soldan et al, 2003). In under-developed parts of the world, particularly 
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in rural areas, blood screening does not occur. Many infections in these areas 
occur as a result of blood transfusion or, more commonly, re-use of needles and 
syringes. 
1.3 HCV disease and diagnosis 
Most people have no signs or symptoms of acute HCV infection and are diagnosed 
as a result of routine blood tests. Many people are, therefore, unaware of their 
infected status, increasing the risk of transmission. When symptoms do occur, 
these include flu-like illness, nausea, fatigue, depression, jaundice and abdominal 
pain. Blood samples may reveal abnormal liver function tests (LFTs) within 4-12 
weeks including raised alanine aminotransferase (ALT) which is a crude indicator 
of liver injury. 
Diagnosis of HCV is via serological detection of HCV antibodies with enzyme 
immunoassays (EIAs) which have antigens derived from the core and/or non- 
structural proteins. Initial positive anti-HCV results are confirmed using either a 
second EIA, or a line assay which has antigens impregnated onto strips. Antibody 
detection is less useful to diagnose infection in the immunocompromised patient 
(including those co-infected with HIV) (Chamot et al, 1990) and those receiving 
haemodialysis (Schneeberger et al, 1998) as they may not have a detectable HCV 
antibody response. Antibody detection is not useful to detect mother-to-baby 
transmission as neonates will have maternal antibody for several months after 
birth. 
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Serological techniques are limited as it can take up to three months for antibodies 
to HCV to become detectable following infection. Combined assays which detect 
both HCV antigen (Ag) and antibody (Ab) are invaluable to detect infections prior to 
seroconversion and are often used as confirmatory tests. The Bio-Rad 
MONOLISA HCV Ag-Ab ultra kit consists of a microplate coated with a mixture of 
recombinant proteins (from the NS3 region), antigen (from the NS4 region), 
mutated peptide (from the capsid) as well as monoclonal antibodies (against the 
capsid protein). This allows simultaneous detection of anti-HCV via an indirect test 
and HCV core antigen via a sandwich test. This shortens the pre-seroconversion 
window period over conventional HCV Ab screening assays. The detection of HCV 
RNA by PCR can also be used to confirm HCV diagnosis in individuals pre- 
seroconversion and in those for whom serological test results are weakly reactive 
(indeterminate). HCV RNA is seen in the blood 1-3 weeks after initial exposure. 
1.4 HCV progression 
The clinical progression of HCV varies considerably. HCV persists in 70-80% of 
primary infections, causing chronic hepatitis. Around 20% of people with chronic 
infection will develop serious liver disease, such as cirrhosis and fibrosis; 1-4% of 
those with cirrhosis will develop hepatocellular carcinoma (HCC) each year (DoH, 
2002). Figure 1.2 indicates the estimated overall progression of HCV infection, 
according to Department of Health data. However, recent analysis has 
demonstrated that event-biased recruitment in studies of HCV progression which 
often use liver clinic cohorts may produce upwardly biased estimations of 
progression rates (Freeman et al, 2001; Fu et al, 2007). Sweeting and colleagues 
(2006) demonstrated that disease progression varied according to cohort, with the 
estimated 20-year probability of progression to cirrhosis being 12% in a hospital- 
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based cohort, 6% in a post-transfusion cohort and 23% in a cohort recruited from a 
tertiary referral centre (Sweeting et al, 2006). 
Chronic infection is usually asymptomatic for many years, with symptoms of liver 
disease usually occurring long after initial infection. However, certain independent 
host factors are linked to rapid progression to liver disease including being over 40 
years old at infection, male gender and high alcohol consumption (Poynard et al, 
1997). Accelerated development of liver disease appears to be independent of 
HCV genotype or viral load (Poynard et a/, 2001). Once chronic HCV has 
progressed to cirrhosis, symptoms include ascites (accumulation of fluid in the 
abdomen), bruising/bleeding tendency and varices (enlarged veins, especially in 
the stomach and oesophagus). Chronic HCV also has many extrahepatic 
manifestations affecting the joints, muscles, neural and gastrointestinal tissues and 
skin (Sterling and Bralow, 2006). 
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Figure 1.2: Clinical progression of HCV infection. Taken from 'Hepatitis C 
Strategy for England', DoH 2002. 
HCV infection places a substantial burden on health care. Hospital admissions 
and liver transplants for HCV end stage liver disease continue to rise. Statistical 
modelling has demonstrated that HCV-related cirrhosis and deaths from 
hepatocellular carcinoma (HCC) are likely to increase dramatically in the next 
decade (Sweeting et al, 2007). The financial burden of HCV will continue to 
increase, as although new cases are decreasing due to blood screening, many 
people who experimented with IDU in the 1960-80s are unknowingly infected with 
HCV and represent an unknown number of asymptomatic infections which may 
result in clinical disease. 
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1.5 Spontaneous clearance 
Spontaneous resolution of HCV infection, as determined by normalisation of liver 
function tests and disappearance of HCV RNA from serum, occurs in 20-30% of 
HCV-infected individuals. This group is of particular interest as identifying the 
mechanisms associated with spontaneous clearance may aid in vaccine 
development. Clinical factors such as symptomatic infection (Gerlach et al, 2003) 
and HBV co-infection (Piasecki et al, 2004) have been linked to spontaneous 
clearance. Host factors including female sex (Alric et al, 2000; Micallef et al, 2006) 
and ethnicity (Thomas et al, 2000; Piasecki at al, 2004) have been found to be 
significantly associated with spontaneous clearance. The host immune response 
is also thought to have an important role in spontaneous clearance. It is possible 
that production of inappropriate levels of some cytokines, which mediate hepatic 
inflammation and fibrosis in HCV infection, can lead to viral persistence and 
chronic HCV infection. The difference between individuals in their ability to 
produce IL-10, TNF-a or IFN-y cytokines, attributed to certain gene polymorphisms, 
have been reported as indicators of likelihood of spontaneous viral clearance (Lio 
et al, 2003; Mangia at al, 2004) although these findings remain controversial 
(Kusomoto at al, 2006; Minton et al, 2005). Certain polymorphisms in some 
interferon-induced genes whose protein products have antiviral action have been 
associated with spontaneous clearance (Knapp at al, 2003) as have specific HLA 
type II alleles, (DQB1*0301 and DRB1*1101) (Yee, 2004). 
Viral factors have also been reported to affect viral clearance. A study, in 
Germany, of anti-HCV positive males with history of IDU demonstrated a significant 
prevalence of genotype 3 in individuals who spontaneously cleared the virus (86% 
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of type 3 cleared vs. 7% of type 1, n=92) (Lehmann et al, 2004). Infection with 
genotype I and specifically subtype lb has been linked to chronicity (Amoroso et 
al, 1998; Hwang et al, 2001). More recently, in a large study, Harris and 
colleagues (Harris et al, 2007) have suggested that HCV genotype 1 infection is 
more likely to be associated with spontaneous viral clearance than non-1 genotype 
infection. 
Most of the studies examining spontaneous HCV clearance have been very small, 
with some contradictory results. A recent systematic review of 31 longitudinal 
studies with 675 study subjects, concluded that the only factors significantly 
associated with viral clearance were sex, with men being less likely to clear the 
virus (0.20 vs. 0.42, RR 0.43,95% 0.36-0.53), and acute symptomatic HCV (0.31, 
95% Cl 0.26-0.36) (Micallef et al, 2006). 
True spontaneous clearance is, however, difficult to determine. It is presently 
unclear whether spontaneous clearance is associated with complete eradication of 
the virus, or whether low-level viral replication persists but is controlled by the 
cellular and humoral immune responses. Several small studies suggest that HCV 
RNA can be repeatedly undetectable in serum or plasma by laboratory assays, but 
are identifiable in serum and peripheral blood mononuclear cells (PBMCs) by 
molecular tests of enhanced sensitivity in patients thought to have spontaneously 
resolved HCV infection. Pham and colleagues (Pham et a/, 2004) detected HCV 
RNA in serum and/or PBMCs from all tested patients thought to have 
spontaneously resolved HCV infection (n=5). Similarly, Radkowski et a/ (2005) 
studied 11 spontaneous clearers and detected HCV RNA in serum samples from 2 
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(18.2%), in PBMCs from 3 (27.3%) and in both serum and PBMCs from 4 of them. 
Following stimulation by mitogens which is thought to enhance HCV replication, 
HCV RNA was detected from all eleven spontaneous clearers. 
1.6 HCV structure 
Hepatitis C virus (HCV) is the sole member of the genus hepacivirus of the 
Flaviviridae family. It is a small, enveloped virus which is covered in projections 
which are complexes of the envelope glycoproteins El and E2 (Figure 1.3). 
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Figure 1.3: The structure of the hepatitis C virus illustrating the RNA genome, 
nucleocapsid and envelope glycoproteins El and E2. Adapted from 
hftp: //www. viralgenomix. com/vgx_41 0-HCV. html. 
The nucleotide sequence and genetic organisation of HCV was reported in 1991 
(Choo et al, 1991) and the molecular virology has now been described extensively 
(Major and Feinstone, 1997; De Francesco, 1999; Lemon et al, 2007). The HCV 
genome is single-strand positive-sense RNA of approximately 9,600 nucleotides in 
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length and carries a single open reading frame (ORF) which encodes a single 
polyprotein of around 3000 amino acids. Translation of the ORF is directed via a 5' 
untranslated region (UTR) which has an internal ribosome entry site (IRES) that 
functions to bring ribosomes into close contact with the start codon (Lemon et al, 
2007). The polyprotein is cleaved by viral and cellular proteases into 10 structural 
and non-structural viral proteins. These consist of 3 structural proteins (core, El 
and E2) located at the N-terminus, p7 and NS2 proteins which probably play 
essential roles in viral morphogenesis and release and 5 non-structural (NS) 
proteins which are required for RNA replication (NS3, NS4A, NS4B, NS5A and 
NS5B) in the remainder of the polyprotein (Figure 1.4). 
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Figure 1.4: A schematic representation of the organisation of the HCV genome 
and polyprotein. A: The HCV genome with non-translated RNA segments shown 
as thin lines. B: Functional organisation and processing of the viral polyprotein. 
Sites of cleavage by host cell and viral proteases are indicated by symbols. 
Adapted from Lemon et al, 2007, p1256. 
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The core protein forms the viral nucleocapsid. It can also interact with numerous 
cellular proteins and affect host cell functions. The envelope glycoproteins El and 
E2 are transmembrane proteins with C-terminal hydrophobic anchors. They are 
glycosylated in the host cell endoplasmic reticulum (ER). The El and E2 
glycoproteins are associated in the form of a heterodimer (Deleersnyder et al, 
1997). The envelope proteins vary considerably among HCV sequences, 
especially at a hypervariable region (HVR1) located at the amino terminus of E2. 
HVRI is also thought to be a critical neutralisation domain for the antibody 
response to HCV infection (Farci et al, 1996). This region mutates rapidly in-vivo 
under the selective pressure of the antibody response, producing many 
neutralisation escape mutants, a strategy by which the virus can evade the host 
immune response. p7 may have ion channel activity (Griffin et al, 2003), and has 
been demonstrated to be similar to the M2 ion channel of influenza virus (Griffin et 
a/, 2004). It belongs to a group of viral proteins known as `viroporins' which are 
hydrophobic proteins which form cation channels. The precise role of p7 in HCV 
replication is uncertain. NS2 and the N-terminal of NS3 form an autoprotease 
which cleaves the NS2/NS3 junction. NS3 is a multifunctional protein consisting of 
a serine proteinase which cleaves all other non-structural protein junctions, an 
NTPase (nucleotide triphosphatase) and an RNA helicase. The latter protein is 
involved in the viral replication complex and probably functions to unwind 
replicative double strand RNA intermediates and to eliminate RNA secondary 
structures. NS4a is a co-factor for the NS3 serine protease and localises NS3 to 
the ER. Relatively little is known about the NS4b protein; it localises to the ER and 
appears to induce the expression of'membranous webs' which are important in the 
assembly of the replication complex (Egger et al, 2002). NS5a is a zinc 
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metalloproteinase and is an essential component of the replicase complex. Its 
phosphorylation status may regulate viral RNA replication (Evans et al, 2004). 
NS5a also contains the interferon sensitivity determining region (ISDR) which can 
determine response to therapy (Enomoto et al, 1996). The NS5b RNA-dependent 
RNA polymerase is the enzyme for synthesis of new RNA genomes (Oh et al, 
1999). Table 1.1 shows a summary of each of the HCV proteins and their 
functions. 
Genome Region Function 
5' UTR Highly conserved. Contains IRES - binds ribosome to 
initiation codon 
Core (C) Nucleocapsid protein 
El Envelope glycoprotein 
E2 Envelope glycoprotein 
p7 Potential ion channel activity vivo Orin 
NS2 Auto protease 
NS3 Multifunctional protein - serine protease (NH2 
terminal), NTPase and helicase (COOH terminal) 
NS4a Co-factor for full expression of NS3 protease 
NS4b Hydrophobic membrane-associated protein 
NS5a Multifunctional protein - essential component of 
replicase complex 
NS5b RNA-dependent RNA polymerase activity 
3'UTR Contains a variable region, a U/C rich region and a 
highly conserved 3' terminal domain 
Table 1.1: HCV proteins and their functions. NS; non-structural, UTR; untranslated 
region. 
1.7 HCV replication 
The investigation of the HCV life cycle was hampered by the lack of efficient cell 
culture systems and animal models. However, with in-vitro and in-vivo model 
systems now in place, investigation of the life-cycle has intensified and much is 
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now known about the stages of HCV replication (Bartenschlager and Lohman, 
2000; Lemon et al, 2007). 
1.7.1 Virus attachment and entry 
HCV has a predilection for hepatocytes and the liver is the major site of HCV 
replication. Several groups have suggested the existence of extrahepatic 
reservoirs of HCV replication, specifically in PBMCs (Wang et al, 1992; Muller et al, 
1993). However, more specific methods for detection of the HCV RNA negative 
strand, the template for new genomic HCV RNA, failed to detect this in PBMCs, 
throwing into doubt the possibility of extrahepatic HCV replication (Lanford et al, 
1995; Laskus et al, 1997). This is still subject to controversy as several studies 
have demonstrated extrahepatic HCV replication occurring in immunosuppressed 
individuals (Laskus et al, 1998; 2007; Radkowski et al, 1998). 
The first step in replication is the attachment of HCV to specific host cell receptors. 
It is thought that cell entry requires a set of co-receptors that include the CD81 
tetraspanin and the human scavenger receptor class B type 1 (SR-B1) (a high- 
density lipoprotein internalisation molecule) in addition to other hepatocyte-specific 
co-factor(s) (Pileri et al, 1998; Agnello et al, 1999; Bartosch et al, 2003). HCV 
attachment is via the E1-E2 complex, although it remains unclear whether El or E2 
harbours the fusion peptide. Mutational analysis has indicated that E2 plays a role 
in refolding of the glycoproteins during fusion (Drummer and Poumbourios, 2004). 
Cell attachment of HCV leads to clathrin-mediated endocytosis of bound virions 
(Blanchard et a/, 2006). 
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1.7.2 Polyprotein translation and processing 
Once inside the cytoplasm, the virus is uncoated and genomic RNA is directly 
translated. The IRES, comprising almost the entire 5'UTR, directs translation of 
the polyprotein at the ribosome (Wang et al, 1993). The polyprotein is cleaved co- 
and post-translationally by host signal peptidases and two viral proteinases (see 
Figure 1.4) to form the 10 protein products. The non-structural proteins form a 
replication complex which binds to the rough endoplasmic reticulum and 
coordinates viral replication. Following cleavage from the polyprotein, El and E2 
enter the lumen of the ER and are glycosylated and joined to form heterodimers. 
1.7.3 RNA replication 
Following viral protein processing the HCV genome is replicated. The original 
positive sense RNA strand is used as a template for negative strand synthesis, 
which is carried out by the RNA-dependent RNA polymerase. The negative strand 
is then used as a template to produce new genomic HCV RNA. This forms a 
double-stranded RNA intermediate which must be separated as double-stranded 
RNA can trigger cellular defences and also takes away the template. The NS3 
helicase unwinds the RNA strands using the NTPase. Strand synthesis occurs 
within a viral replication complex formed by the non-structural proteins which 
sequesters the process. This complex forms a 'membranous web' on the ER, 
whose synthesis is thought to involve NS4b (Egger et al, 2002). 
HCV replication generates virus variants due to the high production rate of viral 
particles along with the high error rates of the viral RNA-dependent RNA 
polymerase during RNA replication. A mutation rate of 1.44 x 10"3 base 
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substitutions per site per year was found over a 13 year period in an HCV-infected 
patient (Ogata et al, 1991). Variability is not spread equally through the genome. 
El and E2 demonstrate the greatest variability, especially in the hypervariable 
region of E2 (Weiner at a!, 1991); whilst the core gene and some non-structural 
genes (such as NS3) are more conserved. The 5' UTR shows the least variability, 
as specific sequences and RNA secondary structures are required for transcription 
and translation. Even within an infected individual, HCV exists as a highly 
heterogeneous viral population. This complex mix of related molecular species, 
known as quasispecies, consists of a single dominant sequence and a mixture of 
mutants (Martell at a!, 1992). In two regions of the E2 protein, termed the 
hypervariable regions (HVRs), high frequencies of mutations have been identified, 
which accumulate during chronic infection. The production of quasispecies 
enables the virus to evade the host immune system and prevents elimination of the 
virus by the infected host (Weiner et a!, 1992; Shimizu et a!, 1994). 
Due to this variability, HCV has been classified into six major genotypes of HCV (1- 
6) which vary by up to 35% in sequence. Within each genotype there are closely 
related strains, or subtypes (a-k) that differ in sequence by 20-25%. Currently 
more than 70 subtypes have been identified (Simmonds et al, 1993; 1994, 
Simmonds, 1995). Novel variants from Vietnam, Thailand and Indonesia classified 
as genotypes 7,8,9,10 and 11 were re-classified into subtypes of type 6 or type 3 
(Simmonds et a/, 1996). International standardisation and nomenclature of HCV 
genotypes/subtypes is complex and is continually reviewed and updated 
(Simmonds et al, 2005). 
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1.7.4 Virus assembly and release 
Following viral genome replication, viral assembly occurs. The capsid self- 
assembles from multiple units of the core protein and the genomic RNA is 
enclosed within the capsid shell. It is thought that, like other flaviviruses, HCV 
acquires its envelope through budding into the lumen of the ER (where El and E2 
are attached) and is released from host cells by exocytosis via the Golgi complex 
(Lemon et al, 2007). A schematic representation of the HCV replication cycle is 
shown in Figure 1.5. 
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Figure 1.5: An hypothetical model of the HCV replication cycle. The large 
rectangle represents the host cell. Once inside the cell, the genomic RNA (+RNA) 
is released into the cytoplasm and translated. The polyprotein is processed and 
the viral proteins remain tightly associated with the membranes of the ER. The 
non-structural proteins form a replication complex (3-5B replicase) which binds to 
the rough endoplasmic reticulum. The original positive sense RNA strand is used 
as a template for negative strand synthesis which is then used to produce new 
genomic HCV RNA. The viral particles are enveloped by budding into the lumen of 
the ER and then exported via transit through the Golgi complex. (Figure adapted 
from Bartenschlager and Lohmann, 2000). 
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1.8 HCV epidemiology 
HCV is endemic in most parts of the world, with an overall prevalence of around 
3%. However, there is great geographical variation in the incidence of HCV, which 
varies from I% to greater than 10% (WHO, 2002). The prevalence in some African 
countries, the Eastern Mediterranean, South East Asia and the Western Pacific are 
higher than North America and Europe (WHO, 1999). The high number of HCV 
cases in Egypt is thought to be due to the administration of parenteral anti- 
schistosomal treatment that requires 10-12 injections, mostly given with reusable 
needles (Frank et al, 2000). The prevalence in blood donors in European countries 
is 1% with a North-South gradient ranging from 0.04-2% (Touzet et al, 2000). This 
grossly underestimates overall prevalence as blood donors are not representative 
of the true population and do not include those most at risk from HCV. 
The distribution of genotypes also varies geographically. Genotypes 1,2 and 3 
have worldwide distribution but their prevalence varies between regions (Zein, 
2000). Subtypes 1a and lb are the most common and account for over 60% of 
infections worldwide (Maertens and Stuyver, 1997). In Japan, subtype lb is 
responsible for 73% of infections (Takada, 1993). It is thought to be through 
intravenous drug use that subtypes la and 3a have become widely distributed in 
Western countries (Pawlotsky et al, 1995). In Western Africa, genotype 2 causes 
the majority of infections, whilst in North and Central Africa, genotypes 1 and 4 
predominate (Xu et al, 1994). Genotype 3 is endemic in South East Asia. In the 
Middle East (including Egypt) (Chamberlain et al, 1997), 4 is the major genotype. 
Genotypes 5 and 6 are rare and are generally confined to South Africa (genotype 
5) and Hong Kong and South East Asia (genotype 6). In Africa and South East 
18 
Asia there is far greater diversity of subtypes, supporting the theory that HCV has 
been endemic in these areas for a long time. The limited diversity of subtypes in 
the USA and Europe indicates that the occurrence in Western countries is 
relatively recent, appearing in new risk groups for infection (Simmonds, 2001). 
Using age-specific prevalence data, Wasley and Alter (2000) outlined three distinct 
transmission patterns. In some countries (e. g. Australia and USA), most infections 
are found in people 30-49 years of age, indicating relatively recent transmission, 
primarily affecting young adults. In countries such as Japan and Italy, 
demonstrating the second transmission pattern, most infections are in the older 
person, indicating infection in the distant past. The third transmission pattern, 
which is seen in countries such as Egypt, has HCV infection occurring in all age 
groups indicating ongoing risk of infection. This mirrors the risk factors which are 
predominantly injecting drug use in countries with the first transmission pattern, 
and unsafe healthcare procedures seen in countries with the latter two 
transmission patterns (Wasley and Alter, 2000). 
1.9 HCV treatment 
There is no effective vaccine available for HCV. Much effort has, therefore, gone 
into producing a therapeutic regime for its treatment. Interferon (IFN) is the 
treatment of choice for chronic HCV. The mechanism of action of IFN is not fully 
understood. It is thought to induce IFN-stimulated genes (ISGs) which establish an 
antiviral state within the cell (Sen et al, 2001). IFN also has an important role in 
immunomodulation, promoting memory cell proliferation and stimulating natural 
killer cell activity. 
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IFN monotherapy has only limited success. A meta-analysis of clinical trials 
indicated that monotherapy produced an end of treatment virological response in 
only 29% of treated individuals (Carithers and Emerson, 1997). The addition of 
ribavirin (a broad-spectrum nucleoside analogue which inhibits a range of DNA and 
RNA viruses) to IFN treatment, vastly improved the response rate compared to 
monotherapy for both initial treatment (McHutchison et a/, 1998; McHutchison and 
Poynard, 1999) and relapse (Davis et a/, 1998). More recently, a pegylated form of 
interferon (peginterferon) has been developed. Two different peginterferons are 
available, alpha 2a (a-2a) and alpha 2b (a-2b). These have a large molecule of 
polyethylene glycol (PEG) covalently attached to the interferon molecule. This 
slows the rate of elimination from the body and has much higher success rates for 
viral clearance than conventional interferon (Zeuzem et al, 2000; Manns et al, 
2001; Fried et al, 2002). Side effects from therapy can be severe. Interferon 
treatment can lead to influenza-like symptoms, anorexia, nausea, lethargy, 
cardiovascular problems, nephrotoxicity, hepatotoxicity and depression (including 
suicidal behaviour) (Fried et al, 2002; Joint Formulary Committee, 2008). In 
addition, ribavirin has a multitude of multi-systemic and unpleasant side effects 
including haemolytic anaemia. 
The aim of interferon therapy is sustained virological response (SVR) which is 
defined as undetectable levels of HCV RNA following treatment and 6 months 
thereafter. Early virological response (EVR), which is defined as a reduction in 
HCV RNA level by at least 2-log from baseline (pre-treatment) at week 12 of 
therapy is a good indicator of SVR. Failure to achieve EVR is a strong predictor of 
non-response to treatment. The percentage of patients who do not achieve EVR 
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and subsequently do not have a SVR is 97-100% (Lee et al, 2002; Davis et al, 
2003). Rapid virological response (RVR) which is defined as undetectable levels 
of HCV RNA following four weeks of treatment is frequently an indicator of both 
EVR and SVR. Patients who become HCV RNA negative after 4 weeks have the 
best chance of achieving a SVR (Jensen et al, 2006; Yu et al, 2007). Recent 
studies have demonstrated that achievement of RVR may be used as an indicator 
for shortening treatment duration for genotypes 1,2 and 3 (Poordad et al, 2008). A 
transient treatment response occurs in 10-25% of individuals with optimum 
regimens. SVR may be achieved in these patients following longer courses or 
higher doses of treatment (Shiffman et al, 2002). 
HCV genotype is important in predicting response to therapy. Studies have shown 
that optimal duration of, and response to, treatment are strongly associated with 
genotype, with response rates 2 to 3 fold higher in patients infected with genotypes 
2 and 3 than with genotype 1 (Martinot-Peignoux et al, 1995; Poynard et a/, 1998; 
Manns et al, 2001; Zeuzem at al, 2001; Hadziyannis et al, 2004). National Institute 
of Health and Clinical Excellence (NICE) guidelines recommend that patients 
should be treated with peginterferon-a and ribavirin, with duration of therapy 
adjusted according to genotype. Those with genotype 2 and/or 3 infection should 
be treated for 24 weeks, as maximum rate of SVR is attained in this time period for 
these individuals. For people infected with other genotypes, it may take longer to 
achieve SVR. Therefore, those with genotypes 1,4,5 or 6 should be treated 
initially for 12 weeks and then a further 36 weeks only if an EVR has been 
achieved. If this has not occurred then treatment should be discontinued in these 
patients as it is unlikely that viral eradication will occur. This treatment regime is 
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quite successful in patients with HCV genotypes 2 and 3 infection, achieving HCV 
eradication rates of 76-93% (Zeuzem et al, 2004; von Wagner et al, 2005). 
However, it is much less effective in patients with genotype 1 infections, with 
eradication rates of between 42-47% (Manns et al, 2001; Fried et al, 2002; Zeuzem 
of al, 2004a; Ferenci et al, 2005; ). Treatment was initially reserved for patients 
with moderate to severe chronic HCV (NICE, 2004). However, the NICE 
guidelines have subsequently been updated and now recommend that all patients 
with chronic HCV infection can be considered for treatment without deferring 
treatment until the disease has progressed to moderate or severe (NICE, 2006). 
Liver biopsy is the most specific test to assess the nature and severity of liver 
diseases and is an integral part of assessing the extent of chronic HCV. It is the 
most reliable method to determine the extent of necroinflammatory activity and 
fibrosis, especially as liver enzymes do not reflect liver damage reliably (Nutt et al, 
2000). Liver biopsies are stained and examined for evidence of periportal 
necrosis, intralobular degeneration, portal inflammation and fibrosis or cirrhosis 
(Figure 1.6). However, it is not always possible to carry out a biopsy and the stage 
of liver disease must be assessed by alternate methods such as ultrasound scans. 
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Figure 1.6: Haematoxylin and eosin stained liver biopsies (x1000). (A) Healthy 
liver. (B) Post hepatic cirrhosis with thickening of Glisson's capsule (outer capsule 
surrounding the liver) showing severe fibrotic strands with regenerative nodules. 
Taken from www. tigeroath. com. 
1.9.1 New agents for HCV treatment 
In the last few years, progress in the understanding of HCV and its life-cycle has 
lead to a great deal of attention in the field of HCV therapy. In particular, the 
development of specifically targeted antiviral therapy for HCV (STAT-C) is rapidly 
advancing. This involves the development of drugs which target specific enzymes 
important in the replication of HCV. Several effective inhibitors of the viral 
NS3/NS4a protease and NS5b polymerase have been identified and are now 
progressing through clinical trials (De Francesco and Carfi, 2007). Telaprevir 
(Vertex Pharmaceuticals) for example, is an inhibitor of the NS3/NS4a serine 
protease. Recent large phase II clinical trials have shown that, compared to 
current treatment, telaprevir, in combination with peg-interferon a-2a and ribavirin 
resulted in higher rates of RVR and produced greater anti-viral effects within 
shorter treatment duration (Dusheiko et al, 2008; McHutchison et al, 2008). R1626 
(Roche Pharmaceuticals) is an NS5b polymerase inhibitor. A recent phase Ila 
study has shown that R1626 in combination with peg-IFN a-2a and ribavirin for four 
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weeks followed by 44 weeks of peg-IFN a-2a and ribavirin demonstrated higher 
end of treatment response (84%) in genotype 1-infected individuals compared to 
those who had received 48 weeks peg-IFN a-2a and ribavirin alone (65%). 
Additionally, attention is being focussed on immunomodulatory agents such as 
Toll-like receptor (TLR) agonists. TLRs are key mediators of innate immunity 
which are activated by microorganisms and induce signalling cascades leading to 
the production of cytokines and interferons. In phase 1 studies, HCV-infected 
patients given a TLR-9 agonist, CPG10101, demonstrated increased markers of 
immune activation and decreased HCV RNA levels (McHutchison et al, 2007). 
Development of new antivirals is a slow process, and many of the potential agents 
will never be available for the treatment of HCV due to withdrawal from 
development as a result of issues with toxicity. 
1.10 Diagnosis/Monitoring of HCV infection 
1.10.1 HCV viral load 
Determination of HCV RNA level is an integral part of diagnosis and management 
of patients with HCV. Routine diagnosis of HCV is based on the detection of HCV- 
specific antibodies. However, by this means, it is impossible to determine whether 
the patient has active infection, or has had a past infection which has cleared. 
Detection of HCV RNA is required as an absolute marker of current infection and 
can be qualitative. Management of the treatment of HCV is based on quantitative 
HCV RNA measurements before, during and after interferon therapy. Pre- 
treatment viral load is thought to be an important predictor of SVR with high pre- 
treatment viral loads less likely to respond to therapy than low viral loads (Manns et 
a/, 2001; Lee et al, 2002). HCV viral load measurements also have clinical utility 
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prior to initiation of therapy and after 12 weeks to determine if EVR has been 
achieved and the likelihood of SVR (Lee et al, 2002; Davis et al, 2003). 
Quantitation of HCV is problematic as it can circulate in the blood at low copy 
number and its heterogeneity makes it difficult to ensure sensitivity of detection. 
Quantitation assays must have linearity over a broad range of viral loads as these 
cover a wide range from >107 copies/ml, to below 1000 copies/ml in some 
chronically infected patients and even lower in patients on interferon therapy (Yasui 
et al, 1998; Zeuzem et al, 1998). Initially, comparison of assay performance for 
quantitative HCV RNA detection was hampered by the lack of standardisation of 
methods for HCV quantitation. This issue was resolved by the introduction of an 
HCV World Health Organisation (WHO) first international standard for Nucleic Acid 
Amplification Technology Assays (96/790). This is a lipophilised genotype 1 
sample which was assigned a value of 105 IU/ml. This allowed the calibration of all 
available assays to international units (lU) and standardisation of HCV RNA 
quantitation (Saidanha et al, 1999; Pawlotsky et al, 2000). This has recently been 
replaced by the second international standard (96/798) which was assigned the 
same unitage as the first standard (Saldanha et al, 2005). There is, however, no 
standard formula for converting the amount of HCV RNA reported in copies/ml to 
the amount reported in IU. The conversion factor ranges from one to around five 
HCV RNA copies per IU, depending on the assay used. HCV RNA assays should 
have a sensitivity of 50 IU/ml to detect low HCV RNA levels after treatment and to 
distinguish spontaneous viral clearance from low levels of circulating HCV. 
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1.10.1.1 Commercial HCV quantitation assays 
Several qualitative/quantitative HCV viral load kits are commercially available 
which differ in the lower detection limits and linear ranges of amplification. The 
branched DNA (bDNA) assay, developed by Chiron relies on signal, rather than 
target amplification. Viral RNA is captured on microwells by specific synthetic 
oligonucleotide capture probes. The captured RNA is then hybridised to branched 
oligonucleotides which are, in turn, hybridised to enzyme-conjugated 
oligonucleotides which are quantified. A semi-automated bDNA system was 
introduced (VERSANT HCV RNA 3.0 assay, Bayer Diagnostics, UK) which has a 
dynamic range of 615-7,700,000 IU/ml and was thought to be equally sensitive 
across all genotypes (Elbeik et al, 2004). However, it has been found recently to 
underestimate the quantity of genotypes 1 and 3 (Sarrazin et a/, 2006). The bDNA 
method is easy and relatively inexpensive for use on a large number of samples 
and does not have the contamination risk that is associated with molecular 
methods, but its lower detection limit of -600 IU/ml means that it lacks sensitivity 
(Beld et al, 2002). 
The Cobas Amplicor HCV Monitor 2.0 assay (Roche Diagnostics, UK) is a 
molecular assay based on conventional RT-PCR in which the amplified products 
are hybridised, in a separate step, to specific oligonucleotide probes which are 
detected by colorimetric determination. This assay has a relatively small linear 
range of 600-<500,000 IU/ml. The test lacks sensitivity as it uses a limited number 
of amplification cycles so that high target concentrations do not reach saturation 
(Lee et al, 2000; Mellor et al, 1999). The low upper end of the linear range means 
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that sample dilution and re-testing is required for as many as 47.4% of samples 
(Castelain et al, 2004). 
Conventional RT-PCR measures the level of product at the end of the amplification 
which is not ideal as small changes in the amplification efficiency can dramatically 
affect the amount of final product. Handling of the sample after target amplification 
causes major problems with contamination. Consequently, real-time PCR has 
become the preferred method for HCV quantitation with product quantity calculated 
during the logarithmic phase of the reaction, before the reaction components 
become limiting and the reaction plateaus. The latest versions of the Roche and 
Abbott HCV quantitation assays - the Cobas Taqman HCV assay (Roche 
Diagnostics, West Sussex, UK) and the Abbott RealTime HCV assay (Abbott 
Diagnostics Division, Berkshire, UK) are both based on automated sample 
preparation followed by real-time PCR (Kleiber et a!, 2000). Both assays exhibit a 
large dynamic range; between 12 - 1x108 IU/ml with the Abbott assay (Halfon eta!, 
2006) and 25 - 5x106 IU/ml with the Roche assay (Germer et a!, 2005) and are 
extremely sensitive (Sizmann et a!, 2007). Some genotypic variability in viral load 
was reported for both assays (Caliendo et al, 2006; Sarrazin et a!, 2006; Michelin 
et a!, 2007). Good correlation has been observed between these two assays 
which also have the benefit of high throughput, automation and an internal control 
(Wolff et a!, 2007). 
1.10.1.2 In-house HCV quantitation assays 
Although the latest commercial HCV quantitation assays are sensitive, accurate 
and suitable for high-throughput testing, the major disadvantage is their high cost. 
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As a result, in-house methods for HCV quantitation based on real-time PCR have 
been developed. Different methodologies have been described using non-probe 
based SYBR Green, which rely on melting-curve analysis to determine specificity. 
SYBR Green binds to all double-stranded DNA and, as a result, non-specific peaks 
can occur in low positive and HCV negative samples (Komurian-Pradel et al, 2001; 
White et al, 2002). Probe-based systems have been designed using either FRET 
hybridisation probes (Ratge et al, 2002), molecular beacons (Yang et al, 2002; 
Morandi et al, 2007) or hydrolysis probes (Martell et al, 1999; Takeuchi et al, 1999; 
Castelain et al, 2004). These are based on calibration to an external standard 
curve created by modified HCV RNA (Komurian-Pradel et al, 2001), commercial 
RNA standards (Ratge et al, 2002; Morandi et al, 2007), a dilution of a clinical 
specimen (Castelain et al, 2004) or RNA transcripts produced from plasmid 
constructs harbouring the HCV template (Takeuchi et al, 1999; Yang at al, 2002). 
Modified HCV RNA can be difficult to prepare, commercial RNA standards are 
expensive and clinical specimens cannot be used long-term as they degrade. 
Some assays are more prone to contamination as they use a separate reverse 
transcription step (Komurian-Pradel et al, 2001), or require a two-round nested- 
PCR, which although takes place in a closed capillary, requires a separate 
centrifugation step to combine first and second round mixtures (Ratge et al, 2002). 
1.10.1.3 Internal control (IC) 
An IC is an important addition to any diagnostic PCR assay. It is included in the 
preliminary (extraction) step and allows the process to be monitored at all stages. 
The IC is co-amplified with the target sequence, with a negative IC result being 
indicative of extraction and/or PCR failure. If both target and IC are negative, then 
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the sample must be re-extracted and re-tested. ICs can detect false negatives due 
to inhibition, nucleic acid degradation or user/equipment error. Heparin is a potent 
inhibitor present in blood specimens that may cause false-negative PCR results 
(Willems et a/, 1993). It is used as an anticoagulant for blood collection and can 
cause problems in HCV quantitation of haemodialysis patients. Other inhibitors 
found in blood include haemoglobin, haem and urea. 
The use of ICs is not a new concept and many types have been developed 
(reviewed in Hoorfar et al, 2004). Non-competitive ICs are amplified using a 
different primer set to that of the target. This requires two reactions, which may 
have different kinetics, to proceed concurrently. The use of competitive ICs has 
been described for use in diagnostic assays (Kim et al, 2002). These are amplified 
with the same primer set as the target; but are modified in some way so as to be 
differentiated from it. Competition by the IC can lower the sensitivity of target 
detection and these ICs also require complicated cloning and mutagenesis steps to 
produce the internal sequence and incorporate it between the primer sites. ICs 
can be inactivated human or animal viruses spiked into clinical specimens 
(Castelain et al, 2004; Scheltinga et al, 2005). These need cultivation in tissue 
culture systems, which may not be available in laboratories and may also raise 
issues of safety. ICs for viral RNA assays must be very stable to resist 
degradation by RNAses. Naked RNA molecules can be used, (Escobar-Herrera et 
al, 2006) but must be pre-treated to ensure stability. 'Armoured RNA', in which the 
RNA is packaged into bacteriophage proteins to protect it from degradation solves 
this problem (Beld et a/, 2004). This technology has been used to produce both 
RNA ICs and standards (Pasloske, 1998), but is expensive. 
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Although several in-house real-time RT-PCR assays for HCV quantitation have 
been developed; only those of Castelain (2004) and Morandi (2007) include an IC. 
The former assay utilises an inactivated virus, whilst the latter incorporates 
armoured RNA. All other assays, therefore, risk false negative results due to 
extraction failure, user error or PCR inhibition. The consequences of releasing an 
erroneous `undetectable' HCV RNA result are dire in terms of the likelihood of 
onward transmission of the virus and of progression of the disease. It is, therefore, 
imperative that all HCV RNA quantitation assays include an IC to prevent this. 
1.10.2 HCV Genotyping 
1.10.2.1 Sequencing - the gold standard 
The `gold-standard' for HCV genotyping is nucleotide sequencing of the entire 
genome followed by phylogenetic analysis. However, this approach is impractical 
for routine use. Consequently, defined regions of the genome can be amplified, 
sequenced and analysed as a representative of the entire genome. There is 
controversy over which region to sequence, with the core, envelope, NS5b and 5' 
UTR each being used. The HCV genotype classification system is based on NS5b 
sequencing (Simmonds et al, 1993). However, the high variability in this region 
reduces primer specificity and thus assay sensitivity and is, therefore, not suitable 
for routine genotyping. The 5' UTR is highly conserved yet displays a number of 
genotype-specific motifs, and is usually selected for sequencing. The TRUGENE 
HCV 5'NC genotyping kit (Siemens Medical Solutions Diagnostics, formerly Bayer 
Diagnostics) utilises PCR fragments produced from the Roche Amplicor HCV test 
which are subsequently subjected to simultaneous PCR amplification and direct 
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sequencing (CLIP sequencing) of the 5'UTR (Ross et al, 2000). This is a very 
accurate method for genotype assignation and its sequence databank can be 
continually updated for improved phylogenetic analysis (Halfon et al, 2001; Germer 
et al, 2003). However, it does have the disadvantage of being a time-consuming, 
labour-intensive methodology. 
1.10.2.2 Molecular HCV genotyping methods 
Several molecular methods for HCV genotyping have been published. One of the 
first described utilised amplification of HCV RNA from clinical specimens, followed 
by amplification with a common 5' primer and a set of type-specific primers, which 
produced different-sized amplicons on agarose gel electrophoresis (Okamoto et a!, 
1992). This early method was based only on genotypes 1a, 1b and 2a and lacked 
sensitivity and specificity. It was improved with modifications to include 3a 
(Okamato et al, 1993,1996), and adapted by others to extend the genotype range 
(Ohno et al, 1997). This method has relatively low specificity/sensitivity (Furione et 
a!, 1999) and has the contamination issues involved with nested-PCR assays. 
The line-probe assay (LiPA) manufactured by Innogenetics (Belgium) and 
distributed as the VERSANTTM HCV Genotype Assay (LiPA), version 1 (Siemens 
Medical Solutions Diagnostics) has historically been the most frequently used 
protocol for HCV genotyping in clinical laboratories. This is a two stage process 
which requires PCR amplification of the 5'UTR with biotinylated primers followed 
by hybridisation with 21 genotype/subtype specific probes which are immobilised 
on a nitrocellulose membrane. This gives different reactivity patterns used to 
differentiate the 6 genotypes and many of the subtypes (Stuyver et al, 1993,1996). 
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This assay shows good specificity of genotype identification but lacks sensitivity 
(Haushofer et al, 2003; Zheng et al, 2003). The DNA enzyme immunoassay 
(DEIA) kit (Gen-Eti-K DeIA; Sorin Biomedica, Saluggia, Italy) also utilises 
genotype-specific probes but these are adsorbed onto microwell plates which are 
hybridised with amplicons from the HCV core fragment rather than the 5'UTR. This 
method compares very favourably against other HCV genotyping methods (Ross et 
a/, 2000). 
Restriction fragment length polymorphism (RFLP) analysis has also been tested 
and predicted patterns suggested for each genotype (Nakao et al, 1991; McOmish 
et al, 1994). This labour-intensive process involves PCR amplification and 
digestion with specific restriction endonucleases, followed by gel electrophoresis. 
Since restriction sites can be created or abolished with a single base mutation, 
there may be many combinations of RFLP patterns within a genotype and samples 
often do not match the published patterns (Khan et al, 1997). 
1.10.2.3 HCV serotyping 
Serotyping, uses genotype-specific antibodies as indirect markers for HCV 
genotypes. However, studies of patients with a defined exposure, such as 
transfusion, have shown that antibodies are not generally detectable for at least six 
weeks and may not appear for several months (Alter et al, 1989). Serotyping is not 
clinically useful for those who are immunocompromised, who may lack an immune 
response. Also, although simple to perform, serotyping often lacks sensitivity 
compared to other methods (Pawlotsky et al, 1997). It is also a costly assay, 
limiting its usefulness for routine genotyping (Beld et al, 1998). HCV serotyping 
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has, however, found a use in assigning genotype to individuals who have 
spontaneously cleared HCV infection (Harris et al, 2007). 
1.10.2.4 Real-time PCR genotyping methods 
Real-time PCR is rapidly becoming a platform for HCV genotyping. Two groups 
(Bullock et al, 2002; Schröter et al, 2002) have designed a one-step LightCycler 
method with FRET (hybridisation) probes to detect genotypes 1-4 which can be 
distinguished by melting point (Tm) curve analysis. Schröter's group relied on two 
probes with different wavelengths to distinguish genotypes 1,2 and 4 in one 
channel and genotype 3 in the other channel. Bullock et al optimised their assay 
so that genotypes 1-4 could be detected with a single set of probes within a single 
channel. A recent method, the HCV genotyping analyte-specific reagent (ASR) 
assay (Abbott Molecular Inc, Des Plaines, IL) based on real-time PCR which 
targets the NS5b region for genotype 1 identification and the 5'UTR for genotypes 
2a, 2b, 3,4,5 and 6, has been described (Martrö et al, 2008). This has yet to be 
fully evaluated but of concern is the high level (4.4%, n=295) of 'indeterminate' 
results which were not reactive with any genotype/subtype specific probes. 
1.10.3 HCV Subtyping 
1.10.3.1 Subtyping applications 
HCV subtyping is not only of academic interest, it can have applications in the 
study of HCV evolution, epidemiology and outbreak/transmission investigations. 
Nosocomial outbreaks of HCV have been reported, especially in settings such as 
haemodialysis units and haematology wards where vascular access is required for 
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long periods (Allander et al, 1995; Wreghitt, 1999,2004). Patients who undergo 
haemodialysis long-term are at increased risk of HCV and prevalence of HCV 
infection in dialysis patients has been reported to be as high as 14% (Corcoran et 
al, 1994). There have also been several reports of transmission from HCV-infected 
health care workers (HCWs) to patients during exposure prone procedures (EPPs). 
Health care workers themselves are also at risk of acquiring HCV from infected 
patients. Between 1997 and 2005, there were 11 cases of HCV seroconversion in 
healthcare workers in the UK following significant occupational exposure to HCV 
(HPA, 2006a). Genotype determination is often not sufficiently discriminatory for 
outbreak/transmission investigation and knowledge of subtype is required. Most 
studies of the molecular epidemiology of HCV outbreak/transmission have utilised 
phylogenetic analysis of variable regions of the HCV genome such as NS5b or E2 
(Abacioglu et al, 2000; Kondili et al, 2006). Other studies have found that only the 
hypervariable regions show sufficient discriminatory power for outbreak studies 
(Bracho et al, 2005). 
Knowledge of HCV subtype may become increasingly important in treatment 
protocols and predicting HCV progression. An association has been made 
between infection with subtype lb and poor response to interferon therapy 
(Manesis et al, 1997) although this is controversial and may depend on other 
factors, in addition to infecting subtype (Nakano et al, 2001). There are also 
tentative associations between subtype Ib and increased likelihood of chronicity 
and severity of disease (Amoroso et al, 1998; Hwang et a/, 2001) as well as 
development of HCC (Silini et al, 1996; Bruno et al, 1997) but this association has 
not been confirmed by other studies (Benvegnü et a/, 1997; Nakano et al, 2001 a). 
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Subtype lb is associated with older age, which may explain, in part, the link with 
chronicity and HCC (Nousbaum et al, 1995). 
1.10.3.2 Subtyping using the 5'UTR 
Subtyping is problematic as a genomic region must be selected which is sufficiently 
conserved for maximum sensitivity, but with enough variability to allow 
discrimination between subtypes. Although the 5'UTR is ideal for genotype 
assignation, it is of limited use in HCV subtyping. HCV genotyping assays which 
target the 5'UTR, although highly specific for genotype discrimination, have limited 
ability to accurately subtype HCV strains (Halfon et al, 2001; Germer et a/, 2003; 
Nolte et al, 2003; Ross et al, 2007). The TRUGENE HCV 5'NC genotyping kit, for 
example, often fails to differentiate subtypes of genotypes 1 and 2 (Ross et al, 
2000). The discrimination between 1a and 1b subtypes, for example is based on a 
single nucleotide substitution which may not occur consistently (Chen and Weck 
2002). 
1.10.3.3 Subtyping using other HCV regions 
The NS5b-encoded RNA-dependent RNA polymerase region of the HCV genome 
shows more variability than the 5' UTR, making it superior for subtyping purposes. 
A prototype commercial assay, the Trugene HCV NS5b assay, based on 
sequencing of a 450 bp fragment of the NS5b region, has been developed. A 
comparison of this assay with the Trugene 5'NC HCV typing kit using a relatively 
small number of isolates (n=68) demonstrated that whilst both regions were 
comparable for genotyping of isolates, subtype assignation was superior using the 
NS5b region, with the 5'NC kit failing to correctly assign subtype or to discriminate 
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between subtypes in 25.8% of samples. However, the NS5b region was found to 
be less sensitive, with failure of PCR amplification preventing typing in a small 
percentage (8.8%) of specimens (Othman et al, 2004). An in-house method has 
also been described (Sandres-Saune et a/, 2003) which is based on direct 
sequencing of a 401 bp amplicon of the NS5b region. In a clinical study of 203 
HCV-infected individuals, samples were sequenced following a single-round PCR 
step and successfully subtyped in 190 (93.6%) samples. If cDNA failed to be 
amplified then a hemi-nested PCR was used which enabled subtyping of a further 
10 (4.9%) samples. Three (1.5%) samples could not be subtyped. This method 
was found to be superior for HCV subtyping when compared to the Trugene 5'NC 
genotyping kit which, in this study, could not identify at the subtype level in 67 
(33%) of isolates. 
There has been recent renewed vigour in the development of HCV subtyping 
assays, due in part perhaps to the fact that new antiviral compounds are likely to 
show distinct activities against HCV isolates belonging to certain subtypes 
(Hinrichsen et al, 2004). Transfer of the target of CLIPM sequencing from the 
5'UTR to the core region has expanded its utility for HCV subtyping. CLIPTM 
sequencing of the core fragment led to an adequate subtype assignment in 97% 
(n=110) of isolates compared to 81% with the TRUEGENE 5'NC genotyping kit 
(Ross et al, 2008). A new version of the line probe assay (Versant HCV Genotype 
Assay (LiPA), version 2) has recently been developed. The principle format 
remains unchanged, but the assay now targets part of the HCV core region in 
addition to the 5'UTR. This has enhanced its subtype discrimination when 
compared to the original line probe assay, especially with regard to subtype 1 a/1 b 
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and the recognition of certain genotype 6 variants (Ross et al, 2007). However, the 
improvements to this assay have not enabled it to achieve better subtyping with 
regards to genotypes 2 and 4. 
1.11 Real-time PCR 
Real-time PCR is becoming increasingly important in diagnostic laboratories and is 
becoming the preferred platform for HCV diagnosis/monitoring. This technique 
combines the amplification of nucleic acid with the detection of amplified products 
during each reaction cycle - in real time. This is less labour-intensive than 
conventional PCR as there is no analysis of end products by gel electrophoresis. It 
also prevents contamination by amplicons as the reaction tubes remain closed 
during the analysis process. Real-time PCR relies on the detection and 
quantification of a fluorescent reporter, the signal of which increases in direct 
proportion to the amount of PCR product in the reaction. The initial copy number 
can be calculated from the cycle number at which a detection threshold is crossed; 
the threshold cycle (CT). The higher the starting copy number, the earlier the 
amplified product is detected. The fluorescent signal is detected on a thermal 
cycler attached to computer software for data analysis. 
1.11.1 Hydrolysis (Taqman) probes 
The research described herein uses real-time technology and hydrolysis (Taqman) 
probes. These are dual labeled hydrolysis probes which utilise the 5' exonuclease 
of the Taq polymerase enzyme for measuring the amount of target sequence in a 
sample. If the target of interest is present, the probe, which is complementary to 
an internal sequence between forward and reverse primer sites, anneals. Taqman 
probes have a fluorescent reporter dye attached to the 5' end (FAM, JOENIC, 
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ROX or Cy5) and a non-fluorescent quencher at the 3' end (NFQ, TAMRA or BHQ- 
2). In this state, when irradiated, the excited fluorescent dye transfers energy to the 
nearby quencher rather than fluorescing. During PCR, when the polymerase 
replicates a template on which a Taqman probe is bound, its 5'-3' exonuclease 
activity cleaves the probe during the displacement stage. The reporter becomes 
released from the quencher and fluoresces (Figure 1.7). The intensity of the 
reporter dye fluorescence increases exponentially as PCR products accumulate. 
Because cleavage occurs only if the probe hybridises to the target, the 
fluorescence detected originates from specific amplification. 
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Figure 1.7: Taqman probe technology. (Taken from www. probes. com/handbook/figures/0710. html). 
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1.11.1.1 Modification of Tagman probes 
Taqman probes can be modified to increase their melting temperature (Tm) which 
allows the use of shorter probes. Two types of modified Taqman probes were 
used: 
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1.11.1.2 Taqman® MGB probes 
Minor Groove Binding (MGB) probes have a small crescent-shaped molecule that 
fits into the minor groove of duplex DNA situated at the 3' end of the Taqman 
probe. This increases the melting temperature by approximately 15°C. Taqmane 
MGB probes were synthesised by Applied Biosystems (Applied Biosystems, 
Warrington, UK). 
1.11.1.3 Locked Nucleic Acid® probes (LNA®) 
LNA is a novel type of nucleic acid analogue that contains a 2'-0,4'-C methylene 
bridge (Figure 1.8). This bridge - locked in 3'-endo conformation - restricts the 
flexibility of the ribofuranose ring and locks the structure into a rigid conformation. 
This chemical structure enhances the stability of the hybridisation of the probe to 
its target, improving specificity and allowing the use of shorter probes. The duplex 
melting temperature increases by up to 8°C per LNA monomer substitution. LNAs 
can be integrated into different types of probes and are available with FAM, HEX, 
TET or Cy5 fluorescent labels. LNA probes can be even shorter than MGB probes. 
These probes also use a different type of quencher molecule, known as Black Hole 
Quenchers""" which have no native fluorescence, resulting in lower background 
noise and increased efficiency of quenching. These probes are purchased from 
Proligo (www. proligo. com). 
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Figure 1.8: Structure of the LNA monomer (taken from www. sigmaaldrich. com). 
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CHAPTER ONE 
Part Two 
Mitochondria, Oxidative Stress and 
HCV 
1.11 Mitochondrial structure 
Mitochondria are organelles found in all eukaryotic cells except for mature 
erythrocytes. They consist of a mitochondrial matrix enclosed within two 
membranes (Figure 1.9). The outer membrane contains numerous porins and is 
permeable to all molecules of 5000 daltons or less. The inner membrane has no 
porins and is highly impermeable. This inner membrane divides the mitochondrion 
into two internal compartments. The first is the intermembrane space, the narrow 
region between inner and outer membranes. Proteins that function in respiration, 
such as those which generate adenosine triphosphate (ATP) are built into the inner 
membrane which has numerous convolutions known as cristae that expand its 
inner surface (Palade, 1952). The second compartment is the mitochondria) 
matrix, enclosed by the inner membrane which is rich in enzymes important for 
metabolic functions. Mitochondria contain their own genome which is separate and 
distinct from the cell's chromosomal genome. 
ATP synthase pari clos 
inter membrane space 
f Matrix 
Ribosome 
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DNA 
Figure 1.9: A representation of the structure of a mitochondrion showing its major 
components. Adapted from http: //en. citizendium. org/wiki/Mitochondrion. 
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1.12 Mitochondrial function 
Mitochondria are the site of energy production within cells. Tissues that require 
high amounts of energy such as skeletal and cardiac muscle, brain and liver have 
the greatest number of mitochondria per cell. Their major role is the generation of 
ATP through oxidative phosphorylation (OXPHOS). Mitochondria generate over 
90% of cellular energy by this process (Chance et al, 1979). Pyruvate produced 
from cellular glycolysis passes into the mitochondrion and enters the matrix. Here 
it is converted to acetyl co-enzyme A (Acetyl-CoA) and enters the Krebs cycle, also 
known as the tricarboxylic acid (TCA) cycle. Acetyl-CoA is oxidised in a series of 
steps and the carbon atoms of the acetyl groups are converted to carbon dioxide 
(CO2). The hydrogen atoms are transferred to the carrier molecules flavin adenine 
nucleotide (FAD) and nicotinamide adenine nucleotide (NAD) to produce the 
reduced forms FADH2 and NADH. These two molecules transfer electrons from 
the hydrogen atoms to the electron transport chain (ETC), a series of molecules 
(complexes I-V) built into the inner mitochondrial membrane (Darley-Usmar et al, 
1994; Lodish et al, 2004) (Figure 1.10). The electrons are passed along this series 
of complexes which are alternately oxidised and reduced as they accept and 
donate electrons (Hatefi, 1985). The final electron acceptor is molecular oxygen 
which is reduced through the addition of four electrons to water. The exergonic 
flow of electrons through the ETC is used to pump protons (H+) from the matrix 
through the inner mitochondrial membrane at complexes I, III and IV to the 
intermembrane space. This establishes an electrochemical gradient known as the 
'proton motive force' (expressed as mitochondrial membrane potential). This force 
drives a flux of protons back into the matrix through ATP synthases (complex V) 
which are the only parts of the inner membrane that are freely permeable to 
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protons. As the protons pass through complex V, the ATP synthases harness the 
exergonic flow to phosphorylate adenosine diphosphate (ADP) to produce ATP, 
the cellular energy source (Alberts et al, 2002) (Figure 1.10). Calcium ions (Ca 2+) 
are an important physiological stimulus for ATP synthesis, and mitochondria have 
several mechanisms for their uptake. 
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Figure 1.10: A schematic representation of OXPHOS occurring within a mitochondrion. 
The electron transport chain (ETC) is shown with the efflux of protons (H+) from the 
carriers NADH and FADH2 through complexes I, III and IV into the intermembrane 
space and the influx of protons back into the mitochondrial matrix through the ATP 
synthase molecule, driving the production of ATP from ADP. Adapted from 
http: //www. answers. com/topic/electron-transport-chain. 
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1.13 Mitochondrial DNA (mtDNA) 
Mitochondria contain the only non-chromosomal DNA in human cells and are able 
to replicate, transcribe and translate their own genome independently. 
Mitochondrial DNA (mtDNA) is a maternally inherited, double-stranded, 16,569 bp 
circular molecule. The human mitochondrial genome was sequenced completely 
in the early 1980s (Anderson et al, 1981). This sequence has recently been re- 
analysed (Andrews et al, 1999) and is available as the revised Cambridge 
Reference Sequence (rCRS) at www. mitomap. org. mtDNA is smaller than many 
nuclear genes which encode a single protein, yet it contains 37 genes which 
encode 13 of the polypeptides necessary for OXPHOS as well as the 2 ribosomal 
RNAs (rRNAs) and 22 transfer RNAs (tRNAs) required for intramitochondrial 
protein synthesis (Anderson et al, 1981) (Figure 1.11). Accordingly, mtDNA 
contains virtually no non-coding regions. The two strands of mtDNA can be 
separated based on their density, due to their differing nucleotide composition and 
are thus designated as the heavy (H)-strand and light (L)-strand. The H-strand 
carries 28 genes whilst the L-strand carries only 9 genes. Each cell contains 
hundreds of mitochondria and each mitochondrion has 2-10 copies of mtDNA; thus 
there are approximately 103 to 104 mtDNA copies per human cell (Bogenhagen 
and Clayton, 1974; Miller et al, 2003). 
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Figure 1.11: A schematic diagram of the 16,569 bp mitochondrial genome 
(adapted from Van Houten et al, 2006). ND1-6; NADH dehydrogenase subunits, 
COI-III; cytochrome C oxidase subunits, OH; origin of heavy strand replication, OL; 
origin of light strand replication, PH and PL; heavy and light-strand promoters 
respectively, ATP ase6 and 8; ATP synthase FO subunits. Single capital letters 
represent the various transfer RNAs (tRNAs). 
Normal assembly and operation of the ETC requires an intact and functional 
mitochondrial genome. This depends on both the copy number and integrity of 
mtDNA molecules. The importance of the mitochondrial genome is illustrated by 
the fact that mtDNA defects are a common cause of genetic disease which can 
have severe manifestations. More than 200 disorders are associated with specific 
mtDNA point mutations or deletions. Among the most devastating are 
mitochondrial encephalomyopathy with lactic-acidosis and stroke-like episodes 
(MELAS) (Goto et al, 1990), resulting from an A-to-G transition mutation at 
nucleotide position 3,243 in the leucine tRNA gene and Kearns-Sayre syndrome 
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(KSS) which is characterised by adult onset, progressive external ophthalmoplegia 
and pigmentary retinal degradation (Moraes et al, 1989). About one half of KSS 
patients have a common 5 kb mtDNA deletion which is usually detected only in 
muscle cells. mtDNA mutations are usually maternally inherited whereas deletions 
or rearrangements can be sporadic (Wallace et al, 1992). Mitochondrial 
hepatopathies are numerous and are classified into primary disorders in which the 
mitochondrial defect is the primary cause of liver disease and secondary disorders 
in which hepatic mitochondria undergo injury or dysfunction resulting from another 
pathologic process such as exposure to toxins, drugs or chronic viral infection 
(Sokol and Treem, 2001; Bandyopadhyay and Dutta, 2005). 
Since each cell contains thousands of copies of each mitochondrial gene, a 
mutation/deletion in an mtDNA molecule creates a mixture of wild-type and mutant 
mtDNAs. Individuals with mitochondrial disease usually harbour a mixture of wild- 
type and mutant mtDNA, a situation known as heteroplasmy (Lightowlers et al, 
1997). The percentage of mutant mtDNAs must surpass a critical level to produce 
a clinical defect - the threshold effect. Studies using cybrid cell lines indicate that 
the threshold is greater than 90% for mutant tRNA point mutations (Boulet et a!, 
1992; Hanna et a!, 1995) and must exceed 60% for large scale mtDNA deletions 
(Bourgeron et a!, 1993; Sciacco et a/ 1994; He et a!, 2002). The precise threshold 
differs from mutation to mutation and between tissue types. Tissues with high 
requirements for oxidative energy have relatively low thresholds and are 
particularly vulnerable to mtDNA mutations/deletions. 
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Mammalian mtDNA is inherited down the maternal line, in a manner which does 
not conform to Mendel's laws of heredity. If a mother has mitochondrial disease, 
her offspring may be born without disease or be mildly or severely affected. There 
may also be variation in severity of disease between siblings. This occurs as a 
result of the 'mitochondrial genetic bottleneck'. A precursor cell divides early in a 
woman's development to form a number of oocytes, so the mitochondria from this 
precursor cell become greatly reduced and randomly distributed between oocytes. 
In mitochondrial disease, due to this random distribution, females harbouring a 
mixture of mutant and wild-type mtDNA will form oocytes with a varying proportion 
of mutant mtDNA. Depending on which one of these oocytes is fertilised, a high 
proportion of mutant mtDNA may be passed onto the offspring, correlating with 
increased severity of disease. Alternately an oocyte with a low level of mutant 
mtDNA may be fertilised, resulting in no or mild mitochondrial disease in the 
offspring (Cree et a/, 2008). 
1.14 Mitochondrial D-loop and mtDNA replication 
The displacement or D-loop encompasses 1122 bp of the mitochondrial genome, 
between nt 16024 and 576 and is the only major non-coding region (Figure 1.11). 
It serves as the main site for mitochondrial genomic replication and transcription 
(Kasamatsu and Vinograd, 1974). It is known as the 'control region' as it contains 
the signals that control mitochondrial RNA and DNA synthesis (Clayton, 1982; 
Walberg and Clayton, 1982). It has two major transcription initiation sites - the ITH 
which directs transcription of the H-strand and the ITL which directs transcription of 
the L-strand. Both initiation sites are encompassed by promoters, which are 
essential for transcription (Chang et al, 1984). The origin of replication of the 
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heavy strand (OH) is also contained within the D-loop (Figure 1.12). Despite its 
important role in both mitochondrial transcription and translation, the D-loop is 
highly polymorphic in the general population. 
576 1/16569 16024 
D-loop 
ITH r -º HTL OH 
Figure 1.12: Schematic map of the 1.1 Kb mtDNA D-loop region located between 
nt 16024 and 576 of the circular mitochondrial genome. HSP/LSP; heavy/light 
strand promoter, ITH/ITL; initiation of heavy/light strand transcription, F and P; 
tRNAs for phenylalanine and proline respectively, CSB; conserved sequence 
blocks. 
mtDNA is replicated from two origins and the replication process is bi-directional 
and asynchronous (Clayton et al, 1982; Brown et al, 2005). The H-strand is the 
leading strand during replication which commences at the OH and gives rise to a 
triple-stranded `loop' structure in which the parental H-strand is displaced as a 
single-strand segment due to synthesis of a nascent H-strand (Ter Schegget et al, 
1971). Replication proceeds until two thirds of the genome length at which point 
the OL is exposed. mtDNA synthesis from the L-strand then initiates in the 
opposite direction and elongation continues using the displaced H-strand as a 
template. 
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1.15 Oxidative stress 
During OXPHOS, some electrons escape from the ETC and combine with oxygen 
to produce superoxide anions (021 The electron leakage occurs at two sites in 
the ETC, complexes I and Ill. Superoxide anions are converted to hydrogen 
peroxide (H202) by superoxide dismutase (SOD). In the presence of iron, both 
H202 and 02 can be reduced to the highly reactive hydroxyl radical (OH'), through 
the Fenton reaction in a sequence of events which can be summarised as: 
Fe2'/ Fei` 
H202 + 02 02 + OH' + OH" 
Hydrogen peroxide, superoxide anions and hydroxyl radicals are collectively known 
as reactive oxygen species (ROS). They are extremely active molecules due to 
the presence of unpaired electrons. High levels of ROS can result in significant 
damage to cellular structures, causing lipid peroxidation, oxidation of amino acids 
in proteins and DNA damage (Yu and Anderson, 1997). Malondialdehyde (MDA) 
is a lipid peroxidation product and 8-hydroxydeoxyguanosine (8-OHdG) is a 
product of DNA base modification. Both serve as markers of oxidative stress. 
Nitric oxide and calcium are two biological molecules which have important roles in 
normal cellular function but are also implicated in the cascade of processes leading 
to oxidative stress. Nitric oxide (NO) is widely used in the body as a signalling 
molecule. It has roles in vasodilation and regulates the binding and release of 
oxygen from haemoglobin. It is formed by different isoforms of NO synthase 
including a constitutively expressed mitochondrial form (mtNOS) (Giulivi et al, 
1998) and an inducible form (iNOS) which generates NO from L-arginine. NO is, 
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however, a toxic compound as it reacts with 02 to form peroxynitrite anions 
(ONOO-) which acts as a ROS, destroying cellular constituents (Beckman et al, 
1990; Wink et al, 1991). Peroxynitrite also irreversibly inhibits mitochondrial 
respiration by blocking the ETC (complexes I, II and V) and disrupting the 
mitochondrial membrane potential. 
Calcium ions (Ca 2) have an important role as second messengers used in cellular 
signal transduction. They are also an important physiological stimulus for ATP 
synthesis, and mitochondria have several mechanisms for their uptake. Calcium 
ions are usually sequestered in the cell's endoplasmic reticulum (ER) but cellular 
disturbance leads to ER stress and the release of Ca2+ into the cytoplasm. The 
released Ca2+ are accumulated by mitochondria which causes depolarisation of the 
mitochondrial membrane potential, decreasing the OXPHOS capacity of 
mitochondria. High levels of intramitochondrial Ca2+ activate mtNOS generating 
NO and thus cellular damage (Schild et al, 2003). 
Around 2% of oxygen consumed by mitochondria is converted to ROS under 
physiological conditions (Boveris and Chance, 1973). Cells can usually defend 
themselves against this level of ROS as they have a number of anti-oxidants such 
as superoxide dismutases (SOD) and catalases. SOD converts superoxide anions 
to H202 which is then transformed to water by either catalase or glutathione (GSH), 
an enzyme which becomes oxidised to glutathione disulphide (GSSG) in the 
process. Manganese superoxide dismutase (MnSOD) is an important 
mitochondrial anti-oxidant which is translated in the cytoplasm and transported via 
a mitochondrion-targeting sequence into the mitochondria (Wispe et al, 1989). It is 
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an inducible enzyme whose expression is enhanced by tumour necrosis factor-a 
(TNFa), an inflammatory mediator (Larrea et al, 1996). In healthy cells, anti- 
oxidants are plentiful and scavenge for ROS, counteracting their effects. However, 
during times of cellular stress, the anti-oxidant system may become overwhelmed 
and ROS accumulate -a state known as oxidative stress. 
As OXPHOS occurs within mitochondria, these organelles represent the major 
source of ROS. They are also its major target as mitochondrial lipid membranes, 
proteins and DNA lie in close proximity to the ROS. mtDNA is more vulnerable to 
oxidative damage than nuclear DNA, due in part to its location on the mitochondrial 
inner membrane. mtDNA damage has been shown to persist longer than nuclear 
DNA damage (Yakes and Van Hauten, 1997). Unlike nuclear DNA, mtDNA lack 
protective histones which are also required for repair of double-strand DNA breaks 
(Richter et al, 1988; Celeste et al, 2003). All components of mtDNA are targets for 
ROS which can (i) attack deoxyribose causing release of purine and pyrimidine 
bases, (ii) attack the bases directly, leading to their modification and (iii) cause 
DNA strand breaks. 
Integrity of mtDNA is required for maintenance of OXPHOS; when defects occur 
they lead to depletion of cellular energy stores. In a vicious cycle, damage to 
mtDNA impairs the ETC, increasing electron leakage and thus production of ROS 
causing further damage to the mitochondria. Part of the ageing process is due to a 
build-up of oxidative damage to various biological molecules within tissue cells 
(Harman, 1956) with mitochondria being the major target of attack (Harman, 1972, 
1981), the so-called 'free-radical theory of ageing'. This theory has gained wide 
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support and it is now believed that the accumulation of somatic mutations in 
mtDNA is a significant contributor to human ageing and degenerative disease - the 
'mitochondrial theory of ageing' (Linnane et al, 1989; Shigenaga et al, 1994; 
Beckman and Ames, 1998). 
1.16 mtDNA Damage 
1.16.1 mtDNA mutations 
ROS induce oxidative damage to mtDNA, including strand breaks and base and 
nucleotide modifications. Spontaneous mutagenesis results mainly from oxidative 
events (Rossman and Goncharova, 1998). In mitochondria, oxidative stress 
causes a vicious cycle, whereby ROS-induced mtDNA mutations interfere with the 
transcription of mitochondrially-encoded genes including ETC components, 
inhibiting electron transport, promoting mitochondria) dysfunction and ultimately 
producing more ROS. Most lesions which persist within DNA result in mutation. 
mtDNA continues to replicate in post-mitotic cells thus mutations accumulate and 
erode mitochondrial function. Because of the high mtDNA gene density, any point 
mutations are likely to affect the expression of mitochondrial genes. 
The most documented oxidative stress-associated DNA lesion is the consequence 
of oxidation of the deoxyguanosine moiety following attack by the hydroxyl 
molecule forming 8-hydroxydeoxyguanosine (8-OHdG). When DNA becomes 
single-stranded during replication or transcription, the incorporated 8-OHdG 
changes conformation and preferentially pairs with adenine rather than cytosine 
(Shibutani et al, 1991). If this is not repaired its presence can result in mutations 
through G: C-to-T: A transversions. Once incorporated, the 8-OHdG is only very 
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rarely excised by the proofreading exonuclease of the mitochondrial polymerase 
(Hanes et al, 2006) and the polymerase introduces this mutation at high frequency 
when replicating past 8-OHdG (Pinz et al, 1995). Detection and quantification of 8- 
OHdG is often used as an indicator of oxidative stress and to compare levels of 
damage to mtDNA relative to that of nuclear DNA. The usual detection method is 
via immunohistochemistry, with a monoclonal antibody against 8-OHdG. Richter et 
al (1988) found 8-OHdG to be present at levels of 1 per 130,000 bases in nuclear 
DNA and 1 per 8000 bases in mtDNA, indicating that the latter was more prone to 
oxidative damage. Early studies have been criticised as they are thought to have 
produced erroneously high levels of background oxidation from the methods used 
for mitochondrial isolation (Helbock et al, 1998). Quantitative PCR has been used 
to compare formation of hydrogen-peroxide induced damage in mitochondrial and 
nuclear DNA (Yakes and Van Houten, 1997). The technique used was based on 
the premise that DNA lesions will block the progression of polymerase resulting in 
a decrease in amplification of the target. Quantitation of a large fragment of 
mtDNA and of ß-globin (a nuclear gene) from transformed cells treated with 
hydrogen-peroxide demonstrated lower amplification of the mtDNA fragment. This 
illustrated that mtDNA suffers 3-10 fold more damage than nuclear DNA following 
oxidative stress. Unlike other studies, the method used did not involve the 
potentially oxidative mitochondrial isolation steps. 
1.16.2 mtDNA deletions 
There are 116 mtDNA deletions reported (www. mitomac. org. uk, as of August 27th 
2007) which range in length from 4 to 10,987 nucleotides. The most well 
documented mtDNA deletion removes 4977 bp of the mitochondrial genome and is 
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known as the 'common deletion' due to the frequency with which it has been 
reported. This deletion, (identified henceforth as mt4977) spans from nt 8469-13447. 
The deleted region encodes seven polypeptides which are essential for the 
OXPHOS pathway; four for complex I (ND3, ND4, ND4L and ND5), one for 
complex IV (COIII) and two for complex V (ATP6 and ATP8) as well as five tRNA 
genes (Porteus et al, 1998) (Figure 1.13). Another well documented deletion is 
that of 7436 bp (identified henceforth as mt7436) spanning from nt 8648-16085. 
This eliminates many of the same genes as mt4977 as well as a further subunit of 
complex 1 (ND6), three additional tRNAs and the complex III cytochrome b gene 
(Figure 1.13). This deletion has been reported to accumulate in heart tissue during 
ageing (Hattori et al, 1991; Hayakawa et al, 1992) and in cirrhotic liver surrounding 
hepatic tumours (Yamamoto et al, 1992). 
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Figure 1.13: A schematic figure of the coding region of mitochondria) genome 
showing the positions of the mt497 and mt7436 deletions. From this Figure, the 
genes that are truncated or removed by each deletion can be visualised. H; heavy 
strand, L; light strand, 12S and 16S; 12S rRNA and 16S rRNA respectively, ND; 
NADH dehydrogenase, CO; cytochrome oxidase, Cyt b; cytochrome b, OH and OL; 
origins of replication of heavy and light strands of mtDNA respectively. Figure 
adapted from Wei et al, (1996). 
53 
Recombination via flanking direct repeats is a major cause of large scale deletions 
in human mtDNA (Mita et al, 1990; Johns et al, 1989). Most mtDNA deletions 
(-60%) are flanked by two short homologous direct repeat sequences, one being 
removed by the deletion process. These are known as class I deletions. Around 
30% of mtDNA deletions, known as class II deletions, are flanked by imperfect 
repeats. Around 10% of mtDNA deletions have no repeats involved. mt497 is 
found between two 13 bp repeats at nucleotide positions 8470-8482 and 13447- 
13459. This is the largest perfect direct repeat sequence in the mitochondrial 
genome and it is thought that this direct repeat creates a hotspot for deletion and 
may be the principal factor behind the formation of most deletions (Samuels et al, 
2004). Shoffner et al (1989) suggested that mt497 occurs as a result of a slip- 
replication mechanism. They hypothesise that whilst the H-strand is displaced 
during replication, the first direct repeat (DRI) from the H-strand can base pair with 
the down stream second direct repeat (DR2) of the L-strand which is exposed by 
the replicating fork. If a break occurred in the H-strand downstream from DR1, 
base-pairing with DR2 of the L-strand would permit further replicative extension of 
the H-strand along the L-strand template. This would generate a normal mtDNA 
molecule from the original parent L-strand and an mtDNA molecule harbouring 
mt4977 from the slip-replicated H-strand. During oxidative stress, the deletion is 
thought to occur as a result of intragenomic recombination between the direct 
repeats after a single-strand break caused by ROS (Schon et al, 1989; Mita et al, 
1990). mt7436 is also flanked by direct repeats of 12 bp located at nt 8637-8648 and 
16073-16084. This deletion probably occurs via the same mechanisms as mtas» 
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mt497 has been observed in many mitochondrial disease pathologies such as 
Kearns-Sayres syndrome (KSS) and chronic progressive external ophthalmoplegia 
(Shanske et al, 1990; Holt et al, 1989; Moraes et al, 1989; Schon et al, 1989; 
Zeviani et al, 1988). It has also been detected in some human cancers including 
oesophageal squamous cell carcinoma (Abnet et al, 2004) and oral cancer (Shieh 
et al, 2004). Other studies have found lower quantities in tumour tissue compared 
to surrounding healthy tissue (Ye et al, 2008). The accumulation of both mt497 and 
mt7436 in the ageing process is well documented (e. g. Cortopassi et al, 1990,1992; 
Lee et al, 1994; Wei et al, 1996; Zhang et al, 1998; Mohamed et al, 2006; ). 
However, the significance of these deletions in ageing is uncertain. Studies that 
have quantified these deletions demonstrate an increase in abundance with age, 
but even in the oldest individuals studied, the quantities of these deletions are 
minute. Corral-Debrinski and colleagues (1992) for example detected mt497 at 
0.007% in the heart muscle of elderly individuals with heart disease and Wei and 
colleagues (1996) detected this deletion at 0.06,0.076 and 0.053% in the muscle, 
liver and testis of elderly individuals respectively. It is doubtful that these levels 
would surpass the threshold needed for detrimental cellular effect. 
1.16.3 D-loop mutations 
mtDNA damage is region-dependent, with the D-loop being most susceptible 
(Mambo et a/, 2003). The sensitivity of the D-loop to mtDNA damage may be due 
to several factors: 
(i) During mtDNA replication it has a unique structure, the short 
three-stranded 'loop', in which the parental H-strand is displaced, 
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with the single strand being prone to damage (ter Schegget et al, 
1971). 
(ii) The D-loop attaches the mtDNA to the mitochondrial inner 
membrane which leaves it exposed to mutagens (Hruszkewycz, 
1988). 
(iii) mtDNA damage repair process is mediated by polymerase 
gamma (y) which has decreased proof-reading ability (Pinz et al, 
1995) and may itself be a target of oxidative damage (Graziewicz 
et al, 2002). 
(iv) The level of repair in the D-loop region has also been found to be 
lower than seen in other regions of mtDNA (Mambo et al, 2003), 
allowing mtDNA damage to accumulate in this region. 
The D-loop, therefore, provides an excellent -target on which to study mtDNA 
damage as it is not only more susceptible to damage but also less efficiently 
repaired than other regions of mtDNA. 
The D-loop is a non-coding region and, therefore, the significance of damage 
within this region could be questioned. However, as the D-loop is responsible for 
control of transcription and expression of mtDNA, mutations in this region may 
affect the copy number and/or repression of gene expression of the mitochondrial 
genome. Damage to this region could interfere with the interaction of proteins 
involved in mtDNA transcription/translation by altering the recognition site or 
causing bending of the mtDNA and modifying the binding affinity of proteins. This 
could either increase the rate of replication, which could lead to higher levels of 
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mtDNA damage, or decrease replication, leading to a low copy number of 
mitochondria and reduced energy production capacity. 
The non-coding region of mtDNA contains two well-characterised hypervariable 
segments, HVSI (nt 16024-16383) and HVS2 (nt 57-372) which have been found 
to be hotspots for mtDNA alterations (Stoneking, 2000). Within these hotspots, 
there are areas which are particularly prone to damage. Microsatellites are regions 
of DNA with repetitions of a small number of base pairs. Microsatellite alterations 
occur at a rate much higher than seen in non-repetitive DNA, probably due to DNA 
polymerase slippage (Sia et al, 1997). A microsatellite consisting of 12-18 cytidine 
residues interrupted by a thymidine at nucleotide position 310 (known as the D310 
region) has been found to be a hotspot of mutation in many human cancers 
(Sanchez-Cespedes et al, 2001; Wang et al, 2005). Mutations within the D310 
region may be biologically significant as it is found within a conserved sequence 
block (CSB) which is thought to be involved in mtDNA replication/transcription. 
Polymorphisms in this region were thought at first not to be relevant as numerous 
substitutions, small deletions and insertions were observed in normal human 
beings. However, a large number of sequence variants were found in the non- 
coding region of patients with mitochondrial disease, suggesting a link between 
mutations in this region and mutations in coding regions (Marchington et al, 1996). 
mtDNA mutations have been detected in almost all types of human cancer 
including uterine (Pejovic et al, 2004), colorectal (Lievre et al, 2005), liver cancer 
(Nomoto et al, 2002) as well as in bladder, head and neck and lung tumours (Fliss 
et al, 2000). These are often located in the D-loop region. These studies indicate 
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that the accumulation of mtDNA mutations could be a crucial step in 
carcinogenesis, although more work is required to determine their functional 
consequence in cancer development. 
1.17 Repair of oxidatively damaged DNA 
One reason for increased damage of mtDNA relative to nuclear DNA was initially 
thought to be due to the limited mechanisms of mtDNA repair. Early studies 
demonstrated that, following prolonged exposure to oxidative stress, nuclear DNA 
damage was completely repaired, whereas mtDNA damage persisted (Yakes and 
Van Houten, 1997). More recent studies have demonstrated that mitochondria do 
have several mechanisms for DNA repair, (reviewed in Larsen et al, 2005). Base 
excision repair (BER), the principle pathway for the removal of oxidative DNA 
damage does occur (Fortini et a/, 2003). BER involves the recognition and 
removal of damaged bases by specific glycosylases which cleave the bond 
between the base and the deoxyribose moiety of DNA. Once the base is removed, 
the apurinic/apyrimidinic site is removed by an endonuclease. DNA polymerase 
then fills in the gap and the nick is sealed by DNA ligase (Bogenhagen et a/, 2001). 
OGG1 is the major DNA glycosylase for the removal of the 8-OHdG residue, and 
has been demonstrated to have a mitochondrial targeting sequence and to localise 
to mitochondria (Takao et al, 1998). OGG1 appears to be more important in 
removal of 8-OHdG lesions in mtDNA than nuclear DNA (de Souza-Pinto et a/, 
2001). 8-OHdG residues that escape OGG1 repair can generate misincorporation 
of an adenine during replication thus producing 8-OHdG/A mismatches. If this 
occurs, the mismatched adenine is removed by an enzyme termed hMYH which is 
a homologue of the Escherichia co/i repair enzyme MutY. This is followed by 
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preferential insertion of a cytosine leading to the formation of 8-OHdG/C pairs 
which are then corrected by OGG1-mediated BER (Gao et al, 2004; Fortini et al, 
2003). hMYH is encoded by a chromosomal gene, but the protein has a 
mitochondrial-targeting sequence enabling it to localise to the mitochondria 
(Ohtsubo at al, 2000). 
Errors of replication that result in a mismatch or small loop are detected by the 
mismatch repair system. Recent evidence suggests that mitochondria also have 
the capacity for mismatch repair. Using a nicked substrate containing G/G and G/T 
mismatches, Mason et al, (2003a) observed a low level repair activity in rat liver 
mitochondrial extracts. However, a functional mismatch repair system is 
necessary to prevent microsatellite instability. Given that microsatellite instability 
has been observed in polycytidine tracts in the D-loop region of mtDNA (Sanchez- 
Cespedes et al, 2001; Wang et al, 2005), it may be that this system is not efficient 
enough to provide adequate repair. 
Mitochondria, therefore, appear to contain several mechanisms of DNA repair. Of 
note, one mechanism that appears to be absent in mitochondria is nucleotide 
excision repair, (NER) a more complex process than BER, which involves the 
detection of lesions arising from distortions of the DNA helix. This means that a 
large group of DNA lesions may not be repaired (LeDoux et al, 1992). 
1.18 HCV, oxidative stress and mtDNA damage 
The sequelae for individuals chronically infected with HCV are often severe. 
Approximately 20% will develop liver cirrhosis with progression to hepatocellular 
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carcinoma (HCC) in 1-4% of these individuals per year. The mechanisms of HCV 
pathogenesis remain unclear, but oxidative stress, resulting from the host immune 
response or the virus itself, may play a key role in HCV-induced liver damage (Choi 
and Ou, 2006). In chronic viral infection there is elevated oxidative stress over a 
long time period which diminishes the probability of mtDNA repair (Yakes et al, 
1997). Additionally, hepatocytes contain many mitochondria and, therefore, have 
high ROS production. These factors suggest that chronic HCV infection would 
have a high propensity to elevate levels of ROS and therefore cellular damage 
within infected individuals. Oxidative stress has long been known to be involved in 
the pathophysiology of human cancers (Franco et a/, 2008) and it could be that its 
destructive effects are what drive the development of HCC in HCV-infected 
individuals. 
The host immune response to HCV may play a role in the production of oxidative 
stress. HCV-infected individuals exhibit increased production of tumour necrosis 
factor-a (TNF-a), a cytokine important in the inflammatory response which can 
produce oxidative stress by stimulating the generation of ROS (Larrea et al, 1996). 
Serum levels of TNF-a have been seen to correlate significantly with severity of 
HCV disease (Zylberberg, 1999). Elevated levels of ROS have been detected in 
transgenic mice expressing HCV core protein, even with the absence of 
inflammation (Moriya et al, 2001). This suggests that the virus rather than the host 
immune response may be more significant in the production of oxidative stress. 
Accordingly, the majority of studies have focussed on the role of the virus in 
augmenting oxidative stress and cellular damage in infected HCV-individuals. 
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1.18.1 Oxidative stress in HCV-infected individuals 
There is a plethora of data which demonstrate that infection with HCV is associated 
with increased oxidative stress, both in the liver and systemically. Most studies 
utilise the detection of 8-OHdG, an indicator of oxidatively-generated DNA 
damage, as the marker of oxidative stress. High levels of 8-OHdG have been 
found in leucocytes and liver tissue from patients with chronic HCV infection. 
Elevated levels correlated with advanced progression of disease and increased 
amount of liver steatosis (Shimoda et al, 1994; Farinati et at, 1999; Cardin et al, 
2001; Fujita et al, 2007). Kitada et al (2001) detected 8-OHdG 
immunohistochemically in various forms of chronic liver disease, regardless of 
aetiology, although they did not undertake quantification for comparison between 
the different aetiologies. Expression of hepatic 8-OHdG in the livers of HCV- 
infected individuals who developed HCC was significantly higher than in those that 
did not develop HCC (Tanaka et a/, 2008). Other studies have measured levels of 
malondialdehyde (MDA) -a marker of lipid peroxidation in HCV-infected 
individuals. Elevated levels of MDA were observed in these individuals when 
compared to controls (De Maria et al, 1996; Vidali et al, 2008). Accumulation of 
lipid peroxidation products were seen to be reversed by successful interferon 
therapy (Kageyama et al, 2000). 
Quantitation of the oxidised and reduced forms of anti-oxidants is a useful marker 
of oxidative stress. Levels of the antioxidant GSH were found to be significantly 
decreased in patients with chronic HCV infection with a concurrent increase in the 
oxidised form, GSSG, suggesting a high turnover of GSH in response to liver 
damage (Farinati et al, 1995; Mahmood et al, 2004). Jain et al (2002) measured a 
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variety of markers of oxidative stress including pro- and anti-oxidants and found 
that there was clear evidence of oxidant stress in HCV-infected individuals, even in 
the absence of cirrhosis - demonstrating that oxidative stress occurred early in 
infection. Induction of MnSOD, the mitochondrial antioxidant, is enhanced in 
PBMCs of patients with HCV but depleted in the liver cells (Larrea et al, 1998), 
suggesting that this organ could be less protected against oxidative damage. A 
genetic polymorphism which maps within the mitochondrion-targeting sequence of 
the MnSOD gene and prevents translocation into the mitochondria was found to 
increase the risk of developing HCC in a cohort of HCV-infected Moroccan patients 
(Ezzikouri et al, 2008). This suggests that anti-oxidants could be vital for the 
prevention of oxidative stress and progression to HCC, although this finding has 
yet to be confirmed by other studies. Supporting these studies are the findings in 
patients with chronic HCV infection where the extent of liver injury was reduced 
significantly by the administration of anti-oxidant therapy (Houglum et al, 1997). 
The liver is an iron-rich organ and so a plentiful source of ferrous iron (Fe2+) which 
produces ROS through the Fenton reaction. HCV infection is associated with iron 
accumulation (Bonkovsky et al, 1997). Increased iron deposition was found to be 
positively correlated with levels of hepatic 8-OHdG in the livers of patients with 
chronic HCV infection (Fujita et al, 2007). Supporting this, decreases in the level of 
8-OHdG were seen following iron-depletion therapy in patients with HCV (Kato et 
a/, 2001). The increased iron storage in the liver tissue of HCV-infected individuals 
correlated with increased lipid peroxidation and anti-oxidant turnover (Farinati et al, 
1995) indicating that excess iron storage in the liver provides a source of ROS 
production contributing to cellular damage. 
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1.18.2 HCV pathogenesis and oxidative stress 
Although HCV-infected individuals demonstrate elevated markers of oxidative 
stress, it is difficult to determine how the virus is involved. Studies of the 
pathogenesis of HCV were hampered by the lack of a cell culture system 
permissive for HCV infection and replication. Cell lines expressing HCV 
sequences from chromosomally integrated cDNA constructs have gone some way 
to resolve this (Lohmann et al, 1999). Okuda and colleagues (2002) expressed the 
HCV core protein in 3 different cell lines and demonstrated that core expression by 
itself was sufficient to increase oxidative stress, lipid peroxidation and antioxidant 
gene expression. Other studies have produced similar results, demonstrating 
increased oxidative stress and anti-oxidant turnover in cell lines expressing the 
HCV core protein (Otani et al, 2005; Li et al, 2007). Abdalla et al (2005) found that 
expression of both the core and NS5 proteins led to increased oxidative stress and 
that the magnitude of ROS formation correlated with the level and length of time of 
core protein expression. Oxidative stress was demonstrated to be induced in both 
core- and NS5a-transfected cells but an earlier and more marked increase was 
observed in cells expressing NS5a protein (Garcia-Mediavilla et al, 2005). 
The HCV non-structural proteins including NS5a make up a ribonucleoprotein 
replication complex which is associated with the host cell's endoplasmic reticulum 
(ER) membrane (Mottola et al, 2002). It is thought that this localisation permits 
NS5a to induce ER stress, causing a release of Ca 2+ which are taken up by 
mitochondria, resulting in increased ROS (Gong et al, 2001; Robinson and 
Marchant, 2008). The expression of NS5a protein was demonstrated to disturb 
intracellular calcium and trigger the elevation of ROS in mitochondria, leading to 
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the activation of transcription factors STAT-3 and NF-KB which are induced by 
oxidative stress (Gong et al, 2001; Waris et al, 2002). These processes were 
dramatically reduced with the addition of reagents which chelated calcium or 
eliminated oxygen radicals. Various deletion mutants of NS5a were also unable to 
induce these processes (Gong et al, 2001). The activation of STAT-3 and NF- KB 
may be beneficial to the virus as these proteins are known to be involved in cell 
proliferation and the expression of anti-apoptotic genes (Bromberg et al, 1999; 
Mercurio and Manning, 1999). Moreover, STAT-3 activation has been found to 
contribute to the stimulation of HCV replication (Waris et al, 2005). Thus NS5a 
may have a potential role in the establishment of chronic liver disease. A very 
recent study has indicated that other non-structural HCV proteins may be important 
in cellular damage. HCV NS3/4a was found to impair the efficiency of DNA repair 
by interacting with ataxia-telangiectasia mutated (ATM) a cellular protein kinase 
which is essential for response to double-stranded DNA breaks, rendering the cell 
more sensitive to DNA damage (Lai et al, 2008). 
The use of cell culture systems may produce erroneous results as the quantities of 
proteins expressed in the cell system is far greater than seen in human infection. 
Expression of the entire HCV polyprotein in inducible cell lines, under the tight 
control of the regulatory elements of the Escherichla coil tetracycline resistance 
operon, has allowed improved simulation of HCV infection (Moradpour et al, 1998). 
With this system HCV gene expression can not only be switched on and off, but 
fine-tuned over a broad range by varying the concentration of tetracycline in the 
culture medium. Studies using such a system have supported earlier work by 
demonstrating that HCV proteins co-localise to the mitochondria and have several 
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deleterious effects including an increase in ROS, decreased mitochondrial 
membrane potential, decreased cellular respiratory activity and inhibition of 
complex I of the ETC (Piccoli et al, 2006). Transgenic mice which express HCV 
proteins at levels characteristic of human disease have been created and results 
using these animal models support those from cell culture studies (Moriya et al, 
1998; Okuda et al, 2002; Korenaga et al, 2005). These studies also allowed the 
visualisation of the direct association of the HCV core protein with the outer 
mitochondrial membrane. Korenaga and colleagues (2005) also demonstrated that 
expression of structural proteins, including the core protein, stimulated Ca 2+ uptake 
into the mitochondria which was followed by increased ROS production, oxidation 
of glutathione and a defective electron transport complex I, leading to an increase 
in complex I-mediated ROS production. They postulated that the localisation of the 
core protein to the outer mitochondrial membrane resulted in mitochondrial 
dysfunction by facilitating Ca 2+ uptake. 
Chronic inflammatory states frequently lead to the increased production of nitric 
oxide (NO) via inducible NO synthase (iNOS). NO reacts with 02- to form 
peroxynitrite (ONOO"), which acts as a ROS, destroying cellular constituents. NO 
causes double-stranded DNA breaks and enhances the mutation frequency of 
cellular genes. In an eloquent series of studies, using both cell lines expressing 
various viral proteins and transgenic mice expressing the HCV core protein, 
Machida and colleagues (2004,2006) have shown that the induction of both NO 
and ROS by HCV proteins leads ultimately to DNA damage. They first 
demonstrated that core and NS3 proteins induced iNOS expression and production 
of NO which in turn caused DNA damage, with the pathway blocked by treatment 
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of infected cells with iNOS inhibitors (Machida et al, 2004). They then 
demonstrated that core, NS3 and E1 proteins induced ROS production, enhanced 
lipid peroxidation and reduced mitochondrial membrane potential. In addition, 
using a mouse model, they demonstrated that the expression of the core protein 
induced lipid peroxidation and oxidative DNA damage in the livers of core- 
transgenic mice (Machida et al, 2006). 
Cells have various cell cycle check points which ensure that repair of DNA lesions 
occurs before cell cycle progression resumes. Production of oxidative stress by 
HCV could be advantageous to the virus as its DNA-damaging effects may drive 
the infected cell to cell cycle arrest. Viruses are thought to replicate more 
efficiently in cells in an arrested state, as they can utilise fully the host cell 
machinery without competition from the host cell itself. Several viruses, such as 
the herpesviruses are known to interact with the host cell cycle control pathways 
(Flemington et al, 2001). Recent work has demonstrated that chronic HCV 
infection drives cells into an arrested state (Marshall et al, 2005). However, in a 
study by Choi and colleagues (2004) where human hepatoma cells expressing 
HCV replicons were treated with DNA-damaging peroxide, a decrease in HCV 
RNA was observed. This was found to occur rapidly at the level of HCV RNA 
replication, disrupting HCV replication complexes by reducing the amount of NS3 
and NS5a. This finding is as yet unsupported, but suggests that production of 
ROS is detrimental to the virus, suppressing its replication. 
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1.19 Summary and aims 
This thesis is divided into two clear parts with the continuing theme of hepatitis C 
virus. HCV is the most common blood-borne virus in Europe, and currently the 
main cause of infectious hepatitis in the UK. There is, therefore, an increasing 
demand on diagnostic laboratories to provide rapid assays to aid clinicians in HCV 
diagnosis and monitoring using accurate and sensitive state-of-the-art methods. 
The aims of the research described in Chapter three were to design, develop, 
optimise and implement rapid and inexpensive real-time PCR assays for HCV 
quantitation (with internal control) and genotyping to support clinical practice. An 
additional objective was to develop methods for defining HCV isolates at the 
subtype level, for epidemiological and transmission studies. 
Primary infection persists in 70-80% of infected individuals with spontaneous 
resolution of infection in approximately 20%. Chapter three also describes the 
application of the fully optimised assays in a series of clinical studies to investigate 
the role of HCV genotype in spontaneous clearance of HCV infection and to 
examine the epidemiology, at subtype level, of HCV isolates circulating within the 
eastern region of the UK. 
Chronic infection with HCV will lead to serious liver disease such as cirrhosis and 
fibrosis in 20% of individuals. Between 1-4% of those with cirrhosis per year will 
develop hepatocellular carcinoma. Infection with HCV is, therefore, very damaging 
and one way in which this is thought to occur is through the production of cellular 
oxidative stress especially through the action of viral proteins such as the core and 
NS5a proteins. Cellular oxidative stress causes DNA damage and mtDNA is 
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particularly susceptible. Accumulation of mtDNA damage decreases the 
bioenergetic potential of cells, but damage must reach a critical threshold level 
before detrimental effects are observed. Mitochondria are vitally important cellular 
organelles, with their major function being the generation of the cellular energy 
source - ATP - through the OXPHOS pathway. 
Most studies examining the damaging effects of oxidative stress on DNA in 
individuals with HCV have focussed on detecting 8-OHdG as a marker of DNA 
damage. Although a useful marker of DNA damage, the amounts of oxidative 
modifications detected by different methods can vary considerably. There is also 
the possibility of introducing oxidation during DNA isolation, artificially elevating the 
detectable 8-OHdG. Direct examination of mtDNA to scan for and quantify specific 
mtDNA deletions and mutations within the mitochondrial genome is a far superior 
method for detection of mtDNA damage. mtDNA provides an excellent target to 
measure DNA damage due to its increased susceptibility to ROS. The aims of the 
research reported in Chapters four and five were to develop rapid PCR methods 
for the detection/quantitation of mtDNA damage. Chapter four describes the 
development of assays to detect and quantify two specific and well-documented 
mtDNA deletions - mt'977 and mt7436. Chapter five outlines the development of a 
method to scan for mtDNA mutations occurring within the mtDNA D-loop -a region 
particularly susceptible to damage. 
All of the assays developed in this thesis were exploited in a clinical study of liver 
biopsies from patients with chronic HCV infection and other liver aetiologies. The 
level of mtDNA damage occurring in the livers of these patients was established. 
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The hypothesis that was addressed was whether individuals with HCV infection 
were experiencing greater levels of oxidative stress and thus mtDNA damage than 
those with other liver aetiologies. 
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CHAPTER TWO 
Materials and Methods 
2.1 Reagents and solutions 
Reagents used were all of the highest quality (AnalaR grade or equivalent) and 
were stored at the appropriate temperature and conditions stated by the 
manufacturer. All relevant glassware and other materials used were washed with 
distilled and deionised water (ddH2O) before use (Optima Water Purifier, Triple Red 
Ltd, Buckinghamshire). Solutions were prepared with ddH2O and, where 
appropriate, autoclaved at 121 C for 15 min at a pressure of 1.1 bar. Stock 
solutions were prepared according to published guidelines (Sambrook and Russell, 
2001). Stock and working solutions are detailed in Appendix A. The ultraPURETM 
DNAse, RNAse-free water used in the following methods was purchased from 
Invitrogen (Paisley UK, cat. no. 10977035). 
2.2 Clinical specimens 
2.2.1 Blood specimen collection and storage 
Blood samples were taken from HCV-infected individuals attending the Hepatology 
Clinic at Addenbrooke's Hospital, Cambridge, as part of routine 
diagnosis/monitoring. The HCV genotyping assay was developed and utilised on 
all patients attending the clinic who had detectable HCV RNA and for whom HCV 
genotyping was requested as part of routine monitoring. HCV serotyping was 
carried out on all patients attending the clinic that had a detectable HCV antibody 
response by routine laboratory testing but were found to be HCV RNA negative by 
PCR. 
Blood specimens were taken by hospital phlebotomists into labelled EDTA blood 
tubes. These were spun in a Centaur 1 centrifuge (R W Jennings and Company 
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Ltd, Nottingham UK) to separate the serum. This was aliquoted into labelled 
eppendorf tubes and stored at -70°C until required. 
2.2.2 Liver biopsy collection and storage 
Liver biopsy specimens were obtained from a total of 79 patients (55 male and 24 
female, with an average age of 46.2 years). These had all attended the Planned 
Short Stay Unit (PSSU) at Addenbrooke's Hospital, Cambridge between 2005 and 
2007. Ethical approval for liver biopsy collection and storage had been obtained 
from the Cambridge Local Research Ethics Committee (LREC reference number 
04/Q0108/124, Appendix E) prior to the commencement of the study. A biopsy 
specimen was obtained from patients who had read an information sheet and 
signed a consent form permitting the use of their liver tissue for research purposes 
(Appendix F), and for which there was sufficient tissue remaining from that required 
for routine diagnostic/investigative purposes. 
A small segment of the liver biopsy was immediately transferred to a sterile 1.5 ml 
eppendorf tube containing 1 ml of RNAlaterT"' (Sigma, USA, cat. no. R 0901). The 
biopsies were kept at 4°C until collection. The RNAlaterT"" was then removed with 
a pastette and the eppendorf, containing the biopsy transferred to a -70°C freezer 
for storage until use. 
2.3 Nucleic acid extraction - homogenisation of liver biopsy specimens 
2.3.1 Manual homogenisation 
Tissue samples were manually homogenised using a sterile 1.5 ml pestle (Starlab 
Ltd, Milton Keynes UK, cat. no. 11415-5390) in a 1.5 ml eppendorf containing the 
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appropriate buffer (depending on the extraction method to be utilised, see Sections 
2.4 and 2.5). 
2.3.2 Automated homogenisation 
Tissue samples were homogenised using the MagNA Lyser (Roche Diagnostics 
Ltd, Burgess Hill UK, cat. no. 03358976001) with MagNA Lyser green beads 
(Roche Diagnostics GmbH, cat. no. 3358941) in the appropriate buffer (depending 
on the extraction method to be utilised, see Sections 2.4 and 2.5). 
Homogenisation took place at 7000 rpm for 60 s. 
2.4 Nucleic acid extraction - automated extraction methods 
2.4.1 MagNAPure extractor 
Nucleic acid was extracted from 200 pi of serum with a MagNAPure LC Total 
Nucleic Acid Isolation kit (Roche Diagnostics, Burgess Hill UK, cat. no. 3038505) 
using automated MagNAPure extraction equipment and the total NA variable 
elution protocol eluting in 60 pl elution buffer, according to manufacturer's 
guidelines. 
2.4.2 BioRobot MDx workstation (Qiagen, Crawley UK, cat. no. 
900600) using the QlAamp Virus BioRobot MDx kit (cat. no. 965652) 
Lyophilised carrier RNA was dissolved in 450 pi AVE buffer. Two hundred and 
thirty microlitres of carrier RNA reconstituted in buffer AVE were transferred to one 
bottle containing 33 ml buffer AL (lysis buffer) and mixed. Liver biopsy specimens 
were homogenised in 350 pl of the AL/carrier RNA solution. These were 
transferred to sterile 2 ml microtubes (Sarstedt Ltd, Leicester, UK). The BiRobot 
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MDx workstation was prepared and the extraction run set up following 
manufacturer's guidelines. Nucleic acid was eluted in 100 pi buffer AVE. 
2.5 Nucleic acid extraction - manual extraction methods 
Three different manual extraction methods were evaluated for the extraction of 
DNA from liver biopsy specimens: 
2.5.1 Modified Trizol® DNA isolation (Invitrogen Life Technologies, 
cat. no. 15596-018) 
DNA was extracted from liver biopsies using the Trizol® reagent, but altering the 
protocol from the published manufacturer's guidelines to improve yield of DNA. 
The liver biopsy specimen was homogenised in 800 pl of Trizol® reagent, using 
either manual or automated homogenisation as described (Section 2.3). The 
homogenised sample was left to incubate for 5 min at room temperature. One 
hundred and sixty microlitres of chloroform (Sigma-Aldrich, Dorset UK, cat. no. 
496189) were added and the tubes were shaken vigorously by hand for 15 s and 
then incubated at room temperature for 2 min. The sample was then centrifuged at 
13000 rpm for 15 min. Following this centrifugation step, the mixture separates 
into a lower, red, phenol-chloroform phase, an interphase and a colourless upper 
aqueous phase. The upper aqueous phase which contains the RNA was carefully 
removed and dispensed into a fresh tube. 
Two hundred and forty microlitres of absolute ethanol (Sigma-Aldrich, Dorset UK, 
cat. no. 32221) were added to the lower and interphase and the sample was mixed 
by inversion. The sample was then stored at room temperature for 2 min and the 
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DNA was sedimented by centrifugation at 8000 rpm for 5 min. The phenol-ethanol 
supernatant (containing protein) was removed. Thirty microlitres of 3M sodium 
acetate (Sigma-Aldrich, Dorset, UK, cat. no. S-7899) were added and the sample 
was mixed briefly. Three hundred microlitres of isopropanol (Sigma-Aldrich, 
Dorset, UK, cat. no. 33539) were added and the sample was vortexed briefly and 
incubated at room temperature for 2 min. The sample was spun at 13,000 rpm for 
10 min and the supernatant was carefully decanted. The pellet was washed with 
0.5 ml of 70% ethanol (Appendix A), vortexed, incubated for 10 min at room 
temperature and spun at 13,000 rpm for 15 min. The wash, vortex and incubation 
steps were repeated. The DNA pellet was air-dryed for 2-5 min in an open tube. 
The pellet was then re-dissolved in 70 pl ultraPURETM' water. Incubation of the 
partially dissolved pellet for two hours at room temperature or 4°C overnight was 
found to improve DNA solubilisation. The DNA was stored at -20°C until use. 
RNA was extracted from the upper aqueous phase and stored as a resource for 
future work. A 0.4 ml volume of isopropanol was mixed with the aqueous phase 
and the samples were incubated at room temperature for 10 min. The samples 
were then centrifuged at 12,000 xg for 10 min at 4°C in a Heraeus Biofuge Stratos 
centrifuge (Kendro Laboratory Products, Hertfordshire UK). The supernatant was 
discarded and the RNA pellet was washed in 0.8 ml of 75% ethanol (Appendix A). 
The sample was mixed by vortexing and centrifuged at 7,500 xg for 5 min at 4°C. 
The RNA pellet was allowed to air dry for 5 min and was then dissolved in 200 UI of 
ultraPURETM water, by passing the solution a few times through a pipette tip and 
incubating for 10 min at 60°C. The solution was then kept at -70°C for long-term 
storage. 
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2.5.2 QlAamp Viral RNA Kit (Qiagen, UK, cat. no. 52906) 
Prior to commencing the extraction, one vial of carrier RNA was added to one 
bottle of AVL buffer. Two hundred and eighty microlitres of prepared AVL buffer 
were added to either a sterile, labelled 1.5 ml eppendorf (manual homogenisation) 
or a MagnaLyser tube (automated homogenisation) and the biopsy specimen 
added. The biopsy was then homogenised in the AVL buffer as described in 
Section 2.3. The homogenate was removed and placed in a new sterile 1.5 ml 
eppendorf tube; this was incubated at room temperature for 10 min. Two hundred 
and eighty microlitres of absolute ethanol (Sigma-Aldrich, Dorset UK, cat. no. 
32221) were added and the sample was vortexed and then pulse spun at 13,000 
rpm. The mixture was added to a QlAamp spin column which was centrifuged at 
8000 rpm for 1 min. The waste from the collection tube was discarded into a 
universal tube. The QlAamp spin column was then placed in a clean 2 ml 
collecting tube. Two hundred and fifty microlitres of buffer AW-1 were added to the 
column and this was centrifuged at 8000 rpm for I min. The waste from the 
collection tube was discarded into a new universal tube and the QlAamp spin 
column was placed in a clean 2 ml collecting tube. Two hundred and fifty 
microlitres of buffer AW-2 were added to the column and this was centrifuged at 
8000 rpm for 1 min. The waste from the collection tube was discarded into the 
same universal tube as the previous step. The QlAamp spin column was replaced 
in the same collecting tube which was centrifuged at 13000 rpm to remove any 
residual buffer. The QlAamp spin column was then place in a labelled 1.5 ml 
eppendorf tube (after removing the flip-top lid with a pair of scissors). The 
eppendorf tube with the spin column was then placed into a heating block set at 
80°C, with the column lid opened and this was incubated for 1 min. Sixty 
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microlitres of preheated (to 80°C) AVE buffer were added to the centre of the 
column and the lid closed. This was incubated for a further 5 min. The nucleic 
acid was then centrifuged at 8000 rpm for 1 min. The spin column was discarded 
and the eppendorf tube, containing the eluted nucleic acid was re-capped. The 
nucleic acid was stored at -20°C until use. 
2.5.3 DNeasy® Blood and Tissue kit (Qiagen, Crawley UK, cat. no. 
69504) 
Nucleic acid was extracted from liver biopsy specimens using the DNeasy® Blood 
and Tissue Kit following manufacturer's guidelines. In brief, the biopsy specimen 
was homogenised in 180 pl Buffer ATL. Twenty microlitres of proteinase K 
(provided with the kit) were added and the mixture was vortexed and incubated at 
56°C for 1 h. The solution was then vortexed for 15 s and 200 pl buffer AL were 
added to the sample which was mixed thoroughly by vortexing. Two hundred 
microlitres of ethanol (96-100%) were added and the sample was mixed again. 
The mixture was pipetted into a DNeasy Mini spin column in a2 ml collection tube 
which was centrifuged at 8000 rpm for 1 min. The flow-through and the collection 
tube were discarded. The spin column was then placed in a new 2 ml collection 
tube and 500 pl of buffer AW1 were added. This was centrifuged at 8000 rpm for I 
min and the flow-through and collection tube were discarded. The spin column was 
then placed in a new 2 ml collection tube and 500 pl of buffer AW2 were added. 
This was centrifuged at 13000 rpm for 3 min and the flow-through and collection 
tube were discarded. The spin column was transferred to a new, labelled, 1.5 ml 
microcentrifuge tube and 100 pl of elution buffer AE were added directly onto the 
DNeasy membrane. This was incubated at room temperature for 1 min and then 
centrifuged at 8000 rpm for I min to elute the nucleic acid from the DNeasy 
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membrane into the microcentrifuge tube. The nucleic acid was stored at -20°C 
until use. 
2.5.4 Salting-out method 
DNA was extracted from peripheral blood mononuclear cells (PBMCs) by adapting 
an existing protocol (Miller eta!, 1988). A5 ml EDTA blood sample was spun in a 
Centaur 1 centrifuge for 10 min at 3000 rpm. After centrifugation, two layers are 
formed - the top layer comprising plasma and a bottom layer of red blood cells. 
The interface between the two layers contains the PBMCs (buffy coat). Using a 
pastette the plasma was carefully removed into a waste container. The buffy coat 
was then removed and transferred to a labeled 15 ml polypropylene tube (Elkay 
Laboratory Products, Basingstoke UK, cat. no. 2088-000). Five millilitres of red cell 
lysis buffer (RCLB) (Appendix A) were added to the tube, and the tube was 
inverted several times and left to stand for 5 min, mixing gently on two occasions. 
The mixture was spun in a centrifuge for 10 min at 3000 rpm. The supernatant 
was decanted into a waste container, leaving the white cell pellet at the base of the 
tube. One millilitre of RCLB was added and the pellet was resuspended using a 
pastette. A further 5 ml of RCLB were added and the sample incubated at room 
temperature for 10 min, again with occasional mixing. The sample was centrifuged 
as before and the supernatant discarded. The pellet was resuspended in the 
residual RCLB and the solution transferred to a sterile 1.5 ml eppendorf tube. One 
millilitre of nuclei lysis buffer (NLB) (Appendix A), 53 pl of 10% sodium dodecyl 
sulphate solution (SDS) (Sigma-Aldrich, Dorset, UK, cat. no. 71736) and 16 p1 of 
proteinase K (at 10 mg/ml concentration) (Appendix A) were added to the tube 
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which was then vortexed for 15 s. The tube was left on a BT3 heating block (Grant 
Instruments, Cambridge UK) at 56°C for 2 h. 
A bottle of saturated (-6M) NaCl (Appendix A) was shaken well and 0.3 ml were 
added to the tube which was then capped and vortexed for 10 s. In a fume 
cupboard, 0.7 ml of chloroform (Sigma-Aldrich, Dorset UK, cat. no. 496189) were 
added to the tube and it was capped and shaken vigorously for 15 s until a milky 
froth appeared. The tube was then vortexed for 10 s and spun on the centrifuge 
for 10 min at 3000 rpm. The upper layer (containing the DNA) was removed into a 
fresh pre-labeled 15 ml polypropylene tube, leaving 2 mm of fluid above the 
interface to avoid sucking up protein. An equal volume of isopropanol (Sigma- 
Aldrich, Dorset UK, cat. no. 33539) was added to the tube and the solution was 
mixed gently until the DNA was observed as a visible string-like precipitate. The 
string was pulled out with a sterile pastette and transferred to a fresh, sterile 
eppendorf tube. One millilitre of 70% ethanol (Appendix A) was added to the pellet 
and this was mixed gently with a pipette. The tube was spun in a micro-centrifuge 
for 5 min at 13000 rpm. The ethanol was gently removed with a pipette. The 
ethanol wash was repeated and the tube was spun as before. The tube was left to 
air dry for several minutes. Depending on the size of the DNA pellet, 300-400 pl of 
lx TE buffer (Appendix A) were added. The tube was left at room temperature and 
vortexed regularly until the DNA pellet had completely dissolved. The solution was 
then stored at -20°C until required. 
2.6 Determination of DNA concentration by spectrophotometry 
A 1: 100 dilution of DNA sample was prepared by adding a5 {VI aliquot of DNA to 
495 pl of distilled water in a microcentrifuge tube. The DNA mixture was then 
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transferred to a quartz microcell cuvette and the absorbance was read at 260nm in 
a Model 6505 UVNIS spectrophotometer (Jenway, Dunmow UK), using water as a 
blank. The DNA concentration of the sample was calculated on the basis that an 
optical density reading (OD) of 1.0 is equivalent to a double stranded DNA 
concentration of 50 Ng/ml, using the equation below: 
A260 x5= Concentration of DNA (pg/pl) 
2.7 Agarose gel electrophoresis 
Following amplification, PCR products were monitored by 2% agarose gel 
electrophoresis. One point two grams of 3: 1 NuSieve® agarose (Lonza, 
Wokingham Ltd, Berkshire UK, cat. no. 50090) were added to 60 ml 1x TBE buffer 
(Appendix A) in a 500 ml conical flask and the contents mixed by swirling. This 
was boiled in a microwave oven for approximately 90 s. The gel solution was 
cooled to 65°C, 20 µl ethidium bromide (2 mg/ml) (Appendix A) were added and 
the solution mixed by gentle swirling. Two 20 well combs and end pieces were 
inserted into a level 24 cm x 15 cm gel tank (Engineering and Design Plastic Ltd, 
Cambridge UK, cat. no. EM100). The solution was poured in and allowed to set 
for 30 min at room temperature. The combs were removed and 5 µl of PCR 
product which had been mixed with 10 µl Orange G loading buffer (Appendix A) 
was loaded into each gel slot. Five microlitres of PCR markers (Promega, 
Southampton UK, cat. no. G3161) were loaded into the first well of each row. 
Each marker contains -35 ng of DNA fragment and allows approximate 
quantitation of PCR products by comparison with the band intensity of the markers. 
The gel tank was carefully flooded with -75 ml of 1x TBE buffer and the samples 
were electrophoresed for -40 min using a Shandon Vokam Power Supply (Model 
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SAE2761, Shandon Scientific, Cheshire UK) set at 75 Volts (V) for electrophoresis 
at 5 V/cm. Following electrophoresis, the gel was photographed under UV 
illumination, viewed and documented using the AlphalmagerTM digital imaging 
system using AlphaEase software (Alpha Innotech Corporation, California USA). 
2.8 HCV serotyping 
HCV serotyping was carried out using the Murex HCV Serotyping Kit (Abbott 
Murex, Dartford UK, cat. no. 2G26-01), following manufacturer's guidelines. In 
brief, the conjugate was reconstituted by adding the whole bottle of conjugate 
diluent to the bottle of conjugate. This was mixed by gentle inversion and allowed 
to rehydrate for at least 30 min. The substrate solution was prepared by pouring 
the entire bottle of substrate diluent into the bottle of substrate concentrate. This 
was kept away from direct sunlight. The wash fluid was prepared by diluting it 1 in 
20 with ddH2O. 
The required number of strips was assembled in the plate frame, including one for 
a typing control (genotype 1). Each sample to be serotyped was incubated in eight 
separate microwells which are each coated with HCV peptides. Different 
competing solutions were added to each well as follows: 
A. 10 pl of CS Type 6 to well A (specific peptides for serotypes 1,2,3,4 
and 5) 
B. 10 pl of CS Type 5 to well B (specific peptides for serotypes 1,2,3,4 
and 6) 
C. 10 pl of CS Type 4 to well C (specific peptides for serotypes 1,2,3,5 
and 6) 
D. 10 pl of CS Type 3 to well D (specific peptides for serotypes 1,2,4,5 
and 6) 
E. 10 pl of CS Type 2 to well E (specific peptides for serotypes 1,3,4,5 
and 6) 
F. 10 pl of CS Type 1 to well F (specific peptides for serotypes 2,3,4,5 
and 6) 
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G. 10 pl of CS ALL to well G (specific peptides for all six serotypes) 
H. No CS added 
Eighty microlitres of sample diluent were added to wells A to H using a multi- 
pipette. Ten microlitres of sample or HCV typing control were added to each of the 
8 wells of one strip, using a clean tip for each well. This was mixed thoroughly by 
pipetting up and down at least four times. The wells were covered with a lid and 
incubated for 30 min at 37°C. The plate was then washed using an automated 
ELx5O bioelisawasher (Biokit, Barcelona Spain) performing 5 wash cycles using 
wash fluid with a fill volume of 500 pl/well and an aspirate/wash/soak cycle of 30 s. 
One hundred microlitres of reconstituted conjugate were then added to each well 
using a multi-pipette. The plate was covered with a lid and incubated for 30 min at 
37°C. The plate was then washed as before. One hundred microlitres of substrate 
solution were added to each well using a multi-pipette. The plate was covered with 
a lid and incubated for 30 min at 37°C. Fifty microlitres of stop solution (2 M 
sulphuric acid, Fisher Scientific, Leicestershire UK, cat. no. J/8410/PB15) were 
added to each well using a multi-pipette. The optical density (OD) for each well 
was determined by reading the absorbance at 450 nm within 15 min, using 690 nm 
as the reference wavelength. The instrument was first blanked on air (no plate). 
For each sample the 'All' OD value (AC) (well G) was subtracted from the OD 
value of each of the serotyping wells (A-F). The typing ratio was then calculated 
for the serotyping well demonstrating the highest resulting value (HT) (only if this 
value was >0.1). The typing ratio was calculated as follows: 
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Typing Ratio [HT-AC] 
[NC-AC] 
NC = no competition (OD from well H) 
AC = All competition (OD from well G) 
HT= highest type (serotyping well (A-F) with highest OD) 
For a valid typing signal 
" NC-AC >0.1 
" HT-AC>O. 1 
" Typing ratio >0.2 
If no serotyping wells demonstrated a value of >0.1 following subtraction of the AC 
value, then the sample was regarded as negative. If multiple serotyping wells 
demonstrated a value >0.1 then the sample was regarded as non-typable. 
2.9 Ultracentrifugation 
Prior to HCV serotyping, serum specimens were ultracentrifuged and subjected to 
HCV quantitative PCR to ensure that HCV RNA was not present. The 
ultracentrifugation step allowed increased sensitivity in order to detect even minute 
amounts of HCV RNA. Ultracentrifugation was carried out on aI ml aliquot of 
serum which was transferred to a sterile 1.5 ml flat cap microcentrifuge tube and 
spun at 23,000 xg for 60 min in a Heraeus Biofuge Stratos centrifuge (Kendro 
Laboratory Products, Germany) set at 4°C. The supernatant was carefully 
decanted and the nucleic acid pellet was then re-suspended in 350 pl of 
ultraPURETM water and extracted using the BioRobot MDx workstation as 
described in section 2.4.2. 
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2.10 Preparation of MS2 internal control 
2.10.1 Re-hydration of freeze-dried MS2 phage and phage propagation 
Phage MS2 (15597-B1 TM) and host (15597 Escherichia coli strain) were acquired 
from the American Type Culture Collection (ATCC) (www. lgcpromochem- 
atcc. com . The host was supplied as a 
lypophilised preparation and was 
reconstituted in #271 broth (Appendix A) and incubated overnight at 370C 
aerobically. Using a sterile 1 pl loop, colonies were streaked onto a #271 agar 
plate (Appendix A) and incubated overnight at 37°C aerobically and stored. A 
colony of MS2 host was inoculated in #271 broth and incubated in an orbital 
incubator at 200 revolutions per minute at 37 *C overnight. Freeze dried phage 
stock was re-hydrated in 1 ml of #271 broth under aseptic conditions. 
2.10.2 Agar layer method 
A high titre stock was prepared from 0.25 ml of the re-hydrated MS2 phage using 
the agar layer method (the remainder was stored frozen at -200C). Five sterile 
universals, each containing 0.2 ml of the host and 50 pl of MS2 phage were 
incubated at room temperature for 10 min to allow the phage to adsorb onto the 
host. A control universal containing MS2 host without phage was also prepared. 
To 100 ml of soft agar (5%) (Appendix A) cooled to 45°C was added 1 ml of 10% 
glucose (Appendix A), 0.2 ml of 1M calcium chloride (Appendix A) and 0.1 ml of 10 
mg/ml thiamine (Appendix A). Four millilitres of the soft agar (still in liquid form) 
were added to each of the 6 universals, mixed and then immediately poured on to 
fresh pre-warmed (37°C) #271 agar plates, and allowed to set. The plates were 
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then incubated overnight at 37°C aerobically and plaque formation was visualised 
the next day. 
Twenty millitres of #271 broth were added to each of the 5 plates (displaying clear 
confluent lysis as compared to the control). The soft agar was then scraped off 
using a sterile spreader into two 50 ml polypropylene tubes (Elkay Laboratory 
Products, Basingstoke UK, cat. no. 2092-000) and the contents vigorously mixed. 
The agar/bacterial debris was removed by centrifugation at 3000 rpm for 25 min. 
The supernatant containing the phage was filtered through a 0.22 pm Millex-GP 
sterilising filter unit (Millipore Ireland BV, Cork, cat. no. SLGP 033 RS) and the 
phage stored at -20°C. 
2.10.3 Determining plaque forming units 
The phage stock was serially diluted (10.1,10"2,10"3, to 10.10) in #271 broth and 25 
pl of each dilution was spotted, in triplicate, on the surface of #271 agar plates 
which contained an overlay of soft agar with MS2 host (0.2 ml of overnight culture). 
The plates were allowed to dry, incubated overnight at 37°C and visualised the next 
day for plaque formation. At the dilution where 20-100 plaques were visible, 
counts were made and the titre determined by working back with the dilution factor. 
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Figure 2.1: Determining plaque forming units (pfu) of MS2. The plate on the left 
show confluent growth of E. coli host (no MS2 added). The plate on the right 
shows plaques produced when a1 0-' dilution of MS2 was added to the host. 
2.11 Reverse transcription (cDNA preparation) 
Twenty microlitres of extracted RNA and 1 pl pd(N)6 random hexamer (GE 
Healthcare, New Jersey USA, cat. no. 27-2166-01) were added to labeled 0.2 ml 
PCR tubes (Corbett Research, Cambridge, UK). These were placed in a PTC-200 
Peltier thermal cycler (MJ Research, Waltham USA) and heated to 70°C for 5 min 
to unfold the secondary structure and facilitate annealing prior to reverse 
transcription. Meanwhile, a master mix for reverse transcription was prepared in 
1.5 ml flat cap microcentrifuge tubes (Starlab Ltd, Milton Keynes UK) using M- 
MLV Reverse Transcriptase (RT) 2000/pl (Invitrogen, Paisley UK, cat. no. 28025- 
013) (Appendix C). After 5 min on the thermal cycler, the tubes containing 
linearised nucleic acid were transferred immediately to ice, incubated for 2 min and 
then pulse spun in a Micro Centaur centrifuge (MSE, London UK). Fourteen 
microlitres of prepared master mix were added to each tube, which were then 
vortexed and pulse spun. Reverse transcription took place on the thermal cycler at 
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37°C for 60 min and denaturation at 95°C for 5 min. The cDNA was then stored at 
-20°C until use. 
2.12 PCR 
PCR was carried out under stringent conditions in the molecular diagnostic 
laboratory. This has separate accommodation with clear spatial separation of the 
different stages in the procedure. Master mixes were prepared in a clean room 
and were then transferred to the extraction room where nucleic acid was extracted 
and samples were prepared. PCR occurred in an amplification room which 
contained the thermal cyclers. Any subsequent amplicon analysis, such as gel 
electrophoresis was carried out in the detection room. The flow of work was uni- 
directional with amplicons never entering the clean or extraction rooms. Each of 
the rooms was equipped with its own consumable items, protective clothing, 
reagents, pipettes and equipment. 
2.12.1 Block-based PCR 
Block-based (conventional) PCR assays were carried out using the Taq DNA 
polymerase kit (Invitrogen, Paisley UK, cat. no. 10342-020). This kit includes 10x 
PCR buffer-II (200mM Tris-HCI [pH8.4], 500mM KCI), 50 mM MgCl2 and Taq DNA 
polymerase. A master mix containing the appropriate volumes of buffer, MgCl2, 
Taq polymerase, dNTPS (dATP, dCTP, dGTP, dTTP) at 10 mM (Appendix A), and 
primers was prepared in 1.5 ml flat cap microcentrifuge tubes (StarLab Ltd, Milton 
Keynes UK) and aliquoted into labeled 0.2 ml PCR tubes (Corbett Research, 
Cambridge UK). Nucleic acid (DNA or cDNA) was then added and the mixture 
vortexed and pulse spun. Positive and negative controls were included in every 
run. PCR was carried out on a PTC-200 Peltier thermal cycler (MJ Research, 
86 
Waltham USA). Optimised master mixes and cycling conditions for all block-based 
PCR assays are given in Appendix C. 
2.12.2 Real-time PCR 
Two different thermal cyclers were used in this research, the Rotor-GeneTM 3000 
(Corbett Life Sciences, Cambridge UK) and the LightCycler 1.5 (Roche 
Diagnostics, Burgess Hill UK). 
2.12.2.1 Rotor-GeneTM 3000 
The Rotor-GeneTM 3000 is a centrifugal real-time DNA amplification system. Its 4 
channel multiplexing allows up to 4 different fluorescently labelled probes to be 
monitored in a single tube with no spectral overlap. During the run, the rotor spins 
at approximately 500 rpm as the tubes are thermally cycled in a low-mass air oven. 
The 4 channel LED source irradiates the tube from the side wall and the 
photomultiplier detects the energy from the base of the chamber (Figure 2.2). 
Each dye is excited at its peak wavelength, maximising sensitivity and reducing 
cross-talk between channels (Table 2.1). The detection filter wheel has six 
different filters, four are band pass that are used in four channel multiplex runs, the 
other two are high pass filters that can be used for specialised applications. The 
unit holds either 36 x 0.2 ml PCR tubes (Corbett Research, Cambridge UK, cat. no. 
3001-001) or 72 x 0.1 ml PCR tubes (Corbett Research, Cambridge UK, cat. no. 
3001-001), loaded into a carousel. 
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LED source 
6 emission filters 
F'ýI 
Emission detection 
Figure 2.2: Rotor-GeneTM 3000 side view 
Dye Source Detector 
FAM 470 nm 510 nm 
JOENIC 530 nm 555 nm 
ROX 585 nm 610 nm 
C y5 625 nm 660 hp 
Table 2.1: Wavelength of the source LED and detection filter for each of the 
probes used by the Rotor-GeneTM 3000. Hp; high pass filter used 
2.12.2.2 LightCycler® 
The LightCycler 1.5 Real-Time PCR System is a carousel based thermal cycler. 
PCR occurs in glass capillaries (Roche Diagnostics, Burgess Hill, UK, cat. no. 
11909339001) which have an optimal surface-to-volume ratio to ensure rapid 
equilibration between the air and reaction components, resulting in rapid 
amplification cycles. It has three detection channels which measure fluorescence 
at 530,640 and 705 nm. LightCycler® Software 3.5.3 controls the instrument and 
performs analyses which can be absolute quantification, melting curve analysis 
and mutation/SNP analysis. 
Although the LightCycler can be used with fluorescent labelled dyes, in this study it 
was only used for non-specific detection using SYBR Green I. This fluoresecent 
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intercalates into double-stranded (ds) DNA and produces a fluorescent signal. The 
resulting DNA-Sybr green complex absorbs blue light and emits green light. The 
intensity of the signal is proportional to the amount of dsDNA. 
2.13 Oligonucleotide primer design 
Primers were designed around reference sequences extracted from National 
Centre for Biotechnology Information (NCBI) website (http: //www. ncbi. nlm. nih. gov). 
The required sequence data was aligned with MegAlign software in the DNASTAR 
Lasergene Software package (DNASTAR Inc, Madison, USA. See 
www. dnastar. com). Alternatively, lengthy sequences were aligned and 
interrogated using the European Bioinformatics Institute website 
(http: //www. ebi. ac. uk . 
Primers were designed following published recommendations (Innis and Gelfand, 
1990). Primers were designed to be 15-30 nucleotides in length with G+C content 
of between 40-60% and a melting temperature (Tm) of between 50-70°C. Each 
primer in a set was designed to have approximately equal melting temperatures. 
Complementarity, especially at the 3' end (to prevent primer-dimer formation) and 
runs of 3-4 repeats of the same base were avoided. To introduce relative 
instability to the 3' end of primers and to reduce non-specific priming, the number 
of Gs and Cs in the last 5 nucleotides at the 3' end did not exceed two. Primers 
were designed, where possible, to end in aG or C- the 'GC clamp' to increase 
stability. The primer sequence was entered onto the OligoAnalyzer 3.0 software, 
available on the Integrated DNA Technologies website 
(httf): //eu. idtdna. com/analyzer/Applications/OliqoAnalyzer), to check for self- 
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complementarity leading to self-dimerisation and 'hairpin' structures. A BLAST 
database search of the primer sequence was carried out to ensure no homology to 
other sequences. If necessary, primers were modified with LNA additions (see 
section 1.11.1.3). Primers (including fluorescent-labelled primers) were 
synthesised by Metabion GmbH, Germany. LNA primers were synthesised by 
Proligo (www. proligo. com). Nucleotide sequences for all primers used are given in 
Appendix B. 
2.14 Oligonucleotide probe design 
Design of Taqman probes followed the same rules as those described for primer 
design. The probes were designed to have a Tm of around 5-10°C higher than 
that of the primers. The DNA strand which gave the probe more Cs than Gs was 
selected. The placement of aG at the 5' end was avoided. The probes were 
labelled at the 5' end with a specific fluorophore, either FAM, JOE(VIC), ROX or 
Cy5. The 3' end had an attached quencher with was either NFQ, TAMRA, or BHQ- 
2. All probe sequences are given in Appendix B. 
2.15 Real-time PCR master mix preparation and assay set-up 
2.15.1 Rotor-Gene 
All Rotor-Gene PCR assays (except for HCV quantitation and ß-globin quantitation) 
were carried out using the LightCycler® FastStart DNA Master HybProbe kit 
(Roche Diagnostics, Burgess Hill UK, cat. no. 12239272001). HCV quantitation 
was carried out using the SuperScriptTM III RT/Platinum® One-Step Quantitative 
RT-PCR System (Invitrogen, Paisley UK, cat. no. 11732-088). ß-globin 
quantitation was carried out using the Platinum® Quantitative PCR SuperMix-UDG 
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kit (Invitrogen, Paisley, UK, cat. no. 11730-025). A PCR master mix was prepared 
by combining the appropriate reagents in a 1.5 ml flat cap microcentrifuge tube. 
Following gentle mixing, the mix was dispensed in appropriate volumes into 0.1 ml 
(Rotor-Gene 72-sample carousel) or 0.2 ml PCR tubes (Rotor-Gene 36-sample 
carousel). Target DNA/cDNA was added to each appropriate tube. Positive and 
negative controls were included in every analysis. Optimised master mixes for all 
assays are given in Appendix C. The samples were then loaded into the Rotor- 
Gene 3000 carousel. 
Amplification profiles were created for each assay, determined by optimisation 
experiments and are outlined in Appendix C. Prior to the commencement of every 
run, a calibration was carried out on all the channels which would be utilised during 
the run; this adjusted the gains for the channels selected. Following the 
completion of the run, the threshold, which determines the threshold cycle (CT) for 
each sample, was set. This was normally between 0.1-0.2. If plasmid standards 
were used, then 'auto threshold' was selected. This gives the best line of fit for the 
standard curve. 
2.15.2 LightCycler 
A PCR master mix was prepared (LightCycler® DNA Master SYBR Green I kit; 
Roche Diagnostics, Burgess Hill UK cat. no. 12158817001) by combining the 
appropriate reagents (Appendix C) in a 1.5 ml flat cap microcentrifuge tube. 
Following gentle mixing, this was dispensed in appropriate volumes into 20 NI 
LightCycler capillaries. Target DNA/cDNA was added to each appropriate capillary 
which was then capped. The samples were pulse spun in a LC carousel centrifuge 
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(Roche Diagnostics, Burgess Hill, UK, cat no. 12189682001). Optimised master 
mixes for all assays are given in Appendix C. The samples were then loaded into 
the LightCycler 1.5 for real-time PCR. Amplification profiles are outlined in 
Appendix C. 
2.16 PCR optimisation 
For each amplification reaction, optimal PCR reagent and cycling conditions were 
achieved by experimenting with various annealing temperatures and by varying the 
concentration of MgCI2, PCR primers and probes according to published guidelines 
(Innis and Gelfand, 1990). 
To determine the appropriate annealing temperature for each primer set, the 
melting temperature (Tm) for each primer was calculated using the OligoAnalyzer 
3.0 software, as described in section 2.13. The starting annealing temperature 
was taken as 4°C below the average Tm for each primer set. If necessary, this 
temperature was increased or decreased by increments of 1-2°C until the desired 
specificity of product was obtained. 
Once the appropriate annealing temperature was established, the product intensity 
was improved by applying the following reagent titration experiments: 
(i) titration of MgCl2 
(ii) variation of primer concentration 
(iii) variation of one primer with respect to the other, depending on whether the 
probe annealed to the plus or minus strand of DNA 
(iv) variation of probe concentration 
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2.17 Purification of PCR products 
PCR products were purified using the QlAquick® PCR Purification Kit (Qiagen, 
Crawley, UK, cat. no. 28106). All centrifugation steps were at 13000 rpm. Prior to 
purification, PCR products were electrophoresed on 2% agarose (Section 2.7) to 
determine the approximate concentration of each product. In brief, to purify PCR 
products, 5 volumes of buffer PB were added to 1 volume of the PCR sample and 
mixed in a 1.5 ml flat cap microcentrifuge tube (StarLab Ltd, Milton Keynes UK). 
The PB/PCR product mix was added to a QlAquick spin column which had been 
placed in a2 ml collection tube. To bind the DNA, the sample was centrifuged for 
1 min. The flow-through was discarded and the QlAquick column was replaced in 
the same collection tube. To wash, 0.75 ml of Buffer PE (containing 96% ethanol) 
were added to the QlAquick column and centrifuged for 1 min. The flow-through 
was discarded and the QlAquick column was placed back in the same collection 
tube and centrifuged for 1 min to remove any residual fluid. The QlAquick column 
was then placed in a 1.5 ml flat cap microcentrifuge tube (StarLab UK Ltd, 
Buckinghamshire). To elute the DNA, 50pl (or 3Opl if the original PCR product was 
weak - as determined by comparison with PCR markers on gel electrophoresis) of 
buffer EB were added to the centre of the QlAquick membrane. The column was 
left to stand for 1 min and then centrifuged for 1 min to collect the product. To 
determine the yield following purification, purified PCR products were run on a 2% 
agarose gel (Section 2.7). The products were stored at -20°C until required. 
2.18 ABI 3100-Avant genetic analyzer 
The ABI 3100-Avant Genetic Analyzer (Applied Biosystems, Warrington UK) is a 
fully automated DNA analysis system which uses capillary electrophoresis. 
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Samples are simultaneous injected into a parallel four-capillary array using 
electrokinetic injection. This allows faster run times and increases run-to-run 
consistency. The DNA passes through a detection cell and a laser beam 
simultaneously illuminates the four capillaries on both sides of the array. The 
omitted fluorescent light is collected, separated by wavelength and focussed onto a 
charge-coupled device (CCD). The data is then transferred to the instrument 
computer where chemometric algorithmic processing transforms the data into a4 
or 5-dye electropherogram. The ABI 3100-Avant has multiple applications and in 
this study was used for both DNA sequencing and fragment analysis. 
2.19 ABI 3100-Avant system preparation 
The ABI 3100-Avant was prepared as outlined in the manufacturer's guidelines. 
The POP-6TM polymer (Applied Biosystems, Warrington UK, cat. no. 4316357) was 
allowed to equilibrate to room temperature. The 5 ml polymer reserve syringe and 
the 250 pl array-fill syringe were first primed with polymer which was then 
discarded. The 5 ml syringe was filled with 0.5 ml of polymer and the 250 pl 
syringe was completely filled with polymer. All air bubbles were removed by 
inverting the syringe and pushing the air bubbles out. Both syringes were screwed 
into the upper polymer block. 
A 1x working solution of the 10x Genetic Analysis Buffer 310 (running buffer) (Web 
Scientific Ltd, Crewe UK, cat. no. DAD-025) was prepared by adding 2.5 ml to 22.5 
ml ddH2O in a 50 ml polypropylene tube (Elkay Laboratory Products, Basingstoke 
UK, cat. no. 2092-000) and mixing by inversion. The anode buffer reserve was 
filled to the marked level with prepared buffer and attached to the lower polymer 
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block. The interconnecting tube was fastened between the upper and lower 
polymer blocks. A 50 cm ABI 3130/3100-Avant capillary array (Applied 
Biosystems, Warrington UK, cat. no. 4333466) was installed and connected to the 
upper polymer block via the array ferrule knob. The detection cell was secured into 
the detection block. All air bubbles were removed from the system by pushing 
down on each of the syringe plungers in turn whilst holding down the pin valve 
above the lower polymer block and then releasing it to allow air bubbles to flow into 
the anode buffer reserve. Three autosampler reservoirs were filled to the mark 
with ddH2O and the cathode reservoir with 1x running buffer and covered with 
septa. 
Samples were loaded into a 96-well optical reaction plate, fitted with a genetic 
analyser septa and loaded into a 96-well autosampler tray (all included in the 
3100/3100-Avant Genetic Analyser Autosampler Plate kit, Applied Biosystems, 
Warrington, UK, cat. no. 4316471) 
2.20 ABI 3100-Avant calibration 
2.20.1 Spatial calibration 
A spatial calibration was carried out each time that a capillary array was installed, 
and as part of the weekly maintenance, as described in the users manual. This 
maps the position of each capillary on the CCD camera. The capillaries were filled 
each time the spatial analysis was performed. The peak shape and peak spacing 
were visually evaluated each time and the calibration accepted if satisfactory. 
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2.20.2 Spectral calibration 
A spectral calibration was carried out when a new dye set was run for the first time 
or if the dyes were being run under new conditions. The spectral calibration 
creates a mathematical matrix to correct for the overlapping of fluorescence 
emission spectra for the dyes. This creates a matrix file which is then applied to 
samples run under similar conditions. A matrix standard set is used to generate 
the 'multicomponent matrix' required when analysing DNA fragments on the ABI 
3100-Avant. The data collection software for the instrument uses the 
multicomponent matrix to automatically analyse the different coloured fluorescent 
dye-labelled samples in a single capillary. For sequencing analysis, the BigDye® 
Terminator v3.1 Matrix Standard Kit (Applied Biosystems, Warrington, UK, cat. no. 
4336974) (dye set Z) was used. Ten microlitres of the standard were combined 
with 190 pl of Hi-Dim formamide (Applied Biosystems, Warrington UK, cat. no. 
4311320). This was mixed thoroughly, spun in a centrifuge and denatured at 95°C 
for 5 min and immediately placed on ice for 2 min. Ten microlitres of the mixture 
were then dispensed into four wells of a 96-well optical reaction plate which was 
loaded into the autosampler as described in section 2.19. The Plate Editor 
spreadsheet was completed for the wells that were loaded and the correct dye set 
and run module were selected (Spect50_POP6DefaultModule). The spectral 
calibration was run and accepted if the results were within acceptable limits 
outlined in the User Manual. 
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2.21 Sequencing 
2.21.1 Preparation of sequencing reactions 
PCR products were sequenced by automated fluorescent cycle sequencing using 
the BigDye® Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, 
Warrington, UK, cat. no. 4337455). PCR products to be sequenced were first 
purified (section 2.17) and run on gel electrophoresis to check for adequate 
purification and to estimate DNA concentration. 
Products were always sequenced in both directions using the forward and reverse 
primers at 2 pmol/pI concentrations. For each PCR product to be sequenced, two 
reaction mixes were made up in 1.5 ml flat cap microcentrifuge tubes one with the 
forward primer and one with the reverse primer. For each sequencing reaction, 4 
pl of BigDye Terminator v3.1 Ready Reaction Premix (included in sequencing kit) 
and 2 pl of BigDye sequencing buffer (5x) (Applied Biosystems, Warrington, UK, 
cat. no. 4336697) were added to labelled 0.2 ml PCR tubes along with 4 pmol of 
the appropriate primer. Between 1 and 8 pl of purified PCR product were added 
and the volume made up to 20 pl with ultraPURETM water. The amount of PCR 
product added was dependent upon the estimated concentration of the product, 
ascertained from comparison with markers of known concentration on gel 
electrophoresis (section 2.7). Good quality sequence data was usually obtained 
with the addition of 1 pl of PCR product for strong/medium bands on gel 
electrophoresis. All components of the sequencing mix were added in the clean 
room, apart from the PCR products which were added in the detection room. The 
sample tubes were kept on ice whilst the sequencing mix was being made. 
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Cycle sequencing was carried out on a PTC-200 Peltier thermal cycler (MJ 
Research, Waltham USA) programmed to perform the following: 
Denaturation: Rapid thermal ramp to 960C* 
96°C for 1 min 
25 cycles: Rapid thermal ramp to 96°C 
96°C for 10 s 
Rapid thermal ramp to 50°C 
50°C for 5s 
Rapid thermal ramp to 60°C 
60°C for 4 min 
Rapid thermal ramp to 4°C and hold until ready to purify. 
* rapid thermal ramp is 1°C/s 
The sequencing products were then removed from the thermal cycler and spun 
briefly. 
2.21.2 Ethanol/EDTAlsodium acetate purification and precipitation 
The sequencing reactions were purified and precipitated using the 
ethanol/EDTA/Sodium Acetate method. A stop solution consisting of equal 
volumes of 125 mM EDTA (Appendix A) and 3M sodium acetate (Sigma-Aldrich, 
Dorset, UK, cat. no. S-7899) was made up. Four microlitres of the solution were 
added to each well to be used in a 96-well optical reaction plate making sure that 
the solution reached the base of each well. The sequencing products were then 
added to each well. Fifty microlitres of absolute ethanol (Sigma-Aldrich, Dorset 
UK, cat. no. 32221) were added to each well using a multi-pipette and each 
reaction was mixed by pipetting gently up and down. The plate was sealed with 
transparent sealant and left to incubate for 15 min at room temperature. The plate 
was then spun at 2000 xg for 30 min in a Sigma 4-15°C laboratory centrifuge 
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(SciQuip, Shropshire UK, cat no. 10733). Immediately following centrifugation, the 
plate was inverted over lint-free tissue and spun up to 185 xg and then removed 
from the centrifuge. Seventy microlitres of 70% ethanol (Appendix A) were added 
to each well and the plate was spun at 1650 xg for 15 min. The plate was again 
inverted over lint-free tissue and spun up to 185 xg for 1 min (from when the rotor 
started moving) The plate was removed from the centrifuge, inverted and left to air 
dry for 10 min, with the plate protected from the light. The samples were 
resuspended in 10 pl of Hi-Dim formamide (Applied Biosystems, Warrington, UK, 
cat. no. 4311320), pipetting up and down the sides of the wells to ensure the 
samples were fully resuspended. The prepared 96 well sample plate containing the 
purified sequencing products was covered with a plate septum, fixed into a plate 
base and covered with a plate container. The prepared plate assembly was loaded 
into the autosampler. 
Sequencing was carried out on the ABI 3100-Avant Genetic Analyzer using a 50 
cm capillary array (Applied Biosystems, Warrington, UK, cat. no. 4333466) using 
POP-6TM polymer (Applied Biosystems, Warrington, UK, cat. no. 4316357). The 
system was set up as described in section 2.19. The Plate Editor spreadsheet was 
completed for the wells that were loaded. The correct dye set (Z), mobility file 
(DT3100POP6{BDv3}vl. mob), run module (StdSeg50_POP6DefaultModule) and 
analysis module (BC-3100POP6SR_SegOffFtOff. saz) were selected and the run 
was launched. 
2.22 Sequence analysis and alignment 
Sequences were viewed using Sequencing Analysis software v5.2 (Applied 
Biosystems, Warrington UK) to check the quality of the data. Good quality 
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sequence data was then saved and analysed using the DNASTAR Lasergene 
Software package (DNASTAR Inc, Madison, USA. See www. dnastar. com). This 
includes programmes for sequence visualisation (SeqMan), editing (EditSeq) and 
alignment and phylogenetic analysis (MegAlign). 
2.23 PCR product cloning 
PCR products were cloned using the TOPO TA Cloning® Kit for Sequencing with 
TOP10 chemically competent One Shot® cells (Invitrogen, Paisley UK, cat. no. 
K4575-01) following manufacturer's guidelines. Prior to cloning, PCR products 
were purified, as described in section 2.17. 
2.23.1 Ligation 
Ligation reactions were set up using the TOPO vector® as outlined in Table 2.2. 
The amount of PCR product added to the reaction mix was determined by the 
product yield on gel electrophoresis (section 2.7). 
Reagent 
Fresh PCR product 0.5 to 4 pl 
Salt solution 1 NI 
Water Add to a volume of 5 pl 
TOPO vector 1 NI 
Final Volume 6 pl 
Table 2.2: PCR product cloning. Reaction mix for product ligation 
100 
The reaction mix was left overnight at room temperature for maximum uptake of 
the PCR product into the vector. 
2.23.2 Transformation 
The following day a vial of One Shot® Chemically Competent E. coli were thawed 
on ice, one vial for each cloning reaction. Two microlitres of cloning reaction were 
added to a vial and mixed gently. The reaction was incubated on ice for 30 min. 
The cells were heat-shocked by placing the vials in a waterbath set to 42°C for 30 
s. The vials were then immediately transferred to ice. Two hundred and fifty 
microlitres of room temperature S. O. C medium were added to each vial. The vial 
was tightly closed and shaken horizontally in an incubator at 37°C for 1 h. 
Following incubation, the S. O. C medium was spread onto pre-warmed 
LB/Ampicillin agar plates containing 50 pg/ml ampicillin (Appendix A). Different 
volumes, ranging from 10-200 pl were plated onto a total of five plates for each 
transformation to ensure that at least one plate would have well-placed colonies; 
additional S. O. C medium was added to low volumes to ensure even spreading 
over the entire plate. The plates were incubated overnight at 37°C. The following 
day, numbered grids were drawn on the bottom of fresh, prewarmed LB/ampicillin 
agar plates. Using sterile 1 pl loops, 20 individual putative transformants from the 
overnight incubation plates were selected and smeared diagonally within each grid 
square of the new plate. The plate was then incubated at 37°C overnight. The 
plates were covered with ParafilmTN and stored at 4°C until ready for testing. 
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2.23.3 Insert verification 
A small quantity of cells from each of 20 streaked colonies was removed using a 
sterile 1 µl loop and placed individually into 30 µl ddH2O in 1.5 ml flat cap 
microcentrifuge tubes. The samples were placed in a Grant BT3 heating block 
(Grant Instruments, Cambridge, UK) set at 95°C for 10 min and then spun for 2 min 
at 13,000 rpm in a microcentrifuge, to pellet down any agar or cell debris. One 
microlitre of the solution was subjected to colony PCR using the M13 primer pair 
(Appendix B) with a mastermix prepared as outlined in (Appendix C). Gel 
electrophoresis (section 2.7) of the PCR product was carried out to verify the 
presence of the insert. Absence of the insert was demonstrated by a band of 198 
bp. 
2.23.4 Cell harvesting 
A Ioopful of cells from a streaked colony containing the insert was incubated 
overnight in a shaking incubator set at 37°C in 2 separate universals, each 
containing 5 ml of prewarmed LB/Ampicillin broth medium (Appendix A). The 
following day, cells were harvested from one of the universals by repeated 
centrifugation, at 13,000 rpm, of 1 ml aliquots in the same 1.5 ml flat cap 
microcentrifuge tube (Starlab UK Ltd, Buckinghamshire) tube leading to a sizeable 
bacterial pellet at the base of the tube. 
2.24 Plasmids 
2.24.1 Long-term storage of plasmids 
The 5 ml of LB broth containing transformed cells in the duplicate universal which 
were not harvested for the plasmids was mixed with an equal volume of 50% 
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glycerol (Appendix A). The universal was clearly labelled and kept at -70°C for 
long-term storage. 
2.24.2 Plasmid purification 
Plasmids were purified using the QlAprep® Miniprep Kit (Qiagen, Crawley, UK), 
following manufacturer's guidelines. In brief, the pelleted bacterial cells were 
resuspended in 250 pl of Buffer P1. Two hundred and fifty microlitres of Buffer P2 
were then added and the solution mixed thoroughly by inverting 6 times. Three 
hundred and fifty microlitres of Buffer N3 were then added and mixed immediately 
and thoroughly by inverting 6 times. The mixture was then centrifuged at 13,000 
rpm, producing a compact white pellet. The supernatants were decanted into a 
QlAprep spin column and centrifuged for 1 min. The flow-through was discarded 
and the QlAprep spin column was washed by addition of 0.75 ml Buffer PE and 
centrifuged for 1 min. The flow-through was discarded and the spin column was 
centrifuged for a further 1 min to remove residual wash buffer. The QlAprep spin 
column was then placed in a clean 1.5 ml microcentrifuge tube. To elute the DNA, 
50 pl of elution buffer (EB) were added to the centre of the QlAquick membrane. 
This was left to stand for 1 min and then centrifuged to collect the product. 
Presence of the plasmid and determination of concentration was carried out by 
subjecting 5 pl of eluted purified plasmid to gel electrophoresis (section 2.7). 
Plasmids were mixed with 50 pl of 1x TE (Appendix A) and stored at -20°C until 
use. 
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2.24.3 Plasmid quantitation 
Plasmids were quantified using the PicoGreen® dsDNA Quantitation Kit and 
reagents (Invitrogen, Crawley, UK Molecular Probes, cat. no. P-7589 [kit], P-11495 
[reagent]) following manufacturer's guidelines. The method was adapted for 
quantitation on the Rotor-Gene 3000. 
A working solution of TE was made by diluting the 20x TE provided with the kit 
(100 pl into 2 ml ddH2O) in a sterile 5 ml universal. A working solution of the 
PicoGreen dsDNA quantitation reagent in DMSO was produced by making a 200- 
fold dilution (10 pi into 2 ml TE) in a sterile 5 ml universal. The solution was 
protected from light and used within a few hours of its preparation. To produce a 
low-range standard curve, the bacteriophage lambda DNA standard provided with 
the kit at 100 pg/ml was diluted 50-fold in TE, in sterile eppendorfs to make a2 
ug/ml working solution. This was then serially diluted 2-fold in TE as shown in 
Table 2.3. Each lambda standard dilution was then mixed 1: 1 with PicoGreen (25 
pI of standard to 25 pI of PicoGreen). This produced a set of 6 standards with a 
DNA concentration range from 1.562-50 ng as outlined in Table 2.3. 
Standard 
number 
Volume (NI) of 
lambda DNA stock 
Volume (NI) 
of TE 
Concentration 
of DNA 
Final amount of 
DNA in reaction 
tube (ng) 
1 5 245 2 /mI 50 
2 100 100 1 /mI 25 
3 100 100 500 ng/ml 12.5 
4 100 100 250 ng/ml 6.25 
5 100 100 125 ng/ml 3.125 
6 100 100 65 n /ml 1.562 
I able 2.3: Production of lambda DNA standard curve for plasmid DNA quantitation 
using PicoGreen®dsDNA Quantitation Kit 
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A1 in 10 dilution of the purified plasmid stock was made in TE (5 pl of plasmid into 
45 pl TE) and then a series of four 1 in 2 dilutions in TE was made (25 pi plasmid 
dilution with 25 pl of TE) in sterile 0.2 ml tubes. Each dilution was then mixed with 
an equal volume of PicoGreen (25 pl of plasmid dilution to 25 pI of PicoGreen) in 
sterile flat-lid tubes. These were loaded onto the Rotor-Gene 3000 carousel and 
were run using the following conditions: 
Hold 30°C 5 min 
Cycling 8 cycles 30°C 20 s acquiring to FAM 
The lambda standards were used to create a standard curve. The appropriate 
dilution of plasmid whose concentration fell within the standard curve was used to 
calculate the DNA concentration of the plasmid stock solution. 
2.24.4 Plasmid linearisation 
Linearisation of recombinant plasmids was carried out using the Pst / enzyme 
(Invitrogen Life Technologies, cat. no. 15215-015). The reaction buffer was diluted 
1 part in 10 with ddH2O and recombinant plasmid was added to the buffer and left 
to incubate at 37°C for 2.5 h. 
2.25 Development of reference strand conformation analysis (RSCA) on the 
ABI 3100-Avant 
2.25.1 Preparation of fluorescent labelled references (FLRs) 
To create a plasmid stock of D-loop amplicon from which FLR could be continually 
produced, extracted nucleic acid was first amplified using the primers DloopF and 
DloopR (Appendix B) in an optimised block-based PCR protocol (Appendix C). 
The PCR product was monitored by 2% agarose gel electrophoresis (section 2.7), 
purified (section 2.17) and cloned (section 2.23). The purified plasmid was diluted 
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in a working solution of Ing/pl herring sperm DNA (Invitrogen, Paisley, UK, cat. no. 
15634-017, stock solution at 10 mg/ml) to a 10 -6 dilution. 
To create the FLR, PCR amplification of an appropriate dilution of the D-loop 
plasmid (found by experimentation to be 10-6) was carried out as described above, 
substituting the DloopF primer for DloopFLab (labelled at the 5' end with FAM 
fluorophore). Products were monitored and purified as described before. The 
purified FLR was mixed with 50 pl of 10 mM EDTA (Appendix A) to inactivate the 
polymerase. This was stored at -70°C until required. 
2.25.2 Duplex formation 
To form duplexes, one microlitre of the FLR was added to a 0.2 ml microtube and 
mixed with 3 pi of the PCR product (generated using primers DloopF and DloopR 
as described in section 2.25.1). Samples were then placed in a thermal cycler and 
denatured at 96°C for 4 min. The temperature was then reduced slowly over a 
period of 5 min to 55°C and held there for 1 min to facilitate hybridisation of the 
complementary sense and anti-sense strands. The temperature was then reduced 
over a period of 5 min to 15°C and held there for 8 min. 
2.25.3 Dilution of duplexes prior to RSCA 
Following duplex formation, the product required dilution to produce optimum 
fluorescent signal intensity without 'pull-up' peaks from overloading of sample or 
low intensity from over-dilution. The optimised dilution protocol required the 
product to be first diluted 1 in 10 by adding 36 pl of ddH2O and mixing. Ten 
microlitres of this dilution were then mixed with 10 pl of ddH2O and 0.5 pl of 2500 
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(ROX) GeneScan size standards (Applied Biosystems, Warrington, UK) in a new 
0.2 ml tube. The samples were then transferred to a 96-well optical reaction plate, 
fitted with a genetic analyser septa and loaded into a 96-well autosampler tray (all 
included in the 3100/3100-Avant Genetic Analyser Autosampler Plate kit, Applied 
Biosystems, Warrington, UK, cat. no. 4316471) and run on the ABI 3100-Avant 
analyser. 
2.25.4 Spectral calibration 
In this particular application, only two fluorescent dyes were run (FAM for the FLR 
and ROX on the size standards). The DS-30 (dye set D- 6FAM, HEX, NED and 
ROX) Matrix Standard Kit was used (Applied Biosytems, Warrington UK, cat. no. 
4345827) to create the matrix file. A spectral calibration was performed with DS-30 
as described for dye set Z in section 2.20.2 but with 5 pl in 195 pi Hi-Dim 
Formamide for DS-30. After correction, the fluorescent intensities are colour- 
coded and displayed as peaks in the electropherogram which allows the samples 
and size standards to be distinguished. 
2.25.5 Experimental design considerations 
Before samples were run on the ABI 3100-Avant Genetic Analyser, certain basic 
design factors had to be considered: 
" Fluorescent signal intensity had to be between 150-2000 relative fluorescent 
units (RFU) 
" Optimisation of electrokinetic injection parameters 
" Optimisation of electrophoresis conditions e. g. polymer type and run time for 
accurate detection of all fragments 
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Extensive experimental work was required to determine the optimal conditions in 
terms of fragment resolution and fluorescent signal intensity for the RSCA analysis. 
2.25.6 Capillary electrophoresis 
Samples were run on the ABI 3100-Avant Genetic Analyser (Applied Biosystems, 
Warrington, UK) which was prepared as described in section 2.19. A plate record 
for fragment analysis was created using the plate editor in the GeneScan 
application. Each sample was entered into the spreadsheet. The size standard 
dye colour was kept as the default (red) which corresponds to ROX label being 
present on the size standards. The appropriate dye set (D) was selected. The 
appropriate, optimised run module was generated in the Module Editor. All 
parameters of the run module had been determined experimentally to produce 
conditions for electrophoresis which produced optimum fluorescent signal intensity, 
fragment resolution and run time. The following parameters were applied in each 
run: injection time = 45 s, injection voltage =2v, run voltage = 15 v, run time = 
3600 s, run temperature = 30°C with POP-6 polymer and a 50 cm capillary array in 
situ. The GS500analysis. gsp module was selected for data analysis and the 
samples were then run. 
2.25.7 GeneMapper analysis 
Following electrophoresis, fragment analysis of RSCA data was carried out using 
GeneMapper® software v4.0 (Applied Biosystems, Warrington, UK). To set up the 
software for fragment analysis, the analysis settings were configured in the 
GeneMapper Manager. The 'basic' peak detection algorithm was selected and 50 
rfu was selected as the user-specified minimum peak height for all of the dyes. The 
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fragment sizes of the GeneScan-2500 ROX internal size standards (ISS) were 
entered into the size standard editor of the GeneMapper Manager, as a new size 
standard. The fragment sizes for this set of standards are shown in Figure 2.3. 
Following electrophoresis, sample data was imported into a new project on the 
software. The configured analysis method and size standards were selected. The 
samples were then analysed. The sample sizing quality was assessed and the 
peak assignments for any low quality samples was checked in the Size Match 
Editor and altered if necessary. The plots were displayed which enabled 
visualisation of the internal standards and the fragments for each sample. The 
migration of each fragment could be determined by the mobility value which was 
recorded in a sizing table for each detectable fragment. 
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Figure 2.3: Electropherogram of the GeneScan-2500 size standards run 
under non-denaturing conditions. An * for the 508 bp peak denotes a peak 
result from abnormal migration. This peak should not be used to size 
samples. Taken from the GeneScan Reference Guide p5-17. (Applied 
Biosystems, 2000). 
2.26 Statistics 
For the HCV clearance study, detailed statistical analysis was carried out using the 
SPSS statistical analysis software (SSPS Inc, Chicago, IL, USA). Mutlivariable 
regression analysis was performed using STATA® data analysis and statistical 
software (StataCorp LP, Texas, USA), using the Binreg Command to obtain 
relative risks (RR). For the study on mtDNA deletions (Chapter 4), statistical 
analysis of data was carried out with the chi-square test using the StatsDirect 
software package (StatsDirect Ltd, Cheshire, UK). Probit analysis for the HCV 
quantitation assay was also carried out with the StatsDirect software package. 
I lo 
CHAPTER THREE 
Molecular Diagnosis/Monitoring of 
HCV Infection 
3.2 HCV Genotyping 
3.3 HCV Subtyping 
3.4 HCV Quantitation 
3.5 HCV Clearance Study 
3.1 Overview 
The increasing incidence of HCV and the resulting demand for diagnostic 
techniques has led to the need for rapid, sensitive and accurate methods for 
HCV quantitation and genotyping. Due to the potential high number of mild 
cases of HCV, the recent extension of the original NICE guidance by the re- 
named National Institute for Health and Clinical Excellence recommends that, in 
addition to those with moderate to severe HCV infection, patients diagnosed 
with mild chronic HCV should also be offered treatment (NICE, 2006). This has 
put further pressure on laboratories for high-throughput diagnostic techniques 
to support clinical practice. 
The requirement for HCV isolates to be genotyped was recognised in 2004 with 
the publication of NICE guidance (NICE, 2004,2006) which recommended that 
treatment of moderate to severe chronic HCV (and more recently for mild 
disease) in people over the age of 18 years should be tailored according to 
genotype. The gold-standard for HCV genotyping is nucleotide sequencing 
followed by phylogenetic analysis (Robertson et al, 1998; Simmonds et al, 
2005). The 5'UTR which is highly conserved yet displays genotype-specific 
motifs is the preferred target (Germer et a/, 1999). Sequencing is, however, 
labour-intensive and time-consuming, reducing its value in a high-throughput 
laboratory. 
HCV genotype may also be an indicator of whether an individual is able to 
spontaneously resolve HCV genotype without treatment. Spontaneous viral 
clearance occurs in around 25% of infected individuals (Micallef et al, 2006). 
Early studies have suggested that genotype 3 infections are more likely to clear, 
with genotype 1 infections more likely to proceed to chronicity (Lehmann et al, 
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2004; Hwang et al, 2001). However, a recent study has indicated that 
individuals with HCV genotype 1 infections are more likely to clear the infection 
than those with non-1 types (Harris et al, 2007). 
Although identification of HCV isolates at the subtype level is not yet a 
requirement for patient management, HCV subtyping is not merely of academic 
interest. It can have applications in the study of HCV evolution, epidemiology 
and outbreak/transmission investigations. The possibility of an association 
between subtype 1b, progression to chronicity and its refractory nature with 
regards to treatment, means that the ability to distinguish subtype 1b from non- 
lb subtypes could be a valuable tool in the future. Attempts have been made to 
use the 5'UTR for subtyping purposes, with limited success. This region is 
simply too conserved to have the necessary discriminatory power for subtype 
determination. Attention has therefore turned to other regions of the HCV 
genome, with the NS5b region being a prime target, due to its variability. 
Real-time PCR has become increasingly important in the diagnostic laboratory 
and promotes itself as the best platform to provide assays necessary for the 
diagnosis and management of patients with HCV infection. Recent advances in 
probe technology include the addition of 3' minor groove binding (MGB) groups 
and the incorporation of locked nucleic acids (LNA). These modifications 
stabilise the template probe hybrid and have allowed the design of shorter 
probes which are highly sequence-specific over small regions and therefore 
ideal for genotyping assays. The ever-increasing array of fluorescent labels for 
these probes, along with the evolution of multi-channel, real-time DNA 
amplification systems, permits the design of multiplex, rapid and relatively 
inexpensive genotyping/subtyping assays. 
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Detection and quantitation of HCV viral load is important both in diagnosis and 
clinical management of HCV. Commercial PCR-based tests are expensive and 
so the development of in-house assays is advantageous. HCV can circulate in 
low titres in infected individuals; therefore the lower detection limit (-500 IU/ml) 
of some commercial kits can give rise to false-negative results with serious 
implications for virus transmission. False-negative results can also occur as a 
result of degradation of nucleic acid or inhibitors within the serum sample. An 
internal control (IC) is a vital component of nucleic acid amplification assays to 
detect false-negative results. It can be added at the extraction stage and is co- 
amplified with the sample. If the IC cannot be detected, this demonstrates a 
problem with the assay/sample which can then be re-extracted and re-tested. 
3.1.1 Aims 
The primary aim of the research described in this chapter was to develop an 
HCV diagnostic/monitoring service to support clinical practice, using the latest 
real-time PCR technology. These assays would need to be rapid, to provide 
good turn-around times in a high through-put laboratory and inexpensive for the 
service to be competitive. High speed and low cost could not be at a detriment 
to accuracy and reproducibility. The main targets were: 
" to develop a real-time PCR HCV genotyping assay, capable of 
detecting all the currently circulating genotypes in the region of the 
UK covered by the hepatology service 
" to develop a real-time PCR HCV quantitation assay complete with 
an IC, to accurately determine HCV viral load whilst removing the 
possibility of releasing false-negative results 
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" to develop an assay for the accurate subtyping of HCV isolates to 
provide a useful tool for epidemiological studies and transmission 
investigations 
" to apply these techniques to elucidate the role of HCV genotype in 
the spontaneous clearance of HCV from certain infected 
individuals. 
3.2 Development of an HCV genotyping assay 
The HCV Taqman genotyping assay described herein was developed as a 
novel technique for identifying the four most common HCV genotypes seen in 
the UK (1-4). This assay has been improved continuously and updated. The 
progress of this evolution to the highly specific, accurate and sensitive method 
now used routinely in our diagnostic laboratory is detailed. 
3.2.1 HCV genotyping primer selection and probe design 
A BLAST database search (http: //www. ncbi. nlm. nih. gov/BLAST) of the 5'UTR 
was carried out to produce a sequence databank of well characterised isolates 
from each of the 6 genotypes (Table 3.1). These sequences were aligned using 
MegAlign software (Section 2.22). The PCR primers HCV3 (NCR4) (Garson et 
al, 1990) and HCV4 (OKA1) (Okamoto et al, 1990) (Appendix B) have been 
reported previously. These primers target highly conserved regions of the 
5'UTR, produce a 259 bp amplicon and were selected for their robustness. 
These primers had been in long-term use within the laboratory for qualitative 
HCV detection in a block-based nested-PCR and had been found to be highly 
specific and sensitive (laboratory data). As a result of the analysis of the 
aligned sequence data, primer HCV3 was modified slightly for improved 
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amplification of all genotypes (a T-+G and a G--+A change, in the 5' proximal 
third of the primer sequence) (Appendix B). 
Genotype Accession Number 
I 1 aAF011752,1 aAF00055302,1 aD29815,1 aD29817,1 aY10150, 
1 bAF483269,1 bAJ006336,1 bAJ238799, I bD31603,1 bD45867,1 bD45870, 
1bD45871,1eL38349 1fL38350 
2 2aD31604,2aD31605,2aD45875,2aL29462,2bAB030907,2bAF057147, 
2bAF057148,2bAF057149,2bD29816,2bD31606,2bD45877,2bD45878, 
2bD45879,2bL29464,2cAF041329,2cL29465,2cL38319 
3 3aAF057151,3aAF057152,3aAF057153,3aAJ006318,3aAJ006323, 
3AJ006331 3bD49374,3 X91421 
4 4aAF057154,4aAF057155,4AJ006324 4aY11604,4U33432,4U81284 
5 5aY13184 5L29585 5L29612 
6 6aY12083,6U33431 
Table 3.1: Accession numbers of the reference sequences used for HCV 
genotyping primer and probe design. All accession numbers are preceded by 
the HCV subtype. All reference sequences are available in the Entrez 
Nucleotide database at http: //Www. ncbi. nlm. nih. gov/sites/entrez. 
The sequence alignment was then utilised to design probes for genotypes 1-4 
by looking for genotype-specific motifs within this region (Figure 3.1). Initially, 
seven type-specific probes were designed, two each for genotypes 1,2 and 3 
and one for genotype 4 (Appendix B and Figure 3.1) using the 
recommendations for probe design (Innis and Gelfand, 1990) outlined in section 
2.14. In brief, all probes: 
" had a Tm of around 5-10°C higher than that of the primers 
" avoided the placement of aG at the 5' end 
" used the DNA strand which gave the probe more Cs than Gs 
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CCATGGCGTTAGTATGAGTGTCGTGCAGCCTCCAGGACCCCCCCTCCCGG Majority 
1.................................................. 1aAFO11752 
1.................................................. lbP F483269 
1........................ A........... C............. 2aD31605 
1........................ A........... C............. 2bD29816 
1---------------------... A........... C............. 2cL38319 
1.............. C................................... 3aAJ006318 
1............. C.................... C........ T.... 3bD49374 
1............... T..... -...... 4U81284 
1 .......... .................. 
4aY11604 
1....................... AA......................... 5aY13184 
1........................ A........... C............. 6U33431 
GAGAGCCATAGTGGTCTGCGGAACCGGTGAGTACACCGG ! Majority 
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.......................................... 
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.......................................... 
C....... 4081284 
51 
................. 
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.................................................. 
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51 
.............................................. 
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A... T........ CC...... 2aD31605 
1c 
.A... T.......... --...... 
A..... A... T... T.... TC...... 2bD29816 
80 
.......... -- ...... A. .... 
A.. T. .CC 2cL38319 
10'1 ............... --........... 
3aAJ006318 
101 ............... --..... A........................... 
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100 ............... --................................. 
4081284 
101 ............... --...... T.......................... 
4aY11604 
....................... 101 ............... --...... AG 
5aY13184 
101 
............... CA...... 
6033431 
GCGTGCCCCCGCGAGACTGCTAGCCGAGTAGTGTTGGGTCGCGAAAGGCC Majority 
149 
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1aAF011752 
149 
.................................................. 
lbAF4832 69 
149 
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149 
............ A.................. 
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3bD49374 
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.................................................. 
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............ A..................................... 
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149 
... ............................................... 
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Panel 1 Panel 2 
Genotype 1 (FAM)- (Cy5) 
Genotype 2 (JOE) T22 (Cy5) 
Genotype 3 T3 (ROX) (JOE) (ROX)* 
Genotype 4 (FAM) 
Figure 3.1: Alignment of the PCR target sequences (devoid of primer sequences) of 
representatives of the six major HCV genotypes displaying the site and context of 
each of the seven Taqman probes designed for HCV genotyping. Dashes indicate 
complete identity with the majority sequence. Probe sites are block shaded within 
their respective sequences, notated with their accession numbers prefixed by the 
genotype number/subtype. The 100% identity of genotype 6 with probe T11 is also 
highlighted. The complete sequence for each probe is given in Appendix B. *The 
NCT333 probe is incorporated into the improved Taqman genotyping assay described 
later in the chapter. In the original genotyping assay the T22 and T4 probes were 
both labelled with FAM and the panel was carried out as two separate Rotor-Gene 
runs. 
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Each probe was labelled with a specific fluorescent dye at the 5' end (FAM, 
Cy5, ROX or JOE) and a quencher at the 3' end (Tamra, BHQ-2 or NFQ) 
(Appendix B). These probes were incorporated into two panels for detection 
and confirmation of each genotype. The first panel included two probes for 
genotype 1 detection (TI, T11) and a single probe each for genotypes 2 (T2) 
and 3 (T3). The second panel, consisting of MGB probes, provided 
confirmation of genotypes 2 (T22) and 3 (T33) and a probe for detection of 
genotype 4 (T4). The restriction on the types of fluorescent dye which could be 
put on the MGB probes meant that both the T22 and T4 probes were labelled 
with a FAM fluorophore. For the second panel, therefore, two reaction mixes 
were needed, one with T22 and T33 and the other with T33 and T4 which 
required two separate assay runs. 
3.2.2 HCV genotyping by sequence analysis 
HCV RNA from the serum of 154 patients with chronic HCV infection, attending 
hepatology out-patients in Cambridge and 4 Quality Control for Molecular 
Diagnostics (QCMD) specimens was studied (n=158). The nucleic acid was 
extracted using the MagnaPure extraction equipment (Section 2.4.1) and 
reverse-transcribed to produce cDNA (Section 2.11). Amplification of the 5'UTR 
took place using the HCV3 and HCV4 primers using a qualitative LightCycler- 
based technique (Section 2.12.2.2 and Appendix C). PCR products were 
retrieved from the glass capillaries and purified (Section 2.17). The purified 
PCR products were sequenced using the HCV3 and HCV4 primers separately 
(Section 2.21). The sequences were trimmed and aligned using MegAlign 
software (Section 2.22). Genotype was determined through both phylogenetic 
analysis using the reference databank and examination of the sequence data 
for the characteristic genotype specific motifs, according to the classification 
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proposed by Simmonds et al (1993). Quantitation of HCV RNA (viral load) was 
carried out using the RealArt HCVTM RG RT PCR reagents (Appendix C). 
Among the genotypes determined by sequencing, 78 (49%) were genotype 1, 
18 (11 %) genotype 2,47 (30%) genotype 3, and 10 (6%) genotype 4. For two 
samples, the heterogeneity of the sequence data indicated mixed infection with 
more than one genotype, with insufficient clarity to identify the involved 
genotypes. Three samples failed to be amplified, the viral load of these were 
very low (<1000 IU/ml). 
3.2.3 Rotor-Gene optimisation 
A selection of cDNA preparations from HCV isolates of known genotype were 
used to optimise reaction conditions for real-time HCV genotyping on the Rotor- 
Gene 3000 DNA Analyser (Corbett Research). Optimisation of the assay was 
carried out as described in section 2.16 to ensure optimum sensitivity and 
specificity with no probe cross-reaction. Each panel of probes was optimised 
separately and reaction conditions for each panel are outlined in Appendix C. 
3.2.4 Sequence-based genotyping vs. Taqman genotyping 
All of the samples which had been genotyped by sequencing were 
subsequently genotyped using the Taqman method and results compared. 
Concordant results were obtained for 77/78 (99%) of the genotype 1 isolates. 
All of these isolates were positive with both the FAM and Cy5 probes. One 
genotype 1 isolate was negative in the Taqman assay, but this had a very low 
viral load (1,095 IU/ml). Results for genotype 2 were concordant with 
sequencing in 17/18 (94%) of isolates. One genotype 2 isolate (3770) was 
negative with both panels in the Taqman assay. This had an undetectable viral 
load with the RealArt quantitation assay. 
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With regards to genotype 3, the Taqman assay was concordant with 
sequencing in 43/47 isolates (91%). One isolate (2242) was negative with both 
panels. Analysis of sequence data demonstrated that this isolate had neither 
the motif for T3 or T33 probe hybridisation having reverted to the consensus 
sequence at both sites (Figure 3.2). This isolate had proven very difficult to 
genotype by sequencing, as the data were difficult to analyse. A BLAST 
database search using the sequence data from isolate 2242 matched it with 
HCV isolate JK055 (acc no D49756) (100% identity). This was an isolate from 
Indonesia, classified as a genotype 3k (Tokita et al, 1996). 
Another isolate (2216) was negative only with the first panel. Sequence data 
analysis revealed that the specific T3 motif had altered from TCA to CCG 
(Figure 3.2). A further isolate, (4886) negative with both panels, was shown 
upon sequence analysis to have both the necessary genotype 3 motifs. This 
isolate had a very low viral load (1127 IU/ml) which may explain the failure of 
the Taqman assay. 
Consensus AAT GCC CGG AAA TTT GGG CGT GCC CCC GCG AGA CTG CTA G 
Genotype 3 --- A---------------------------- TCA --- - 
T3 probe --- --R --- TCA --- - 
T33 probe --- A------------ 
2242 --- --- --- --- --- --- --- --- --- --- --- --- --- - 
2216 --- A-- -A- --- --- --- --- --- --- --- --- -C- --- - 
Figure 3.2: Sequence data, around the sites of the genotype 3 probes, from 
isolates 2242 and 2216, which could not be assigned genotype with the 
Taqman HCV genotyping assay. The consensus sequence is shown along with 
a typical genotype 3 isolate and the probe sequences for the genotype 3 probes 
(T3 and T33). Isolate 2242 lacks both the T3 and T33 probe-binding motifs. 
Isolate 2216 has the T33 probe-binding motif but has two base pair mismatches 
with the T3 probe-binding motif. Nucleotides identical to the consensus are 
indicated with a'-'. R=A or G 
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Isolate 4252 was detected with both the T3 and T11 probes but was negative 
with all other probes including T33. Sequencing analysis identified this isolate 
as subtype 3b and confirmed it lacked the T33 specific binding motif, consistent 
with the known reference subtype 3b sequence (Figure 3.3; acc no D49374). 
Genotype 3b isolates only contain one mismatch with the T11 probe which 
explains the observed cross reaction and shallow curve, devoid of a true 
exponential rise seen with the T11 probe for this isolate. 
Consensus AAT GCC CGG AAA TTT GGG CGT GCC CCC GCG AGA CTG CTA G 
Genotype 3 --- A---------------------------- TCA --- - 
T3 probe --- --R --- TCA 
T33 probe --- A-- -A- --- --- -- 
4252 --- --- --- -G- --- --- --- --- --- --- --- TCA --- - 
Ti]. probe --- --- T-- -G- --- -- 
Figure 3.3: Sequence data, around the sites of the genotype 3 probes, from 
isolate 4252, which could not be assigned genotype with the Taqman HCV 
genotyping assay. The consensus sequence is shown along with a typical 
genotype 3 isolate and the probe sequences for the genotype 3 probes (T3 and 
T33). The T11 (genotype 1) probe sequence data is also shown to demonstrate 
the mismatch of 4252 with this probe. Dashes indicate nucleotides identical to 
the consensus. R=A or G. 
No Taqman probe in the first panel had been designed to detect genotype 4. 
However, it was seen that 6/10 (60%) of the genotype 4 samples were positive 
for Cy5 but not FAM, differentiating them from genotype 1 isolates. This trait 
was observed probably as a consequence of genotype 4 isolates having only 
two mismatches with the T11 probe (Figure 3.1). Genotype 4 isolates share 
exact sequence identity to genotype 3b at this site; therefore, as with the 
genotype 3b, cross-reaction occurred. Sequence data for the TI1 probe site 
was examined to ascertain why only 60% of the genotype 4 isolates cross- 
reacted. No explanation in terms of sequence or viral load arose to account for 
these findings. Genotype 4 isolates could be distinguished from genotype 1 
isolates as they were positive with only one of the two genotype 1 probes (Cy5). 
Moreover, curves with this probe were also distinct from that seen with 
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genotype 1 isolates as they were shallow without a true exponential rise (Figure 
3.4). This could be used as a probable marker for genotype 4 detection. 
The other four genotype 4 isolates were negative with the first panel of Taqman 
probes. All (n = 10) of the genotype 4 isolates were positive with the T4 MGB 
probe. Interestingly, 2 of the 10 were QCMD samples and represented the 
genotype 4 sequence (Figure 3.1, acc no U81284) containing a single mismatch 
(A-G) with the T4 MGB probe, demonstrating that the probe could tolerate this 
single mismatch found in some genotype 4 isolates. Reassuringly, no cross- 
reaction was observed with any of the type I isolates which would contain two 
mismatches with this probe. 
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With the exception of the few cases outlined above, the sequence data 
confirmed the presence of the expected sequence motifs for all the designed 
probes in all the other isolates and no other unexpected probe cross reactions 
were observed (see Table 3.2 for complete probe patterns observed). With 
regards to the two samples for which sequencing had indicated mixed 
infections, one of these was detected with both type 1 probes in the first panel 
and both genotype 2 probes, confirming the possibility of a mixed genotype I 
and 2 infection. The other sample was detected with both genotype 1 probes 
and the genotype 2 probe in the first panel but was negative with the second 
panel genotype 2 probe. This may indicate a slight reduction in sensitivity of the 
second panel for genotype 2 detection. 
The Taqman assay was negative for four isolates (one each of genotype 1,2 
and two genotype 3) genotyped successfully with the LightCycler. They all had 
very low viral loads (1095, undetectable and 1127 IU/ml respectively), which 
could explain the negative result. The fact that they could be amplified with the 
LightCycler assay may reflect a slightly enhanced sensitivity of the latter assay. 
Two of the three isolates negative with sequencing were also negative with the 
Taqman assay, the viral loads for these were extremely low. A sample with an 
'undetected' viral load (6957) whose genotype could not be ascertained with 
sequence data analysis was identified as a genotype 1 with the Taqman assay. 
Results of the comparison between sequence analysis and the Taqman HCV 
genotyping assay are shown in Table 3.2. 
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No of 
isolates (ID) 
Sequence 
Result 
Taqman 
Result 
Probe Patterns 
TI T11 T2 T3 T22 T33 T4 
77 Genotype 1 Genotype 1 + + - - - - - 
17 Genotype 2 Genotype 2 - - + - + - - 
43 Genotype 3 Genotype 3 - - - + - + - 
6 Genotype 4 Genotype 4 - + - - - - + 
4 Genotype 4 Genotype 4 - - - - - - + 
2 Negative Negative - - - - - - - 
1 (3492) ? Mixed Mixed 1 and 2 + + + - + - - 
1 (5493) ? Mixed ? Mixed + + + - - - - 
1 (6050) Genotype 1 Negative - - - - - - - 
1 (3770) Genotype 2 Negative - - - - - - - 
1 (2242) Genotype 3 Negative - - - - - - - 
1 (4886) Genotype 3 Negative - - - - - - - 
1 (2216) Genotype 3 ? - - - - - + - 
1 (4252) Genotype 3b ? - + - + - - - 
1 (6957) Negative Genotype 1 + + - - - - - 
11 5S 
Table 3.2: Concordance between genotype results for the 158 HCV isolates 
assigned genotype via sequenced-based and Taqman genotyping assays. The 
HCV Taqman assay probe pattern for each of the isolates is shown. Non- 
concordant results (n=7,4.4%) are indicated in red type. 
3.2.5 Improvements to the Taqman HCV genotyping assay 
Following optimisation of the genotyping assay and incorporation into routine 
use, failings of the Taqman genotyping assay were identified and four major 
improvements/additions to the original protocol were made: 
3.2.5.1 Positive controls 
A limitation of the original Taqman genotyping assay was the absence of 
positive controls for each genotype. This is important to detect false negatives 
due to probe breakdown or user error when setting up the assay. During the 
initial development of the assay, stored HCV cDNA from previously identified 
genotype 1,2,3 and 4 isolates were included in every run as positive controls 
for each probe. However, these could not be stored long-term due to cDNA 
degradation and were not always available for the less common genotypes (2 
and 4). Positive controls were created by isolating the PCR product of a high 
titre positive for each genotype; purifying it (Section 2.17) and producing 
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plasmid clones of this region (Section 2.23). The plasmid DNA was purified 
(Section 2.24.2) and quantified for each genotype (Section 2.24.3). A dilution 
of plasmid for each genotype, which was sufficiently high to be consistently 
detected, but not to pose a contamination risk was included with each panel on 
each run. Plasmid stock was prepared for long term storage at -20°C (Section 
2.24.1). 
3.2.5.2 New T22 probe 
Subsequent to the initial development of the genotyping assay, the advance in 
probe technology meant that an LNA® probe with a Cy5 attachment became 
available. In the original assay, panel two could not be carried out as a single 
run as the probes for genotypes 2 and 4 were both labelled with a FAM 
fluorophore. A new Cy5-labelled T22 LNA probe was designed (Appendix B). 
This was identical in sequence to the original T22 probe, but had LNA additions 
incorporated at conserved positions within the probe. This was tested against a 
panel of isolates previously identified as genotype 2. This probe could 
successfully detect all genotype 2 isolates. The probe was incorporated into 
panel two and tested against a set of genotype 2,3 and 4 isolates to ensure 
that the reaction conditions were adequate for the new probe, no cross-reaction 
with other probes occurred and to ensure that there was no loss of sensitivity of 
the panel. As a result of this new probe, the HCV Taqman genotyping assay 
was streamlined with a reduction from three to two assay runs per test. The 
second panel now contained probes for genotype 2 and 3 confirmation and for 
genotype 4 detection with no compromise to the assay. 
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3.2.5.3 New NCT333 probe 
Routine genotyping using the original assay identified three isolates that were 
negative with the T3 (panel one) probe but positive with the T33 (panel two) 
probe. Sequence analysis identified that these isolates had no mismatches with 
the T3 probe. It was therefore thought that the failure of the T3 probe was due 
to a stronger stringency and reduced sensitivity with panel one. 
Since a spare channel (ROX) was available with panel two and due to the high 
number of genotype 3 isolates seen in our region (around 46%), it was decided 
to design a further genotype 3 probe (NCT333) which would act as a 
confirmatory probe if T3 was negative. The reference databank was 
interrogated for a further genotype 3 specific motif in the 5'UTR. A putative 
motif was identified (Figure 3.1) and a Taqman probe, NCT333, labelled with a 
ROX fluorophore was designed (Appendix B). This probe was tested against all 
genotype 3 isolates identified during assay development and it detected each of 
them, including those that were negative with the T3 probe. The probe was 
incorporated into panel two and tested against a set of genotype 2,3 and 4 
isolates to ensure that the reaction conditions were adequate for the new probe 
and to ensure that no loss of sensitivity or cross-reactivity occurred with the 
other probes. The new probe was found to have no effect on the 
efficiency/specificity of panel two as all isolates were correctly genotyped with 
no loss of sensitivity. 
3.2.5.4 Additional probe - NS53 
With the original assay, several HCV isolates failed to be correctly genotyped as 
they were positive with the panel one T3 probe but negative with the panel two 
T33 probe (and subsequently found also to be negative by the new NCT333 
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probe). Sequence analysis determined that these isolates lacked the specific 
probe-binding motifs of the T3 and NCT333 probes whilst maintaining the T3 
probe-binding site. A BLAST database search, with the generated sequence 
data, indicated that these isolates were subtype 3b which indeed lacked panel 
two genotype 3 probe-binding motifs (Figure 3.5). 
Consensus TCA ATG CCC GGA AAT TTG G 
T33 --- --A --- A-- --- --- - 
Subtype 3b --- --- --- --- --- --- - 
Consensus CCC GGT CAT CCC GGC AAT TC 
NCT333 --- --- --C --- A-- G-- 
Subtype 3b --- --- --- --- --- G-- 
Figure 3.5: Mismatches occurring with subtype 3b isolates at the T33 and 
NCT333 probe-binding sites. Nucleotides identical to the consensus are 
indicated with a '-'. The NCT333 probe is on the reverse strand and it is this 
sequence that is indicated. 
The relative infrequency of this probe pattern result indicated that subtype 3b 
was not commonly observed. However, to ensure complete coverage of the 
genotyping assay for all observed subtypes, especially with the high prevalence 
of genotype 3 within our region, it was deemed prudent to design a further 
genotype 3 probe to identify subtype 3b isolates specifically. This would 
remove the need to undertake sequencing of these isolates. No further 
genotype 3 specific motifs were available in the 5'UTR, therefore, attention was 
shifted to the NS5b region. This is amplified using the subtyping primers 
(NS5bF2 and NS5bR) described further in the subtyping section (3.3). Using a 
sequence alignment of reference sequences of the NS5b region from genotype 
3 isolates (see Table 3.3 and Figure 3.6), a probe was designed around a 
genotype 3-specific motif in the NS5b region. There were no suitable motifs 
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that were specific for subtype 3b isolates and so the probe was designed to 
detect all subtypes of genotype 3. This probe, NS53, was labelled with a ROX 
fluorophore (Appendix B). Reaction conditions for this additional probe were 
optimised using a panel of genotype 3 isolates, including subtype 3b isolates. A 
subset of isolates of non-3 genotype was also tested to check for probe cross- 
reaction. The fully optimised reaction conditions are given in Appendix C. This 
probe would be utilised to confirm an isolate as genotype 3 in the absence of a 
confirmed genotype 3 probe pattern with panels one and two. 
Subtype Accession Number 
3a AJ291256, AY003970, D17763*, 
D28917* 
3b AF279121, AY443346, AY443347, 
AY515261, D49374* 
Table 3.3: Accession numbers of the reference sequences used for the design 
of the NS53 probe. All reference sequences are available in the Entrez 
Nucleotide database at ham: //vwvw. ncbi. nim. nih. gov/sites/entrez. 
* indicates full-length genome. 
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3.2.6 HCV genotyping algorithm 
To aid implementation of the improved assay into routine diagnostic use, an 
algorithm was conceived to cover all permutations seen in routine HCV 
genotyping (Figure 3.7). Isolates could be assigned a genotype if positive by 
two of the same genotype-specific probes. Only a single probe was available for 
genotype 4, but these are rarely seen and could be considered a confirmed 
genotype 4 with one probe result only. All isolates which were negative with all 
probes, with a viral load >1000 IU/ml or positive with non-concordant genotype- 
specific probes would be identified by sequence analysis. 
3.2.7 Sensitivity and reproducibility 
HCV quantitation of all specimens genotyped using the Taqman assay was 
carried out using the Artus RealArt HCVTM RG RT PCR reagents (Appendix C). 
Viral loads for these samples ranged from 872 to 21,920,463 IU/ml. The viral 
load of the samples negative in the Taqman assay ranged from undetected to 
6053 IU/ml. Any loss of sensitivity at lower viral loads was likely to have been 
caused by the optimisation of cycling temperature and magnesium 
concentrations which enabled maximum stringency and minimal non-specific 
binding of the probes, possibly reducing the sensitivity. From the results, it 
would appear that panel one was more stringent than panel two which would 
reduce its sensitivity somewhat. 
To analyse the variance of repeated runs, a selection of isolates from each of 
the four genotypes were tested on different days. Every sample could be typed 
clearly and no differences were noted between results on the respective days. 
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HCV: RNA 
Positive 
t 
Report as 
type-1 
Subtype if 
required 
PANEL I 
T1 
T11 
P 
P 
N N N 
T2 N P N N 
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Figure IT An algorithm for Taqman HCV genotyping. All isolates can be 
assigned a genotype if positive by two of the same genotype-specific probes 
(except for genotype 4 which has a single probe). All isolates negative with all 
probes, with a viral load >1000 IU/ml and all isolates giving ambiguous probe 
results would be identified by sequence analysis. P; positive, N; negative. 
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3.2.8 Incorporation of the improved Taqman HCV genotyping 
assay into routine use 
Following its modifications, the improved Taqman HCV genotyping assay was 
put into routine use in the diagnostic laboratory. To date (May 2008), 809 
genotyping tests have been carried out on 785 clinical specimens and 24 
external quality assessment samples. The breakdown of results for the clinical 
isolates is given in Table 3.4. 
Genotype Number Percentage of total(%) 
(n=785) 
1 379 48.2 
2 66 8.4 
3 300 38.2 
4 22 2.8 
Mixed 1/3 1 0.1 
Neg 14 1.8 
Unusual probe pattern 3 0.4 
Table 3.4: Genotype identification of 785 clinical specimens genotyped using 
the improved HCV genotyping assay 
Fourteen clinical isolates (1.8%) were negative with the Taqman assay. Of 
these, 12 were samples sent from external laboratories and so the HCV viral 
load was unknown and sequencing was not carried out. The other negative 
isolates were from Addenbrooke's Hospital. One negative isolate was 
sequenced and found to have all genotype 3 specific probe motifs but with low 
viral load (<1000 lU/ml) which could explain the negative Taqman result. The 
other negative isolate was found, on sequencing, to have an absence of all 
probe-binding motifs. A BLAST analysis using the generated sequence data 
indicated that this isolate had 99% homology with an HCV viral variant isolated 
from Jakarta, Indonesia (JK049, acc. no. D49762.1). This isolate had been 
classified into a '10a' genetic group, which is now assigned to a subset of 
genotype 3 (Tokita et al, 1996; Simmonds et al, 2005). 
132 
Three isolates (0.4%) displayed unusual probe patterns with the improved 
Taqman assay and could not be assigned a genotype, according to the 
algorithm. Two isolates (15554 and 16284) were found to be positive with both 
genotype 1 probes and demonstrated a non-exponential curve with the T3 
probe in panel one and negative with panel two. These were sequenced and 
found to have both the genotype 1 probe-motifs and a one basepair mismatch 
with the T3 probe-binding motif (Figure 3.8). A BLAST analysis using the 
generated sequence data indicated that these isolates had 98% homology in 
the amplified region with a subset of 27 subtype 1a isolates. Identical sequence 
homology was seen at the T3 probe-binding site with these reference isolates 
which had all been isolated in South America (e. g. acc no AM 400879). 
Consensus CCC CGC GAG ACT GCT AGC CGA GT 
T3 probe --- --- R-- -TC A-- --- --- -- 
15554/16284 --- --- A-- -TC G-- --- --- -- 
AM400879 --- --- A-- -T'' G-- --- --- -- 
Figure 3.8: The T3 probe sequence indicating (in red) the genotype 3-specific 
motif and the one basepair mismatch of clinical isolates 15554 and 16284 with 
this probe. The exact homology of clinical isolate 15554 with HCV reference 
isolate accession number AM400879 (available at 
http: //www. ncbi. nlm. nih. gov/sites/entrez) from South America is also 
demonstrated. Dashes indicate nucleotides identical to the consensus. R=A 
or G. 
One clinical isolate was negative with all probes with a non-exponential cross- 
reaction with the T11 (Cy5) probe on panel one. A BLAST analysis, using the 
generated sequence data, identified this as genotype 5. The HCV Taqman 
assay was able to assign genotype identity to 98% of clinical isolates. 
Regarding the 24 external quality assessment isolates, the Taqman genotyping 
assay successfully genotyped 21/24 (87.5%). The other isolates were negative 
and were found, on sequencing, to belong to genotype 5. 
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Concerning the epidemiology in the Eastern region, a breakdown of the 773 
clinical isolates successfully genotyped using the improved HCV Taqman 
genotyping assay and sequencing of discrepant isolates is given in Table 3.5. 
Genotype Number Percentage of total (%) 
(n=773) 
1 381 49.2 
2 66 8.5 
3 302 39.1 
4 22 2.8 
5 1 0.1 
Mixed 1/3 1 0.1 
Sex 
Male 490 63.4 
Female 259 33.5 
Unspecified 24 3.1 
Table 3.5: Epidemiology of HCV isolates in the Eastern region 
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3.3 HCV Subtyping 
3.3.1 Description of subtyping assays 
With a clear rationale for the need for an HCV subtyping tool, two assays have 
been developed for this purpose, focussing on the NS5b region. The first is a 
generic assay which is a non-probe based method using SybrGreen to detect 
all known HCV subtypes. This method assigns HCV subtype by direct 
sequencing of a 383 bp NS5b fragment followed by phylogenetic analysis 
against a databank of reference isolates of known subtype. The second 
subtyping assay is a Taqman probe-based method which enables subtype lb 
isolates to be differentiated from `non-1 b' genotype I subtypes. 
3.3.2 Primer design and reference databank preparation 
To design primers for the subtyping assays, a reference databank of isolates 
from all common subtypes was prepared by retrieving reference strain 
sequence data from NCBI and other sources (e. g. Sandres-Saune et al, 2003; 
Simmonds et al, 2005) (Table 3.6). The reference sequences were aligned with 
the MegAlign software in the DNASTAR Lasergene software package, using the 
Clustal W method. Primers were then designed which target the most 
conserved regions of the NS5b gene. Several different primers were tested on 
a panel of HCV isolates, and the most sensitive, NS5F2 and NSFR, (Appendix 
B) were selected for use in the subtyping assays. These primers amplify a 383 
bp fragment of the NS5b gene. Figure 3.9 shows a subset of the alignment of 
reference strains used to design the primers, and indicates the conserved 
nature of the primer sites and the necessity for a certain level of degeneracy 
within the primers to allow for the known sequence variation in HCV isolates. 
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Subtype Accession Numbers 
la D 10749*, M62321 *, AJ291247, AY004022 
lb AY003957, AY003965, AJ291273, AJ238799*, 
AJ849954, AJ849955, AY003957 
1c AY051292*, D14853* 
1d AF037233 
le L38361 
lg AF271798 
Ih AY257087 
ii L48495 
ii AY434113 
2a D00944*, AJ231479 
2b D10988*, AB030907* 
2c AJ231468, D50409* 
2d AB031663* 
2e(2n) L44602 
2f(2p) L44601 
3a D17763*, AY003970, D28917* 
3b AF279121 
3k D63821* 
4a(4r) AJ291282, Y11604 
4d AY743168 
4f AY743145 
4k AY743167 
4o AY743113, AF271815 
4r AY743159, AJ291282 
5a AJ291281, Y13184* 
6a AY973866 
6b D84262* 
6d D84263* 
Table 3.6: Accession numbers of the reference isolates for HCV subtyping. All 
reference sequences are available in the Entrez Nucleotide database at 
http: //www. ncbi. nlm. nih. gov/sites/entrez. "indicates complete genome 
sequence, all other sequences are of the NS5b region only. 
For phylogenetic analysis, it was necessary to trim the sequences used for 
primer design (Table 3.6) to exactly match the amplicon (383 bp), using EditSeq 
in the DNASTAR Lasergene software package to exactly match the target 
amplicon sequence (Section 2.22). 
138 
3.3.3 Generic HCV subtyping assay 
To develop the generic HCV subtyping assay, a real-time PCR method using 
SybrGreen on the Rotor-Gene 3000 was developed to amplify part of the NS5b 
gene using the NS5F2 and NS5R primers. A subset of cDNA preparations of 
isolates previously genotyped using the Taqman genotyping assay was 
selected to optimise reaction conditions. Optimisation experiments included a 
range of isolates from different genotypes to ensure that the assay was equally 
sensitive across all commonly seen genotypes (1-4). The fully optimised PCR 
conditions are outlined in Appendix C. 
3.3.4 Evaluation of HCV generic subtyping assay 
To evaluate the HCV generic subtyping assay, it was used on 50 isolates which 
had previously been subtyped using the TRUGENETM NS5b and the 
TRUGENETM HCV 5'NC (which targets the 5'UTR) commercial assays by 
another laboratory (Visible Genetics, Cambridge). Following amplification with 
the optimised SybrGreen method, the PCR products were purified (Section 
2.17) and sequenced in both directions using the NS5b primers (Section 2.21). 
The sequence data was trimmed to the correct size (if necessary) and imported 
into the reference databank in the MegAlign programme (Section 2.22). The 
sequences were aligned using the Clustal W method. The phylogenetic tree 
was examined and subtype was assigned according to phylogenetic 
relatedness to the reference isolates. In the evaluation study, genotype was 
concordant between all three assays. A comparison of subtyping results 
between the three assays for 50 HCV isolates is shown in Table 3.7. The 5'NC 
assay failed to assign subtype for 12 (24%) of samples. These were eleven 
genotype 1 isolates and one genotype 4 isolate. The TRUGENETM NS5b assay 
and the generic HCV subtyping assay were concordant with all subtypes, with 
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the exception of one isolate which was negative with the generic HCV subtyping 
assay (subtype 2b, by the commercial NS5b assay), due to poor sequence 
data. The TRUGENETM 5'NC assay had two discordant subtyping results, an 
isolate assigned as subtype 1b was identified as a 1a by both NS5b assays and 
a subtype 2a isolate by the 5'NC assay was a 2b by the NS5b assays. Two 
isolates failed to be amplified by both of the NS5b assays. These were 
identified as a 1a and a 3a by the 5'NC assay. 
Commercial assays In-house assay 
Genotype/subtype TRUGENETM 
5'NC 
TRUGENETM 
NS5b 
Generic HCV 
Typing 
1 11 - - 
1a 13 24 24 
lb 6 5 5 
2a 2 1 1 
2b 4 4 3 
2c - 1 1 
4 1 - - 
4a 1 1 1 
4d - 1 1 
3a 12 11 11 
Neg - 2 3 
Table 3.7: Results from the subtyping of 50 isolates by the commercial 
TRUGENET"' 5'NC and NS5b assays and the in-house generic HCV subtyping 
assay. The Trugene NS5b and the Generic HCV Typing assays were 
concordant with all subtypes, with the exception of one isolate which was 
negative with the in-house assay. The Trugene 5'NC assay failed to assign 
subtype for 12 (24%) of samples. 
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3.3.5 Clinical study 
The generic HCV subtyping assay was used on 121 clinical isolates from 
patients attending the hepatology clinic at Addenbrooke's Hospital, Cambridge. 
This included 83 males aged between 26-82 years and 38 females aged 
between 24-72 years. These had been previously genotyped using the HCV 
Taqman genotyping assay, described in section 3.2. Of these 121 samples, 
113 (93.4%) were successfully amplified using the NS5b assay. Eight of the 
specimens could not be amplified using the NS5b assay. A further four 
specimens were amplified but produced sequence data of a quality which was 
too poor to allow phylogenetic analysis. Of the remaining 109 (90.1%) samples 
successfully amplified and subjected to direct sequencing of the NS5b region, 
there was 100% concordance with the Taqman assay with regards to 
assignation of genotype. The NS5b assay classified the 109 specimens into 
seven different subgroups by phylogenetic analysis. HCV subtype distribution 
was 1 a, 46 (42.2%), 1 b, 17 (15.6%), 2a, 4 (3.7%), 2b, 5 (4.6%), 3a, 32 (29.4%), 
3b, 2 (1.8%) and 4a, 3 (2.8%). Thus the most prevalent subtypes were 1a 
followed by 3a then I lb. Figure 3.10 shows an example phylogenetic tree 
demonstrating the subtyping of unknown clinical isolates. 
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AY003965.1 b 
CB670 
C B6866 
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Nucleotide Substitutions (x100) 
Figure 3.10: An example phylogenetic tree showing a subset of reference 
isolates used for HCV subtyping. Accession numbers of the reference 
isolates are shown followed by their subtype assignation. All reference 
sequences are available in the Entrez Nucleotide database at 
http: //www. ncbi. nlm. nih. gov/sites/entrez. `Unknown' (clinical) isolates are 
highlighted. 
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33. 
3.3.6 Tagman HCV subtyping of genotype I isolates 
To develop an assay for subtyping of genotype 1 isolates, the NS5b reference 
databank was interrogated to identify subtype lb and non-1b specific motifs in 
the region between the NS5bF2 and NS5bR primers. Figure 3.11 shows the 
subtype Ib and non-lb specific motifs of a selection of reference sequences 
and clinical isolates. Two probes were designed around these motifs, one for 
subtype lb and one for non-lb subtypes. These Taqman probes were labelled 
with different fluorophores, JOE for lb and FAM for non-lb isolates to allow 
simultaneous detection (Appendix B). The cDNA from a subset of 20 clinical 
HCV isolates, identified as subtype lb and non-lb with the generic HCV 
subtyping assay, was used for assay development and optimisation. The fully 
optimised conditions are outlined in Appendix C. There was 100% concordance 
between the results with the generic HCV subtyping assay and the Taqman 
HCV subtyping assay for genotype I isolates with no probe cross-reaction. 
This assay was only designed for use on genotype 1 isolates. However, to 
ensure that no cross-reaction occurred with other genotypes, a subset of 
isolates from genotypes 2 (n=20), 3 (n=20) and 4 (n=5) were subjected to the 
Taqman HCV subtyping assay. These were all negative, demonstrating that the 
assay was specific for genotype 1 isolates. 
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3.3.7 Taqman HCV subtyping of clinical isolates 
The 1 b/non 1b subtyping assay was used to subtype 108 clinical isolates which 
had been identified as genotype 1 in the Taqman genotyping assay. Of these 
isolates, 77 were positive with the la probe and 26 with the lb probe. Five 
isolates were negative. Figure 3.12 shows a typical Rotor-Gene run with a 
selection of lb and non-lb isolates. Of the negative results, three out of five of 
these came up very late in the genotyping assay (between 32 and 35 Ct). 
These could not be sequenced to ascertain subtype due to weak amplification 
products. This indicated that the subtyping assay was not as sensitive as the 
genotyping assay, which was not unexpected, as the 5'UTR is known to be 
more sensitive. The other two isolates had produced strong positive results 
with the genotyping assay (24 and 29 Ct). These two negative isolates were 
sequenced using the NS5b primers (Section 2.21). The sequence data was 
analysed and the subtype lb and non-lb motifs were examined. The first of 
these (16653) was found to have a one base pair mismatch at the 1b probe site 
(Figure 3.13). The sequence from this isolate was subjected to the generic 
HCV subtyping assay and was found to be phylogenetically related to subtype 
lb isolates. This indicated that failure of the assay was due to the mutation of 
the NS5b sequence at the lb probe binding site. The other isolate (13350) was 
shown, by sequence analysis, to have a two basepair mismatch at the non-lb 
probe-binding site (Figure 3.13). This was subjected to the generic HCV 
subtyping assay and was found to be genetically related to 1a subtypes. 
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8.1 b probe CCG AAG CCA GRC AG 
16653 --- -G- --- -A- -- 
b. Non-lb probe GAY ATC CGT ACG GAG GAG GCA ATC TA 
13350 --T --- --- -T- --- --- --- --A - 
Figure 3.13: The mismatches between (a) the I lb probe and isolate 16653 and 
(b) the non-lb probe and isolate 13350. Mismatches are indicated in blue type. 
R=AorG, Y=CorT. 
Fifteen isolates positive with the 1a probe and ten isolates positive with the lb 
probe had their subtype identity confirmed using the generic HCV subtyping 
assay described above. This confirmed the subtype assignation through 
phylogenetic relatedness to reference strains. 
3.3.8 Positive controls 
Positive controls were created by isolating the PCR product of a high titre 
positive for each subtype; purifying it (Section 2.17) and producing plasmid 
clones of this region (Section 2.23). The purified plasmid DNA was quantified 
for each subtype (Section 2.24.3). A dilution of plasmid for each subtype, which 
was sufficiently high to be consistently detected, but to not pose a 
contamination risk, was included with each panel on each run. Plasmid stock 
was prepared for long term storage at -20 °C (Section 2.24.1). 
3.3.9 Reproducibility 
To analyse the variance of repeated runs, a selection of isolates identified as 1b 
and non-lb were tested on different days. Every sample could be subtyped 
clearly and no differences were noted between the results on the respective 
days. 
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3.3.10 Use of the NS5b subtyping assays in a possible nosocomial 
transmission 
The advantage of having access to HCV subtyping assays was demonstrated 
with the occurrence of a possible transmission situation. It was necessary to 
identify whether nosocomial transmission of HCV had occurred between two 
individuals. The clinical scenario involved two patients who were admitted to 
hospital and were being treated in adjacent beds on the same ward. One 
patient (A) was a known HCV-positive individual. Another patient (B) who was 
not thought, at the time, to be HCV positive was subsequently found, post- 
admission to be infected with the virus. Patient B claimed that his/her lifestyle 
did not leave him/her 'at risk' of HCV and that his/her infection must have been 
acquired from patient A, whom he/she knew to be HCV positive. This has 
important medico-legal issues regarding HCV transmission within the hospital 
setting and could have involved substantial compensation to patient B if 
nosocomial transmission had occurred. The HCV subtyping (and genotyping) 
assays were vital to establish the relatedness of the HCV isolates from patients 
A and B to determine if nosocomial transmission was a possibility. The HCV 
isolates from both patients were genotyped with the Taqman assay and were 
found to be genotype 1. The isolates were then subjected to the lb/non-lb 
assay and were both found to be non-lb, subtype. Finally the isolates were 
subjected to the generic subtyping assay. Analysis of the sequence data and of 
the phylogenetic tree indicated that there were 18 nucleotide differences 
between the two isolates (Figure 3.14). This level of variation (5.14% disparity) 
indicated that it was highly unlikely that transmission of the virus had occurred 
between these two individuals. 
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3.4 HCV Quantitation 
3.4.1 HCV quantitation assay description 
An HCV quantitation assay was designed which would use a serial dilution of 
recombinant plasmid standards, incorporating the HCV target site, as an 
external calibration system. These standards are included in each run 
alongside the samples to be tested. A standard curve is generated by the 
Rotor-Gene by plotting the threshold cycle (Ct) versus the concentration of the 
standards. The HCV RNA quantity of each unknown sample is determined by 
locating its Ct on the standard curve. 
3.4.2 HCV target site 
Two genome target sites within the 5'UTR were tested for HCV quantitation. 
The HCV3 and HCV4 primers used in the genotyping assay were selected for 
their robustness (Appendix B). These primers amplify 259 bp of the 5'UTR. 
Primers established for HCV quantitation in another laboratory (Grant & Garson, 
unpublished) were also tested (Appendix B). These primers - Tag1 and Taq2, 
amplify 90 bp of the 5'UTR. A FAM labelled probe, HCVTaq was designed 
within a conserved area common to both amplicons. Figure 3.15 shows the 
positions of the HCV3 and HCV4 primers, the Tag1 and Taq 2 primers and the 
HCVTaq probe. 
1 gccagccccctgatgggggcgacactccaccatgaatcactcccctgtgaggaactactg 
61 tcttcacgcagaaagcgtctagccatggcgttagtatgagtgtcgtgcagcctccaggac 
121 cccccctcccgggagagccatagtggtctgcggaaccggtgagtacaccggaattgccag 
181 gacgaccgggtcctttcttggatcaacccgctcaatgcctggagatttgggcgtgccccc 
241 gcaagactgctagccgagtagtgttgggtcgcgaaaggccttgtggtactgcctgatagg 
301 gtgcttgcgagtgccccggg 
Figure 3.15: Position of the HCV3/HCV4 primers (bold red font), Tagl/Taq2 
primers (shaded in yellow) and the HCVTaq probe (bold black font). The 
position is relative to HCV type la sequence (GenBank accession number 
M62321). Note the overlap of the HCV4 and Tag1 primer sites. 
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In a direct head-to-head comparison of twenty clinical samples tested on the 
same day, the assay generating a shorter amplicon shifted the crossing point an 
average of 3.4 Ct to the left (SD 2.12 Ct) (Table 3.8), thus showing increased 
sensitivity. The shorter amplicon was therefore selected for further 
development. 
Sample ID HCV3 and HCV4 
259 bp amplicon 
Taq I and Taq 2 
98 bp amplicon 
Ct Variation 
Ct 
6924 22.4 22.1 0.3 
7929 27.6 25.2 2.4 
8555 26.2 22.1 4.1 
8769 25.3 22.7 2.6 
6175 26.7 22.9 3.8 
6433 22.6 22.1 0.5 
5545 22.6 20.8 1.8 
9881 26.3 25 1.3 
7718 36.9 30.1 6.8 
7847 27.4 22.5 4.9 
7857 28.5 24 4.5 
8938 26.4 22.6 3.8 
6193 25.5 21.9 3.6 
6484 25.8 20.7 5.1 
6525 39.3 31.1 8.2 
6080 26.4 25.7 0.7 
886 21.9 21.3 0.6 
7586 27.3 23 4.3 
6026 26.5 22.2 4.3 
2202 27.9 24.1 3.8 
Average: 3.4 
Table 3.8: A comparison of the threshold cycles (Ct) of twenty clinical samples 
amplified using primers which generated either a 259 bp (primers HCV3 and 
HCV4) or a 90 bp (primers Tag1 and Taq2) amplicon from the 5'UTR. The 
difference in Ct values between amplification with each primer set is shown. 
This table illustrates that primers Tag1 and Taq2 are superior. 
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3.4.3 Production and quantitation of plasmid standard 
A plasmid standard was created by cloning the 259 bp 5'UTR amplicon, using 
the HCV3 and HCV4 primers derived from a genotype 4 isolate into the Topo 
TA vector (Section 2.23). Sequencing, using the M13 primer pair (Appendix B), 
was carried out to determine that the amplicon had been correctly incorporated 
into the plasmid (Section 2.21). The plasmid standard was linearised with the 
Pst I restriction enzyme (Section 2.24.4) and serially diluted in polyA for long- 
term storage. The plasmid was quantified and pinned to the World Health 
Organisation (WHO) HCV RNA standard (96/798) which has a known titre of 
5x104 IU per vial. Triplicates of the WHO standard dilutions (neat to 10-3 ) were 
run alongside triplicates of the HCV plasmid standard (Figure 3.16) to quantify 
each plasmid dilution. 
The 10-8 plasmid dilution was then repeated ten times in a single run and an 
average IU calculated (Figure 3.17). The 10.8 plasmid was found to have an 
average of 40,913 IU/ml. The IU of the surrounding plasmid dilutions was then 
extrapolated from this figure. Plasmids dilutions from 10-6 to 10.10 were deemed 
to have a sufficient dynamic range (4,091,300 to 409 IU/ml) to be incorporated 
into the HCV quantitation assay. These plasmids would be used as standards 
in each run, along with a positive and negative control. Ten microlitre aliquots 
of each plasmid dilution were made in polyA and stored at -70°C and thawed 
before use. 
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3.4.4 HCV quantitation optimisation 
To determine the optimal conditions for HCV quantitation (without MS2) the 
plasmid standards were used in a series of optimisation experiments using the 
SuperScriptT"' III Platinum® One-Step Quantitative RT-PCR System. This is a 
one-step system which incorporates the reverse transcription step, thus 
removing the need for a separate cDNA preparation step. A serial dilution of a 
high titre HCV RNA extract was utilised to produce an assay with optimum 
sensitivity. 
3.4.5 MS2 internal control 
Sequence data for MS2 was obtained from NCBI (www. ncbi. nim. nih. gov, 
accession number NC_001417) and used to design the primer oligonucleotide 
sequences (Appendix B) which targeted a 99 bp region, close to the 5' end of 
the MS2 genome (nt 289-387). A probe was designed within the amplified 
region. This was labelled with a JOE fluorophore (Appendix B). 
3.4.5.1 MS2 detection 
MS2 detection was optimised and sensitivity ascertained using a serial dilution 
of the commercially available MS2 RNA supplied at a concentration of 0.8 pg/pl. 
The optimised conditions for MS2 detection on the Rotor-Gene are outlined in 
Appendix C. Using these conditions, MSZ RNA could be detected down to 2 
copies/reaction. 
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3.4.5.2 MS2 bacteriophage propagation 
From plating assays (Section 2.10.3) the stock solution of MS2 phage was 
calculated to have 2.3x109 pfu/ml. Using MS2 RNA as standards, the genome 
copy number was calculated as 9.18 per pfu of stock. Thus the phage stock 
had an estimated 2.1 x1 010 genome copies/ml. 
Determination of optimal input of IC per extraction was carried out by producing 
a 10-fold serial dilution to 10$ of MS2 phage in PBS from the stock solution and 
adding 20 pl of the lower dilutions (10"3 to 10-8) to the extraction tray along with 
200 pl of HCV-negative serum prior to MagNAPure extraction (Section 2.4.1). 
This indicated that 20 pl of a 10-5 dilution (in PBS) of stock was the most reliable 
input per extraction for reproducible MS2 detection. At this dilution, the MS2 
was detected at -27 Ct (Figure 3.18). Below this dilution, the MS2 was 
detected late, -31.5 Ct at the 10-6 dilution and was detected inconsistently at 
lower dilutions. 
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3.4.5.3 Implementation of MS2 into the HCV quantitation 
assay 
The HCV quantitation assay with internal control was optimised primarily to 
HCV target detection, to ensure that the sensitivity and amplification efficiency 
were not compromised by the presence of MS2. The conditions for HCV 
quantitation were not altered from the optimisation experiments. The 
primer/probe concentrations for MS2 detection were reduced to the minimum 
which could consistently detect the MS2 (2 pmol for each primer and the probe). 
Because the reaction was not optimal for MS2 detection, a higher dilution (10-4) 
than expected needed to be added to the extraction tray prior to nucleic acid 
isolation. This equates to 4600 pfu per extraction and, therefore, in the case of 
a 60 pl elution followed by addition of 5 pl of extract, 383 pfu (3516 copies) per 
PCR reaction. At this dilution, the MS2 was consistently detected between 24 
and 26 Ct. The optimised conditions for HCV quantitation with MS2 internal 
control are outlined in Appendix C. 
To ensure that addition of MS2 RNA and MS2 primer and probes did not 
suppress amplification of HCV RNA, RT-PCR profiles of clinical serum samples 
serially diluted and extracted with and without addition of MS2 RNA and 
primer/probes were compared. No significant difference in viral load was noted 
in the HCV/MS2 duplex assay. On 30 specimens the difference in Ct when 
MS2 was included in the run, varied from 0.2-2.39 with an average variance of 
0.9 (Figure 3.19). The sensitivity of the duplex assay was not reduced as 
compared to the HCV assay without MS2. 
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3.4.6 Correlation between the Taqman assay and a commercial 
HCV RNA quantitation assay 
The RealArtTM HCV RG RT PCR kit (Corbett Research) was used in parallel 
with the Taqman HCV quantitation assay to check the accuracy of the 
developed assay. The RealArt kit targets a 240 bp region of the HCV genome. 
It includes 4 quantitation standards of 5x103 (QS1), 5x102 (QS2), 5x101 (QS3) 
and 5x10° (QS4) IU/pI and an internal control. The commercial assay was 
carried out as per the manufacturer's guidelines and recommended Rotor-Gene 
conditions (Appendix C). Thirty HCV positive clinical specimens were quantified 
concurrently, using the Taqman HCV/MS2 assay and the ReaIArtT"" HCV RG 
RT PCR kit. HCV viral load for the specimens ranged from 72 to 6,539,133 
IU/ml. Correlations were statistically significant between these two assays 
(P<0.0001) (Figure 3.20). The plasmid dilutions were also given an equivalent 
concentration when quantified using the Artus standards as when the WHO 
standards had been used for quantitation. 
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L140 
Lop Tagmmn 
Equation: Log Artus = 0.7937 Log Taqman + 1.3631 
Correlation coefficient (r) = 0.964722 (r2 = 0.930689) 
Figure 3.20: Simple linear regression of commercial HCV quantitation vs. in- 
house Taqman assay. Thirty HCV positive clinical specimens were quantified 
concurrently, using the Taqman HCV/MS2 assay and the ReaIArtTM HCV RG 
RT PCR kit. An R value of 0.93 demonstrates good linear relationship between 
the two assays. 
3.4.7 Precision and range of quantitation 
To evaluate the inter-assay reproducibility, plasmid dilutions (4,091,300 to 409 
IU/ml) were examined on five separate consecutive days. Table 3.9 
demonstrates that the co-efficient of variation (CV) of Ct values was between 
1.48 and 3.52%. To evaluate the reproducibility within a run (intra-assay), 
clinical samples were run in triplicate to check for variations in Ct, the co- 
efficients of variation for a set of 7 clinical specimens (A-G) is outlined in Table 
3.10. This ranged from 0.6-2.9%. 
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Threshold c cle (CO 
10 10" 10,0 10' 10" 
Run 
1 20.08 25.00 27.3 30.11 32.40 
2 19.79 23.05 26.36 29.10 31.40 
3 19.54 23.07 26.05 28.70 31.13 
4 20.02 23.11 27.28 29.59 31.76 
5 20.55 23.63 26.79 28.71 31.51 
Mean ±SD 20.00±0.38 23.57±0.83 26.76±0.55 29.24±0.61 31.66±0.47 
CV 1.9 3.52 2.06 2.09 1.48 
Table 3.9: Inter-assay reproducibility of the HCV quantitation assay. The 
plasmids were examined on five consecutive days (runs 1 to 5) and the Ct value 
recorded on each day. SD; standard deviation, CV; co-efficient of variation 
Threshold Cycle (Ct) 
A B C D E F G 
Run 
1 20.16 23.76 27.92 31.28 21.78 26.65 30.5 
2 20.62 23.45 26.95 30.6 21.56 25.3 30.63 
3 20.44 22.59 27.02 30.3 21.58 26.58 30.28 
Mean 
±SD 
20.41 
±0.23 
23.27 
± 0.61 
27.3 
± 0.54 
30.73 
±0.5 
21.64 
±0.12 
26.18 
±0.76 
30.47 
±0.18 
CV 1.14 2.6 1.98 1.63 0.55 2.9 0.6 
Table 3.10: Intra-assay reproducibility of the HCV quantitation assay. 
Triplicates of 7 clinical specimens (A-G) were quantified in a single run and the 
average Ct value calculated. SD; standard deviation, CV; co-efficient of 
variation 
The accuracy of the quantitation assay was also verified using the OptiQuant® 
HCV RNA Quantification Panel (AcroMetrix, cat. no. 94-2011). This is a panel 
of seven samples at pre-determined levels calibrated against the WHO 
standard, ranging from negative to 5x106 IU/ml. Using the plasmids as 
standards, the correct quantities were assigned for each member of the 
OptiQuant® panel. 
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3.4.8 Limit of detection and linearity 
Probit analysis to determine the lower detection limit of the HCV/MS2 duplex 
assay was performed (Section 2.26). The 10"9 plasmid dilution (4103.9 lU/ml) 
was further diluted to produce a series containing 300,150,100,75,50,25 and 
5 IU/ml. These were run in replicates of 10 each in a single run and the number 
of positives per dilution was counted. From these results, a probit analysis was 
performed. This calculated the sensitivity of the assay to be 25 IU/ml (6.3-38.6 
at 95%CL). The linearity was found to be excellent over the dynamic range 
covered by the plasmid standards with a slope of -1.0 on the loglo scale on all 
assay runs. 
3.4.9 Genotype sensitivity 
The NIBSC HCV RNA genotype panel for nucleic acid amplification techniques 
(NIBSC code 02/202) was used to assess the capability of the HCV quantitation 
assay to detect all six genotypes. This panel consists of six vials each 
representing one of the six major genotypes at a concentration of 1000 IU/ml for 
each genotype. These were extracted and subjected to the HCV quantitation 
assay. All six genotypes could be detected using the assay. The sensitivity of 
the assay did not vary according to genotype. All six genotypes had a Ct value 
between 30.3 and 31.8 (Figure 3.21). 
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3.4.10 Implementation of the HCV quantitation assay into routine 
use 
The HCV quantitation assay with MS2 internal control has been carried out on 
-6000 clinical specimens. From the optimisation experiments, it was decided 
that any specimen which was found to be HCV RNA negative with an MS2 Ct of 
>29 would be re-extracted and re-tested. Of the clinical samples tested, 10 
(0.17%) were found to be HCV RNA negative with MS2 not detected, or 
detected at Ct >26 and were re-extracted and re-tested. All of these isolates 
were found to be HCV RNA negative on repeat, with positive MS2. 
3.5 HCV clearance study 
The Taqman genotyping, subtyping and quantitation assays described in this 
chapter were all utilised in a study which was designed to investigate whether 
viral genotype was associated with the ability to clear HCV spontaneously. All 
patients presenting as new referrals to the hepatology clinic at Addenbrooke's 
Hospital between April 2004 and April 2007 who were HCV antibody positive by 
routine testing were identified; a total of 370 individuals. Of these, a serum 
sample was located with a sufficient volume for testing in 336 individuals. 
These were divided into two cohorts dependent on their HCV PCR result, a 
cohort of 'chronically infected' (HCV RNA positive) and 'spontaneous clearers' 
(HCV RNA negative on PCR). An individual was identified as a spontaneous 
clearer only if they had a positive antibody result (all those with an 
indeterminate antibody result were excluded), had always tested HCV RNA 
negative and had never received treatment for HCV. In total, 219 chronically 
infected and 117 spontaneous clearers were identified. Fifteen clearers were 
subsequently excluded as they were found to have been previously treated for 
HCV. 
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For the HCV RNA positives, infecting genotype was ascertained using the fully 
optimised Taqman HCV genotyping assay described in section 3.2. Three 
isolates had ambiguous results and required sequencing for confirmation. Two 
of these isolates were positive with the two genotype 1 probes but also had a 
cross-reaction with the T3 probe in panel one of the genotyping assay (Section 
3.2). Sequence analysis indicated that with one isolate (10719), there was a 
one basepair mismatch with the T3 probe (as seen with isolate 15554, 
described in section 3.2.8, Figure 3.8). The other isolate which displayed this 
pattern (18854) demonstrated a strong cross-reaction with the T3 probe and 
was seen, on sequence analysis, to have a mix of genotype 1 (CCG) and 
genotype 3 (TCA) specific motifs at the T3 probe-binding site (Figure 3.22). 
This isolate did not display any other genotype 3 specific motifs. To rule out the 
possibility of a recombination event, this isolate was also subtyped using the 
NS5b region, with the methods described in section 3.3 and was found to be 
subtype la. These isolates (10719 and 18854) were both reported as genotype 
1. One isolate (12394) was positive with all genotype 1 and 3 probes. This was 
found, by sequencing, to be a mixed genotype 1 and 3 infection, and was 
excluded from the study. Table 3.11 shows the genotyping results for the 218 
patients successfully genotyped and included in the clearance study. 
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TCA motif 
170 1 
G C G T G C C C C C G C G A G A C C G IC T A G C C G_ A G T A 
C G T G C C C C C G C G A G A N C N C T A G C C G A G A 
IG CGTGCCCCCGCGAGA9CNCTAGCCGAGTA 
Figure 3.22: Sequence data from isolate 18854 which was positive with both 
genotype 1 probes and cross-reacted with the T3 probe. The genotype 3- 
specific TCA motif is shown which demonstrates the mixed sequence, 
displaying elements of both genotypes 1 and 3 at this motif. 
For the spontaneous clearers, the infecting genotype was ascertained by 
serotyping using the Abbot Murex HCV Serotyping kit, following manufacturer's 
guidelines (Section 2.8). In total, 102 specimens were serotyped. Thirty-seven 
isolates were negative and 3 were mixed/non-typable by serotyping and were 
excluded from the analysis, leaving a cohort of 62 isolates successfully 
serotyped (Table 3.11). 
HCV - chronic HCV-clearers 
Genotype Numb er 
1 98 45.0 40 64.5 
2 16(7.3) 4(6.5) 
3 102 46.8 16 25.8 
4 2(0.9) 0 
5 0 1(1-6) 
6 0 1(1-6) 
n= 218 n= 62 
Table 3.11: HCV genotyping and serotyping results of isolates included in the 
HCV clearance study. 
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The specimens from the spontaneous clearers had, at the time of presentation 
to clinic, been identified as HCV RNA negative by PCR during routine laboratory 
testing using the HCV quantitation assay described above (Section 3.4). To 
rule out the possibility that RNA was present, but at levels below the sensitivity 
of the HCV quantitation assay, 1 ml of serum (where available) was 
ultracentrifuged prior to extraction (Section 2.9). The serum was then extracted 
on the BioRobot MDx workstation (Section 2.4.2), on a run that was free from 
HCV RNA positive specimens, and amplified using the HCV quantitation assay. 
HCV RNA remained undetectable in all sera ultracentrifuged prior to extraction; 
MS2 was amplified in these samples within the acceptable range. 
The clinical details for all individuals for whom a serum specimen was available 
(n=336) were collated. These included sex, age, ethnicity (white or non-white), 
country of birth (UK or non-UK), mode of HCV acquisition (IDU or known 
transfusion), alcohol consumption (< or >21 units per week for males and < or 
>14 units for females), age at infection and duration of infection. The duration 
of infection was calculated as the date of sample - age at infection. For each 
individual, infecting genotype was reported either as type I or non-1 type. 
Statistical analysis was carried out using SSPS package (Section 2.26) to 
compare the chronically infected and spontaneous clearers cohort. Univariable 
analysis was carried out on the cohort of individuals for whom a HCV 
genotyping/serotyping result was available (n=280), comparing those who had 
tested positive for HCV RNA (n=218) with those who were presumed to have 
spontaneously cleared the virus (n=62). The clinical details for this cohort and 
univariable analysis for each patient characteristic are shown in Table 3.12. 
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Chronics 
n=218 
Clearers 
n=62 
Statistic (with 
`not knowns' 
excluded) 
P value (with 
`not knowns' 
excluded) 
Male 137 (62.8) 44 (71.0) 42 = 1.39 0.24 
Female 81 (37.2) 18 (29.0) 
UK 81 (37.2) 34 (54.8) x' = 9.82 
(x= = 9.22) 
0.007 
(0.002) 
Non-UK 41 (18.8) 3 (4.8) 
Not-known 96 (44.0) 25 (40.3) 
White 174 (79.8) 47 (75.8) x== 4.64 
(XZ = 1.44) 
0.098 
(0.383) 
Non-white 18 (8.3) 2 (3.2) 
Not-known 26 (11.9) 13 (21.0) 
IDU 134 (61.5) 49 (79.0) X2 = 12.16 
(X= = 0.04) 
0.002 
(0.953) 
Transfusion 24 (11.0) 9(14.5) 
Not-known 60 (27.5) 4 (6.5) 
<21 (M) or <14 
units (F) alcohol 
123 (56.4) 38(61.3) Xs = 0.492 
(x== 0.492) 
0.782 
(0.552) 
>21 (M) or >14 
units (F) alcohol 
88 (40.4) 22 (35.5) 
Not known 7 (3.2) 2 (3.2) 
Type 1 98 (45.0) 40 (64.5) x= = 7.39 0.007 
Non-1 type 120 (55.0) 22 (35.5) 
Mean age at 
infection (yrs)* 
22.6 19.2 t= 2.79 0.006 
Mean duration 
of infection 
rs 
20.9 22.2 t= 0.76 0.448 
Table 3.12: Characteristics and univariable statistical analyses comparing 
those who tested positive for HCV RNA and those who tested negative for HCV 
RNA. *age at infection (and therefore duration of infection) was unknown for 
105 cases. 
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Univariable analysis suggested that HCV PCR negatives (clearers) were 
significantly more likely to be UK-born (P=0.007), have type 1 infection 
(P=0.007) and be younger at infection (P=0.006). To investigate whether the 
association between viral type and viral clearance was independent of other 
potential confounding factors (sex, age at infection, country of birth), a 
multivariable logistic regression analysis was undertaken in STATA using the 
Binreg Command to obtain relative risks rather than Odds Ratios (OR) (Table 
3.13). Age at infection was unknown for 105 individuals and so these cases 
were excluded from the multivariable analysis (leaving 175 individuals eligible 
for inclusion). Factors included in the model were age at infection and country 
of birth (as these two factors were found to have significant effects in the 
univariable analysis (see table 3.12). Sex was also included because of its 
reported influence on viral clearance in other studies (see Section 3.6.4). 
Multivariable analysis demonstrated that a statistically significant association 
remained between viral serotype and viral clearance (RR=1.75,95%CI: 1.151- 
2.663; P=0.009). Additionally, age at infection was also seen to be significantly 
independently associated with PCR negativity (OR=1.849,95%Cl: 1.531,2.233; 
P=<0.001). These results suggest that those individuals who acquired their 
infections at a younger age and who had type 1 infections were more likely to 
clear them. Individuals who had type 1 infections were nearly twice (1.8x) as 
likely to clear them. Similarly, the risk of clearing nearly doubled (1.8x) for every 
10 years younger individuals were at infection. Although those born outside the 
UK were significantly less likely to clear in the univariable analysis, this was no 
longer statistically significant after adjusting for the other factors (Table 3.13). 
However, the point estimate for the relative risk of clearance was less than 0.5 
suggesting this could still be important, in particular considering that the loss of 
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statistical significance was probably a combination of adjustment for the other 
factors and also loss of study power due to missing data for age at infection. 
Factors RR P 95%CI 
Sex (male vs. female) 1.374 0.268 0.784,2.409 
Genotype (1 vs. non-1 1.751 0.009 1.151,2.663 
Age at infection (per 10 year decrease) 1.849 <0.001 1.531,2.233 
Country (baseline UK born) 
Non-UK 
Not known 
0.423 
0.666 
0.204 
0.050 
0.112,1.598 
0.444,0.999 
Table 3.13: Multivariable logistic regression for the 175 individuals for whom 
complete data were available. RR; relative risk. 
Further univariable analyses comparing those individuals included in the 
multivariable analysis (n=175) with those from whom serum specimens were 
available (n=336) but were excluded from any statistical analysis (n=161), were 
undertaken. The results of these analyses are given in Appendix D. 
Regarding the two factors which were shown to be significantly associated with 
viral clearance (age at infection and genotype), no significant difference in age 
at infection was found between those included and excluded from the study 
(P=0.220). With regards to genotype, the analysis demonstrated that there was 
a significant difference between those included and those excluded from the 
study. This simply illustrates that the distribution of genotypes in the final 
sample entering the multivariable analysis varied from that in the original 
sample (x2=55.156, P=<0.001). 
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3.6 Discussion 
3.6.1 HCV genotyping 
The gold-standard for HCV genotyping is sequencing of the genome followed 
by phylogenetic analysis. However, this is impractical on a large scale basis in 
a clinical laboratory. Real-time PCR has recently been identified as a rapid, 
sensitive and specific method for HCV genotyping with two groups recently 
recognising its potential (Schröter et al, 2002; Bullock et al, 2002) These 
protocols used FRET (hybridisation) probes to identify different genotypes using 
melt curve analysis on the LightCycler detection system. Two formats have 
been described using either three sets of probes and two channels (Schröter et 
a/, 2002) or a single set of probes within a single channel (Bullock et al, 2002; 
Haverstick et al, 2004). Although accurate and sensitive, this method does, 
however use amplification products created from separate RT-PCR assays, 
requiring tubes containing amplicons to be opened prior to the genotyping step 
which introduces the possibility for contamination. 
The development of the Taqman HCV genotyping assay described in this 
chapter was the first published report using Taqman probes for HCV genotyping 
(Rolfe et al, 2005). An alternative Taqman-based HCV genotyping assay, using 
a complicated 96-well PCR plate method with each sample being amplified in 
four adjacent wells with probes matching genotypes 1,2,3 or 4 respectively, 
was simultaneously developed (Lindh and Hannoun, 2005). This lacked 
sensitivity compared to the Taqman method described here (10,000-20,000 
IU/ml lower detection limit for most genotypes) and also showed cross-reaction 
between genotype 1 and 4 probes. 
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The Taqman HCV genotyping assay has been continually improved and 
enhanced over the past two years whilst in routine use by sequencing of 
isolates which failed to be genotyped and designing/incorporating new probes 
as required. The current HCV Taqman assay is extremely specific and 
sensitive. Of the 773 clinical isolates that have been genotyped with the latest 
version (excluding the external laboratory specimens which were negative but 
not sequenced), only 5 (0.6%) have required sequencing for identification. 
Failure of the Tagman HCV genotyping assay is due either to very low viral load 
(<1000 IU/ml) or base mutations at a probe binding site. The strict algorithm 
requires all isolates to be positive with two probes (except genotype 4) and, as 
a result, even if a mismatch has occurred at one probe site, then the genotype 
will not be confirmed. Of the isolates that have been positive with one probe, 
and subsequently sequenced, the initial probe result was always correct. HCV 
genotyping of all patients presenting at Addenbrooke's Hospital, Cambridge 
gives a clear indication of the epidemiology of chronic HCV infection in 
Cambridge and the surrounding region between 2005 and 2007 (Table 3.5). 
The findings mirror those of other studies on the epidemiologically of HCV 
infection in the UK which have also demonstrated that genotypes I and 3 
predominate (Watson et al, 1996; Harris et al, 1999; Mohsen et al, 2001). In the 
Eastern region, genotype 1 infection is more common that genotype 3 infection 
(49.2% vs. 39.1 %). This does not reflect the results from a recent large sentinel 
surveillance study (n= 2208) which demonstrated that genotype 3 is slightly 
more common than genotype 1 infection (HPA, 2006). 
This assay was designed to identify the four most common genotypes (1-4) 
seen in the Eastern region of the UK. The assay is not designed to detect 
genotypes 5 or 6. These are singled out as a result of their negativity or non- 
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specific probe reactivity (genotype 6) in the Taqman genotyping assay and are 
sequenced to confirm their identity. There has only been one genotype 5 
isolate from a clinical specimen which had a non-exponential curve with the T11 
probe. Genotype 6 isolates have been part of external quality assurance 
schemes. A genotype 6 result can be predicted by an unusual probe pattern of 
a positive result with only the T11 probe (Cy5) in panel one, which earmarks the 
isolate for sequencing. At present, genotypes 5 and 6 are seen predominantly 
in South Africa and South East Asia, respectively. A limitation of the assay, 
would, therefore be its bias towards UK-based HCV genotypes. This could 
lessen its utility in countries where genotypes 5 and 6 predominate. It could 
also pose a problem if the UK HCV epidemiology alters dramatically in the 
coming years. Detailed analysis of the 5'UTR region has identified that there 
are no motifs which could be used to differentiate genotypes 5 and 6. At 
present only 1 clinical isolate (and three external quality assessment samples) 
have failed to be genotyped by the HCV Taqman assay and were found to be 
genotypes 5. The sequencing burden is therefore very low. If, in future years, 
the numbers of genotypes 5 and 6 increased, then changes would need to be 
made in the HCV genotyping assay. Attention would need to be focused on an 
alternative target with genotype 5 and 6-specific motifs. A further multiplex 
Taqman PCR assay could be developed and any isolates negative with the 
Taqman assay described herein could be subjected to a second genotype 5 
and 6-specific genotyping assay. 
Data published from studies using the TRUGENETM 5' NC genotyping kit (Bayer 
Diagnostics) and the VERSANTTM' HCV Genotype Assay (LiPA), version 1 (line 
probe assay) indicate that the HCV Taqman genotyping assay compares very 
favourably against these commercial genotyping kits. The genotyping 
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efficiencies of these two commercial assays was found to be 94.8% (n=96) 
(Germer et al, 2003). These assays have recently been updated for enhanced 
subtype discrimination which may have slightly improved their genotyping 
capacity (Ross et al, 2007; Ross et al, 2008). The Taqman HCV genotyping 
assay is superior to the TRUGENETM 5'NC genotyping kit as it does not require 
the lengthy sequencing and data analysis steps. The line probe assay has 
equivalent specificity to the Taqman genotyping assay, demonstrating between 
97-100% concordance with sequencing (Haushofer et al, 2003; Zheng et al, 
2003), but lacks the sensitivity seen by the Taqman assay with a lower limit for 
typing reported to be around 20,000 IU/ml (Zheng et a/, 2003). 
The HCV Taqman genotyping assay focuses on a single region of the HCV 
genome. Consequently this assay, as with all commercially available 
techniques, would have limitations if widespread recombination existed 
(Simmonds et al, 2005). At present, reports of recombinant forms of HCV are 
limited (Noppornpanth et al, 2006, Legrand-Abravanel et al, 2007). A 
recombinant consisting of structural genes from genotype 2 and non-structural 
genes from genotype lb has been reported in St Petersburg, Russia (Kalinina 
et al, 2002,2004). Recombination has been reported in other flaviviruses, such 
as the dengue virus (Holmes et al, 1999; Tolou et al, 2001) so it is plausible that 
HCV recombination could occur in patients with multiple exposures. With the 
availability of a subtyping method using the NS5b region, there is the possibility 
of detecting recombination events as both the 5' and a region close to the 3' 
end (NS5b) of the HCV genome can be interrogated to verify whether a 
recombination event has occurred. This, of course, would only be useful if 
recombination was suspected. 
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The field of HCV diagnosis and monitoring is not stationary and continues to 
evolve as new techniques become available. Indeed, since the development of 
the Taqman HCV genotyping assay, other techniques for genotyping have been 
published. Pyrosequencing, a method of DNA sequencing based on a 
chemiluminescent enzymatic reaction (Ronaghi et al, 1998), has been used 
recently to determine HCV genotype (Elahi et al, 2003) and appears to identify 
successfully isolates to the subtype level, despite the short (237 nt) region of 
the 5'UTR targeted. Pyrosequencing has also recently been used successfully 
to identify minority HCV genotypes in multitypic HCV infection (Buckton et al, 
2006) which appears, on examination, to be a rare event, even in people at high 
risk of repeated HCV infection. 
With the updated NICE guidance recommending that all patients, regardless of 
disease severity, should be offered interferon therapy, and the resulting 
increased demand for HCV genotyping, the development of a rapid assay for 
genotyping to support clinical practice was required. The HCV Taqman 
genotyping assay is fast without compromising reliability, sensitivity and 
reproducibility. It also compares favourably in terms of cost when compared 
with sequencing, both in terms of the price of consumables and in worker costs 
per man hour. A worthwhile future development would be to develop this 
method into an assay which could both quantify and genotype in a single assay 
which would dramatically increase throughput for monitoring HCV infection. 
3.6.2 HCV subtyping 
Several groups maintain that their methods for HCV genotyping can also define 
isolates at the subtype level. The INNO-LiPA HCV II, manufactured by 
Innogenetics, is one such example (Stuyver et al, 1993; Andonov and 
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Chaudhary, 1995). Several studies have demonstrated that the line assay is 
unsuitable for subtyping purposes (Ansaldi et a/ 2001: Halfon et a/ 2001; Nolte 
et al, 2003). In particular, it has been demonstrated to be unreliable in the 
differentiation between la/1b, 2a/2c and in assigning subtype to genotype 4 
isolates. The original INNO-LiPA assay has been replaced by a new'improved' 
version (Versant HCV Genotype Assay 2.0), with the addition of core probes. 
Concordance with genotype and subtype with sequencing reference was 
improved from 37.5% with the original version, to 64.7% with the new version, 
but still lacked subtyping capability (Bouchardeau et al, 2007). In a study using 
110 clinical specimens, Ross et al (2007), this assay showed improved 
discriminatory power, particularly with regards to discriminating between 1a and 
lb subtypes when compared to the first generation line assay. However, 
despite the use of the additional sequence information derived from the core 
region, the second generation kit was still unable to make a distinction between 
2a and 2c strains. The TRUGENETM 5'NC genotyping kit also has difficulty in 
determining subtype with an accuracy of only 74% when compared to 
sequencing of the NS5b region (Halfon et al, 2001). Many subtyping assays 
target the 5'UTR which, although containing genotype-specific motifs, lacks the 
variability needed for subtype discrimination. Subtypes 1a and 1b, for example, 
share 98.8% homology in this region. The discrimination between 1a and lb 
subtypes is based on a single nucleotide substitution, an A-to-G transition at 
position -99 which occurs in subtype lb isolates, but is also apparent in subtype 
la isolates (Chen and Weck, 2002). The target of choice for subtyping is the 
NS5b region of the HCV genome which has been shown to provide the 
necessary resolution for subtyping purposes. 
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This chapter describes the development of two subtyping assays which serve 
different purposes. The generic HCV subtyping assay, based on sequencing of 
a region of the NS5b gene can be used for all HCV genotypes. This was 
developed with the express interest of providing a powerful tool for 
epidemiological studies. As demonstrated by the use of this assay in a 
suspected nosocomial HCV transmission, the importance of a reliable 
sequence-based method to investigate suspected transmissions is also vital. 
The second, Taqman probe-based HCV subtyping assay is a rapid, real-time 
assay for discrimination between I lb and non-lb isolates. At present, the 
evidence related to the increased risk associated with subtype lb infection of 
disease severity (Zein et al, 1996; Amoroso et al, 1998; Hwang et al, 2001), 
non-response to treatment (Nousbaum et al, 1995; Manesis et al, 1997) and 
development of hepatocellular carcinoma (HCC) (Silini et al, 1996; Bruno et al, 
1997) is controversial (Benvegnü et al, 1997; Nakano et a/, 2001,2001 a). This 
could be due to the mis-classification of subtypes due to the poor resolution of 
the subtyping assays used. This assay could be utilised in a study to clarify the 
relevance of subtype lb in HCV infection and could find a future use as a high 
throughput method for identification of subtype lb if this were to become 
necessary in HCV monitoring. 
The 5'UTR is favoured for genotyping as its highly conserved nature aids the 
design of primers which target sites with very low sequence variability, reducing 
the possibility of mismatches, therefore increasing assay sensitivity and 
reducing false-negative results. The NS5b region is a much more recalcitrant 
target by virtue of its most beneficial feature - its variability; making primer 
design difficult. However, by creating a large reference databank of the NS5b 
region of all known HCV subtypes, primers for the subtyping assays described 
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here could be designed around the most conserved region, adding degenerate 
nucleotides where necessary. The comparison of the lb/non-lb subtyping 
assay with the genotyping results indicated (by failure to subtype low positive 
genotype I isolates), that the subtyping assay was slightly less sensitive than 
the genotyping assay. However, it was highly specific and could accurately 
subtype all genotype 1 isolates with Ct values <32. 
The specificity and sensitivity of the generic HCV subtyping assay mirror the 
results of studies using either a prototype commercial (Othman et al, 2004) or 
an in-house (Sandres-Saune et al, 2003) HCV subtyping system based on the 
NS5b region. The NS5b subtyping assays demonstrated superiority over the 
TRUGENETM 5'NC assay in terms of subtyping, with 24% of isolates failing to 
have subtype assigned using the 5'NC assay. The failure of the TRUGENE 
NS5b and the HCV generic subtyping assays to amplify 2 and 3 isolates 
respectively (Table 3.7) indicates that the NS5b region is less robust than the 
5'UTR with variation at the primer-binding sequences causing lower sensitivity. 
Through the creation of a generic system for HCV subtyping, a large reference 
databank of trimmed 'ready-to-use' reference sequences, tailored to our 
developed assay, has been produced. This is available as a FASTA file to 
diagnostic laboratories. Laperche and co-workers (2006) have recently carried 
out a multicentre study in which they provided laboratories with expertise in 
sequencing techniques a consensus reference databank and some HCV 
isolates. The accuracy of genotype/subtype assignation was higher in these 
laboratories than it had been previously without the provision of a reference 
databank (Laperche et al, 2005,2006). 
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3.6.3 HCV quantitation 
Commercially available assays for HCV quantitation are being continually 
improved and updated. The latest real-time PCR-based assays such as the 
Cobas Taqman HCV assay and the Abbott Real-Time HCV assay benefit from 
high throughput, automation and large dynamic range with sensitivity down to 
tens of IU/ml (Halfon et al, 2006; Germer et al, 2005; Sizmann et a!, 2007). 
Commercial assays have the disadvantage of being much more costly than in- 
house assays, often relying on specific reagents and equipment. Companies 
do not disclose the primer/probe sequences of their products and so there is not 
the opportunity for isolate characterisation as can occur when an in-house 
assay is developed. 
The limit of detection, the lowest level of HCV RNA that can be detected 
consistently (>95% of the time) is a critical determinant of a successful HCV 
quantitation assay. A patient who has a negative HCV RNA result at the end of 
treatment is seen as a 'responder and therapy terminated. However, if the 
detection assay is not sufficiently sensitive, it may be that there is still a low 
level of circulating HCV RNA and the patient may relapse (Sarrazin et al, 2000). 
Another requirement of HCV quantitation assays is linearity over a large 
dynamic range to enable accuracy over a wide range of HCV viral loads. 
Linearity is assessed by the degree to which the standard curve approaches a 
straight line -a slope of 1.0 on the logio scale. Good linearity means that 
observed changes in viral level reflect actual changes, not those due to biases. 
An ideal HCV RNA quantitation assay would have a lower detection limit of 5-50 
IU/ml and a 6-7 logio linear range to eliminate the need for both quantitative and 
qualitative assays and would be equally sensitive across all genotypes. It would 
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be a one-step protocol, use reliable and reproducible standards which can be 
stored long-term without degradation and have a dependable internal control to 
detect false-negative results. The Taqman assay was developed with these 
points in mind. As a single-step assay it reduces labour and prevents 
contamination which can occur in a two-step or nested-PCR process. The 
amplicon produced is small (90 bp) which aids amplification and increases the 
sensitivity of the assay when compared to one generating a larger amplicon, as 
seen in direct head-to-head comparisons with a larger amplicon. The use of 
plasmid standards as an external calibration system allows a broad dynamic 
range, with detection down to 25 IU/ml -a sensitivity not achieved by many non 
real-time PCR-based assays. The high upper range of the assay - with the 
highest plasmid concentration of over 4 million lU/ml means that samples do not 
require dilution prior to testing. Plasmid dilutions with IU values greater than 4 
million could always be incorporated into the assay, if viral loads were found to 
be outside the scope of the standard curve. The linearity of the developed 
assay is excellent over the wide range of viral loads covered by the plasmid 
standards (4,091,300 to 409 IU/ml). This enables quantitation over the wide 
range of HCV viral loads observed pre-, during and post-treatment to accurately 
assess whether a 2logio viral decline has occurred and thus whether treatment 
should be continued or terminated. 
The Taqman HCV quantitation assay utilises recombinant DNA plasmids to 
produce the standard curve. The PicoGreen dsDNA quantitation reagent, the 
ultrasensitive fluorescent nucleic acid stain was used to quantify the plasmids. 
This has several advantages over determination via absorbance which suffers 
from interference caused by contaminants, inability to distinguish between DNA 
and RNA and the large contribution of nucleotides and single-stranded nucleic 
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acids to the signal. It may be argued that, as HCV is an RNA virus, then an 
RNA template should be used to create the external calibration curve, rather 
than the recombinant DNA used in this assay. However, Pfaffl and Hageleit 
(2001), in a direct comparison of recombinant RNA and recombinant DNA as 
external calibrators, found the latter to be more sensitive, reproducible, stable 
and with a larger quantification range. The choice of a genotype 4 isolate for 
use in the recombinant plasmid was to enable contamination issues to be easily 
detected, as genotype 4 isolates are seen very rarely in our region. 
Linearisation of the plasmid prior to use was carried out so that the standards 
better reflected the linear HCV RNA genome, making quantitation more 
accurate. Pst I was selected as the restriction enzyme for linearisation as the 
site of cleavage is found once in the TopoTA vector and not in the 5'UTR 
amplicon, enabling a single cleavage and a linear molecule to be produced. 
The plasmids are diluted in a DNA carrier (herring sperm DNA) and are 
checked every six months by re-quantifying using the WHO standards to ensure 
no degradation has occurred. The Ct values of the plasmids have not 
increased over time, indicating that they are stable, even when stored long-term 
(data not shown). Moreover, the incorporation of an external quality standard 
with every run has demonstrated a consistent value every time. 
A further requirement of a HCV quantitation assay is that it is equally sensitive 
across all genotypes. This should be achieved by targeting the 5'UTR of the 
genome, which is highly conserved. However, poor genotype performance is 
an old problem in HCV RNA quantitation (Mellor et al, 1999) and remains a 
contentious issue, even with more recent commercial HCV quantitation assays 
(Colson at al, 2006; Gelderblom & Beld, 2007). Many of the published 
developed assays do not test for genotype sensitivity and could, therefore, be 
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under-estimating viral load. The equal sensitivity of the developed HCV 
Taqman HCV quantitation assay across all genotypes (1-6) indicates that this 
assay is not affected by genotype. 
One of the central aspects of the developed Taqman quantitation assay is the 
incorporation of MS2 bacteriophage as an internal control to monitor inhibition 
or RNA degradation. Optimisation of the MS2-specific real-time assay, using 
MS2 RNA demonstrated that MS2 detection was highly sensitive, with a limit of 
2 genome copies/reaction. As a non-competitive IC, MS2 was not expected to 
interfere with viral amplification. However, to minimise the risk of competition 
between target and IC, the primer concentration for MS2 detection was reduced 
on incorporation into the HCV assay. Even at low MS2 primer concentration the 
10-4 dilution of MS2 could still be reproducibly detected at 26 +/-3 Ct with no 
compromise to the detection of HCV. 
For an IC to be useful in a clinical setting it must be produced easily, versatile 
(to be used in a number of different assays) and stored for long periods without 
degradation. The MS2 bacteriophage meets all these criteria. It is easily 
propagated on standard media, and high stock yields can be produced. We 
have stored both the stock solution and aliquots of the working solution for over 
a year at -20°C with no increase in Ct value, indicating that MS2 has long-term 
stability. It is also versatile, and could be used as in IC in all RNA virus 
detection/quantitation assays. We have introduced it into our enterovirus, 
influenza and norovirus (Rolfe et al, 2007) detection assays, using exactly the 
same conditions as outlined above, and these assays are now used routinely in 
our laboratory. Figure 3.23 illustrates the use of MS2 in these assays and the 
reproducibility of its detection in each assay. Others have also recently 
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favourably described the use of MS2 bacteriophage as an IC, using an 
alternative target site (Dreier et a/, 2005,2006). The internal controls which are 
supplied with many commercial kits are incorporated into the master mix and 
can therefore only monitor the amplification process. MS2, by being included in 
the extraction tray, allows the assay to be monitored from the outset and can 
therefore identify faults with the extraction and reverse transcription processes 
in addition to inhibition during amplification. If a laboratory does not wish to 
propagate the bacteriophage, then the commercially available purified MS2 
RNA itself provides an IC which can be added (at very low concentration) to a 
master mix. Experimental data indicates that 0.5 pi of a 10-6 dilution (2x103 
copies) is sufficient for detection. This will, of course, not monitor the extraction 
process but will detect inhibition occurring during reverse transcription and 
amplification steps. 
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The need for an internal control in the HCV quantitation assay could be 
questioned, as only 0.17% (n=6000) of tests required repeating, due to MS2 
negativity or Ct >29. Furthermore, on repeat, none were found to be HCV RNA 
positive, indicating no false-negativity. Some have argued that losses of HCV 
RNA from inappropriate storage or repeat freeze-thawing are negligible (in the 
order of half a logio) (Kessler et al, 2001; Krajden et al, 1999). Significant 
losses in HCV RNA have been seen in EDTA blood stored at 4°C for more than 
48 hours (Damen et al, 1998) and in specimens stored for long periods at room 
temperature. The successful amplification of MS2 in the vast majority of serum 
specimens indicates that this specimen type is relatively free from inhibitory 
substances. The implementation of MS2 into our other RNA virus assays has 
demonstrated that this is not the case for all tissues/body fluids. A much higher 
level of MS2 negativity is observed in assays where viral RNA is extracted from 
tissue specimens, respiratory specimens such as bronchoalveolar lavages 
(BALs) and faecal specimens. Thus the implementation of MS2 into the HCV 
quantitation assay could prove very beneficial if/when the assay is used to 
detect HCV RNA in, for example, liver biopsy specimens. 
The propagation of MS2 and its inclusion in a PCR assay is inexpensive. Once 
propagated and if correctly stored, a stock solution of MS2 will provide a supply 
to last the laboratory for many years. The repercussions which could follow the 
reporting of a false-negative HCV result would be severe and could mean that 
HCV is transmitted unknowingly to others and this in itself should justify the 
valuable contribution made by an IC in HCV quantitation. 
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3.6.4 HCV clearance study 
Early treatment of HCV can prevent chronicity. However, interferon therapy has 
severe side effects and is costly. Spontaneous clearance occurs in around 
twenty to thirty per cent of people with acute hepatitis C (Santantonio et al, 
2002; Micallef at al, 2006). It would be advantageous to be able to identify 
these people prior to therapy. Spontaneous clearance is thought to occur within 
3 months of infection (Gerlach et al, 2003) and so delaying treatment of 
individuals who are likely to clear the virus spontaneously is feasible. For the 
strategy of delayed treatment to be possible, there would have to be very clear 
predictors of the factors, either host or viral, which were strongly predictive of 
spontaneous clearance. Excessive alcohol intake, co-infection with HIV and 
black ethnicity have been linked to a decreased likelihood of spontaneous 
clearance (Thomas at al, 2000; Piasecki et al, 2004) whilst female sex (Alric et 
al, 2000; Micallef et al, 2006; Wang et al, 2007), symptomatic infection (Gerlach 
et al, 2003) and HBV co-infection (Piasecki et al, 2004) have been found to be 
significantly associated with HCV clearance. 
Studies on the influence of HCV genotype have suggested that infection with 
genotype 1b is more likely to proceed to chronicity (Amoroso et al, 1998; Hwang 
et al, 2001). A study of male prisoners in Germany with a high prevalence of 
IDU (98%) found the prevalence of genotype 3 infection to be significantly 
higher among individuals who had cleared the virus (Lehmann et a/, 2004). 
Thus these studies suggest that genotype 1 infections are less likely to clear 
than non-type 1 infections. A recent systematic review of 31 longitudinal 
studies, however, has found no association between viral clearance and 
infecting genotype (Micallef et al, 2006). 
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For an individual to be identified as a spontaneous clearer there must be an 
absence of HCV RNA in the serum. Studies of spontaneous HCV clearance 
have relied on routine methods of HCV RNA detection, and often do not state 
the sensitivity of the HCV quantitation/detection assays used. Increasing the 
sensitivity of HCV RNA detection is possible by ultracentrifugation of the serum 
prior to nucleic acid extraction (Forman and Valsamakis, 2004; Bartolome et al, 
2007). McHutchinson et a/, (1999) used ultracentrifugation of serum samples, 
prior to extraction, to look for the presence of HCV RNA in patients who had 
relapsed following termination of therapy. Using this technique, they detected 
HCV RNA in 58% of relapser patients (n=12) at week 12 and 50% (n=14) at 
week 24. These specimens had all been negative by routine HCV PCR. The 
HCV quantitation assay described in this Chapter and utilised for the HCV 
clearance study, demonstrates excellent sensitivity (25 IU/mI, section 3.4.8). 
However, to guarantee HCV RNA negativity in the serum of presumed 
spontaneous clearers, serum specimens from this cohort were subjected to 
routine HCV RNA detection and then re-tested using this method following 
serum ultracentrifugation prior to nucleic acid extraction. Neither method 
detected HCV RNA in the sera from any of the spontaneous clearers in the 
cohort. 
The possibility of occult HCV infection in individuals presumed to have cleared 
the virus cannot be ruled out. Occult HCV infection is a recently characterised 
entity which is defined as the presence of HCV RNA in the liver without serum 
HCV RNA (Castillo et al, 2004). It can be recognised in two clinical situations: 
in anti-HCV negative, serum HCV RNA negative patients with abnormal LFTs, 
and in anti-HCV positive subjects with normal LFTs and without serum HCV- 
RNA (Carreflo, 2006). In a study on presumed spontaneous clearers (anti-HCV 
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positive, serum HCV-RNA negative patients with normal LFTs), the genomic 
HCV RNA strand was detected in the liver of 85% of these individuals (n=12), 
with HCV replication in all of these patients (Carreho et at, 2006). Interestingly, 
all the infections were found to be with subtype 1 b. These findings suggest that 
the term `spontaneous clearer must be used with care, as these individuals 
may still have genomic HCV RNA in their liver tissue. 
The study described herein supplemented the recent work of Harris and 
colleagues (2007). They had ascertained the infecting type in a large cohort of 
individuals who were chronically infected with HCV (n=508) or had 
spontaneously resolved their infection (n=96). This study demonstrated that the 
prevalence of genotype 1 in those who had cleared the virus was 69% and in 
those that had remained HCV RNA positive was 51%, suggesting that 
individuals with HCV genotype 1 infections were more likely to spontaneously 
clear the virus than those infected with non-1 types (OR 0.47,95% Cl 0.29- 
0.78, P= 0.003). The cohort used in this study (Harris et al, 2007) consisted of 
patients enrolled in the UK HCV National Register. Most of these patients 
(90%) had been traced during the National HCV Lookback Programme and had 
acquired their infection at a known date via transfusion of infected blood (prior 
to routine HCV screening) (Harris et al, 2000). Unlike the study of Harris et al 
(2007), many of the patients in the present study would have been ascertained 
by virtue of their clinical symptoms and hence referred to the hepatology clinic 
for further investigation post testing. As such, cohorts of patients from tertiary 
referral centres are more likely to be biased towards symptomatic disease. 
Also, unlike in the study by Harris and colleagues, date of infection would be a 
crude estimate, as high risk activities would give an uncertain date for HCV 
transmission. 
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The results from the HCV clearance study described in this chapter support the 
findings of Harris and colleagues (2007) and strengthen the argument that 
genotype 1 infections are more likely to clear spontaneously. Infecting 
genotype was significantly associated with PCR negativity in both univariable 
and multivariable statistical analyses. Individuals who had type 1 infections 
were nearly twice (1.8x) as likely to clear them. An additional finding suggested 
that those who acquired their infections at a younger age were more likely to 
clear them, with the risk of clearing nearly doubling (1.8x) for every 10 years 
younger individuals were at infection. One hundred and seventy five individuals 
were included in the multivariable analysis (62.5% of the 280 individuals 
genotyped/serotyped for the study). Non-inclusion in this analysis (n=105) was 
the result of missing data relating to unknown dates of infection for many of the 
individuals in the cohort. Although, a comparison of the clinical characteristics 
of individuals included in the multivariable analysis with those excluded from the 
study (Appendix D) did reveal a number of statistical differences between the 
two groups, none of these differences were likely to invalidate the findings of the 
study. 
The indication that genotype 1 infections are more likely to clear than non-type 
1 infections is contrary to other studies (Amoroso et a!, 1998; Hwang et a!, 
2001; Lehmann et a!, 2004). Although viral clearance could be more likely in 
genotype 1 infections, it is thought that, in those individuals with a chronic 
genotype 1 infection, disease may be more severe (Nousbaum et a!, 1995; 
Pozzato et a!, 1994; Lopez-Labrador et a!, 1997; Tanaka et a! 1998; Harris et a!, 
2007). The link between younger age at infection and increased likelihood of 
HCV clearance, demonstrated in the study described herein, does not appear to 
have been previously reported in the literature. However, younger age at 
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infection has recently been found to be associated with spontaneous clearance 
in childhood HCV infection (Yeung et al, 2007) and older age at infection is 
thought to be linked to increased risk of progression to cirrhosis (Minola et al, 
2002). It is pertinent to mention that in the study described herein the age of 
infection was, for the majority, a crude estimate which relied on each 
individual's recollection of risk incident. For those, such as IDUs, who are 
continually involved in risk behaviour, the age of infection may be highly 
inaccurate. The association between younger age at infection and increased 
likelihood of clearance is not surprising as the immune system is more 
responsive and able to fight infection at a young age and degenerates during 
the ageing process. 
This study has demonstrated that age at infection and HCV genotype are 
factors which are strongly associated with the ability to clear HCV 
spontaneously. In theory, this could be used as factors in identifying individuals 
who are likely to clear the virus spontaneously, without the need for treatment. 
However, these factors are likely to be only two of a number of factors which 
work together to influence the outcome of HCV infection. 
3.7 Summary 
The primary aim of the research described in this chapter was to develop an 
HCV diagnostic/monitoring service to support clinical practice, using the latest 
real-time PCR technology. This aim was achieved with: 
9 Development of a state-of-the-art HCV genotyping assay, one of the first 
to be described and the first published report of using Taqman probes for 
HCV genotyping (Rolfe et al, 2005). The HCV genotyping assay has 
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been continually updated and improved and it will shortly form part of a 
Hepatitis C Virus protocols book (Rolfe et al, in press). 
" Development of an accurate HCV quantitation assay with an internal 
control to prevent false-negatives. The internal control can also be used 
effectively in other RNA virus detection/quantitation assays (Rolfe et al, 
2007). 
" Development of an HCV subtyping assay, shortly to be published, (Rolfe 
et al, in press) which has already proved its worth in resolving a possible 
nosocomial HCV transmission investigation. 
In addition the application of these techniques to elucidate the role of HCV 
genotype in spontaneous clearance of HCV has supported earlier work (Harris 
et al, 2007) in suggesting a link between HCV genotype 1 and spontaneous 
resolution of HCV infection. It has also provided new evidence, not reported in 
the literature of an association between younger age at infection and 
spontaneous viral clearance, which warrants further study. 
In terms of future work, the epidemiology of HCV genotypes is dynamic and will 
continue to change. The HCV genotyping assay will need to be continually 
monitored to ensure that sequencing of isolates is kept at a minimum. If the 
sequencing burden increases, as genotypes such as 5 and 6 become more 
prevalent or as new variants arise, then the assay will need to be re-examined 
and further developed as appropriate. If knowledge of HCV subtype gains 
importance in terms of tailoring of interferon therapy or in identifying subtypes 
which are recalcitrant to therapy, then the same will apply to the HCV subtyping 
assay. 
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CHAPTER FOUR 
Detection and Quantitation of mt497 and mt7436 
Mitochondrial DNA Deletions Using Real-time, 
Three-primer PCR 
4.1 Overview 
Oxidative stress within cells can result in damage to all cellular constituents 
including DNA, proteins and lipids. mtDNA is more vulnerable to oxidative 
damage than nuclear DNA (Yakes and Van Houten, 1997). mtDNA damage 
can be in the form of mutations, rearrangements, duplications and deletions. 
The most frequently examined mtDNA deletion is one of 4977 bp, referred to as 
the 'common deletion' or mt4977. This deletion, spanning from nt 8469-13447, 
results in the damage or removal of major structural genes essential for the 
enzyme complexes of the OXPHOS pathway as well as five tRNA genes. A 
less prevalent, but well documented deletion is that of 7436 bp (identified 
henceforth as mt7436), spanning from nt 8648-16085. Both of these deletions 
are flanked by homologous direct repeat sequences (Class I mtDNA deletions). 
For mt497 this is 13 bp in length whilst for mt7436 it is 12 bp in length. It is 
thought that these repeat sequences create hot-spots for mtDNA deletion 
(Samuels et al, 2004). 
The accumulation of both mt497 and mt7436 in the ageing process is well 
documented (Lee et al, 1994; Zhang et al, 1998; Mohamed et al, 2006). The 
decrease in bioenergetic function seen in the ageing process is thought to result 
from the prolonged exposure of mtDNA to oxidative stress, resulting in the 
accumulation of mtDNA damage (Wei et a/, 1998) - the so-called 'mitochondrial 
theory of aging' (Harman, 1972). Although the age-associated increase in 
these two deletions is well documented, the levels detected are extremely small 
(often <1%) (Wei et al, 1996; Corral-Debrinski et a/, 1992). Cells can exist in a 
state of heteroplasmy where wild-type (wt) mtDNA subsists alongside 
damaged/deleted mtDNA. A deleterious effect is generally demonstrated once 
the proportion of damaged mtDNA rises above a threshold. This threshold level 
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varies from 50-90% depending on the mutation and tissues concerned (Hayashi 
et al, 1991; Porteous et al, 1998; Sciacco et al, 1994). 
HCV infection is known to produce large amounts of cellular oxidative stress 
leading to increased DNA damage (Farinati et al, 1999; Kitada et al, 2001; 
Cardin et al, 2001). This is thought to be due to the effects of the virus itself, 
especially the core and NS5a proteins (Machida et al, 2004,2006; Gong et al, 
2001; Korenaga et al, 2005; Okuda et al, 2002; Otani et al, 2005) and the 
body's inflammatory response to HCV infection (Larrea et al, 1998). 
Respiratory chain defects have also been observed in the cirrhotic liver, 
suggesting damage to mitochondria (Müller-Höcker et al, 1997; Barbaro et al, 
1999). Cells chronically infected with HCV could, therefore, be expected to 
demonstrate high levels of mtDNA deletions resulting from the long-term 
exposure to oxidative stress. 
Early studies relied on visualisation of amplicons on agarose gel or by southern 
blot analysis to quantify mtDNA deletions. Neither of these methods is 
particularly accurate and southern blot analysis lacks the sensitivity necessary 
for detecting low level mtDNA deletions. Attention has turned to methods which 
can both detect and quantify mtDNA deletions relative to wt mtDNA (Pogozelski 
et al, 2003; Bai and Wong, 2005). This chapter describes the development of 
real-time PCR assays to detect and quantify mt497 and mt743s The assays are 
based on the three-primer PCR method described by Sciacco and colleagues 
(Sciacco of al, 1994) which has been transferred to a real-time PCR platform for 
this study. Quantitation of the deletions and of wt mtDNA is achieved by 
reference to plasmid standards containing known quantities of the specific 
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mtDNA amplicon; with the quantity of each deletion calculated relative to wt 
mtDNA. 
This chapter describes the application of the fully optimised assays to study the 
extent of mtDNA damage - in the form of major deletions - in the livers of 
patients chronically infected with HCV. The cohort studied includes 79 patients 
undergoing liver biopsy as part of routine investigations at Addenbrooke's 
Hospital between 2005 and 2007. These individuals all suffer from liver disease 
due to HCV or an alternate liver pathology. This study investigates whether the 
high level of oxidative stress reported in HCV infection results in increased 
mtDNA damage in comparison to other liver aetiologies. 
4.2 Development of experimental procedures 
4.2.1 Ethical approval 
Prior to commencement of the study, ethical approval was obtained from the 
Cambridge Local Research Ethics Committee (LREC) (LREC reference number 
041Q0108/124, Appendix E) and the study was approved by the Addenbrooke's 
Hospital Research and Development Office. Patients were given an information 
sheet and a consent form to sign prior to inclusion in the study (Appendix F). 
4.2.2 Analysis of various homogenisation/extraction methods to 
isolate DNA from liver biopsy specimens 
Several methods and combinations for tissue homogenisation and nucleic acid 
extraction were assessed to determine which produced the best yield of total 
DNA from liver biopsy specimens. Two methods of homogenisation were 
tested - manual and automated (Section 2.3). Four extraction methods were 
evaluated (Section 2.4). Three of these were manual extraction protocols - 
using (i) Trizol® reagent, (ii) QlAamp Viral RNA kit or (iii) DNeasy® Blood and 
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Tissue kit. The fourth method was automated extraction using the Qiagen Bio 
Robot MDx. The protocols were all carried out on 1 mg of fresh pig's liver, to 
ensure consistency of results and to conserve human liver tissue samples. 
Figure 4.1 illustrates the yields achieved by the various combinations of 
homogenisation and extraction methods. Regardless of extraction protocol, 
automated homogenisation was found to be superior to manual 
homogenisation, in terms of yield of DNA. Of the three extraction procedures 
tested, manual extraction using the DNeasy Blood and Tissue kit was deemed 
the best in terms of ease, quality and yield of DNA. The major problem with the 
Trizol® reagent extraction procedure was the poor re-suspension of the DNA 
pellet. This was not achieved successfully despite different approaches to aid 
solubilisation including overnight incubation at room temperature, 4°C or 
heating to 60°C. Automated extraction using the Qiagen Bio Robot MDx was 
comparable to the manual method using the DNeasy® Blood and Tissue kit in 
terms of quality and yield of extracted DNA. However, the manual method was 
more suitable for use on small batches of liver biopsy specimens, and was 
therefore selected for DNA extraction in this study. 
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Figure 4.1: Agarose gel electrophoresis of DNA yields from different 
homogenisation/extraction methods. Lanes 1-4; manual homogenisation, lanes 
5-8; automated homogenisation. Lanes 1 and 5; Trizol® extraction, lanes 2 and 
6; QlAamp Viral RNA kit, lanes 3 and 7; Qiagen Bio Robot MDx; lanes 4 and 8; 
DNeasy® kit. Lane 9; water, M; PCR markers, bp; base pairs. 
4.2.3 Primer design 
The method used for quantitation of mtDNA deletions in this study is based on 
three-primer PCR, an approach developed by Sciacco and colleagues (Sciacco 
et al, 1994). As its name suggests and as illustrated in Figure 4.2, this method 
requires three primers. Primer 1 is common to both deletion and wt mtDNA 
amplification products and hybridises to a region outside the deletion. Primer 2 
hybridises to a region inside the deletion, and primer 3 to the other side of the 
breakpoint from primer 1. Primers 1 and 2 amplify a region representing wt 
mtDNA. Primers 1 and 3 are located sufficiently far apart so that an 
amplification product is produced only if a large mtDNA deletion has taken 
place. 
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Figure 4.2: Schematic representation of three-primer PCR. The mtDNA 
molecule illustrated has a large deletion. The deletion is detected using primers 
1 and 3 which are only in sufficiently close proximity for amplification if the 
mtDNA molecule harbours the deletion. Amplification of wt (undeleted) mtDNA 
with primers 1 and 2 will only occur if the deletion is not present, as the primer 2 
site is within the deleted region. 
All primers were designed according to general published guidelines (Innis and 
Gelfand, 1990) using the revised Cambridge Reference Sequence (rCRS) 
(accession number AC_000021) of the mitochondrial genome. To avoid 
positioning the primers at sites with a high frequency of polymorphisms, the 
Human Mitochondrial Genome Database (mtDB), available at 
http: //www. genpat. uu. se/mtDB/index. htmI was consulted. This identifies the 
polymorphisms at each nucleotide site within the mtDNA genome and their 
frequency. The primers for mt497 detection and quantitation (CD1, CD2 and 
SCD) are based around those of Ross and colleagues (Ross et al, 2002) which 
were originally designed to quantify mt497 using a conventional (block-based) 
PCR approach. These primers were modified to increase their melting 
temperature. All primer sequences are given in Appendix B. 
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4.2.4 PCR specificity 
To assess the specificity of the primers, DNA extract from several liver biopsies 
was subjected to a generic block-based PCR (Appendix C) using the 
appropriate primers for each deletion and for wt mtDNA detection. The PCR 
products were electrophoresed on 2% agarose gel (Section 2.7) to visualise the 
PCR product and to determine the size of the amplicon. 
4.2.4.1 wt mtDNA 
Primers CD1 and SCD (equivalent to primers 1 and 2 in Figure 4.2) amplify a 
412 bp region which represents wt mtDNA. Gel electrophoresis following block- 
based PCR amplification using the CD1-SCD primer pair demonstrated one 
amplification product of the correct size for each DNA extract (Figure 4.3). To 
confirm the specificity of the PCR assay, the amplified fragments were 
sequenced as described (Section 2.21) and were confirmed as wt mtDNA 
sequence. 
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Figure 4.3: Image of wt mtDNA PCR products following separation on a 2% 
agarose gel. Lanes 1-12; liver DNA extracts, M; PCR markers, bp; base pairs 
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4.2.4.2 mt4977 
Primers CD1 and CD2 (equivalent to primers 1 and 3 in Figure 4.2) are 
designed to amplify a 271 bp region flanking mt497. Gel electrophoresis 
following block-based PCR amplification using the CD1-CD2 primer pair 
demonstrated a single band on the gel, which appeared to be of the correct 
size. Sequencing of the amplicons (Section 2.21) identified that a mis-priming 
event had occurred. The CD1 primer had annealed at a site similar in 
sequence to the target site and this had resulted in the amplification of a PCR 
product of 247 bp. This was 24 bp smaller than that expected. The site of mis- 
annealing was seen to be within the mt497 deletion site, thus if efficient 
amplification was occurring then it would be expected that the isolated levels 
would be as high as seen with wt mtDNA. The low level of the misprime PCR 
product, compared to wt mtDNA, indicated that amplification was not efficient 
due to the reduced complementarity of the CD1 primer and the site to which it 
(mis)-anneals. 
The stringency of the block-based PCR was increased (Appendix C) and the 
method repeated. Gel electrophoresis of these amplicons, alongside the `mis- 
prime' product indicated that the PCR products formed using more stringent 
conditions were slightly larger (Figure 4.4, lane 9). These amplicons were 
sequenced (Section 2.21) and were found to be the correct mt4977 product. 
These all had identical sequences at the deletion junction site. Figure 4.5 
shows a section of the sequence data, demonstrating the deletion junction after 
a 13 bp repeat. 
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Figure 4.4: Image of mt497 mtDNA PCR products following separation on a 2% 
agarose gel. Lanes 1-8; liver biopsy samples, lane 9; misprime amplicon, lane 
10; water. M; PCR markers. All products were sequenced to confirm identity. 
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4.2.4.3 mt7436 
Due to the relatively close proximity of the start sites for mt497 and mt7436 , the 
CD1 primer was also used for the mt7436 assay in combination with primer 
'mt7436' (equivalent to primer 3 in Figure 4.2). The primer sequence of mt7436 
is given in Appendix B. With the CD1-mt7436 primer combination, amplification 
using the generic block-based PCR did not produce a distinct band on gel 
electrophoresis and this did not improve on increasing the stringency of the 
PCR assay. In order to improve amplification efficiency, the primers were 
altered to have LNA® additions which increase the specificity of hybridisation 
(see Section 1.11.1.3). The CD1-LNA/mt7436-LNA primer combination (see 
Appendix B for primer sequences) amplifies a 381 bp region flanking mt7436. 
With this primer pair, amplification efficiency was significantly improved with a 
single band of the appropriate size seen on agarose gel electophoresis (Figure 
4.6). The amplicons were sequenced (Section 2.21) and were found to be the 
correct mt7436 product, with identical sequences at the deletion junction. Figure 
4.7 shows a section of the sequence data, demonstrating the deletion junction 
after a 12 bp repeat. 
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Figure 4.6: Image of mt7436 PCR products following separation on a 2% 
agarose gel. Lanes 1-6; liver biopsy samples, lane 7; water, M; PCR markers. 
All products were sequenced to confirm identity. 
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4.2.5 Production of plasmid standards 
The wt and deleted (mt497 and mt7436) mtDNA standards were constructed by 
producing recombinant plasmids containing each purified amplicon (Section 
2.23). A recombinant plasmid was also produced with the misprime product 
seen during mt497 assay optimisation. The plasmids were quantified as 
described in Section 2.24. An external calibration curve for each of the 
amplification targets (mt4977 mt7436 and wt mtDNA), was prepared by serial 10- 
fold dilutions from the stock plasmid DNA in nuclease free water containing 1 
ng/pI herring sperm DNA. 
4.2.6 Transfer to real-time PCR format 
To transfer the assays for mt4977 mt7436 and wt mtDNA detection/quantitation to 
a real-time platform, Taqman probes were designed as described (Section 
2.14). Highly polymorphic sites were avoided (by reference to mtDB), and 
degenerate nucleotides were incorporated into the probes where necessary to 
enable optimum sequence complementarity. The probes were positioned as 
indicated in Figure 4.8, to enable detection of wt mtDNA (box 4 in Figure 4.8) or 
deleted mtDNA (box 5 in Figure 4.8). All probe sequences are given in 
Appendix B. 
mtDNA sequence 
Figure 4.8: Positioning of probes for real-time PCR detection of wt mtDNA and 
deleted mtDNA. 1; common forward primer, 2; wt mtDNA reverse primer, 3; 
deleted mtDNA reverse primer, 4; wt mtDNA probe, 5; deleted mtDNA probe. 
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4.2.7 Optimisation of PCR assays 
For each primer pair used in this study, optimal PCR reagent and cycling 
conditions were achieved by varying the concentration of MgCI2, primers and 
probes and by experimenting with various annealing temperatures (Section 
2.16). To determine the appropriate annealing temperature for each primer set, 
the starting annealing temperature was taken at 5°C below the average melting 
temperature (Tm) for each primer set. The temperature was then increased or 
decreased by increments of 2°C to achieve optimum yield of product. 
Once the appropriate annealing temperature was established, the product 
intensity was improved by applying the following reagent titration experiments: 
(i) titration of MgCI2 at 1.0 mM, 1.5 mM, 2.0 mM, 2.5 mM, 3 mM, 3.5 mM 
and 4 mM. (Figure 4.9) 
(ii) variation of primer concentration at 0.15 µM, 0.2 µM and, 0.3 µM 
(iii) variation of the concentration of one primer with respect to the other, 
depending on whether the probe annealed to the plus or minus DNA 
strand (Figure 4.10) 
(iv) variation of probe concentration 
This approach was applied to all PCR target sites. Optimisation was carried out 
using plasmid standards at the lower end (10"7 to 10-10) of the serial dilution for 
each target site, to attain optimal sensitivity for each assay. The results shown 
in Figures 4.9 and 4.10 are typical of results obtained during these optimisation 
experiments. In real-time PCR using the Rotor-Gene the fluorescent signal 
(Figures 4.9 and 4.10, y axis) increases in direct proportion to the amount of 
PCR product in the reaction. The initial copy number can be calculated from 
the cycle number (Figures 4.9 and 4.10, x axis) at which a detection threshold is 
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crossed; the threshold cycle (CT). Each PCR assay was optimised to produce 
the best fluorescent signal and the highest CT for each of the plasmid 
standards, to attain optimal sensitivity to detect very low levels of mtDNA 
deletions. The fully optimised master mixes and Rotor-Gene conditions for 
each of the assays are outlined in Appendix C. 
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Figure 4.9: Optimisation of mt497 assay - titration of MgCI2. Black line; 4 mM 
MgCl2, blue line; 3.5 mM MgCl2, green line; 3 mM MgCl2, red line; 2.5 mM 
MgCl2, purple line; 2 mM MgCI2. At 1 mM MgCI2 all were negative. A serial 
dilution of plasmid standards at the lower end (10-7 to 10-10) was used for 
optimisation experiments. Note the increased sensitivity at 4 mM, with the 
detection of the lowest plasmid dilution (10-10), which is missed with the other 
titrations. 
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Figure 4.10: Optimisation of mt4977 assay - varying one primer with respect to 
the other. In this example the probe anneals to the reverse strand and so 
increasing the concentration of the reverse primer improves the Ct and shape of 
the curve. Black line; 10 pmol forward primer and 20 pmol reverse primer, Blue 
line; 20 pmol forward primer and 10 pmol reverse primer, red line; 10 pmol 
forward primer and 10 pmol reverse primer. 
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4.2.8 Sensitivity and reproducibility of the real-time PCR assays 
To determine the sensitivity of each PCR assay, serial dilutions of each specific 
plasmid were subjected to each assay, in triplicate, and the lowest reproducibly 
detected plasmid was determined as the cut-off (Table 4.1). Intra-assay 
variability was assessed by performing each assay with three replicates per 
plasmid. Inter-assay variability was assessed by performing the assay on four 
separate occasions. The intra- and inter-assay variability was calculated for 
each plasmid that was to be used in the assay (10"3 to 10-6 for the wt mtDNA 
assay and 10-6 to 10.10 for the mt497 and mt7436 assays. The intra- and inter- 
assay co-efficient of variation was calculated (Table 4.1). Each PCR assay 
could detect down to single copy numbers of deleted (mt49n and mt7436) or wt 
mtDNA. The intra- and inter-assay variability was in the region of 1% for each 
of the assays as shown in Table 4.1. 
Assay 
wt mtDNA mt4 77 me436 
Sensitivity (copies/reaction) 4.40 2.37 2.86 
(Calculated concentration) 
Correlation co-efficient 
0.999 0.998 0.999 
Intra-assay co-efficient of 0.67 +/- 0.39 1.04 /- 0.26 1.49 /- 0.67 
variation (%) 
Inter-assay co-efficient of 1.51+/-0.66 0.46 /- 0.45 1.67 /- 0.59 
variation (%) 
Table 4.1: The sensitivity, inter- and intra-assay variability of the mtas», mt7436 
and wt mtDNA detection/quantitation assays. 
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4.2.9 Normalisation of data 
Normalisation of data was carried out by reference to the 11-globin gene, a 
single copy-number chromosomal gene (2 copies/human genome) with an 
assay used routinely in the diagnostic laboratory (Dr Hamid Jalal, personal 
communication). This is a real-time PCR assay which utilises a series of four 
plasmid standards with known quantity of S-globin DNA (1.7 to 1700 copies/pl) 
to quantify the gene in clinical specimens. An external calibration curve for the 
P-globin amplification target was prepared by serial 10-fold dilutions from the 
stock DNA in nuclease free water containing 1 pg/pI poly A RNA. Primers, 
probes and Rotor-Gene conditions for this assay are described (Appendices B 
and C). Total mtDNA content was calculated by the ratio of wt mtDNA: 11- 
globin. This pins the data to a reference and ensures that mitochondrial 
proliferation/depletion had not occurred within the cells. 
4.3 Clinical study 
4.3.1 Cohort characteristics 
Liver biopsy specimens were collected from patients undergoing this procedure 
in the Planned Short Stay Unit (PSSU) at Addenbrooke's Hospital, as part of 
their clinical management, between May 2005 and August 2007. Following the 
stipulations of the ethical approval, liver biopsies were only collected from 
patients who were aged between 18 and 75 years, had been given a patient 
information sheet (Appendix F) to allow informed decision and had given their 
written consent (Appendix F) for their biopsy to be stored and used for this 
study. Biopsy specimens were only received when there was sufficient material 
for research analysis over and above that required for standard diagnostic 
pathology. 
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A total of 79 liver biopsies were collected for this study. The male to female 
ratio was 2.3: 1. The patients were aged between 20 and 70 years, with an 
average age of 46.2 years. Forty-two (53.2%) of the patients had undergone a 
liver biopsy due to HCV infection either as the sole aetiology (n=32) or in 
association with another liver pathology (n=10). Thirty seven (46.8%) had 
undergone liver biopsies for other liver pathologies. Table 4.2 outlines the 
clinical characteristics of the patient cohort described in this study. Further 
cohort characteristics are given in Appendix G. 
Number Average age (years) Male: female 
HCV 32 46.4 (30-70) 5: 3 
HCV + HBV 2 
HCV + HIV 1 10 44.8 (26-63) 9: 1 
HCV + alcohol 7 
n=42 
HBV 8 33.8 (22-62) 3: 1 
NAFLDINASH 5 48.4 (40-58) 5: 0 
Alcohol 10 54.4 (41-65) 7: 3 
Autoimmune 3 45.7 (20-66) 2: 1 
Other 11 47.3 (32-68) 6: 5 
n=37 
Table 4.2: Clinical characteristics of the 79 patients from whom liver biopsy 
specimens were received for this study. 
For each HCV-infected individual, the infecting genotype was identified using 
the Taqman HCV genotyping assay described in Chapter Three. Of the forty- 
two HCV infected individuals there were twenty-six (61.9%) genotype 1 
infections, two (4.8%) genotype 2 infections, eleven (26.2%) genotype 3 
infections and one (2.4%) genotype 4 infection. For two patients (4.8%), the 
HCV viral load was too low for HCV genotyping. For the virally infected 
individuals, the liver viral load was also determined. For the HCV-infected 
individuals, this was carried out using the HCV quantitation assay described in 
Chapter Three. HCV viral load varied from undetectable to 35,668,285 lU/ml. 
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The HBV viral load was determined using an assay already established within 
the diagnostic laboratory (Aliyu et a/, 2004). HBV viral load varied from 3.4x1 03 
to MA06 IU/ml. The liver biopsy specimens all underwent histopathological 
investigation by Consultant Pathologists as part of standard diagnostic 
procedures. The pathology report for each liver biopsy specimen was 
interrogated to determine the stage of fibrosis within the sample (none, minimal, 
mild, mild/moderate, moderate, moderate/severe, severe or cirrhosis) and, in 
the case of specimens which had a viral aetiology, grade of inflammation was 
also recorded (none, minimal, minimal/mild, mild, mild/moderate, moderate). 
4.3.2 rntDNA deletion detection/quantitation 
Liver biopsy specimens were stored and the DNA extracted as described in 
Section 4.2. The extracted DNA from each liver biopsy was subjected to each 
assay, using the optimised conditions (Appendix C) 
* Mt4977 detection/quantitation 
* Mt7436detection/quantitation 
* wt mtDNA detection/quantitation 
* 11 Globin gene detection/quantitation 
For each batch of livers, the assays to detect the deletions, wt mtDNA and the 
11-globin gene were all carried out within days of each other to ensure no loss of 
accuracy due to DNA degradation following prolonged storage. For each liver 
biopsy, following real-time PCR, the amplicons were subjected to agarose gel 
electrophoresis (Section 2.7) as a safeguard to ensure specificity of 
amplification. A very low dilution of the 'misprime' plasmid was also included in 
the mt" assay to ensure that this event was not occurring in the real-time 
assay. Agarose gel electrophoresis of the 'misprime' amplicon and PCR 
products from the Mt4977 assay indicated that all amplification products from the 
212 
liver biopsies were of the correct size. Ten PCR products from the mt4977 and 
mt7a36 assays were sequenced (Section 2.21) as an extra safeguard to ensure 
specificity of amplification. The products all gave the expected sequence. The 
deletion junction of all the products was as expected for both the mt4977and 
mt7a36 deletions. 
Appendix G gives a full summary of the results obtained for all 79 patients 
investigated in this study. Figures 4.11,4.12 and 4.13 demonstrate typical real- 
time amplification Rotor-Gene reports for the Mt4977, Mf7436 and wt mtDNA 
assays respectively. Quantitation Of Mt4977 and Mt7436 was reported as a ratio of 
the quantity of the specific deletion to the quantity of wt mtDNA. For mt4977 this 
ranged from 2.14xi 0-3 to 1.84x10-6. In one liver (1-134), Mt4977 could not be 
detected. For MjM36, the ratio ranged from 2.6x10-4to 2.38x 10-7. Mf7436 was not 
detected in 10 (12.7%) liver biopsies. 
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Statistical analysis of the data was carried out using the chi-square test (Section 
2.26). Several null hypotheses (Ho) were tested: 
" There is no association between HCV infection and quantity of 
mtasn 
" There is no association between age and quantity of mt4977 
9 There is no association between sex and quantity of mt4977 
" All of the above factors with regard to mt7436 
To analyse whether the deletions accumulated with age, the cohort was divided 
into older (50-70 years, n=36) and younger (20-49 years, n=43) individuals. For 
both Mt4977 and Mj7436' there was no statistically significant difference in the 
quantity of the mtDNA deletion related to older age (p=0.309 and p=0.505 
respectively). There was also no statistically significant difference in the 
quantity Of Me977 or Mj7436 between males (n=55) and females (n=24) (p=0.284 
and p=0.761 respectively). 
The major focus of this research was to examine whether mtDNA deletions 
were significantly higher in patients with HCV than with other liver pathologies. 
For statistical analysis, the cohort was divided into patients with HCV infection, 
either alone or with a co-pathology (n=42) and patients with non-HCV liver 
aetiologies (n=37). Initially the data set was stratified into two categories by 
finding the median value for each mtDNA deletion (4.36xlO-5 for me977 and 
4.71xlO"6 for Mt7436) and classifying quantities greater than these values as 
'high' quantity of mtDNA deletion and quantities lower than these values as 'low 
quantity mtDNA deletion. However, this did not produce statistically significant 
results. To further analyse this data, quantity of each deletion was stratified into 
five categories (0 tolo-3,10-3 to 10-4,10-4 to 10-50 10-5 to 10-6 and 10-6 to 10-7). 
The data was analysed in an rxc contingency table to look for a trend within 
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the data. For mt4977 the chi-square value fell just outside statistical significance 
(p=0.0932). For mt7436 there was a significant difference between HCV and 
non-HCV liver aetiologies (p=0.008). However, from the data trend, it is 
impossible to determine whether a greater level of the deletion was occurring in 
HCV-infected or non-HCV infected individuals. Table 4.3 shows the 
contingency table for this data. 
mt HCV Non-HCV 
0 tole 
0 4 7 11 
E 5.4 4.6 
104 101 
O 0 4 4 
to E 2.2 1.8 
10' t 10"5 
O 9 11 20 
o E 10.8 9.2 
10 5t 10$ 
0 20 13 33 
o E 17.8 15.2 
10"7 10$ t 
0 10 1 11 
o E 5.9 5.1 
Total: 79 
Table 4.3: Contingency table for Mf7436 quantity in HCV-infected vs. non-HCV 
infected individuals. 0; observed, E; expected. Chi-square for this data set is 
11.8, P=0.008. 
4.3.3 mt742o -a novel deletion? 
Gel electrophoresis of the mt7436 products revealed that one biopsy (LB3) was 
negative by real-time PCR but showed an amplification product of the correct 
size on the gel. This liver biopsy was re-amplified with the CD1-mt7436 primer 
pair and again showed a product of similar size to the mt7436 product on agarose 
gel electrophoresis (Figure 4.14). 
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150 
Figure 4.14: Image of mt7436 PCIR products following separation on a 2% 
agarose gel illustrating LB3 (lane 1) which is similar in size to the Mt7436 
amplification product (lane 2) but negative on the mt7436 real-time PCR assay. 
M PCR markers. 
This amplification product from LB3 was sequenced (Section 2.21) using the 
CD1-LNA-mt7436 primer pair. The sequence data indicated that LB3 contained 
a mixture of two mtDNA species (Figure 4.15). Analysis of the sequence data, 
with reference to the rCRS (AC_000021), indicated that the majority sequence 
consisted of a region surrounding a deletion of 7420 bp (referred to henceforth 
as Mt7420) occurring between nt 8690 and nt 16109. This deletion begins 40 nt 
after mt7436 and ends 24 nt after Mt7436 making the deletion 16 nt smaller than 
mt7436 (Figure 4.16). The sequence data also provided evidence as to why 
Mt7420 was not detected with the Mt7436 probe, as the Mt7436 probe site lies within 
the Mt7420 deletion site (Figure 4.17). From the sequence data, the minority 
sequence could not be interpreted. The possibility of contamination could not 
be ruled out. 
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Deletion begins: 
nt8649 nt8690 
II 
TCTCATCAACAA--CGACTAATCACCACCCAACAATGACTAATCAAACTAACCTCAAAACAAA 
TT 
7420 bp deletion 
7436 bp deletion starts here 
starts here 
Deletion ends: 
nt 16084 nt 16109 
CATCAACAACCGCTATGTATTTCGTA : -:! 1C ; ''C_'CATGAAT 
T 
7436 bp deletion ends 
here 
T 
7420 bp deletion ends here 
nt 16109 
Figure 4.16: A diagram of the location of Mt7420, compared to that of mt 
7436 
. 
The probe site for Mt7436 detection is shown in red type. The 12 bp repeat 
flanking mt7436 is shown in blue type. 
Interrogation of the Mitornap database (www. mitomap. or-q. uk) indicated that this 
deletion had not previously been reported. To investigate the possibility that 
this could be a novel deletion, a probe was designed which would specifically 
detect Mt7420 . The 5' end of the probe incorporated the 8 nucleotides directly 
ahead of the deletion whilst the 3' end of the probe included the 10 nucleotides 
at the region directly after the deletion (Figure 4.18). Therefore, the probe 
would only hybridise if the exact deletion had occurred. 
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Figure 4.18: Probe design to detect mt 7420. The deletion is within the probe 
site, therefore probe annealing will only be possible if the deletion has occurred. 
Recombinant plasmid standards containing the Mt7420 amplicon were produced 
as described (Sections 2.23 and 2.24). Optimisation experiments were carried 
out as described in Section 4.2.7 and sensitivity and reproducibility of the assay 
was assessed as in Section 4.2.8 (data not shown). Fully optimised conditions 
are outlined in Appendix C. The sensitivity of the assay was 25 copies per 
reaction. 
The real-time PCR assay for Mt7420 detection was carried out on LB3 but was 
unable to detect the deletion in this liver. This could indicate that the deletion 
was occurring at a very low level. The possibility that it is a PCR artefact cannot 
be ruled out. The Mt7420 detection assay was carried out on the remaining 78 
liver biopsies. This deletion was not detected in any of these liver biopsies. 
4.4 Discussion 
4.4.1 Methodology 
4.4.1.1 Nucleic acid homogenisation/extraction 
The liver biopsy specimens received for this study were very small 
(approximately 1 mm thick and 4 mm long). It was, therefore, vital that 
homogenisation and extraction techniques produced the best yield of nucleic 
acid for further analysis. With this in mind, two methods of homogenisation 
(manual and automated) and four extraction protocols were tested. Automated 
homogenisation was superior to manual homogenisation, in terms both of yield 
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of nucleic acid and speed/ease of carrying out the procedure. The nucleic acid 
extraction protocols were all remarkably similar in terms of yield of nucleic acid 
(Figure 4.1). The Trizolo reagent, however, was inferior due to the poor 
solubilisation of extracted nucleic acid, despite several alterations to the 
protocol in an attempt to improve this. All of the extraction methods had the 
added advantage of isolating RNA, in addition to DNA, which provides a useful 
resource which could be utilised in the future for gene expression studies. The 
liver biopsy specimens were collected over a two year time period and were 
homogenised and extracted shortly after receipt. Due to the small batches of 
tissue which required extraction on each occasion, the manual kit which 
provided the best yield (DNeasye Blood and Tissue kit) was selected. 
4.4.1.2 Three-primer PCR 
The three-primer PCIR method used in this study was first described by Sciacco 
and colleagues (Sciacco et a/, 1994) to detect and quantify Mt4977 in patients 
with mitochondrial myopathy. This conventional-PCR approach has been 
adapted and utilised by others (Ross et al, 2002) to study this deletion in 
association with the ageing process. Until very recently, there had been no 
reports of the transfer of the three-primer method to a real-time PCR platform. 
In 2007, Poe and colleagues published results on the development of a three- 
primer real-time PCR assay using molecular beacons (Poe et a/, 2007). This 
multiplex format simultaneously detects a 7522 bp mtDNA deletion and wt 
mtDNA in a single reaction. Standards for quantitation were produced from 
PCR products, which may not show long-term stability. This assay was 
developed on a cybrid cell line, which had been constructed to contain around 
75% deleted mtDNA, far greater than would be observed in vivo. 
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The study described in this chapter further developed the three-primer PCIR 
methodology to enable its conversion to a real-time PCR platform using 
Taqman technology to detect Mt4977 . An additional assay was designed, using 
this methodology to detect another large mtDNA deletion _ Mt7436. Quantitation 
of the deletions is carried out by reference to external plasmid standards. 
Accurate quantitation of mtDNA deletions cannot be determined without 
establishing their proportion relative to undeleted (wt) mtDNA. In addition to 
deleted mtDNA, the developed assay also detects and quantifies undeleted 
mtDNA to allow absolute quantitation of each deletion relative to wt mtDNA. 
Furthermore, the developed protocol includes a method for calculating mtDNA 
copy number by reference to a single-copy number gene (0-globin). mtDNA 
content is equivalent to the wt mtDNA copy number divided by the copy number 
of the P-globin gene. This additional assay, used only in a handful of other 
studies on mtDNA deletions (e. g. Cote et al, 2002; Chabi et a/, 2003) ensures 
that mtDNA proliferation or depletion has not occurred which could have an 
effect on the results. The P-actin gene is often used for this purpose. However, 
it was decided, for this study, to use an assay already utilised in the laboratory 
for the quantitation of Chiamydia trachomatis in clinical specimens. 
The fully optimised assay described in this chapter is excellent in terms of 
specificity, sensitivity and reproducibility. Following the early problems with mis- 
priming, sequencing of a selection of deletion amplicons demonstrated that the 
specific mtDNA deletion (either Me977 or mt7436) was amplified each time. 
Optimisation using plasmid standards demonstrated that all the assays were 
able to detect down to single copy numbers and were highly reproducible, even 
at low levels of mtDNA deletions. This proved to be an extremely important 
feature of the assay, as all mtDNA deletions were found to occur at extremely 
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low levels. Without a highly sensitive assay, detection of these deletions would 
have been impossible. This may be an explanation for the failure to detect 
mtDNA deletions in early studies using conventional-PCR and southern blot 
analysis which are far less sensitive for mtDNA deletion detection (Bai and 
Wong, 2005). With a PCR assay which is detecting very low copy numbers, 
attaining the same result on each run is extremely important. The developed 
assays display very low inter- and intra-assay variability (Table 4.1) 
demonstrating that results are reproducible even at the lower limits of detection. 
Several studies have combined the detection of deleted and wt mtDNA in a 
single, multiplex assay (Pogozelski et al, 2003; Poe et al, 2007). Shorter 
targets are known to be amplified preferentially to longer targets and so these 
assays were designed to amplify short targets of similar size. However, wt 
mtDNA will be in far greater excess than deleted mtDNA and this would mean 
that a multiplex assay would be prone to differential bias of amplification despite 
the size-matched targets. To completely eliminate the possibility of biased 
amplification of wt mtDNA in the study described herein, it was decided to keep 
each assay as a monoplex format - with separate assays for mt4977, me"'6 and 
wt mtDNA detection/quantitation. Each of the assays were carried out on a liver 
biopsy within a short time period to ensure no loss of sensitivity/accu racy due to 
DNA degradation. 
In addition to three-primer PCR, a further method was developed during this 
research to detect and quantify mtDNA deletions. This was designed to 
quantify the amount of mtDNA in two different regions of the genome; one 
which is rarely deleted and the other that is absent in the majority of mtDNA 
molecules harbouring large deletions. This has been carried out by several 
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other groups (He et al, 2002; Bai and Wong, 2005). Attempts to develop a 
similar assay for use in this study, targeting the origin of replication (Ori), a 
region which cannot be deleted in replicating mitochondria and the ND4 gene, 
which is located in the commonly deleted region of mtDNA, were unsuccessful. 
A real-time PCR assay was designed which amplified targets of identical size 
from both these regions. However, the ND4 gene which should have been at a 
lower quantity than the Ori gene, if mtDNA deletions were occurring, was 
actually detected in greater abundance (data not shown). This could have been 
due to an increased reaction efficiency of the ND4 detection/quantitation assay 
compared to the Ori detection/quantitation assay. 
4.4.2 mt4sn/mt7436 and liver disease 
Many different mtDNA deletions have been described (see www. mitomap. orq . 
It was decided, for this study to detect and quantify two mtDNA deletions which 
have already been described, rather than to look for novel deletions. The two 
deletions, Mt4977 and mF4'6 were chosen due to their large size (4977 and 7436 
bp respectively) which eliminates a large part of the 16,569 bp mitochondrial 
genome. These deletions remove many of the genes which are essential for 
the OXPHOS pathway and would therefore have an adverse effect on the 
bioenergetic potential of cells if they accumulated to a significant proportion. 
Me977 and mim'e were also selected as there have been very few studies 
investigating their prevalence in liver disease, with all published studies 
focusing on hepatocellular carcinoma (HCC). Early studies (Yamamoto et a/, 
1992; Fukushima et al, 1995; Kotake et al, 1999; Nishikawa et a/, 2001) were 
carried out on Japanese subjects using conventional PCR. Kotake et al (1999) 
found that the levels of me'77 and Mt7436 were similar between normal and 
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chronically infected livers but were approximately one third in livers with 
cirrhosis and markedly lower in liver with HCC. Yamamoto and colleagues 
(Yamamoto et al, 1992), on comparing hepatic tumour tissue and surrounding 
cirrhotic liver of 10 patients with liver cancer, found multiple deletions in the 
cirrhotic liver tissue of all the individuals, but no deletions in the tumour portion. 
They did not isolate Me977 but did detect Mt7436 and a 7079 bp deletion. 
Fukushima et al (1995) detected Mt4977 in the majority (65%, n=20) of non- 
tumour portions of adult patients with HCC. Mt4977 was not seen in cirrhotic liver 
from paediatric patients (0%, n=16). They suggested that ageing, rather than 
cirrhotic changes in the liver were responsible for the accumulation of this 
deletion. The frequency of mtDNA deletion was significantly lower in tumour 
tissue (25%, n=28) compared to normal liver (65.5%, n=55). These early 
studies demonstrated that HCC is associated with lower levels of mtDNA 
deletions, but do not agree on whether cirrhotic liver tissue demonstrated 
increased levels of the deletions. In a later study, using conventional PCR, but 
with multiple, overlapping primers to screen the entire mitochondrial genome, 
Nishikawa and colleagues (Nishikawa et al, 2001) failed to isolate any deletions 
from either cancerous or non-cancerous liver tissue from Japanese individuals 
with HCC. The studies outlined above all suggest that mtDNA deletions are 
decreased in patients with HCC. This could be due to the rapid proliferation of 
cells in cancerous tissue. Large deletions in mtDNA diminish the capability for 
oxidative phosphorylation of mitochondria and so with the rapid growth of 
tumour cells, these will be at a disadvantage and will be eliminated or diluted 
out, with only mitochondria with fully functional mtDNA surviving. 
These early studies have several limitations. They were all carried out using 
conventional (block-based) PCR, which is less sensitive than real-time PCR. 
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The deletion amplicons in these studies were large, ranging from 800-1000 bp. 
PCR tends to amplify longer products less efficiently than shorter ones and so 
the efficiency of PCR amplification may have been inferior, under-estimating the 
presence of the deletions or may have produced artefacts (Kajander et al, 
1999). Two of the studies (Fukushima et a/, 1995; Kotake et al, 1999) did not 
involve sequence analysis to verify the identity of the amplified products. This 
chapter describes a problem with mispriming where the misprime product was 
similar in size to the expected mtDNA deletion product. Specificity of PCR 
amplification should not be presumed without definitive identification of 
amplicons by sequence analysis. These early studies could not accurately 
quantify deletions, as quantitation of deletion amplicons was achieved by 
autoradiography of PCR products or by southern blot analysis, which have 
limited sensitivity especially of low quantity products. Although wt mtDNA was 
amplified, no attempt was made to quantify the levels of identified deletions 
relative to wt mtDNA. 
More recent studies on the association of mtDNA deletions in liver disease have 
utilised real-time PCR techniques. Shao et a/ (2004) have employed real-time 
PCR with plasmid standards for both wild-type and deleted mtDNA to 
detect/quantify mtDNA deletions in HCC and hepatocellular nodular hyperplasia 
(HNH) in Chinese individuals (Shao et a/, 2004). This group did not detect 
mt4977, but instead isolated a novel 4981 bp deletion. They found the ratio of 
mitochondria with this deletion compared to wt mtDNA (indicated in brackets) to 
be significantly higher in HCC (0.00092) than in paired non-cancerous liver 
tissue (0.000) and HNH tissue (0.0000374); a result which contradicts earlier 
studies (Yamamoto et al, 1992; Fukushima et al, 1995; Kotake et al, 1999). 
However, as these results show, even in HCC, the ratio of deleted to wt mtDNA 
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is extremely low (0.00092). This study utilised paraffin-em bedded liver tissues, 
requiring xylene and alcohol treatment pre-PCR, a process which may, itself, 
have resulted in DNA damage. Despite finding a high number of mtDNA 
mutations in individuals with chronic HCV infection (without HCC), Nishikawa 
and colleagues (2005) could detect no deletions in these individuals, suggesting 
that hepatocytes with deletions may be eliminated. 
4.4.3 Clinical study 
As described above, there is a paucity of research on mtDNA deletions in 
association with liver disease and the vast majority were carried out before the 
advent of real-time PCR. All the published studies on mtDNA deletion in 
association with HCV have been carried out on individuals of Chinese or 
Japanese origin. This study is the first to examine mtDNA deletions in a cohort 
of patients with liver disease residing in the UK. As outlined above, the early 
studies using conventional PCR lack sensitivity and do not accurately quantify 
the mtDNA deletions that were detected. The two, more recent studies using 
real-time PCR do not agree on whether mtDNA deletions are elevated in liver 
cirrhosis. This is, therefore, an area which warrants further investigation. The 
aim of the study described in this chapter was to examine whether levels of 
mtDNA deletions are higher in the liver tissue of patients infected with HCV. 
Due to the obvious ethical implications, it was impossible to obtain liver 
specimens from healthy livers. Therefore, it was decided to compare HCV- 
infected individuals with those undergoing biopsy for other liver aetiologies. As 
discussed in Chapter One, HCV is known to result in high levels of oxidative 
stress in infected individuals (Shimoda et al, 1994; Farinati et a/, 1995; Farinati 
et a/, 1999; Cardin et al, 2001; Jain et al, 2002, Mahmood et al, 2004; Fujita et 
a/, 2007; Tanaka et a/, 2008). This is thought to be through the interactions of 
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viral proteins including the core and NS5 proteins (Gong et al, 2001; Okuda et 
al 2002; Waris et al, 2002; Abdalla et al, 2005; Garcla-Mediavilla et al, 2005; 
Korenaga et al, 2005; Otani et al, 2005; Piccoli et al, 2006; Li et al, 2007). It is 
therefore, not unreasonable to hypothesise that HCV-infected individuals would 
demonstrate much higher levels of mtDNA damage in the form of large 
deletions than non-HCV-infected individuals. 
The clinical study examined a cohort of 79 individuals undergoing a liver biopsy. 
Approximately half (n=42) patients were infected with HCV. The remaining 37 
individuals had undergone a biopsy for a variety of other liver pathologies 
including HBV, high alcohol intake and auto-immune disease (Appendix G). As 
expected, levels of wt mtDNA were high, ranging from 802,967 to 283,445,467 
copies per reaction (3 pl liver biopsy DNA). Levels Of Mt4977 ranged from 0 (in 
one liver biopsy) to 54,738 copies per reaction (3 pi liver biopsy DNA). Levels 
Of Mt7436 ranged from 0 (in ten liver biopsies) to 33,991 copies per reaction (3 pl 
liver biopsy DNA). Although, in terms of copy number, these levels of mtDNA 
deletions appear quite high, it is important to examine them in relation to wt 
mtDNA. When defined as a ratio of deleted: wt mtDNA, levels Of Mt4977 ranged 
from 1.84x10-6 to 2.14xl 0-3 copies per reaction. For Mt7436, levels of mtDNA 
harbouring this deletion ranged from 2.38x10-7to 2.6xl 0-4copies per reaction. It 
is apparent, from these results, that the levels of deleted mtDNA are very low in 
all of the individuals studied. it must be noted, however, that liver biopsy 
specimens remove only a tiny fraction of the liver, the average liver biopsy 
samples only 1/100,000 of the whole liver (HUbscher, 2007). Thus one cannot 
rule out the possibility of sampling variation depending on which part of the liver 
(damaged or non-affected) was extracted in the biopsy specimen. Statistical 
analysis of the data indicated no statistically significant difference between 
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quantities Of Mt4977 between HCV-infected and non-HCV-infected individuals 
(p=0.0932). There was also no association between the amount of this deletion 
and the age (p=0.309) or sex (p=0.284) of the individuals. For Mj7436 there was 
also no significant difference in the amount of this deletion and the age 
(p=0.505) or sex (p=0.761) of the individuals. The results for MjA36 did reach 
statistical significance when the comparison was between HCV-infected and 
non-HCV infected individuals (Table 4.3, p=0.008). This indicates a trend with 
respect to this deletion, however when the data was studied, it was impossible 
to determine whether individuals with HCV were accumulating a greater or 
lower level of this deletion. The cohort size for this study was small (n=79), and 
this may be why many of the results did not reach statistical significance, thus 
an extension of the study, recruiting further individuals, would be required. 
The mt4977deletion has been found to accumulate with age (Cortopassi et al, 
1990,1992; Lee et al, 1994; Wei et al, 1996; Zhang et al, 1998; Mohamed et a/, 
2006). It was therefore important to take into account the effect of age in the 
cohort of patients studied. The mean age of patients studied was 46.2 (/-l 1.6) 
years, and it is therefore not surprising to detect both deletions in the majority of 
individuals. However, no statistically significant increase in the levels of the 
deletions in older (50-70 years) compared to younger (20-49 years) individuals 
was observed for either Mt4977 (p=0.309) or Mt7436 (p=0.505). This may indicate 
that these deletions are present at very low levels in tissues regardless of the 
age of an individual, a result similar to that seen with Me977 in lymphocytes 
(Ross et a/, 2002). With the absence of a control group of healthy liver 
specimens, it is impossible to determine whether the levels of deletions are 
greater in liver disease than in healthy liver. The very low level of mtDNA 
deletions in individuals in this study reflects the findings of several studies 
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looking at the accumulation of mtDNA deletions in the ageing process. These 
studies have identified mtDNA deletions within tissues, at levels of less than 1% 
(Liu et al, 1998; Zhang et al, 1998). The very low levels of mtDNA deletions 
seen in this study would argue against physiologic significance. Large deletions 
such as Me977 and Mt7436 would have an extreme effect on the ability of single 
mitochondria to function, as they remove many genes essential for the enzyme 
complexes of the OXPHOS pathway. However, the co-existence of damaged 
mtDNAs with wt mtDNAs in a state of heteroplasmy within individual cells allows 
normal function to be maintained. The threshold level of mtDNA deletion 
beyond which normal function cannot be maintained is not certain. Cybrids 
containing different levels of mtDNA harbouring large deletions demonstrate 
significant bioenergetic defects only when the proportions of the deleted mtDNA 
is in the region of 50-60% of the total (Hayashi et al, 1991; Porteous et al, 
1998). Patients presenting with symptomatic mitochondrial myopathy 
associated with large mtDNA deletions demonstrated 20-80% of deleted mtDNA 
in muscle biopsies (Holt et a/, 1989). This is far greater than the very low levels 
of mtDNA deletions observed in this study and therefore a bioenergetic defect 
as a result of the deletions is extremely unlikely. 
It would appear, from these results that mtDNA deletions are not accumulating 
within these individuals. There are several possible hypotheses as to why this 
occurs. Traditionally, it was thought that mitochondria harbouring large 
deletions had a replicative advantage due to their smaller, partially deleted, 
genomes, and could repopulate organelles significantly faster than wild-type 
genomes in the same cell (Linnane et al, 1989, Diaz et a/, 2002). However, 
mitochondria harbouring large deletions would have bioenergetic defects 
making energy-requiring processes such as replication difficult. A later 
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hypothesis - the 'survival of the slowest' (de Grey, 1997) suggested that 
defective mitochondria harbouring deletions could accumulate due to a 
decreased rate of degradation. This was thought to be due to the production of 
fewer perhydroxyl radicals due to a reduced proton gradient resulting in less 
membrane damage than non-defective mitochondria. 
The low levels of mtDNA deletions seen in this study and in several studies 
looking at mtDNA deletions in ageing tissues suggests that mtDNA deletions 
are not able to accumulate to significant levels with cells. There is a growing 
body of evidence which suggests that mitochondria harbouring deletions are 
more susceptible to apoptosis. Apoptosis, or programmed cell death, is a 
process which plays an important role in the removal of unwanted cells, and 
mitochondria are recognised as key players in its regulation. Liu and 
colleagues (Liu et a/, 2004,2007) using cybrid human cells harbouring different 
proportions Of Mt4977 demonstrated that deletions in mtDNA increase the 
susceptibility of human cells to apoptosis triggered by exogenous stimuli. This 
was found to be more pronounced in cells harbouring high levels of the deletion. 
Similarly Schoeler and colleagues found that cybrid cells harbouring mt4977 were 
sensitised to apoptosis even when the deletion occurred at low levels (Schoeler 
et al, 2005). Results from a study by Peng and colleagues suggest that small 
amounts of Mt4977_induced mitochondrial defects may accelerate the cell 
towards apoptosis (Peng et al, 2006). 
mtDNA deletions are known to accumulate preferentially in post-mitotic tissue 
such as muscle and nervous tissue and are lower in mitotic tissues such as the 
liver, in which the cells are being continually replaced so that the function of the 
organ can be maintained (Cortopassi et al, 1992). In dividing cells, it may be 
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that deletions are lost as a result of negative (purifying) selective pressure, 
since mitochondrial dysfunction may hamper cell division. In post-mitotic 
tissues, the damaged mitochondria lead to no essential disadvantage to cell 
survival. The mitochondria harbouring deletions would be able to replicate, 
perhaps with the replicative advantage of smaller molecules. The liver 
undergoes rapid cell turnover and apoptosis, which could remove any mtDNA 
changes/deletions. Previous studies on liver have shown that this organ does 
not demonstrate age-associated mutations that are seen in post-mitotic tissues 
(Kovalenko et a/, 1998; Kopsidas et al, 2000). The difference between mitotic 
and post-mitotic tissues may also explain why deletions are seen at very low 
levels (Kotake et al, 1999; Shao et a/, 2004) or appear to be absent in the 
tumour tissue of HCC (Yamamoto et al, 1992; Nishikawa et al, 2001) in that the 
cells with a fully functional complement of mtDNA proliferate more efficiently in 
tumour tissue and become predominant, 'diluting out' any cells which harbour 
damaged mtDNA molecules. This may also explain why mtDNA deletions were 
seen at such a low level in this study. Even if the presence of HCV was 
resulting in an increase in oxidative stress and thus damaged mtDNA 
molecules, these may not have any replicative advantage and may be removed 
during the high cell-turnover which occurs in the liver tissue. 
The lack of a healthy control group does introduce certain limitations to the 
study. The comparison of HCV-infected against non-HCV infected individuals is 
not ideal. Whilst HCV infection is widely acknowledged for its propensity to 
result in increased oxidative stress; that is not to say that other liver pathologies 
are not associated with oxidative stress. Ethanol consumption is known to 
cause an increase in ROS (Cahill et al, 1997; Bailey et a/, 1999; Reinke, 2002) 
and Mt4977 has been observed in alcoholics, especially those with microvascular 
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steatosis, a lesion that is caused by impaired mitochondrial function (Mansouri 
et al, 1997; Fromenty et a/, 1995). Wheelhouse et a/ (2005) have found me 977 
in liver tissue of patients with HCC resulting from HBV infection. Hepatic 
mitochondria are compromised in NASH and NAFLD (Pessayre and Fromenty, 
2005). Mitochondrial abnormalities have been observed in the liver 
mitochondria of patients with NASH, but no evidence of the common deletion 
has been reported (Caldwell et al, 1999). 
One of the major disadvantages of this technique is that it is specific to 
individual deletions. It could be that, although large deletions are occurring only 
at very low levels, other types of mtDNA damage that accumulate during 
oxidative stress (e. g. mutations, resulting from oxidation of bases) may be 
occurring at high levels, but remain undetected by this assay. However, as has 
been shown with the isolation of a possible novel deletion (Me420). this assay 
does have some capacity to detect other deletions. The inability to detect Me 420 
in any of the liver biopsies (apart from LB3 where it was first isolated), cannot 
rule out the possibility of it being a PCR artefact rather than a true deletion. The 
failure of the Mt7420_ specific real4ime PCR assay to detect the deletion in LB3 
is puzzling but reinforces the possibility of a PCR artefact or, alternatively, the 
presence of the deletion below the detection level of the real-time PCR assay. 
4.4.4 Future work 
The difficulty in obtaining liver biopsy specimens sufficient in size to be used for 
research purposes in addition to routine diagnostic requirements has meant that 
the cohort size of the clinical study (n=79) was small. With the continued 
collection of liver biopsies, it is hoped to continue this study which may increase 
the statistical significance of the results obtained thus far. 
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In the present study, the assays failed to detect any significant levels of mtDNA 
deletions in the cohort of individuals studied. However, this research has 
resulted in the development of a sensitive tool which can be used to detect and 
quantify two major mtDNA deletions. This method is extremely versatile and 
could be used to detect these deletions in a variety of settings. For example the 
technology could be used as a biotool to examine the effect of administration of 
mutagens to cells in vitro. Additionally, it could be used to study these deletions 
in other syndromes and clinical disease, where mtDNA damage may be 
occurring at higher, more significant levels. mtDNA damage is known, for 
example to be associated with highly active anti-retroviral therapy (HAART) in 
HIV patients (Miro et al, 2000; Bartley et a/, 2001; Zaera et a/, 2001) resulting in 
lipodystrophy (abnormal fat changes). 
The developed assay also has the added advantage of being able to detect 
mtDNA depletion/proliferation by reference to a nuclear gene (P-globin). There 
are several reports of mtDNA depletion/proliferation in individuals with 
mitochondrial disease (Bai et al, 2004; Bai and Wong, 2005), oesophageal 
cancer (Tan et al, 2006) and in HIV-infected patients on HAART (Cot6 et al, 
2002; de Mendoza et a/, 2004). It is hoped to transfer the methodology 
developed in this Chapter for other applications including the further study of 
mtDNA depletion/proliferation. 
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CHAPTER FIVE 
Detection of Mitochondrial DNA Damage in the 
D-loop Region using Reference Strand 
Conformation Analysis (RSCA) 
5.1 Overview 
The displacement or D-loop of mtDNA (nt 16024-576) serves as the main site for 
mitochondrial genomic replication and transcription (Kasamatsu and Vinograd, 
1974). It is known as the 'control region' as it contains the signals that regulate 
mitochondrial RNA and DNA synthesis (Clayton, 1982) (Figure 5.1). mtDNA is 
more prone to oxidative damage than nuclear DNA and the D-loop region is 
particularly susceptible (Mambo et a/, 2003), due partly to the unique three- 
stranded loop structure which forms during mtDNA replication (Kasamatsu et al, 
1971). Two hotspots of mutation within the D-loop are the hypervariable segments 
HVS1 (nt 16024-16383) and HVS2 (nt 57-372) (Figure 5.1) (Stoneking et al, 2000). 
Due to its role in regulating the transcription and replication of mtDNA, alterations 
in the D-loop may change the rate of mtDNA replication. This could result either in 
a reduced copy number of mtDNA, or an increase in the production of mutated 
mtDNA. Several studies have sequenced the D-loop region to look for mutationý, 
especially in individuals with cancer. However, direct sequencing is relatively 
insensitive at detecting DNA mutations and will not easily identify low-frequency 
differences below 20% (Hancock et a/, 2005). Sequencing is also a time-intensive 
process with substantial data analysis. 
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Figure 5.1: Schematic map of the 1.1 kb mtDNA D-loop region (nt 16024-576). 
The signals that control mitochondrial RNA and DNA synthesis are illustrated. 
HSP/LSP; heavy/light strand promoter, ITWITL; initiation of heavy/light strand 
transcription, F, P; tRNAs for phenylalanine and proline respectively, CSB; 
conserved sequence blocks. Also shown are the locations of the two hypervariable 
segments HVS1 (nt 16024-16383) and HVS2 (nt 57-372). The figure is not drawn 
to scale. 
Reference strand conformation analysis (RSCA) is a heteroduplex-based 
technique which detects differences in DNA conformation when two dissimilar but 
related single-stranded DNA sequences are hybridised to each other, forming 
heteroduplexes (Section 5.2, Figure 5.2). Mismatched base pairs result in 
conformational changes within the heteroduplex leading to retardations in 
electromobility, compared to identically matched sequences (homoduplexes), when 
subjected to electrophoresis. RSCA utilises a fluorescent labelled reference (FLR) 
which forms one strand of each of the homo- and heteroduplexes. The technique 
has recently been transferred from polyacrylamide gel separation of duplexes to 
automated capillary-based electrophoresis systems with laser-based 
instrumentation and computer software; improving its accuracy and reproducibility. 
RSCA provides a platform to study mtDNA damage/mutoltion in the D-loop region. 
Unlike other applications for which RSCA has been developed, its use would not 
be to identify specific mutations but to analyse the region to determine the number 
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of D-loop 'species' harbouring different types of mtDNA damage. The number of 
D-loop species would be indicative of the amount of damage occurring within 
rntDNA and a marker of the overall cellular DNA damage. The D-loop is highly 
polymorphic and varies from individual to individual. It would therefore be usual for 
one heteroduplex to be seen, unless the region in a particular individual was 
identical to the FLR (thus forming a homoduplex). If mtDNA damage was present, 
different types (mutations, deletions and insertions) would result in different 
mismatched base pairs with the FLR. Each mtDNA D-loop species would be 
observed as a heteroduplex, each with a different mobility on electrophoresis. The 
number of heteroduplexes would be indicative of the level of mtDNA damage within 
an individual. This would provide a useful scanning tool to identify mtDNA damage 
in the D-loop region which could then be further analysed to discover the nature of 
the damage. 
This chapter describes the development and optimisation of an RSCA-based 
technique to scan for mtDNA damage occurring within the D-loop region of the 
mitochondrial genome. The fully optimised technique is then applied in a clinical 
study to examine the extent of mtDNA damage in the liver tissue of a cohort of 
patients undergoing a liver biopsy as part of routine diagnostic investigation either 
as a result of HCV infection or an alternate liver aetiology. Oxidative stress leads 
to mtDNA damage (Sections 1.15 and 1.16) and HCV is known to result in 
increased levels of oxidative stress within infected individuals (Section 1.18). The 
repeated necrosis and regeneration of liver tissues associated with chronic viral 
hepatitis may also lead to the accumulation of mtDNA mutations (Nishikawa et al. 
2001). This study aimed to identify whether mtDNA damage was occurring in the 
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liver tissue of HCV-infected individuals to a greater extent than those with other 
liver pathologies. Detection of D-loop species by RSCA could be applied as a 
useful diagnostic tool to determine the extent of DNA damage occurring within cells 
subjected to oxidative stress. 
5.2 Reference strand conformation analysis (RSCA) 
RSCA is a technique which can detect dissimilarity (mismatches, deletions or 
insertions) between two DNA strands which may differ by as little as one 
nucleotide. In RSCA, a locus-specific fluorescent labelled reference (FLR) is 
made, by PCR amplification, using a primer with a fluorescent dye at the 5' end. 
Only one of the primers has the fluorescent dye attached, and so only one strand 
of the FLR is labelled. The FLR is then mixed with an unlabelled PCR product 
from the same locus of the sample to be tested. A process of denaturation 
followed by annealing takes place which allows hybridisation of sense and anti- 
sense DNA strands. This may occur between strands of the same sample (forming 
homoduplexes) or between the FLR and the test sample (forming heteroduplexes). 
The heteroduplexes will have regions in which the nucleotide sequence is 
complementary to the FLR strand and regions where sequence mismatches lead 
to the formation of bulges and loops. Homoduplexes (perfectly matched 
sequences) have a different migration pattern from heteroduplexes (mismatched 
sequences) when subjected to electrophoresis (Figure 5.2). The conformation, 
mobility and therefore migration profile of each heteroduplex is unique and 
influenced by the number and position of the mismatches. Even a single 
nucleotide difference between the sample and the FLR will result in an altered 
mobility of the heteroduplex. Since the fluorescent label is present exclusively on 
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one strand of the FLR, only duplexes formed with this strand will be visualised 
(ArgUello et al, 1998,1998a). 
5.2.1 Capillary electrophoresis using the ABI 3100-Avant 
RSCA was originally developed as a tool for human leucocyte antigen (HLA) typing 
and was of value in donor/patient matching for bone marrow transplantation. HLA 
genes are the most polymorphic in the human genome and RSCA was found to be 
a technique which could accurately and reproducibly identify the many different 
HLA alleles, albeit using several different FLRs to improve resolution due to the 
high level of polyrnorphism (Argaello et al, 1998,1998a; Ramon et a/, 1998). 
Initially, duplexes were separated in a non-denaturing polyacrylamide gel by 
electrophoresis in an automated sequencer. However, gel-based RSCA has 
several limitations. Its low resolution means that it cannot always distinguish 
between closely-linked sequence variations. It is not easy to standardise and 
reproducibility is difficult to achieve as variations in polyacrylamide gel composition, 
buffer and temperature can affect the rate of mobility, resulting in both lane-to-lane 
and gel-to-gel variability. This method is also very time-consuming, with gel 
running times up to 16 hours, greatly reducing its utility as a high-throughput 
screening tool. 
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Figure 5.2: A schematic diagram of RSCA. The sample is mixed with the FLR 
and allowed to denature and re-anneal, either with itself (forming a homoduplex) or 
with the FLR (forming a heteroduplex). The duplexes are then separated by 
electrophoresis and those containing the labelled FLR strand are detected. 
Separation can be by polyacrylamide gel electrophoresis (PAGE) with detection on 
an automated sequencer. More recently, duplex separation has been transferred 
to capillary electrophoresis with detection via a charged coupled device (CCID). 
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The recent development of capillary electrophoresis-based RSCA techniques has 
led to renewed interest in this method. With capillary electrophoresis, samples are 
electrokinetically injected automatically into parallel capillaries organised in an 
array. Specially formulated polymers allow the DNA to migrate from the cathode 
towards the anode, mask the ion boundary at the surface of the capillaries and act 
as a separation matrix. The DNA passes through a detection cell where a laser 
beam simultaneously illuminates the capillaries from both sides of the array. 
Several fluorescent dyes are available, each emitting signals at different 
wavelengths, and so a number of FLRs can be detected simultaneously. As each 
different homo- and heteroduplex passes through the detection cell, the emitted 
fluorescent signals are collected, separated by wavelength and focused onto a 
charged coupled device (CCD). Once the fluorescent signals are collected by the 
CCD, the data are transferred to a computer. The GeneMappero software 
transforms the data into electropherograms, displayed as 'sample plots' (Section 
2.25.7 and Figure 5.3). These represent each duplex as a peak, with heights 
measured as relative fluorescent units (RFUs) (Figure 5.3, y axis). An internal size 
standard (ISS), labelled with its own particular fluorescent dye is added to each 
sample prior to electrophoresis. The ISS is a series of 'fragments' of known size 
(Figure 2.3, Section 2.25.7). Inclusion of an ISS with each sample allows each 
duplex peak to be allocated a base pair size according to their mobility (Fig 5.3, x 
axis) relative to the ISS fragments. The ISS also compensates for run-to-run and 
capillary-to-capillary variations, allowing excellent reproducibility. 
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Figure 5.3: A four-dye electropherogram: The figure demonstrates a run where four 
different fluorescent dyes have been used, each emitting a signal at a particular 
wavelength which are collected by the CCD. RFU; relative fluorescent unit. 
Capillary electrophoresis RSCA is carried out on Applied Biosystems Genetic 
Analyzers such as the ABI 3100-Avant where it is run as 'fragment analysis'. 
Fragment analysis has a wide range of applications including microsatellite 
genotyping, forensics, SNP genotyping, mutation detection and sizing-only 
applications. Unlike gel-based protocols, this method allows automation, is far less 
time-consuming and labour intensive and reduces cost. In addition, a wide range 
of polymers are available (unlike the gel-based method which relies solely on 
polyacrylamide). These polymers offer lower viscosity and improve separation and 
resolution. In addition the ISS offers a vast improvement over the PCIR markers 
utilised in gel-based methods which are run separately from samples, at the edge 
of each gel, making accurate determination of the extent of migration difficult. The 
transfer of HLA-typing from gel-based to capillary electrophoresis greatly improved 
the resolution and throughput of this method (Turner et a/, 1999,2001). 
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5.2.2 Application of capillary RSCA to detect damage In the mtDNA D- 
loop region 
The D-loop region is known to be highly polymorphic; therefore nucleotide 
differences between the FLR and the test sample would be expected. The 
application of this technique would, therefore, not be simply to identify a single 
heteroduplex indicating a single D-loop species, but to observe several 
heteroduplexes, demonstrating that numerous mutations/deletions are occurring 
within the damage-vulnerable D-loop region. This could function as a marker of 
the overall level of mtDNA damage within individuals. RSCA is extremely relevant 
to this application as the aim is not to detect a single, specific mutation, but, 
instead to act as a scanning method to detect various alterations within a defined 
region. Each distinct species would have a specific migration profile and therefore 
each heteroduplex would represent a particular damaged D-loop species. The 
number of species would therefore be representative of the extent of mtDNA 
damage occurring within the target region. 
5.3 Development of experimental procedures 
6.3.1 Primer design and D-loop amplification 
The revised Cambridge reference sequence (rCRS) of the mitochondrial genome 
(available at www. mitomap. orq or GenBank accession number AC000021), was 
examined and one of the two hypervariable segments of the D-loop region (HVSI, 
nt 16024-16383) was chosen as the target for RSCA. Due to the highly 
polymorphic nature of this region and to ensure greatest sensitivity, the primers 
were designed within sequences where there are a minimal number of reported 
polymorphisms (Ingman and Gyllensten, 2006, www. -aenDat. uu, se/mtDBAndex. htmI . 
The discriminatory power of RSCA should be increased when targeting a large 
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region as this would demonstrate greater sequence divergence. With this in mind, 
a region of 457 bp of HVSI (nt 15973 -nt 16430) was targeted. The sequences of 
the designed primers (DLoopF and DLoopR) are given in Appendix B. 
For the optimisation of D-loop amplification and subsequent RSCA development, 
DNA was extracted from six randomly chosen liver biopsies (1-133, LB26, LB33, 
LB34, LB46 and LB47) using the DNeasy'O extraction protocol as described in 
Section 2.5.3. These DNA extracts were utilised in all optimisation experiments. 
Amplification of HVS1 was carried out using a block-based PCR method, with 
primers DLoopF and DLoopR. PCR conditions were optimised as described in 
Section 2.16. Fully optimised conditions for D-loop amplification are given in 
Appendix C. The primers were found to be specific and sensitive for the HVSI 
region of the D-loop. First, the amplicons were subjected to agarose gel 
electrophoresis (Section 2.7) and were found to be of the correct size (457 bp) 
(Figure 5.4). Second, the PCR products were purified (Section 2.17), sequenced 
(Section 2.21) and aligned with the rCRS (Section 2.22) which confirmed that the 
correct region was amplified. 
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Figure 5A Image of HVS1 PCR products following separation on a 2% agarose 
gel. Extracted DNA from six liver biopsy specimens (lanes 1-6) was amplified 
using the D-loop primers (DLoopF and DLoopR). The image demonstrates the 
specificity of amplification, the amplicons are of the correct size (457 bp) and there 
are no other bands which would be indicative of primer non-specificity. M, PCR 
markers, bp; base pairs. 
5.3.2 Selection of an FLR 
The FLR is used as a reference sequence against which 'unknown' samples are 
compared. The best resolution of homoduplexes from heteroduplexes is achieved 
when there are a greater number of nucleotide differences between the FLR and 
the 'unknowns'. If the differences between the FLR and the'unknown' are minimal, 
the heteroduplexes will migrate very close to the homoduplex and make it difficult 
to distinguish the heteroduplexes. In order to select an FLR for HVS1 which would 
display a high number of nucleotide variations, different sources were investigated. 
DNA from peripheral blood mononuclear cells (PBMCs) was extracted from the 
blood of two healthy laboratory volunteers (KR and MC) using the salting-out 
method (Section 2.5.4). The D-loop region was amplified and the amplicons 
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sequenced as described above. These sequences, along with those from the 
amplified liver biopsy specimens (1-133, LB26, LB33, LB34, LB46 and LB47) were 
aligned against the rCRS. 
The sequenced amplicons all displayed nucleotide differences from the rCRS at 
the amplified region of HVS1 (Figure 5.5 and Table 5.1). The percentage 
divergence was calculated from the number of nucleotide differences from the 
rCRS in the 457 bp amplicon (Table 5.1). One of the laboratory workers (MC) had 
a HVSI demonstrating the highest level of sequence divergence (6 nucleotide 
differences, 1.31 % divergence) when compared to the rCRS. This was selected as 
the FLR for RSCA. 
Source Number of nucleotide 
differences from rCRS 
Divergence 
LB3 5 1.09 
LB26 5 1.09 
LB33 3 0.66 
LB34 1 0.22 
LB46 3 0.66 
LB47 2 0.44 
KR 2 0.44 ý 
MC 6 j 1. qý7 
Table 5.1: Divergence between D-loop amplicons from different sources and the 
rCRS. D-loop amplicons from 6 liver biopsies (1-133, LB26, LB33, LB34, LB46 and 
LB47) and two healthy volunteers (KR and MC) were sequenced. The sequences 
were aligned and compared against the revised Cambridge reference sequence 
(rCRS). The number of nucleotide differences between each sequence and the 
rCRS were counted and the percentage divergence, within the 457 bp amplicon, 
calculated. 
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5.3.3 Cloning of HVS1 
In order to create a stock of HVS1 amplicon for FLR production, the purified PCR 
product from laboratory worker MC, which had been selected for use as an FLR, 
was introduced into the pCRP-TOPO cloning vector as described in Section 2.23. 
Insert verification was carried out using colony PCR as described to confirm the 
effective production of a recombinant plasmid. The PCR products generated 
during colony PCR were sequenced in both directions to eliminate the possibility of 
sequence artefacts and to ensure accuracy of data generated. The cells were 
harvested and the plasmids purified (Section 2.24.2). This process created a 
recombinant plasmid containing the 457 bp region of HVS1 which could be 
continually used as the source from which the FLR was synthesised. 
5.3.4 Generation of FLR 
An FLR was created from the recombinant plasmid as described in Section 2.25.1. 
This involved utilising the same block-based PCR conditions for D-loop 
amplification as described above (Section 5.3.1 and Appendix C), but replacing the 
DLoopF primer with one, identical in sequence, but with a FAM-fluorophore at the 
Vend (DloopFLab, Appendix B). 
5.3.5 Optimisation of duplex formation and dilution 
Duplex formation was carried out using a method adapted from ArgOello et al 
(1998) and outlined in Section 2.25.2. This involves mixing sample D-loop 
amplicons with the prepared FLR in a 3: 1 ratio (3 pl sample to 1 pl FLR) and 
allowing the PCR products to denature and re-anneal either with strands of the 
same sample or with the FLR and the 'unknown. It was found that utilising PCR 
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amplicons which had been purified (Section 2.17) prior to duplex formation 
produced better results than non-purified products as there was less background 
noise on RSCA (data not shown). 
Following duplex formation, products are very concentrated and require dilution to 
achieve peaks suitable for RSCA. This is a critical step in the process as over- 
dilution of samples will reduce sensitivity, producing smaller heteroduplex peaks 
which may be difficult to detect. Insufficient dilution results in over-loading which 
can produce so-called pull-up peaks from bleed-through of other dyes. The peak 
heights are measured in relative fluorescence units (RFUs) which are dependent 
on the amount of product which is loaded into the capillary. It is important that the 
protocol is optimised to produce a strong fluorescent signal with the minimum of 
background 'noise'. For the ABI 3100-Avant, the target peaks should be >100 and 
<2000 RFU. Several RSCA protocols (e. g. Maftocks et al, 2007) adopt a dilution 
protocol in which the products of duplex formation are diluted in a two-step 
process. To establish the optimum dilution of products to be loaded into the 
capillary, a range of different dilution combinations were assessed to produce 
peaks within the specified RFU range, with no loss of sensitivity (Figure 5.6). For 
example, a two-step process in which the duplex product was first diluted I in 10 (4 
pl of product in 36 pl ddH20) and then 1 in 2 (10 pl of first dilution product in 10 pl 
ddH20)- Peak size is also dependent on injection time of capillary electrophoresis 
and so optimisation of dilution factor was carried out concurrently with optimisation 
of injection time. The final dilution protocol is outlined in Section 2.25.3 and 
corresponds to run B in Figure 5.6. 
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5.3.6 Optimisation of capillary electrophoresis 
Several different parameters including polymer type, run temperature, injection 
time/voltage and run time can affect the resolution and separation of homo- and 
heteroduplexes. The run time must be sufficient to allow all of the internal size 
standards to pass the detection cell. The injection time controls the peak size and 
must be sufficient to result in target peaks of >100 and <2000 RFU with good 
resolution of homo- and heteroduplexes. On the ABI 3100-Avant, a module editor 
can be utilised to alter these parameters to create and save the optimised run 
conditions. Three polymers were investigated; GeneScan, POP-4 and POP-6 
polymer. GeneScan polymer was found to be non-compatible with the capillary 
array. POP-6 polymer had increased resolution of separation when compared to 
POP-4 polymer (data not shown) and was therefore selected. The optimisation of 
electrophoresis conditions was carried out on an experimental basis. Optimisation 
of capillary electrophoresis was carried out by injecting the same samples multiple 
times using a range of run times (30,45,60,120 mins) and injection parameters 
(10,15,30,45 and 60 sec) (Figure 5.6). The fully optimised conditions are 
outlined in Section 2.25.6. The data was collected and analysed using 
GeneMappere software (Section 2.25.7). 
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5.3.7 Intra- and inter-run variation 
RSCA data was analysed using GeneMapper software as described in Section 
2.25.7. The use of internal size standards allows accurate base pair sizing and 
mobility values to be given to all duplexes. For this method to be successfully 
applied it would need to be highly reproducible with no difference in assignation of 
mobility value to duplexes either within a run (intra-assay variability) or between 
runs (inter-assay variability). 
In order to determine the intra- and inter-run variability and therefore overall 
reproducibility of the RSCA assay, a number of samples were run in triplicate on 
three separate occasions. The mean and standard deviation (SID) for each mobility 
value (homoduplex and heteroduplex) was calculated. The RSCA profiles 
generated on each occasion were highly reproducible and generated a 
characteristic profile each time with minimal intra- and inter-run variation (Tables 
5.2 and 5.3). Detailed results from these analyses are given in Appendix H. 
Run 1 SD Run 2 SD Run 3 SD 
Ho He Ho He Hio He 
LB3 0.223 0.203 0.126 0.633 0 E63 o i 3 0.212 
LB33 
- 
0.124 0.155 0.0757 0.116 L1 ,"l . 214 
j 
-4 0.107 
ýM 41 0.038 0.247 1 0.256 0.204 ý 0.380 0.344 
Table 5.2: Intra-assay variability of RSCA. Three specimens (LB3, LB33 and 
LB34) were run in triplicate on three occasions (runs 1,2 and 3). The mobility 
values were recorded for the homoduplexes (Ho) and heteroduplexes (He) and the 
standard deviation (SID) calculated for each triplicate on each run. 
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Homoduplex SD Heteroduplex SD 
LB3 0.309 0.387 
LB33 0.202 0.185 
LB34 0.340 0.338 
Table 5.3: Inter-assay variability of RSCA. Figures shown are the standard 
deviations (SID) of the mobility values for the homoduplex and heteroduplex 
species of three specimens (1-133, LB33 and LB34) run in triplicate on three 
occasions. 
5.3.8 Assessing the sensitivity of RSCA 
An assay developed for detection of mtDNA damage would need to be highly 
sensitive to ensure detection of all species of damaged mtDNA, including those 
present at very low levels. To test the sensitivity of the optimised RSCA assay, 
DNA extracts from two liver biopsy specimens were mixed prior to D-loop PCR 
amplification to simulate two D-loop species occurring within the same individual. 
Different mixtures were prepared with one liver biopsy being the minority species. 
The D-loop region was then amplified and duplexes formed with the FLR, as 
described previously. Capillary electrophoresis of each mixture was carried out in 
triplicate to ensure that detection of the minority species occurred reproducibly at 
low levels. Figure 5.7 illustrates an example run, in which two liver biopsies (LB3 
and LB26) were mixed prior to D-loop amplification so that one liver biopsy 
represented the minority species (see table in Figure 5.7). In this figure, two 
heteroduplexes are observed for each mixture which corresponds to the two liver 
biopsy specimens. The minority species could be detected accurately and 
reproducibly at the 2% level. Below this only one heteroduplex is seen, as the 
minority species could not be detected when it constituted less than 2% of the 
mixture. 
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5.4 Evaluation of RSCA to detect mtDNA D-loop damage In the clinical 
setting 
The potential of the developed RSCA method to detect mtDNA damage in clinical 
samples was assessed using the collection of liver biopsy specimens from patients 
undergoing a liver biopsy in the Planned Short Stay Unit (PSSU) at Addenbrooke's 
Hospital, as part of their clinical management, between May 2005 and August 
2007. The clinical characteristics of this cohort are described in Section 4.3.1 and 
Appendix G. This study was covered by the ethical approval obtained from the 
Cambridge Local Research Ethics Committee (LREC) (reference number 
04/QOI 081124, see Appendix E). 
In total, seventy-nine liver biopsy specimens were subjected to RSCA. Of these, 
the majority (68/79,86.1 %) exhibited only a single heteroduplex species, indicating 
that only one mtDNA HVS1 species was present at a detectable level. As 
expected, this region exhibited a high level of polymorphism. Of the 68 individuals 
demonstrating a single heteroduplex, 31 different mobility values for the 
heteroduplex were observed (Appendix 1). The mobility value for the 
heteroduplexes ranged from 420.1 - 474.0. Ten of these liver biopsy specimens 
were sequenced and the sequence data examined for evidence of other D-loop 
HVS1 species (data not shown). The sequences of these liver biopsies clearly 
demonstrated only a single HVS1 species. 
Eleven livers (13.9%) displayed multiple heteroduplex species, ranging from 2 to 5 
species. Patient characteristics and number of heteroduplexes seen are outlined 
in Table 5.4. All biopsy specimens exhibiting multiple heteroduplexes were re- 
amplified and RSCA repeated to ensure reproducibility of results. In all cases, 
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identical results were seen on repeat analysis. Figure 5.8 demonstrates a 
selection of RSCA profiles of liver biopsy specimens demonstrating multiple 
heteroduplexes. 
Patient Characteristics 
Liver ID Heteroduplexes Age Sex Liver Aetiology 
LB9 3 35 m Unknown 
LB10 3 44 m HCV, genotype 1 
LB36 2 53 m HCV, genotype 1 
LB41 2 31 m HBV 
LB48 2 63 F Alcoholic liver disease 
LB50 5 29 m HBV 
LB52 4 47 F HCV, genotype 2. Diabetes 
LB58 4 33 m HCV, genotype 4 
LB70 4 52 m HCV, genotype 1 
LB72 3 60 m ? ASH/? NASH 
LB76 4 57 m ? dysplasia 
Table 5.4: Clinical characteristics of the patients displaying multiple 
heteroduplexes on RSCA. HBV; hepatitis B virus, ASH; alcoholic steatohepatitis, 
NASH; non-alcoholic steatohepatitis. 
Five (45.5%) individuals with multiple heteroduplexes were infected with HCV. The 
average age of patients demonstrating multiple heteroduplexes was 45.8 years 
which did not differ significantly from the average age of individuals demonstrating 
only a single heteroduplex species (46.4 years). There was an under- 
representation of females with multiple heteroduplexes. Females made up 32% of 
individuals displaying a single heteroduplex, but only 18% of individuals 
demonstrating multiple heteroduplexes. 
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In order to characterise the observed RSCA profiles in individuals with multiple 
heteroduplexes, the purified D-loop amplicons from these liver biopsies were 
sequenced using the D-loop primers (Section 2.21). Sequence analysis of livers 9, 
50,52,58,70,72 and 76 indicated that an event was occurring around a repeat 
run of cytosine residues (a poly-C tract) between nt 16184 and nt 16193 of the 
mtDNA sequence. For these liver biopsies, the sequence is homogeneous until 
the end of the poly-C tract and then becomes heterogeneous with a mixture of at 
least 3 species. The sequence of each species can be seen as a 'staggered' 
sequence following the final cytosine residue (Figure 5.9). For liver biopsies 9,72 
and 76, the majority sequence has 10 cytosine residues and there are also two 
minor species, one with 9 and one with 11 cytosine residues. For liver biopsies 52, 
58 and 70 there are three species with 10,11 or 12 cytosine residues. For liver 
biopsy 60, there are three species with 11,12 or 13 cytosine residues. 
As Figure 5.8 demonstrates, liver biopsies 36 and 41 display two heteroduplex 
species which are relatively close together, indicating that the differences between 
them are small. Sequence analysis of liver biopsy 36 indicated a polymorphism at 
nt 16093. The majority sequence exhibits a cytosine nucleotide, whilst there is a 
thymidine nucleotide at this position in the minority sequence. This polymorphism 
is seen both in the forward and reverse sequence. According to the mtDNA 
databank (httr): //www. 
-cien-pat. uu. se/mtDB/), 
the majority of recorded mtDNA 
sequences report a thymidine at this position, whilst a cytosine is seen in 98/1768 
(5.5%) of stored sequences. The amino acid change encoded by the T--+C 
alteration is non-coding. Liver biopsy 41 displays a polymorphism at nt 16234. 
The majority sequence exhibits a cytosine residue, whilst there is a thymidine 
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residue in the minority sequence. This polymorphism is, however, not confirmed in 
the reverse sequence. A thymidine in place of a cytosine is seen in 67/1800 
(3.7%) of stored sequences in the mtDNA databank. The amino acid change 
encoded by the T--+C alteration is non-coding. Liver biopsies 10 and 48 displayed 
three and two heteroduplexes respectively. The sequence data for these liver 
biopsies shows heterogeneity, indicating the presence of more than one species. 
Sequence analysis could not determine the nature of these species. 
For some of the liver biopsies, the number of heteroduplexes observed on RSCA 
was greater than the number of species visible on sequence analysis (Table 5.5). 
This could be due to the reduced sensitivity of sequencing when compared to 
RSCA which may have failed to identify species occurring at very low levels. 
Liver ID Heteroduplexes Species visible on 
sequence analysis 
LB9 3 3 
LB1 0 3 multiple 
LB36 2 2 
LB41 2 2 
LB48 2 multiple 
LB50 5 3 
LB52 4 3 
LB58 4 3 
LB70 4 3 
LB72 3 3 
LB76 4 3 
Table 5.5: Comparison of the number of species seen (heteroduplexes) on RSCA 
and the number of species visible on sequence analysis for the eleven liver biopsy 
specimens demonstrating multiple heteroduplexes on RSCA. 
To ensure that the observed results were not artefacts arising during PCR 
amplification of the mtDNA fragments, a liver biopsy specimen which did not 
demonstrate multiple heteroduplexes was amplified five times, with each amplicon 
subjected to both RSCA and sequence analysis. RSCA demonstrated no 
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additional heteroduplexes and sequence analysis confirmed only a single species 
with no evidence of poly-C tract alterations (data not shown). 
5.5 Discussion 
5.5.1 D-loop region as a target for mtDNA damage detection 
This study was undertaken to examine mtDNA damage resulting from attack by 
reactive oxygen species (ROS) during oxidative stress. mtDNA is well recognised 
as being more susceptible to ROS than nuclear DNA (Richter et al, 1988; Yakes 
and Van Houten, 1997). Numerous factors account for this increased 
susceptibility, including lack of protective histones (Celeste et a/, 2003) and the 
generation of substantial amounts of ROS by mitochondria. As mtDNA suffers a 
greater level of damage than nuclear DNA, it is therefore easier to detect, providing 
an ideal marker to determine absolute cellular DNA damage. 
mtDNA damage is region-dependent, with the D-loop being particularly 
susceptible. This is thought to be due to its unique three-strand 'loop' structure 
which is prone to attack (ter Schegget et a/, 1997) and to the reduced level of 
mtDNA repair which occurs in this region (Mambo et al, 2003). Even within the D- 
loop itself, there are certain 'hot-spots' of mutation (Stoneking et al, 2000) known 
as hypervariable segments (HVS1 and HVS2). The heightened level of mutation 
seen within these regions is thought to be due to the presence of micro-satellites - 
stretches of DNA with high base pair repetition (Sia et al, 1997). There are several 
accounts of mtDNA mutations within a poly-cytidine stretch in HVS2 which has 
been observed in human cancers (Sanchez-Cespedes et a/, 2001; Wang et a/, 
2005). 
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Although the D-loop region is 'non-coding', its integrity is vital to mitochondrial 
survival as it contains the signals that control both its DNA and RNA synthesis. 
Small alterations within the region could, therefore, have an extremely detrimental 
effect, disrupting mitochondrial function and therefore reducing the oxidative 
phosphorylation capacity of cells. These functional impairments could also 
enhance the generation of ROS, which in turn would accelerate DNA mutation. 
Accordingly, the D-loop was chosen as the target region to examine oxidative- 
stress related mtDNA damage. To maximise the possibility of detecting damage 
within this region, attention was focused on the hot-spots of mutation. Mutations in 
HVS2 are well documented, primarily in association with human cancer (Sanchez- 
Cespedes, 2001; Nomoto et al, 2002; Okochi et al, 2002). Therefore it was 
decided to focus on the other hot-spot of mutation - HVS1 as the target for this 
research. 
As described extensively in Section 1.18, HCV is strongly associated with 
increased levels of oxidative stress within infected individuals. Attack by ROS 
leads to different types of DNA damage, including strand breaks and base/ 
nucleotide modifications. As cells contain 10%104 mtDNA molecules, the attack by 
ROS would likely lead to a variety of D-loop species each with different amounts 
and types of damage. With this in mind, it was decided to develop a method which 
could be utilised, not to detect specific mutations within the D-loop, but to screen a 
section of the region which is known to be a particular hot-spot of mutation to 
detect and quantify the number of D-loop 'species'within an individual, with each 
species harbouring different types of damage. 
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5.5.2 D-loop mutations/damage and liver disease 
The vast majority of studies examining D-loop mutation in liver disease have 
focused on hepatocellular carcinoma (HCC). This interest in liver cancer stems 
from the accumulating body of evidence that somatic mtDNA mutations occur in a 
variety of human cancers. Somatic mtDNA mutations have been identified in 
bladder, head and neck and lung cancers (Fliss et a/, 2000), ovarian (Liu et a/, 
2001), prostate (Petros et a/, 2005) and colorectal cancers (Lievre et al, 2005) and 
gastric turnours (Alonso et a/, 1997; Wu et al, 2005; Zhao et al, 2005). In contrast 
to inherited mitochondrial diseases, in which mtDNA mutations are mainly 
observed in the tRNA and coding regions, somatic mutations in human cancers are 
commonly located within the D-loop region. 
Approximately 20% of people infected with HCV will develop cirrhosis of the liver, 
and a proportion of these will go on to develop HCC (Figure 1.2, Chapter One). 
Studies on patients with HCC, mirror the findings of other human cancers in that 
somatic mtDNA mutations appear to play an integral role in tumorigenesis, with 
mtDNA mutations associated with HCC occurring mainly within the D-loop region. 
HCC is unique in that the cancer is usually preceded by chronic infection or 
disease for many years before the cancer, although the development of carcinoma 
itself is rapid. The presence of HCV within liver cells prior to progression to HCC 
results in a high level of oxidative stress, further increasing the likelihood of D-loop 
mutations. Direct sequencing of the D-loop of mtDNA has demonstrated somatic 
mutations in the tumour mtDNA of 34% (n=50) (Okochi et al, 2002) and 68% 
(n=19) (Nomoto et al, 2002) of human HCC cases. The matching of mutations in 
paired serum samples from these patients led Okochi and colleagues (2002) to 
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suggest the screening of patients at high risk for HCC for the presence of tumour 
cells in the serum by detection of mtDNA mutations. 
The frequency of mtDNA mutations was found to be markedly increased in both 
the cancerous and non-cancerous liver tissue from individuals with HCC, 
compared to healthy controls. The vast majority of mutations were found to occur 
within the D-loop region (Nishikawa et al, 2001; Lee et al, 2004; Tamori et al, 2004; 
Yoneyama et al, 2005). The frequency of D-loop mutations was found to be 
greater than described previously for other turnours, suggesting accumulation of 
mtDNA mutations as a useful predictor of hepatocarcinogenesis. Many of these 
mutations were located in a poly-cytidine stretch in HVS2. The observation of high 
numbers of mutations in the non-cancerous tissue suggests that the hepatocytes in 
such tissue may already have undergone the initial stage of malignant 
transformation during chronic inflammation. These studies all describe D-loop 
mutation in individuals who have already progressed to HCC. The only published 
study on D-loop damage in chronic HCV infection, in the absence of HCC has 
found the frequency of mtDNA mutations to be increased in liver tissue from 
patients with chronic HCV infection compared to normal controls (Nishikawa et a/, 
2005). The greatest number of mutations was apparent in the D-loop, particularly 
within HVS2. Interferon therapy resulted in a significant decrease in the number of 
mutations within the D-loop. This study suggested that the hepatocytes in these 
patients were continuously undergoing malignant transformation during 
inflammation induced by HCV infection, which was reduced by interferon therapy. 
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The studies described above all utilised direct sequencing for mutation detection. 
This is relatively insensitive at detecting DNA mutations and will not easily identify 
low-frequency differences below 20% (Hancock et al, 2005). It is also a labour- 
intensive process which requires time-consuming sequence data analysis. Very 
few studies have used methods other than sequencing for D-loop mutation 
detection in liver disease. Temporal temperature gradient gel electrophoresis 
(TTGE) involves separation of PCR amplicons on a gel immersed in buffer which 
warms up through the melting temperature range of the fragment of interest. This 
allows the separation of DNA fragments based on minute differences. In the 
presence of homoplasmy, a single band is observed. If heteroplasmy occurs, 
melting and annealing after the last PCR cycle results in two homoduplex and two 
heteroduplex bands with different mobilities. This technique has been used in a 
study by Wong et a/ (2004) in which the entire mitochondrial genome was amplified 
and then subjected to TTGE. This enabled the detection of somatic mutations in 
10/20 (50%) liver tumour biopsies from patients with HCC, with 24 different 
mutations found. Unlike other studies, which focused only on the D-loop region, 
this assay enabled comprehensive mutational analysis of the entire mitochondrial 
genome. All of the identified mutations except one (96%) were in the D-loop 
region, a rate much higher than other tumours and the poly-cytidine stretch in 
HVS2 was seen to be a mutation hot-spot. Onishi et al (2007) have developed a 
PCR-single strand conformation polymorphism (SSCP) assay to study D-loop 
mutations in the liver tissue of rats with HCC induced through diet modifications. 
This method involves PCIR amplification, followed by agarose gel electrophoresis. 
Presence of mutations is detected by abnormally shifted bands on the gel which 
are extracted, re-amplified and directly sequenced. In this study, mutations were 
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detected in the liver tissue of 50% (n=10) of rats with HCC induced by an n- 
nitrosodiethylamine diet. TTGE and PCR-SSCP are methods which are similar to 
RSCA. However, both are gel-based and therefore suffer from poor gel-to-gel 
reproducibility. TGGE is also a time-consuming process, with gel run times of 4-6 
hours. 
These studies have all demonstrated that D-loop mutations are commonly seen in 
association with HCC, at a frequency much higher than observed in other turnours. 
Several of the studies noted alterations in the amount of mtDNA in tumour tissues 
with D-loop mutations (Lee et al, 2004; Wong et al, 2004). This suggests that the 
alterations in the D-loop region are displaying an effect on mtDNA replication, 
which could repress mitochondrial gene expression, resulting in a detrimental 
effect on the bioenergetic function of cells in affected liver tissue. These studies 
have all centred on HCC, often in association with HCV infection, yet there is only 
one report on D-loop mutation/damage in the liver tissue of individuals chronically 
infected with HCV in the absence of HCC (Nishikawa et al, 2005). The methods 
used to detect these mutations have been restricted to sequencing, with its lack of 
sensitivity and gel-based duplex assays (PCR-SSCP and TTGE) which suffer gel- 
variability and poor reproducibility. Thus, the design of a study to examine D-loop 
mutations in individuals chronically infected with HCV, with a new assay which has 
improved sensitivity and reproducibility was thought to be a useful addition to the 
existing literature. 
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5.5.3 Development of RSCA 
The transfer of RSCA from gel-based to capillary electrophoresis has improved its 
resolution and sensitivity and increased throughput. This allowed the further 
development of this method for HLA typing (Turner et al, 1999; 2001). 
Furthermore, it enabled the technique to be used in a number of new applications, 
particularly within the field of genetics in screening for unknown mutations in 
disease-related genes, including those implicated in cancer (Davies et a/, 2002; 
Esteban-Cardenosa et al, 2004). The method utilises simple DNA manipulations 
and short run times for capillary electrophoresis, promoting it as a useful tool in the 
diagnostic environment (Kozlowski et a/, 2005). The high reproducibility of 
migration profiles has also lead RSCA to be developed as a powerful typing tool 
which has been applied for identification of pathogenic fungi (Mclihatton et al, 
2002) and HCV genotyping (White et al, 2000). 
Several studies have indicated that RSCA could be used as a screening method to 
identify multiple species within an individual. RSCA (using gel electrophoresis for 
duplex separation) was able to identify mixed viral infections (HCV and TT virus), 
even when the co-infecting virus represented only 1% of the viral population in the 
serum or 2% of the amplified product (White et al, 2000a). Multiple HCV 
quasispecies could be identified within HCV-infected individuals (Ross! et al 2003), 
with each heteroduplex peak representing an HCV quasispecies. The 
heteroduplex profile within individuals altered considerably during interferon 
treatment and post-liver transplant, demonstrating evolution of quasispecies. 
RSCA has also recently been applied in the detection of dual-subtype HIV 
infections which could be identified by the observation of multiple heteroduplexes 
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following gel electrophoresis (Powell et al, 2008). Ross et a/ (2002) used gel- 
based RSCA to look at the damage in the D-loop region associated with increasing 
age. The technique was able to detect a level of polyplasmy, with the maximum 
number of mtDNA species in any one sample totalling four. However, these 
species were not sequenced to show the nature of the damage. These studies 
have all demonstrated that RSCA could be a useful tool to screen for different D- 
loop species within an individual. 
In the design of RSCA for this study, several factors had to be carefully considered 
to enable to the creation of an assay which had good sensitivity and reproducibility 
and also produced data which was easy to analyse. The generation of a good FLR 
was paramount as this would provide the reference against which all unknowns 
were compared. If the FLR is not significantly different from the unknown samples 
then the migration of heteroduplexes would be restricted and would make 
differentiation between duplexes very difficult. Fortunately, an FLR could be 
created from a laboratory worker who clearly demonstrated a number of 
differences from the rCRS. The alternative would have been to create an FLR 
through site-directed mutagenesis of the target sequence which would have 
produced a unique sequence to be employed as a reference. 
The dilution protocol for the products of duplex formation needed to be carefully 
optimised. Over-dilution of products would have lessened the sensitivity of the 
assay, which may then have failed to detect D-loop species occurring at low-levels. 
Conversely, under-dilution of products would lead to 'pull-up' peaks from bleed 
through of dyes and extremely high fluorescent signals which would produce peaks 
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that were flattened and impossible to accurately size. The two-step dilution 
protocol described in section 5.3.5 resulted from a long series of optimisation 
experiments. The capillary electrophoresis protocol was adapted from that used by 
others (e. g. Mattocks et al, 2007) and was carefully fine-tuned to produce quality 
data and high-throughput. The injection time of capillary electrophoresis also plays 
a role in the quality of peaks and the sensitivity of the assay, and so this needed to 
be carefully optimised in association with the dilution protocol. 
As a result of the optimisation assays, the fully developed RSCA assay was found 
to produce migration profiles with good resolution of homo- and heteroduplexes. 
Experiments simulating mixed D-loop species demonstrated that the assay was 
highly sensitive, with the ability to detect minority species when it represented only 
2% of the product (Section 5.3.8). The developed assay would only be useful in 
the clinical setting if it produced results which were reproducible; its low intra- and 
inter-run variability demonstrated that this was indeed the case. The RSCA assay 
benefits from its ease of use, with straight-forward duplex-formation and capillary 
electrophoresis steps which require minimal hands-on time. The short run time of 
capillary electrophoresis (1 h) enables run through of the entire assay from DNA 
extraction to data analysis to be achievable within a working day. 
5.5.4 Clinical study 
The clinical study described in this chapter examines a cohort of individuals with a 
variety of liver aetiologies including HCV, HBV, excessive alcohol intake and 
NAFLD/NASH (Appendix G). The overall aim was to determine whether mtDNA 
damage was occurring to a greater extent in individuals infected with HCV 
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compared to other liver aetiologies. The optimised RSCA assay was clearly 
demonstrated to be extremely sensitive, with the capacity to detect minority 
species occurring at the 2% level. It was, therefore unexpected that the majority 
(68/79,86.1%) of livers analysed displayed only a single heteroduplex species. 
This indicated that, in these individuals, there was no detectable damage occurring 
in the HVS1 region of the D-loop, or that any damage was below the level of 
detection of the RSCA assay. For the specimens exhibiting a single heteroduplex, 
thirty-one different heteroduplex mobility profiles were observed. This is not 
surprising, as HVS1 is highly polymorphic and therefore used as a tool in human 
identity forensic testing (Budowle et al, 1999) and in the understanding of human 
evolution (Salas et al, 2000). 
Eleven of the liver biopsy specimens (13.9%) exhibited two or more 
heteroduplexes (Table 5.6), indicating that several HVS1 species existed within the 
liver tissue of these individuals. Sequence analysis of the specimens displaying 
two or more heteroduplexes demonstrated that in seven of these, an event was 
occurring at the same location - an uninterrupted run of cytosine residues (a poly- 
cytidine or poly-C tract) between nucleotides 16184 and 16193, close to the origin 
of heavy strand replication (Anderson et al, 1981). Interrogation of the Mitomap 
database indicated that genetic variation of the 16184-16193 poly-C tract had been 
previously reported (Horai and Hayasaka, 1990). In the wild-type mitochondrial 
genome, a thymidine residue at nt 16189 interrupts the poly-C tract 
(CCCCCTCCCC). Several other variants exist in which the tract is interrupted by a 
thymidine at a position other than nt 16189. In approximately 10% of Europeans, 
there is a T--), C substitution at nt 16189, creating a tract of ten uninterrupted 
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cytosine residues (known as the 16184-16193 poly-C tract). This sequence is 
unstable and potentially undergoes expansion/con traction, most likely through 
replication slippage (Hauswirth et al, 1984). This generates a heteroplasmic 
mixture of poly-C tract variants, usually between 9 and 11 cytosine residues in 
length, but ranging from 8 to 14 within a single individual during their lifetime 
(Bendall and Sykes, 1995; Lee et a/, 2004a). 
The significance of the 16184-16193 poly-C tract identified in this study is difficult 
to determine. The clinical characteristics of the individuals demonstrating this 
occurrence did not identify a common link (Table 5.4) and the small number (n=7) 
makes it impossible to assign statistical significance. The majority (57%) had viral 
hepatitis (with viral hepatitis accounting for 63.3% in the study cohort). The 
average age (45.6 years) did not differ substantially from the study cohort (46.1 
years). The male to female ratio (6: 1) was higher than in the study cohort (2.3: 1) 
and the reason for this cannot be ascertained. 
The D-loop region of mtDNA is non-coding and therefore the 16184-16193 poly-C 
tract would not have a direct affect on the transcription of particular mitochondrial 
proteins. However the poly-C tract lies in close proximity to the heavy strand origin 
of mtDNA replication and both heavy and light strand promoters, so any variations 
could exert some effect on mtDNA. Any variations in the poly-C tract could alter 
MtDNA bending thus affecting interaction at these protein-binding sites, resulting in 
decreased mtDNA transcriptionlreplication. Furthermore, the presence of an 
uninterrupted poly-C tract could result in decreased replication of mtDNA as DNA 
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polymerase-y, the enzyme responsible for mtDNA replication, has a reduced 
fidelity for hornopolymeric sequences (Longley et al, 2001). 
The 16184-16193 poly-C tract has been linked to several types of cancer. It has 
been observed in a significantly higher number of women with breast and 
endometrial cancers than in normal individuals (Liu et al, 2003; Wang et al, 2005, 
2006). It has also recently been detected in 501100 D-loop clones from both the 
cancerous and non-cancerous parts of liver tumour tissues (Yoneyama et al, 
2005). This would indicate that the oAdative stress resulting from chronic 
infection/disease in the liver induces instability in the mtDNA D-loop regions in both 
non-cancerous and cancerous parts of the tumour. Alterations in the D-loop poly-C 
tracts have been seen in premalignant lesions and demonstrate a rising incidence 
that parallels histological severity (Ha et a/, 2002). As the D-loop region is the start 
site of replication of the mitochondrial genome, alterations here may play an 
important role for growth advantage in tumour cells. 
The presence of 10 or more cytosine residues has also been associated with a 
variety of multifactorial disorders including susceptibility to idiopathic dilated 
cardiomyopathy (Khogali et a/, 2001), iron-loading in haernochromatosis (Livesey 
et a/, 2004), susceptibility to type 2 diabetes (Casteels et al, 1999) and insulin 
resistance (Poulton et al, 2002), although the latter association has been put into 
question by a further, larger study (Chinnery et al, 2005). There is a body of 
evidence that HCV is linked to and indeed causes type 11 diabetes (Mason et a/, 
1999; Mehta et A 2003; Noto and Raskin, 2006). One of the individuals 
demonstrating the 16184-16193 poly-C tract did have diabetes in addition to HCV 
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infection (LB52). Follow-up analysis of the HCV-infected patients with the 16184- 
16193 poly-C tract in our study would be informative to examine whether these 
individuals go on to develop type 11 diabetes, although further ethical approval 
would need to be sought for this to be possible. 
Four other liver biopsies exhibited multiple heteroduplexes. Two of these 
specimens demonstrated, on sequence analysis, single nucleotide transitions 
(T-+C in both cases) which results in a non-coding amino acid change. The 
significance of these observations is difficult to determine. The other livers 
displaying multiple heteroduplexes demonstrated a mixture of species on 
sequence analysis, but these could not be characterised. Cloning prior to 
sequencing may have allowed the isolation and characterisation of each species, if 
the minority species was present at a sufficient level to be successfully cloned. 
The overall aim of this study was to determine whether D-loop damage was 
occurring to a greater extent in individuals with HCV compared to other liver 
aetiologies. It was thought that some biochemical or physiologic changes within 
infected cells might induce instability in the mtDNA D-loop region. Five (45.5%, 
n=1 1) of the liver biopsies exhibiting multiple heteroduplexes were from individuals 
infected with HCV (Table 5.4). As the percentage of HCV-infected individuals in 
the entire cohort was 53% (n=79), this is not a statistically significant finding and 
does not indicate that mtDNA damage in the D-loop region was occurring more 
frequently in HCV-infected individuals. The cohort size for this study was relatively 
small and would need to be increased to examine further the relationship between 
HCV and mtDNA damage. The level of D-loop mutations reported in this study 
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was less than that observed in previously described studies of individuals with 
HCC in which D-loop mutations were reported in between 34-68% of individuals 
(Okochi et al, 2002; Nomoto et al, 2002; Lee et al, 2004; Wong et al, 2004). As the 
RSCA assay demonstrated increased sensitivity than that reported of sequencing 
(Hancock et al, 2005), it would not seem that the lower level was due to non- 
detection of mutations. It may be that D-loop damage is not apparent until chronic 
infection has proceeded to HCC. 
A disadvantage of this study was the lack of matching serum samples for each liver 
biopsy specimen, which could not be obtained for logistical reasons. A comparison 
between the blood and liver specimens would have been useful to determine 
whether the identified mutations/damage were seen solely in the liver or were 
apparent in the blood. If the latter were the case, this could indicate that the 
observed D-loop mutations were in the germ line and were not occurring as a 
result of oxidative damage. It is also impossible to tell from this analysis if the 
observed alterations in the D-loop were due to the DNA-damaging effects of 
oxidative stress or whether they resulted from some other occurrence such as 
replication slippage (Hauswirth et al, 1984). Detection of markers of oxidative 
stress in the liver biopsies could have identified whether the liver tissues 
demonstrating multiple D-loop species were exhibiting increased levels of oxidative 
stress compared to livers with single D-loop, species. 
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5.6 Conclusion and future work 
The clinical study outlined in this chapter demonstrated detectable D-loop mtDNA 
damage in only a small percentage of individuals with liver disease. Furthermore, 
there was no association between HCV infection and D-loop damage. This could 
be due to the absence of damage occurring within this region, damage occurring at 
levels below the sensitivity of detection of the assay or the presence of efficient 
mtDNA repair pathways. As the RSCA assay was able to detect minority D-loop 
species representing just 2% of the total product, it is likely that damage was either 
occurring at extremely low levels (<2%) or was not present in the individuals 
studied. Repair of mtDNA damage, especially within the D-loop, was thought to be 
less efficient than nuclear DNA repair (Pinz et al, 1995; Yakes and Van Houten, 
1997; Graziewicz et al, 2002). However, as the D-loop damage seen in this study 
was so low, it may be that mtDNA repair mechanisms are more efficient than 
originally thought, with mitochondrially-targeted repair enzymes such as OGG1 
functioning proficiently (Takao et al, 1998; de Souza-Pinto et al, 2001). 
Although the RSCA assay could not detect mtDNA damage in this clinical cohort, it 
is none-the-less a very powerful tool which could be utilised for a variety of 
applications. It could, for example, be used to assess the DNA-damaging potential 
of certain drug therapies or to look at in vitro damage in cell lines. The association 
of D-loop mutations, especially those occurring around poly-C tracts in both the D- 
loop hypervariable segments, with human cancers (Li6vre et a/, 2006; Wang et a/, 
2006) indicates that the developed assay could provide a useful tool to further 
study D-loop damage as a potential biomarker for cancer detection. The ease with 
which the assay can be carried out, with its simple DNA manipulations and short 
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run times for capillary electrophoresis, promotes the developed RSCA assay as a 
high-throughput diagnostic method for pathogen identification and genotyping. 
Progress on this has already been made with the development of RSCA for the 
identification of pathogenic fungi (McIlhatton et al, 2002) and as a method for HCV 
genotyping (White et al, 2000) and will be an extremely useful tool for further 
development within our diagnostic microbiology laboratory. 
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APPENDICES 
Appendix A- Working Solutions 
70% Ethanol 
Fifty millitres of 70% ethanol was prepared by combining 35 ml of absolute ethanol 
(Sigma-Aldrich, Dorset UK, cat. no. 32221) with 15 ml of ddH20. The solution was 
mixed by inversion. 
75% Ethanol 
Fifty millitres of 75% ethanol was prepared by combining 37.5 ml of absolute 
ethanol with 12.5 ml of ddH20. The solution was mixed by inversion. 
Proteinase K (10 mg/ml) 
A 10 mg/ml working solution of proteinase K was made by reconstituting the 
lipophilised powder (Promega, Madison USA, cat. no. V30213) in 10 ml ddH20- 
This was distributed into I ml aliquots and stored at -20"C until required. 
Saturated Sodium Chloride (-6 M NaCI) 
Saturated sodium chloride was prepared by adding 350-64 9 of sodium chloride to 
600 ml of ddH20 and mixing. The solution was then made up to 1 litre with ddH20, 
before being autoclaved to maintain sterility. 
4M sodium chloride (NaCl) 
4M NaCl was made by dissolving 233-75 9 of NaCl (VWR International Ltd, Poole, 
UK cat. no. 301235Q) in 800 ml ddH20 and making up the solution to I litre with 
ddH20. The solution was then autoclaved to maintain sterility. 
Tris-EDTA (TE) buffer (10mm Tris, I mm EDTA JpH 8.01) 
AI litre volume of TE buffer was prepared by adding 10 ml of 100x Tris-EDTA 
buffer (Sigma-Aldrich, Dorset UK, cat. no. T-9285) to 990 ml of ddH20. 
1x Tris Borate EDTA Buffer (TBE) (0.1 M Tris, 0.09 M Boric acid, 0.001 M 
EDTA) 
To prepare 1500 ml of 1x TBE buffer, 150 ml of UltraPureTm IN TBE buffer 
(Invitrogen, Paisley UK, cat. no. 15581-044) was combined with 1350 ml of ddl-120 
and mixed by inversion. 
Ethldlum bromide 
A stock solution of ethidjurn bromide (Sigma-Aldrich, Dorset UK, cat. no. E-8751) 
(10 mg1ml) was diluted I in 20 in TE buffer to give a 500 pg/ml working solution. 
Twenty microlitres of this were added to molten agarose to give a final 
concentration of 2 pg/ml. 
Orange G loading buffer 
Orange G loading buffer was prepared by adding Ig of Ficollo 70 (Fluka 
Biochemika, cat. no. 46326) to 10 ml TBE in a sterile universal and vortexing until 
the solution became clear. A small amount (0.025 g) of orange G powder (Sigma- 
Aldrich, Dorset UK, cat. no. 03756) was added to the solution and mixed. The 
loading buffer was stored at 40C until use. 
10% Glucose 
A 10 ml solution of 10% glucose was prepared by combining Ig of anhydrous D- 
glucose (BDH Laboratory Supplies Poole, UK, cat. no. 1011747) with 9 MI Of 
ddH20 in a sterile universal tube. This was mixed until the powder had dissolved. 
The solution was then made up to 10 ml with ddH20 and sterilised by filtration 
through a 0.22 pm Millex-GP sterilising filter unit (Millipore Ireland BV, Cork, cat. 
no. SLGP 033 RS). 
IM Calcium chloride 
A 10 ml volume of CaC12 0 M) was prepared by combining 1.47 g of CaC12 
(Sigma-Aldrich, Dorset UK, cat. no. C5080) with 9 ml of ddH20 in a sterile universal 
tube. This was mixed until the powder had dissolved. The solution was then made 
up to 10 ml with ddH20 and sterilised by filtration as above. 
Thiamine (10 mg/ml) 
A 10 ml volume of thiamine (10 mg/ml) was prepared by combining 100 mg of 
thiamine hydrochloride (Sigma-Aldrich, Dorset UK, cat. no. T4625) with 9 ml 
ddH20 in a sterile universal tube and mixing until the powder had dissolved. The 
solution was then made up to 10 ml with ddH20 and sterilised by filtration as 
above. 
lOmM dNTP 
A stock dNTP mix was prepared by adding 250 pl of dATP, dTTP, dCTP and dGTP 
together (100 mM each) (Invitrogen, Paisley UK, cat. no. 18427-013). These were 
aliquoted into 100 pf volumes. To prepare a working solution of dNTPs (10 mM of 
each dNTP), 150 pl of UltraPURETm DNase/RNase-free distilled water (Invitrogen, 
Paisley UK, cat. no. 10977035) were added to an aliquot. 
125mM EDTA 
Two millitres of 125 mM EDTA was prepared by combining 0.5 ml of 0.5 M EDTA 
(Sigma Aldrich, Dorset, UK, cat. no. E-7889) with 1.5 ml of ddH20. The solution 
was mixed by inversion. 
4M Sodium hydroxide (NaOH) 
One litre of NaOH was prepared by adding 160 g NaOH in parts to 700 ml ddH20. 
The solution was mixed by inversion and then made up to 1 litre with ddH20. 
Ampicillin solution (10 mg/ml) 
Ampicillin solution was prepared by adding 0.1 g of ampicillin sodium salt (Sigma- 
Aldrich, Dorset UK cat. no. A9518-5G) to 10 ml of ddH20- One to two drops of 4M 
NaOH were added and the solution was vortexed. The solution was filtered 
through a 0.22 pm Millex-GP sterilising filter unit (Millipore Ireland BV, Cork, cat. 
no. SLGP 033 IRS) and stored at -200C until use. 
50% glycerol 
A 200 ml solution of 50% glycerol was prepared by adding 100 ml of ddH20 to 100 
ml of glycerol (Sigma Aldrich, Dorset, UK, cat. no. G5516) and mixing. 
Red Cell Lysis Buffer (RCLB) (0.144 M NH4CI, I mM NaHC03) 
RCLB was prepared by adding 15.41 g of ammonium chloride (VWR International 
Ltd, Poole, UK, cat. no. 100173D) and 0.168 g of sodium hydrogen carbonate 
(international Ltd, Poole UK, cat. no. 102475W) to 500 ml of ddH20 In a fume 
cupboard. The solution was mixed gently and made up to 2 litres with ddH20, 
before being autoclaved to maintain sterility. 
Nuclei Lysis Buffer (NLB) (0.01 M Tris-HCI pH 8.0,0.4 M NaCI, 2 mM EDTA) 
NLB was prepared by combining 20 ml of 1M Trizma&HCI (pH 7.5) (Sigma- 
Aldrich, Dorset UK, cat. no. T-2319), 200 ml of 4M sodium chloride and 8 ml 0.5 M 
EDTA. The solution was adjusted to a final volume of 2 litre with ddH20, before 
being autoclaved to maintain sterility. 
#271 broth 
#271 broth medium was prepared using the same ingredients and quantities as for 
the #271 solid agar with the exception that agar was omitted. The broth was 
autoclaved at 121*C for 30 min at a pressure of 1.1 bar, cooled and stored at 4. C 
until use. Ten millilitres of 10% glucose, 2.0 ml of 1M CaC12 and 1.0 ml of thiamine 
(10 mg/ml) were added to I litre of broth medium prior to use. 
#271 solid agar plates 
Solid agar (#271) was prepared by mixing 10 g tryptone powder, 1g yeast extract 
powder, 8g sodium chloride, 15 g DifcoTm Agar Noble in 1 litre of ddH20. The 
solution was autoclaved at 121"C for 30 min at a pressure of 1.1 bar and cooled to 
- 560C. Ten millilitres of 10% glucose, 2 ml of 1M CaC12 and 1 ml of thiamine (10 
mg/ml) were added and the molten agar was distributed evenly between sterile 
petri dishes. Once set, the plates were inverted and placed in a 37*C Incubator to 
evaporate residual condensation. 
#271 soft (0.5%) agar 
Soft agar (#271) was prepared by mixing 1g tryptone powder, 0.1 g yeast extract, 
0.8 g sodium chloride and 0.5 g DifcoTm Agar Noble in 100 ml ddH20. The solution 
was autoclaved at 1210C for 30 min at a pressure of 1.1 bar. Soft agar was used 
as an overlay for the #271 solid agar plates. Prior to use, it was placed In a 
microwave to melt, and subsequently cooled to 4 -50"C in a water bath. One 
millilitre of 10% glucose, 0.2 ml of 1M CaCI2 and 0.1 ml of thiamine (10 mg/ml) 
were added prior to use and the soft agar was distributed evenly as a layer over 
each of the #271 solid agar plates (after addition of MS2 phage and host). 
1-131ampicillin agar plates (1.5% agar, 1.0% tryptone, 0.5% yeast extract, 0.5% 
NaCl, 0.01 mg/ml ampicillin) 
A batch of 10 plates was made by combining 10 g of tryptone (Oxoid, Basingstoke 
UK, LP0043), 15 g of DifcoTm Agar Noble (Becton, Dickinson and Company, Pont 
de Claix France, cat. no. 214230), 5g of sodium chloride (VWR International Ltd, 
Poole, UK cat. no. 301235Q) and 5g of yeast extract (Oxoid, Basingstoke UK, cat. 
no. LP0021) and dissolving in 800 ml of ddH20. The volume was adjusted to I litre 
with ddH20 and autoclaved at 1210C for 30 min at a pressure of 1.1 bar and cooled 
to - 550C. Ten millitres; of ampicillin solution (10 mg/ml) were added to give a final 
concentration of 100 jig/mi. The molten agar solution was poured evenly between 
10 sterile petri dishes. Once set, the plates were inverted and placed in a 3rC 
incubator to evaporate residual condensation. 
LB/Ampicillin nutrient broth medium 
LB nutrient broth medium was made by dissolving 2g of tryptone, 1g of sodium 
chloride and Ig of yeast extract in 200 ml of ddH20. The solution was autoclaved 
at 121*C for 30 min at a pressure of 1.1 bar and when cooled, the broth medium 
was then stored at room temperature until required. Two millitres of ampicillin 
solution were added to the broth medium to give a final concentration of 50 pg/ml. 
Appendix B- Primer and Probe Sequences 
HCV genotypinq and subtvpinq- 
Primers 
Primer Sequence Positiona 
HCV4 TTCACGCAGAAAGCGTCTAG 63-82 
HCV3 CACTCG'CArA-G-CACCCTATCAGGCAGT 313-288 
NS5bF2 TATGAYACCCGCTGYTTYGACTC 8256-8278 
NS5bR I TACCTNGTCATRGCYTCCGTGAA 1 8638-8616 
Probes 
For all primers/probes: R=A or G, Y= C or T, N=A, C, T or G, A WIn front of the nucleotide indicates an ILINA addition. 
Primers used for HCV genotyping and subtyping. 8 Position relative to HCV type la 
sequence (GenBank accession number M62321). I Modifications to original (NCR4) primer, to improve its generic nature, a T--#G and a 
G--*A change, respectively. 
HCV quantitation with MS2 internal control 
Primers 
Primer Sequence Position 
Taql GTCTAGCCATGGCGTTAGTA 77-96 
Taq2 GTACTCACCGGTTCCGC 166-150 
MS2F TGGCACTACCCCTCTCCGTATTCACG 289-314 
MS2R GTACGGGCGACCCCACGATGAC 387-366 
Probes 
Probe Sequence Position Reported 
Cluencher 
HCVTaq CCCTCCCGGGAGAGCCATAGTG 124-145 FAWTamra 
MS2Taq CACATCGATAGATCAAGGTGCCTACAAGC 330-359 JOEframra 
' Position of the HCV primers/probe is of the 5' base relative to HCV genomic 
sequence with reference to HCV type 1 sequence (acc. no. M62321). b Position of the MS2 primers/probe is of the 5' base relative to the MS2 genomic 
sequence (acc. no. NC001417) 
M13 PCR (primers included with the pCe 4-TOPO cloning vector) 
Primer Sequence I Position 
M13F CGCCAGGGTTTTCCCAGTCACGAC 397-374 
M13R TCACACAGGAAACAGCTATGAC 1 200-221 
Position is according to pCRm 4-TOPO cloning vector (hftp: //www. invitrogen. com) 
For all primerstprobes: R=A or G, Y= C or T, N=A, C, T or G. A'+'ln front of the nucleotide 
indicates an LNA addition. 
mtDNA deletion detection/guantitation 
Primers 
Priiiie-r Sequence Position 
CDI AAGAGAACCAACACCTCTTTACAGTGA 8323-8349 
CD1 LNA G+AGA+ACCAAC+ACCTCT+TTACAGTGA 8325-8349 
CD2 TATTCGAGTGCTATAGGCGCTTGTCAG 13599-13573 
SCD AAGGATACTAGTATAAGAGATCAGGTTCGTC 8735-8705 
7436LNA CTAC+AGG+TGGTCAAG+TAT+TTA+TGGTAC 16156-16130 
Probes 
Probe Sequence Position Reporter/Quencher 
UD(MGB) CGCCRCAGTACTGATC 8565-8580 FAM/NFQ 
DEL(MGB) ATACACAAACGCCTGAGC 13527-13544 JOE/NFQ 
7436(MGB) CATTACTGCCAGCCAC 16099-16114 FAMINFO 
7420(MGB) AACCTCAAGCCACCATGA 
. 
8682-8689/ 
16110-16119 
FAM/NFQ 
Primers and probe for mtDNA deletion detection/quantitation. Position is according 
to the revised Cambridge Reference Sequence (acc. no. AC000021). 
P-Globin gene detection/quantitation 
Primer Sequence Position Reporter/ 
Quencher 
1ý-globin-ffi- CTCTTTCTTTCAGGGCAATA 1268-1287 
"lobin-RP - TTGCCTTAACCCAGAAATTA 1386-1367 
P-globin Probe 
-I 
TATCATGCCTCTTTGCACCA 1309-1328 JOE/BHQ-1 
I 
Position is according to the P-globin gene sequence (acc. no. AY260740) 
RSCA 
Primer I Renortar I Santiane-a I Position 
DLoopFLab* FAM I AACTCCACCATTAGCACCCAAAGC 1 15973-15996 
DLoopR I TGCGGGATATTGATTTCACGGAGGATGG 1 16430-16403 
Position is according to the revised Cambridge Reference Sequence (acc. no. 
AC000021). *The unlabelled D-loop forward (DLoopF) primer is Identical In 
sequence to DLoopFLab, without the 5' FAM attachment. 
For all primers/probes: R=A or G, Y= C or T, N=AC, T or G. A'+' in front of the nucleotide indicates an LNA addition. 
Appendix C- PCR master mixes and cycling conditions 
Unless stated, all PCR reactions were carried out on the Rotor-Gene 3000 using 
the LightCyclero FastStart DNA Master HybProbe kit. 
Reverse transcription (cDNA preparation) 
Reagents pI/l4pl Stock concentration Final concentration 
(per reaction) 
PCR buffer-11 3.5 lox lX 
M9CI2 3.5 50 mm 5 mM 
dNTPs 1 10 mM each 100 pM each 
M-MLV RT a 1 200 U/pl 0.2 U/pl 
RNAse-free water 5 
+21 pl extracted RNA/random hexamer mix 
Carried out on a PTC-200 Peltier thermal cycler (MJ Research, Waltham, USA) 
using the Taq DNA polymerase recombinant kit (Invitrogen, Paisley, UK) 
Total reaction volume is 35 pf 
' M-MLV Reverse Transcriptase (RT) (Invitrogen, Paisley, UK) 
M13 PCR (used In PCR product cloning) 
Reagents PI/1000 PI Stock 
concentration_ 
Final Concentration 
(per pl) 
PCR buffer-11 100 lox 1x 
M9C12 30 50 mm 1.5 mM 
M13F primer 2 100 PM011PI 0.2 pmol 
M13R primer 2 100 pmol/pI 
- 
0.2 pmol 
dNTPs 20 10 mM each 200pM each 
Taq Polymerase 6 5 U/pl 3U/1 00pl 
RNAse-free water 840 
+I pI E. coli lysate 
Carried out on a PTC-200 Peltier thermal cycler using the Taq DNA polymerase 
recombinant kit 
Cycling conditions: 5 min 96T, 30 s 96T, 30 s 50T, I min 72T for 25 cycles 
then 10 min 720C. 
The Master HybProbe of the LightCyclero FastStart DNA Master HybProbe kit and the 2x 
reaction mix of the SuperScriptTm III Platinue One-Step Quantitative RT-PCR System contain 
MqCI2. Therefore the final concentration Of M, 9C12 may differ from that expected. 
HCV Genotyping 
HCV 5'UTR qualititative assay (LightCycler) 
Reagents pl/20pl Stock concentration Final concentration 
tion) 
Mastermix (vial 1) 2 1 Ox 1x 
MgCl2 1.6 25 mM 2 mM 
HCV3 primer 0.75 20 pmol/pI 15 pmol 
HCV4 primer 0.75 20 prnol/pl 15 pmol 
RNAse-free water 12.9 
+2 pl cDNA 
Carried out using FastStart DNA Master SYBR green kit (Roche Diagnostics) 
Cycling conditions: Quantitation: Hold 10 min at 950C. 50 cycles of raising 
temperature up to 95T (20"C/s) then 2s at 55T (20"C/s) and 10 S at 72*C 
(20*C/s). Melt Curve: Hold 1s at 950C then cool/hold for 30 s at 65"C, then ramp 
from 65-95T at 0.1 *C/s with continuous fluorescence acquisition then cool for 10 s 
to 400C. 
HCV genotyping panel one 
Reagents pi/20pi Stock 
concentration 
_ 
Final concentration 
(per reacti2!! L_ 
Master HybProbe 2 1 Ox 1x 
MGC12 0.4 25 mM 1.5 mM 
HCV3 primer 0.75 20 pmol/pi 15 p ol 
HCV4 primer 0.75 20 pmol/pi 15 emol 
TI probe 0.5 10 pmoI/pI 5 pmol 
TI I probe 0.5 10 pmoI/pl 5 pmol 
T2 probe 0.5 10 p OVPI 5 pmol 
T3 probe 10.5 10 PMOVPI 5 pmol 
RNAse-free water 1 11.1 
+3 PI cDNA 
Cycling conditions: Hold 10 min at 950C, then 45 cycles of 8s at 95T (not 
acquiring) and 45 s at 650C (acquiring on FAM, CyS, JOE and ROX). 
The Master HybProbe of the LightCyclerO FastStart DNA Master HybProbe kit and the 2x 
reaction mix of the SuperScriptT'4 III Platinumo One-Step Quantitative RT-PCR System contain 
M9CI2. Therefore the final concentration Of MgC12 may differ from that expected. 
HCV genotyping panel two (original) 
Reagents pi/20pi Stock 
concentration_ 
Final Concentration 
(per reaction) 
Master HybProbe 2 lox ix 
M9CI2 0.8 25 mM 2 mM 
HCV3 primer 0.75 20 pmol/pl 15 pmol 
HCV4 primer 0.75 20 pmol/pl 15 pmol 
T22a probe 0.5 10 pmol/Pl 5 pmol 
T33 probe 10.5 
10 pmol/Pl 5 pmol 
RNAse-free water 111.7 
+3 pi cDNA 
a or T4 
Cycling conditions: Hold 10 min at 950C, then 45 cycles of 8s at 956C (not 
acquiring) and 45 s at 600C (acquiring on FAM and JOE) 
HCV genotyping panel two (new) 
Reagents pi/20pi Stock 
concentration_ 
Final concentration 
(per action) 
Master HybProbe 2 lox Ix 
M9CI2 0.8 25 mM 2 mM 
HCV3 primer 0.75 20 pmoVpI 15 pmol 
HCV4 primer 0.75 20 pmoI/pI 15 p ol 
T22 probe 0.5 10 p 011PI 5 pmol 
T33 probe 0.5 10 pmoI/pI 5 pmol 
NCT333 probe 0.5 10 pmol/pI 5 pmol 
T4 probe 0.5 10 pmol/pI 5 pm I 
RNA se-free water 10.7 
+3 pi cDNA 
Cycling conditions: Hold 10 min at 95T, then 45 cycles of 8s at 95*C (not 
acquiring) and 45 s at 600C (acquiring on FAM, Cy5, JOE and ROX). 
The Master HybProbe of the LightCyclere FastStart DNA Master HybProbe kit and the 
2x 
reaction mix of the SuperScriptTm III Platinue One-Step Quantitative RT-PCR System contain 
M9CI2, Therefore the final concentration Of M902 may differ from that expected. 
HCV additional genotype 3 probe 
Reagents pl/201A Stock 
concentration 
Final concentration 
(per reaction) 
Master HybProbe 
(vial 1) 
2 1 Ox 1x 
MgC12 1.2 25 mM 2.5 mM 
NS5bF2 primer 0.75 20 pmol/pl 15 pmol 
NS5bR primer 0.75 20 pmol/pi 15 pmol 
NS53 probe 0.35 10 pmol/pl 3.5 pmol 
RNAse-free water 111.95 1 
-- 
I 
+3 PI cDNA 
Cycling conditions: Hold 10 min at 95T, then 45 cycles of 8s at 95T (not 
acquiring) and 45 s at 60T (acquiring on ROX) 
HCV subtvpIncl 
HCV generic subtyping assay (LightCycler) 
Reagents pl/20pi Stock 
concentration 
Final concentration 
(per action) 
Mastermix (vial 1) 2 lox lx 
M. 9C12 0.8 25 mM 2 mM 
NS5bF2 Primer 0.3 20 pmol/pl 6 pmol 
NS5bR primer 0.3 20 pmol/pi 6 pm I 
1: 1000 dilution SYBR green I 
Water 12.6 
+3 PI cDNA 
Cycling conditions: Quantitation: Pre-incubation 10 min at 950C. Then 45 
cycles of 10 s at 95*C then 30 s at 600C, then 30 s at 720C (acquiring on FAM). 
Melt Curve: Hold 30 s at 95"C then cool to 50"C. Ramp from 50-99"C rising by 
VC each step, holding the first step for 30 s and 5s for each step afterwards, 
acquiring to MeltA on FAM. 
The Master HybProbe of the LightCyclere FastStart DNA Master HybProbe kit and the 
2x 
reaction mix of the SuperScriptTm III Platinurrio One-Step Quantitative RT-PCR System contain 
M9CI2. Therefore the final concentration Of M9CI2 may differ from that expected. 
HCV subtyping 1 b/non-I b 
Reagents pl/201il Stock 
concentration 
Final Concentration 
(per reaction) 
Master HybProbe (vial 
1) 
2 lox Ix 
M9CI2 0.8 25 mM 2 mM 
NS5bF2 primer 0.3 20 pmol/pl 6 pmol 
NS5bR pfirner 0.6 20 pmol/ I 
Non-I b probe 0.25 10 pmol/pl - 
2.5 pmol 
1b probe 10.25 10 pmol/pl - 
2.5 pmol 
RNAse-free water 1 12.8_ 
+3 pi cDNA 
Cycling conditions: Hold 10 min at 950C, then 40 cycles of 8s at 95T (not 
acquiring) and 45 s at 55T (acquiring on FAM and JOE) 
HCV Quantitation 
RealArirm HCV RG RT PCR Quantitation 
Reagents pl/20pl 
HCV RG Master 1 15 
HCV RG IC 1 0.5 
5 pl extract 
Cycling conditions: Hold 10 min at 50*C (reverse transcription), then 50 s at 
95T. 45 cycles of 8s at 95"C (not acquiring), 20 s at 55*C (acquiring on FAM and 
JOE) and 20 s at 720C (not acquiring). 
The Master HybProbe of the LightCyclero FastStart DNA Master HybProbe kit and the 2x 
reaction mix of the SuperScriptT" III Platinurrio One-Step Quantitative RT-PCR System contain 
MgCI2. Therefore the final concentration Of MqC12 may differ from that expected. 
MS2 detection 
Reagents - pi/25pi Stock 
concentration 
Final concentration 
(per reaction) 
Reaction mix 12.5 2x Ix 
M9SO4 50 mm 4mM 
MS2F primer 0.5 20 pmol/pI 10 Pm I 
MS2R primer 0.5 20 pmoUpI 10 Pmo 
MS2Taq probe 0.2 10 Pmol/Pl 2 pmol 
RT/PlatinuM'9 raq -rrfix 0.8 
RNAse-free water 5.5 
+b P1 M62 extract 
SuperScriptTm III 
Paisley, UK) 
Platinurno One-Step Quantitative RT-PCR System, Invitrogen, 
Cycling conditions: Incubate 30 min at 500C then hold 2 min at 95"C, then 50 
cycles of 15 s at 95T (not acquiring), and I min at 56T (acquiring on JOE). 
HCV quantitation with MS2 internal control 
Reagents pl/25pl Stock 
concentration _ 
Final Concentration 
(per reaction) 
Reaction mix 12.5 2x 1x 
M9SO4 1 50 mm 5 mm 
TaqI primer 0.15 100 PMOI/Pl- 15 mol 
Taq2 primer 0.15 100 pmol/p 1 15 pmol 
HCVTaq probe 0.25 20 pmol/pl 5 pmol 
MS2F primer 0.1 20 pmol/pj 2 pmol 
MS2R primer 0.1 20 pmol/pl 2pm I 
1 MS2Taq Probe 10.2 10 pmoI/pI 2 pmol 
DRT/Platinumu Taq mix 1 0.8PI 
+iu pi extract 
SuperScriptTM III Platinumo One-Step Quantitative RT-PCR System, (Invitrogen, 
Paisley, UK) 
Cycling conditions: Incubate 30 min at 50"C, then hold 2 min at 95"C, then 50 
cycles of 15 s at 95*C (not acquiring), and 1 min at 56T (acquiring on FAM and 
JOE). 
The Master HybProbe of the LightCycl4o FastStart DNA Master HybProbe kit and the 
2x 
reaction Mix of the SuperSc(jptTm III Platinue One-Step Quantitative RT-PCR system contain 
M9CI2. Therefore the final concentration Of M9CI2 may differ from that expected. 
mtDNA deletion detectionlquantitation 
Block-based PCR 
Reagents P1150PI Stock 
concentration 
Final Concentration 
(per reaction) 
PCR buffer-ii 5 1 Ox Ix 
MgC12 1.5 50 M'm 1.5 mm 
dNTPs 1 10 mM each 0.5pM 
CD1_primer 1 20 pmol/pl 
. 
20 pmol 
SCD primer 1 20 pmollpi 20 pmol 
Invitrogen Taq 0.2 5 U/pI lu 
RNAse-free water 35.3 
+t) pi extract 
Carried out on a PTC-200 Peltier thermal cycler (MJ Research, Waltham, USA) 
using the Taq DNA polymerase recombinant kit. 
Cycling conditions: 10 min 95"C, 1 min 95*C, 1 min 600C, 1 min 720C for 35 
cycles then 10 min 72"C. 
Increased stringency block-based PCR 
Reagents PI/60PI Stock 
concentration 
Final Concentration 
(per reaction) 
PCR buffer-ii 5 1 Ox 1x 
MgC12 1 50 mm 1 mm 
dNTPs 1 10 mM each 0.5pM 
COI primer 1 20 pmol/pi 20 Pmol 
CD2 primer 1 20 pmoVpl 20 pmol 
Invitrogen Taq 0.2 5u/pI lu 
RNAse-free water 135.8 1 
+b pi extract 
Carried out on a PTC-200 Peltier thermal cycler (MJ Research, Waltham, USA) 
using the Taq DNA polymerase recombinant kit. 
Cycling conditions: 10 min 95T, I min 95T, I min 650C, I min 720C for 35 
cycles then 10 min 72T. 
The Master HybProbe of the LightCyclere FastStart DNA Master HybProbe kit and the 2x 
reaction mix of the SuperScriptTm III Platinum'o One-Step Quantitative RT-PCR System contain 
M9C12. Therefore the final concentration Of MgC12 may differ from that expected. 
wt mtDNA detectionlquantitation 
Reagents pl/20pl Stock 
concentration 
Final concentration 
(per reaction) 
Master HybProbe (via] 1) 2 1 Ox 1x 
MgC12 0.8 25 mM 2 mM 
C131 primer 0.5 20 pmol/pl 10 pmof 
SCD primer 0.5 20 pmol/pl 10 p Ol 
Undel probe 0.2 10 PMOVPI 2 pmol 
RNAse-free water 13 
+J PI CUNA 
Cycling conditions: Hold 10 min at 950C, then 40 cycles of 8s at 95T (not 
acquiring) and 45 s at 650C (acquiring on FAM). 
Mt4977 detectionlquantitation 
Reagents pl/20pl Stock 
concentration 
Final concentration 
(per reaction) 
Master HybProbe (vial 1) 2 1 Ox 1x 
MgC12 2.4 25 mM 4mM 
CD1 primer 0.75 20 pmol/pI 15 pmol 
-CD2 
primer 0.76 20 pmo! ýpl_ 15 Pmol 
Del probe 0.5 10 MOPI 5 pmol 
RNAse-free water 10.6 
+J PI CUNA 
Cycling conditions: Hold 10 min at 95T, then 45 cycles of 8s at 95T (not 
acquiring) and 45 s at 65T (acquiring on JOE). 
The Master HybProbe of the LightCyclerO FastStart DNA Master HybProbe kit and the 2x 
reaction mix of the SuperScriptT'w III Platinume One-Step Quantitative RT-PCR System contain 
M9CI2, Therefore the final concentration Of MgC12 may differ from that expected. 
Mt7436 detection/quantitation 
Reagents pl/20pl Stock 
concentration 
Final concentration 
(per reaction) 
Master HybProbe (vial 1) 2 1 Ox 1x 
M9Cl2 0.8 25 mM 2mM 
_ CD1 LNA primer 0.75 20 pmoVpl 15 p ol 
7436LNA prLiMer 0.75 20 pmol/pI - 
Lý-Pmol 
-j -- - 7436 probe 0.35 10 pmol/pL_ 3.5 pmol 
RNAse-free water 12.35 
ý%j PI 16LJI-lt-% 
Cycling conditions: Hold 10 min at 95T, then 40 cycles of 8s at 95T (not 
acquiring) and 45 s at 62T (acquiring on FAM). 
Mt7420 detection/quantitation 
Reagents pl/20pl Stock 
concentration 
Final concentration 
(perreaction) 
Master HybProbe (vial 1) 2 lox lx 
M9CI2 0.8 25 mM 2 mM 
CDlLNA primer 0.5 20 pmoVpl 10 pmol 
7436LNA primer 0.5 20 pmoVpj_ 10 pmol 
- 7420 probe 0.5 10 pmol/pl-- 5 pmol 
I RNAse-free water [12.7 1 
+j PI CUNA 
Cycling conditions: Hold 10 min at 95"C, then 40 cycles of 8s at 95*C (not 
acquiring) and 45 s at 60*C (acquiring on FAM). 
The Master HybProbe of the LightCycler'o FastStart DNA Master HybProbe kit and 
the 2x 
reaction mix of the SuperScriptTm III Platinumo One-Step Quantitative RT-PCR System contain 
MqCI2, Therefore the final concentration of MgCI2 may differ from that expected. 
P-Globin quantitation 
Reagents pl/251A Stock 
concentration 
Final concentration 
(per reaction) 
12.5 2x 1x 
M9CI2 1 50 mm 5 mm 
Primer G3 1 0.25 25 pmol 6.25 
Primer G2 = 0.25 25 pmol 1 6.25 
Globin probe 1 0.1 25 DMOI 1 2.5 
+1U pi DNA extract 
Carried out using the Platinurno Quantitative PCR SuperMix-UDG kit (Invitrogen, 
Paisley, UK) 
Cycling conditions: Hold 2 min at 50T, then 2 min at 95"C. 45 cycles of Is at 
95T (not acquiring) and I min at 60T (acquiring on JOE). 
mtDNA D-loop amplification 
Reagents PI/50PI Stock 
concentration 
Final Concentration 
(per reaction) 
PCR buffer-11 5 lox 1x 
M9C12 1.5 50 mM 1.5 mm 
DLoop F primer* 1 20 pmollpl 20 pmol 
DLoop R primer 1 20 pmol/pl 20 Pmol 
dNTPs 1 10 mM each 0.5wM each 
Taq Polymerase 0.2 5 U/ml lu 
RNAse-free water 35.3 
-U PI UIMM extract 
*or DLoopFLab in FLR production 
Carried out on a PTC-200 Peltier thermal cycler using the Taq DNA polymerase 
recombinant kit. 
Cycling conditions: 10 min 95T, 1 Min 95T, 1 min 60T, 1 min 72T for 35 
cycles then 10 min 720C. 
The Master HybProbe of the LightCyclero FastStart DNA Master HybProbe kit and the 2x 
reaction mix of the SuperScriptTm III Platinum* One-Step Quantitative RT-PCR System contain 
MCIC12. Therefore the final concentration of MgCI2 may differ from that expected. 
Appendix D Univarlable analysis comparing cases included in 
multivariable analysis in the HCV clearance study (n=175) with those 
awe-hirlad fn=lr%ll 
Included in 
multivariable 
analysis 
(n=17§) 
Excluded from 
multivariable 
analysis 
(n=161) 
Statistic P value 
Male 118 96 2.207 0.137 
Female 57 65 
U 82 77 xz= 11.996 . 002 
Non-UK 15 33 
Not-known 78 51 
White 143 108 x2= 16.152 <0.001 
Non-white 4 21 
Not-known 28 32 
IDU 154 65 v= 106.302 ýZO. 001 
Transfusion 21 26 
Not-known 0 70 
<21(M)or<14(F) 
units alcohol 
88 117 ); -, = 34.743 <0.001 
>21(M)or>14(F) 
units alcohol 
87 35 
Notknown 0 9 
Type 1 86 60 v= 55.156 <0.001 
Non-1 type 89 57 
Not known 0 44 
Mean age at 
Infection (yrs) 
21.70 22.16 t= 0.361 0.718 
Mean duration-of 
Infection (yrs) 
21.21 22.28- t= 0.327 0.532 
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22 December 2004 
Dr MED Allison 
Addenbrooke's Hospital 
Consultant Hepatologist 
Box 210 
Hills Road, Cambridge 
CB22QQ 
Dear Dr Allison 
. 
14 JAN 2005 
ff FIT/B 
Cambridge Research Ethics Committee 
Victoria House 
Capital Park 
Fulboum 
Cambridge 
CB1 5XB 
Telephone: 01223 597657 
Facsimile: 01223 597645 
Email: karen. ignatian@nscstha. nhs. uk 
Full ING Of study: Investigation into the presence of nuclear and mitochondlial DNA 
damage and induction of DNA repair mechanisms in liver disease 
REC reference number. 041QO1081124 
Thank you for your letter of 17 November 2004, responding to the Committee's request for further Information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chairman, Dr 
Berdos. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting documentation as revised. 
The favourable opinion applies to the research sites listed on the attached form. Confirmation 
of approval for other sites listed in the application will be Issued as soon as local assessors have confirmed that they have no objection. 
Conditions of approval 
The favourable opinion Is given provided that you comply with the conditions set out in the 
attached document. You are advised to study the conditions carefully. 
Approved documents 
The final list of documents reviewed and approved by the Committee Is as follows: 
Document ý9. version: Dated: Date Received: 
Application 30/06/2004 30/06/2004 
Protocol 1 30/06/2004 30/06/2004 
Summary/Synopsis 1 30/06/2004 30106/2004 
Participant Information 
Sheet 
1 30/06/2004 30106/2004 
SL14 Favourable opinion following consideration of further Information Version 2, October 2004 
Participant Information 2 Sheet 07/09/2004 
17/11/2004 
Participant Consent 2 07/09/2004 17/11/2004 Form 
Co s Participant Consent 05/07/2004 30/06/2004 r Form 
Response to Requ 17/11/2004 17/11/2004 for 'urther Inforniation 
Management approval 
The study should not commence at any NHS site until the local Principal Investigator has obtained final management approval from the R&D Department for the relevant NHS care Organisation. 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the attached sheet. 
Notification of other bodies 
The Committee Administrator will notify the research sponsor that the study has a favourable, ethical opinion. 
Statement Of compliance 
The Committee Is constituted In accordance with the Governance Arrangements for Research Ethics Committees (July 2001) and complies fully with the Standard operating Procedures for Research Ethics Committees In the UK. 
I UIWWUIUB/124 Please quote this number on all correspondence 
With the Committee's best wishes for the success of this project, 
YOUrs sincerely, 
Cýýr German Ber os 
- -, --" "ý"Y' 
Chair 
E-mail: karen-ignatian@nscstha. nhs. uk 
Enclosures List of names and professions of members who were present at the 
meeting and those who submitted witten comments 
Standard approval conditlons 
Site approval form (SFI) 
C-44-11, -4 ef-6-1, U-16k A-th 
Appendix F Patient Information Sheet 
Study Title: Investigation into the presence of nuclear and mitochondrial DNA 
damage and induction of DNA repair mechanisms in liver disease. 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to 
take part. 
Purpose of the study 
We would like to you to participate in a research study being conducted in the 
Department looking at the ways in which liver damage is caused in different 
conditions. Although liver damage can be caused by a number of different 
illnesses, the exact way in which the liver is damaged is not fully understood. In 
addition, it is not at all clear why some people get liver damage and others do 
not. Some conditions that can cause liver disease may do so by damaging a 
person's DNA in the liver cells. The aim of this study is to see whether this does 
occur, and to get a better understanding of how the damage occurs. It is hoped 
that this may, in time, allow us to develop better treatment to protect the liver in 
various conditions. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time and 
without giving a reason. A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
If you do agree to take part, when you come into hospital to have your liver 
biopsy, a blood sample will be taken and stored. At the time of the liver biopsy, 
some of the biopsy will be taken for research, once enough has been sent for 
routine clinical analysis. The study does not involve any tests beyond this, and 
no extra clinic visits are required. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you will have your name 
and details removed so that you cannot be recognised from it. 
If you do have any questions, please do 
clinic visit, or by contacting my secretary, 
email at kaye. barra-addenbrookes. nhs. uk. 
not hesitate to ask us, either at your 
, Kaye Barr on 01223 
586641 or by 
Thank-you for taking part in this study. 
Yours sincerely. 
Dr Michael Allison 
Consultant Flepatologist 
Version 2 Date 7 th September 2004 
Appendix F 
CONSENT FORM 
LREC Reference Number: 04/QO108/124 
Title of Project: investigation into the presence of nuclear and mitochondrial DNA 
damage and induction of DNA repair mechanisms in liver disease. 
Name of Lead Investigator: Dr Michael Allison 
Please initial box 
LI confirm that I have read and understand the study Information Sheet 
dated 07-09.04 (version 2) for the above study and have had the opportunity to 
ask questions. 
2.1 understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected. 
3.1 understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to my 
taking part in research. I give permission for these individuals to have access to 
my records. 
4.1 agree to take part in the above study. 
Name of Research Subject Date 
(Please print) 
Narne of Witness to SignatureDate 
(Must not be member of research team) 
(Please print) 
Signature 
Signature 
Signature Name of Research Team Date 
member 
(Please print) 
3 copies required. top copy for researcher, one copy for patient; one copy to be kept with research subject's 
notes. 
Version No: 2/ Dated: 7"' September 2004 
Appendix G- Clinical study data (liver biopsies) 
Biopsy 
. 
ýqe Sex Liver Pathology mt4977: undeleted mt7436: undeleted He 
1 39 M HCV 6.58E-05 2.54E-06 1 
2 65 r alcoholic liver disease 2.14E-03 0 1 
3 32 F HCV 3.70E-05 1.03E-05 1 
4 45 
- 
M genetic haernatochromatosis O. OOE+00 0 1 
5 56 V- WILD 1.46E-04 1.24E-05 1 
6 65 M alcoholic liver disease 5.58E-04 0 ,1 
7 57 ý- -JýC-V 5.03E-06 5.08E-07 11 
8 32 Primary sclerosing cholangitis 2.41 E-05 3.20E+06 11 
9 35 no evidence of fibrosis 2.25E-05 1.12 E-06 3 
10 44 M HCV 1.33E-05 9.06E-07 3 
11 38 
- 
M HCV 4.43E-05 O. OOE+00 1 
12 22 -k- -RBV 2.73E-05 O. OOE+00 1 
13 40 M HCV 1.03E-04 5.41 E-06 1 
14 55 M alcoholic liver disease 2.23E-05 4.75E-05, 1 
15 43 M HCV 1.45E-04 2.59E-061 1 
16 -57 -ý-- -ilpha-7 anti-tryspin 1.93E-04 1.10 E-04 1 
17 
- 
51 ff- HCV and alcohol 4.76E-05 8.86E-06 1 
18 -55 -M- -Uiliary tract abnormality 1.31 E-05 4.33E-05 1 
19 33 M chronic HBV 4.29E-05 0.00011 1 
20 
21 
36 
36 
M 
M 
chronic HBV 
HBV _5.53E-06 1.31 E-05 
4.08E-05 
0.000191 
1 
1 
22 51 f- 6e-netic haernatochromatosis 4.30E-06 5.92E-0-551 1 
23 32 M borderline steatohepatitis 1.08E-05 9.44E-051 1 
24 47 F HCV 2.07E-05 5.41 E-05 1 
25 
26 
50 
52 
-ý- 
F 
HCV 
HCV 
2.44E-04 
8.58E-06 
9.04E-06 1 
O. OOE+00 1 
27 54 r- -R-CV 1.93E-04 O. OOE+00 1 
28 20 10--- Autoimmune 4.68E-04 O. OOE+00 1 
29 54 F HCV 2.81 E-05 3.25E-061 
30 
31 
58 
-50 
M 
Ja- 
NAFLD 
HCV 
7.03E-05 
2.46E-06 
4.33E-05 ý1 
3.41 E-061 1 
32 49 F HCV 2.28E-06 9.01 E-07 1 
33 44 iW- HCV 1.42E-05 :: ýý- 5.7 1 
34 
35 
36 
49 
52 
53 
M 
F 
M-- 
HCV 
ýEEEE 
minimal chronic hepatitis 
-HCV 
9.26&05 
EE 
5.68E-04 
1.03E-05 
2.37E- 1 
O. OOE+ 01 1 
3.14 
37 
38 
26 
47 
M 
M 
HCV and HBV 
HCV 
6,94E-05 
3.63E-06 
2 611_ 
8.1 9E-05! 
39 
40 
41, 
70 
36 
- 31 
M- 
M 
HCV 
genetic haernatochromatosis 
HBV 
3.23E-05 
1.87E-04 
3.85E-05 
4.11 
0.0001 2 
42 41 HCV 4.23E-05 3.09E-071 1 
43 41 M HCV +alcohol 2.23E-05 2., 52E-05 1 
44 
45 
51 
54 
M 
F 
alcoholic liver disease 
HCV 
2.53E-05 
9.40E-05 
01 
3.9E-06: 1 
46, 
47 
31 
42 
M 
Mj 
HCV 
alcoholic liver disease 
1.32E-04 
1.50E-04 
2,66 
- 
51 1 
2.67E-05,1 
- - 48 63 F alcoholic liver disease 1.76E-04 2,66C-6 4 , '2 
49 38 V+HIV 9.73E-05 
50 -29 HBV 8.94E-05 7.86E-06; 5 
51 38 M HCV 4.41 E-05 
52 47 V- HCV 3.12E-04 1.27E-05,4 
53 47 M HCV 4.36E-05 
54 53 F1 HV 1.08E-04 
55 52 M HCV 2.54E-05 
NAFLD; non-alcoholic fatty liver disease, NASH; non-alcoholic steatohepatitis, HBV; hepatitis B viruS 
Appendix G- Clinical study data (liver biopsies) 
Biopsy Age Sex Liver Pathology mt4977: undeleted mt7436: undeleted He - 56 37 F HCV 6.83E-05 6.53E-06 1 
- 57 21 -P7- RBV 6.74E-05 2.65E-06 4 
58 33 a HCV 1.51 E-04 3.50E-06 1 
59 41 F Alcohol 1.49E-05 9.78E-07 1 
60 40 M WILD 1.50E-04 1.92E-06 1 
61 30 M HCV alcohol 1.84E-06 7.88E-07 ,1 62 40 - -RAFLD 2.06E-05 2.71 E-06 1 
63 66 Autoimmune 7.59E-05 5.79E-06 1 
64 48 COlitis + previous alcohol 1.08E-04 4.20E-05 1 
65 68 F non-s ecific reactive hepatitis c 1.91 E-05 2.78E-06 I 
66 48 M ?N MASH 1.98E-04 5.79E-06 1 
67 30 M 
J i 
H( HCV 1.23E-05 1.76E-05 1 
68 55 F HC HCV and alcohol 5.61 E-06 1.33E-06 1 
69 39 M HCV and previous HBV 7.40E-05 2.53E-06 1 
70 52 M HCV 1.09E-05 1.49E-06 4 
71 63 
- 
M HCV + alcohol 2.05E-05 7.11 E-06 1 
72 60 - m- Alcohol ? ASH/? NASH 1.73E-04 2.59E-05 3 
73 51 M Autoimmune 1.22E-04 7.81 E-06 1 
74 50 W HCV +alcohol 8.94E-06 1.22E-06 1 
75 62 F H13V 3.75E-05 4.71 E-061 1 
76 57 M ? dysplasia 1.60E-04 6.68E-06 ý 
- 
4 
77 59 M- HCV 4.14E-04 3.24E-061 
-1 78 54 M alcoholic liver di-sease 1.55E-04 8.86E-06 1 
79 55 M HCV +alcohol 2.11 E-05 7.73E-07 1 
median 4.36E-05, 4.71 E-06 - 
NAFLD; non-alcoholic fatty liver disease, NASH; non-alcoholic steatohepatitis, HBV; hepatitis B virus 
Appendix H- RSCA inter- and intra-assay variability 
Homoduplex mobility 
value 
Heteroduplex 
mobility value 
ý EB§ý3 4u--n -1 416.19 446.1 
41-6.53 446.5 
- 
416.11 446.24 
M-ean 416.28 446.28 
ýýD- 0.22 0.20 
- - - k un 2 415.88 446.67 
416.13 446.81 
- 
415.98 445.65 
a n 
- - 
416.00 446.38 
§ D 0.13 0.63 
- n 3 415.45 446.2 
415.73 445.78 
416.17 446.04 
Mean- 415.78 446.01 
SD 0.36 0.21 
- ý 06333 Run 1 416.44 1 438.31 
416.65 438.15 
416.43 438 
Mean 416.51 438.15 
SID 0.12 0.16 
Run 2 416.54 1 438.14 
416.4 1 438 
416.52 438.23 
Mean 416.49 438.12 
SID 0.08 0.12 
Run 3 415.94 438.34 
416.31 438.41 
- 
416.31 438.55 
M-ean 416.191 438.43 
SD 0.211 0.11 
UB634 Run 1 416.89 422.26 
416.82 421.92 
416.83 421.78 
Mean 416.85 421.99 
SD 0.038 0.25 
Run 2 416.44 421.23 
416.73 421.55 
416.221 421.61 
ean 416.461 421.46 
SID 0.261 0.204 
I 
- 
I 
Run 3 416.71 421.95 
415.99 421.33 
416.14 421.38 
Mean 416.28 
1 
421.55 
I SD 0.38 6-. ý4 
Appendix I- RSCA heteroduplex data 
- 
Mobility Values 
Blo s Age e ý-ex Nof He -Number of He Ho mobility He I He 2 He 3 He 4 He 6 
1 39 3ý M 1 1 416.89 422.26 
2 65 1 416.15 430.44 
3 32 1 417.57 457.53 
4 445 m 11 416.44 438.31 
5 
1 
5E6 M 
r 
415.5 437.06 
6 65 M 1 416.53 429.01 
7 57 F 11 415.39 , 425.45 , 8 322 F 11 415 *1 15 31 9 99 5 35 M 33 416.06 
Z9.66 
432. ýl 436.1 
10 10 444 M 3 432.12 439.76 443.6 
11 1 388 M 1 
1 2 1,292 1 13 40 M 1 1 416.01 454.58 
14 55 M 1 416.97 432.94 
15 43 M 1 416.54 431.91 
16 57 F 1 416.19 432.85 
17 51 M 1 416.85 447.7 
18 55 M 1 417.71 434.29 1 
19 33 M 1 , 417.18 431.45 20 36 M 1 1 417.47 454.97 
21 36 M 1 1 415.5 474.01 
22 51 F 1 1 417.21 , 
428.42 
23 32 M 1 1 417.15 432.69 
24 47 F 1 ý 416.96 428.66 
25 50 F 1 416.46 432.2 
26 52 F 1 416.53 431.18 
27 54 F 1 416.45 , 427.72 28 20 M 1 416.3 ý 428.44 
29 54 F 1, 417.091 427.71 
30 58 M 11 - 415.64 F 442.46 
31 50 M 11 416.01 440.17 
32 49 F 11 415.27 439.23, 
33 44 M 11 415.23 463.31 
34 49 M 11 415.02 444.08 
35 52 F 11 417.63 427.18 
36 53 M 21 416.111 428.91 433.011 
37 26 M 11 416.63 459.5 
38 47 M 11 416.031 435.49, 
39 70 M 11 416.421 428.56 
40 6 M 11 415.98 420.85 
41 31 M 2 416.25 441.74 448.08 
42 41 M 1 416.23 429.93 
43 41 M 1 416.37 440.66 
44 51 M 1 415.7 433.17 
45 4 5 ý5-4 54 F 417.58 421.72 
46 4 6 31 M 415.9 442.76 
47 4 7 42 M 1 416.34 440.86 
48 4 63 F 2 417.19 430.43 440.69 
[9 4 
F 
38 M 
* 
1 417.06, 440.37 
- - 50 .0 ' 29 M 5 416.981 438.44 447.01 449.16 471 . 
66T 4 7T89 
51 
52 2 '1 
381 
471 
M 
F 
1 
4 
416.68 
416.42 
444.2q 
455.54 461.99 465.53 493.2ý-7--------- 
, 
-531 4 7 M 1 416.24 4ý2-. dY - - - 
541 53 ý F 1 416.25 4Y178-ý] 
Ho; homoduplex, He; heteroduplex 
Appendix I- RSCA heteroduplex data 
Mobility Values 
Biopsy Ae Sex Number of He Ho mobility He I He 2 He 3 He4 HeS 
55 52 M f - 416.85 421.9 
56 37 F 1 415.94 437.67 
57 21 F 4 415.37 439.02 
58 33 M 1 416.87 437.62 444.28 447.12 453.6 
59 41 F f 416.12 433.71 
60 40 M 1 415.13 426.61 
61 30 M 1 , 416.63 438.39 62 40 M 1 415.28 432.27 
63 66 1 416.45 459.5 
64 48 1 417.38 421.14 
65 68 1 415.27 462 
66 48 1 416.32 427.22 
67 30 M 1 415.74 426.82 
68 F 1 416.53 428.81 
69 39 M 1 416.96 442.76 
70 52 M 4 416.46 439.95 445.41 449.851 476.96 
71 63 hMA 1 416.07 443.44 
72 60 3 416.38 432.31 438.75 461.93 
73 51 
- 
1 416.88 426-04 
- 74 ý o 
- 
1 416.07 461.45, - 
75 ý 2 1 416.16, 420.141 
76 57 M 4 416.25 429.63 432.47 473.03 461.441 
77 59 M 1 416.4 427.16 
78 54 
1 
m m 1 416.35 430.41 =7 9 5 5) m 1 415.15 426.37 
Ho; homoduplex, He; heteroduplex 
